0001213900-24-09852310-Q BiomX Inc. 20241114202411141648451648451648451

Â 165,435Â Â Â (149,573)Â Â 15,865Â Stock-based compensation expensesÂ Â -Â Â Â -Â Â Â 195Â Â Â -Â Â Â 195Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (7,906)Â Â (7,906) Balance as of September 30, 2023Â Â 4,722,733Â Â Â 3Â Â Â 165,630Â Â Â (157,479)Â Â 8,154Â Â (*) Less than $1. (**) See Note 10A. (***) All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A.Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â F-5 Â BIOMX INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD in thousands, except share and per share data) (unaudited) Â Â Â For the NineÂ MonthsÂ Ended SeptemberÂ 30,Â Â Â 2024Â Â 2023Â CASH FLOWS â€“ OPERATING ACTIVITIESÂ Â Â Â Â Net lossÂ Â (3,214)Â Â (20,678) Â Â Â Â Â Â Â Â Adjustments required to reconcile cash flows used in operating activities:Â Â Â Â Â Â Depreciation and amortizationÂ Â 882Â Â Â 659Â Stock-based compensationÂ Â 1,083Â Â Â 641Â Amortization of debt issuance costsÂ Â -Â Â Â 453Â Finance income, netÂ Â (478)Â Â (293) Revaluation of contingent considerationÂ Â 6Â Â Â (40) Income from change in fair value of Private Placement WarrantsÂ Â (24,417)Â Â -Â Private Placement Warrants issuance costÂ Â 732Â Â Â -Â Change in contract liabilityÂ Â (1,976)Â Â -Â Loss from sale and disposal of fixed assets, netÂ Â 145Â Â Â -Â Goodwill impairmentÂ Â 801Â Â Â -Â Â Â Â Â Â Â Â Changes in operating assets and liabilities:Â Â Â Â Â Â Other current and non-current assetsÂ Â (213)Â Â 679Â Trade accounts payableÂ Â (2,691)Â Â 241Â Other accounts payableÂ Â (1,169)Â Â 3,354Â Net change in operating leasesÂ Â (181)Â Â (60) Net cash used in operating activitiesÂ Â (30,690)Â Â (15,044) Â Â Â Â Â Â Â Â Â CASH FLOWS â€“ INVESTING ACTIVITIESÂ Â Â Â Â Â Â Cash and restricted cash acquired from the APT acquisitionÂ Â 663Â Â Â -Â Proceeds from short-term depositsÂ Â -Â Â Â 2,000Â Proceeds from sale of property and equipmentÂ Â 72Â Â Â -Â Purchases of property and equipmentÂ Â (19)Â Â (43) Net cash provided by investing activitiesÂ Â 716Â Â Â 1,957Â Â Â Â Â Â Â Â Â CASH FLOWS â€“ FINANCING ACTIVITIESÂ Â Â Â Â Â Â Issuance of Private Placement Warrants under March 2024 PIPEÂ Â 28,745Â Â Â -Â Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPEÂ Â 21,269Â Â Â -Â March 2024 PIPE issuance costsÂ Â (507)Â Â -Â Issuance costs from February 2023 PIPEÂ Â -Â Â Â (333) Issuance of Common Stock and Warrants under February 2023 PIPEÂ Â -Â Â Â 7,485Â Pre-Funded Warrants exerciseÂ Â 6Â Â Â -Â Issuance of Common Stock under Open Market Sales Agreement, net of issuance costsÂ Â 19Â Â Â -Â Issuance cost from the APT acquisitionÂ Â (13)Â Â -Â Repayment of long-term debtÂ Â (10,747)Â Â (2,929) Net cash provided by financing activitiesÂ Â 38,772Â Â Â 4,223Â Â Â Â Â Â Â Â Increase (decrease) in cash and cash equivalents and restricted cashÂ Â 8,798Â Â Â (8,864) Effect of exchange rate changes on cash and cash equivalents and restricted cashÂ Â (11)Â Â (37) Cash and cash equivalents and restricted cash at the beginning of the periodÂ Â 15,864Â Â Â 32,294Â Cash and cash equivalents and restricted cash at the end of the periodÂ Â 24,651Â Â Â 23,393Â Â Â Â Â Â Â Â RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETSÂ Â Â Â Â Â Â Cash and cash equivalentsÂ Â 23,537Â Â Â 22,450Â Restricted cashÂ Â 1,114Â Â Â 943Â Total cash and cash equivalents and restricted cashÂ Â 24,651Â Â Â 23,393Â Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Â Â Â Â Â Â Cash paid for interestÂ Â 1,437Â Â Â 1,455Â Taxes paidÂ Â 10Â Â Â 50Â Â Â Â Â Â Â Â Â SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:Â Â Â Â Â Â Property and equipment purchases included in accounts payable and Trade payableÂ Â 11Â Â Â 5Â Issuance cost from March 2024 PIPEÂ Â 1,685Â Â Â -Â Issuance of Common Stock under the APT acquisitionÂ Â 3,041Â Â Â -Â Issuance of Redeemable Convertible Preferred Shares under the APT acquisitionÂ Â 12,610Â Â Â -Â Issuance of Merger Warrants under the APT acquisitionÂ Â 200Â Â Â -Â Redeemable Convertible Preferred Shares conversion into shares of Common StockÂ Â 13,774Â Â Â -Â Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â F-6 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 1 â€“ GENERAL Â Â A. General information Â BiomX Inc. (individually, and together with its subsidiaries, BiomX Ltd. (â€œBiomX Israelâ€), RondinX Ltd. and Adaptive Phage Therapeutics LLC, (â€œAPTâ€), the â€œCompanyâ€ or â€œBiomXâ€) was incorporated in 2017. The Companyâ€™s shares of Common Stock are traded on the NYSE American under the symbol PHGE. The Companyâ€™s units, consisting of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (â€œUnitsâ€), were traded on the NYSE American under the symbol PHGE.U until a mandatory unit separation of the units became effective on October 25, 2024. Certain warrants were quoted on OTC Pink under the symbol â€œPHGEWâ€ and expired on October 28, 2024. Â Â BiomX is developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, focusing its efforts, at this point, on cystic fibrosis and on diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The Companyâ€™s headquarters are located in Ness Ziona, Israel. Â On March 6, 2024, the Company entered into an agreement and plan of merger (the â€œMerger Agreementâ€) with APT and certain other parties, as a result of which APT became a wholly-owned subsidiary of the Company (the â€œAcquisitionâ€), as further described below. Additionally, on March 15, 2024, concurrently with the consummation of the Acquisition, the Company consummated a private placement (the â€œMarch 2024 PIPEâ€) with certain investors pursuant to which such investors purchased an aggregate of 216,417 shares of the Companyâ€™s Series X non-voting convertible preferred share, par value $0.0001 per share (the â€œRedeemable Convertible Preferred Sharesâ€), with each share of Redeemable Convertible Preferred Shares being convertible into 100 shares of the Companyâ€™s Common Stock, after giving effect to the Reverse Split (as defined below), and warrants (the â€œPrivate Placement Warrantsâ€) to purchase up to an aggregate of 10,820,850 shares of the Companyâ€™s Common Stock, for aggregate gross proceeds of approximately $50,000. See Note 1D for further information regarding the Acquisition and the conversion of the Redeemable Convertible Preferred Shares. Â On August 8, 2024, the Board of Directors approved a 1-for-10 reverse stock split of the Companyâ€™s shares of Common Stock (the â€œReverse Splitâ€), effective on August 26, 2024. See Note 10A for further information. Â Â B. The war with Hamas and Hezbollah Â On October 7, 2023, an unprecedented attack was launched against Israel by terrorists from the Hamas terrorist organization that infiltrated Israelâ€™s southern border from the Gaza Strip and in other areas within the state of Israel attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, has attacked military and civilian targets in Northern Israel, to which Israel has responded. Moreover, Iran recently launched a direct attack on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. Such clashes may escalate in the future into a greater regional conflict. Â To date, the State of Israel continues to be at war with Hamas and Hezbollah and in an armed conflict with Iran and its rebel militia groups. Â BiomX headquarters are located in Ness Ziona, Israel; as well as most of its operations. In addition, most of the key employees and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect its business. Â While a few employees of the Company were called to reserve duty in the Israel Defense Forces, the ongoing war with Hamas and Hezbollah has not, since its inception, materially impacted BiomXâ€™s business or operations. Furthermore, BiomX does not expect any delays to its programs as a result of the situation. However, at this time, it is not possible to predict the intensity or duration of Israelâ€™s war against Hamas and Hezbollah, nor predict how this war will ultimately affect BiomX business and operations or Israelâ€™s economy in general.Â F-7 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 1 â€“ GENERAL (Cont.) Â Â C. Going concern Â As of September 30, 2024, the Company has an accumulated deficit of $166,184 and has incurred significant losses and negative cash flows from operations. These are expected to continue in the foreseeable future. The Company plans to continue to fund its ongoing operations, as well as other development activities relating to additional product candidates, through issuance of debt and/or equity securities, loans, and government grants. Management believes that its current funds are not sufficient to fund its operations for at least one year from the issuance date of these financial statements. Increased research and development, clinical, or operating expenses may require additional funding or expense postponement. The Companyâ€™s ability to raise capital is subject to market conditions and other aspects, which may affect the terms and availability of such funding. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of such circumstances. Â Â D. Merger Agreement Â On March 6, 2024, the Company, entered into the Merger Agreement with BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (â€œFirst Merger Subâ€), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (â€œSecond Merger Subâ€), and APT. Pursuant to the Merger Agreement, First Merger Sub merged with and into APT, with APT being the surviving corporation and becoming a wholly owned subsidiary of the Company (the â€œFirst Mergerâ€). Immediately following the First Merger, APT merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. APT was a U.S.-based privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infection. As a result of the Acquisition, the Company is expected to have a pipeline that includes two Phase 2 assets each aimed at treating serious infections with unmet medical needs. Â On March 15, 2024, the effective date of the Acquisition (the â€œClosing Dateâ€), APTâ€™s former stockholders were issued an aggregate of 916,497 shares of the Companyâ€™s Common Stock, 40,470 Redeemable Convertible Preferred Shares and Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock (â€œMerger Warrantsâ€). Each share of Redeemable Convertible Preferred Shares is convertible into an aggregate of 100 shares, after giving effect to the Reverse Split of Common Stock.Â The Merger Warrants will be exercisable at any time after the date of the receipt of BiomX stockholder approval at an exercise price of $50.00 per share and will expire on January 28, 2027. In the event the Redeemable Convertible Preferred Shares are not converted by the earlier to occur of (i) the time that meeting of BiomX stockholders is ultimately concluded or (ii) five months after the initial issuance of the Redeemable Convertible Preferred Shares, the Company may be required to pay to each holder of the Redeemable Convertible Preferred Shares an amount in cash equal to the fair value of the Redeemable Convertible Preferred Shares. On July 9, 2024, the Companyâ€™s stockholders approved the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock and the issuance of shares of Common Stock upon the exercise of the Merger Warrants. Â The Redeemable Convertible Preferred Shares are entitled to receive dividends on shares of the Redeemable Convertible Preferred Shares equal to, on an as-if-converted-to Common-Stock basis, and in the same form as, dividends actually paid on shares of the Common Stock. Except as otherwise required by law or with respect to the Redeemable Convertible Preferred Shares protective provisions set forth in the Companyâ€™s Certificate of Designations, the Redeemable Convertible Preferred Shares does not have voting rights. Â At the Closing Date, the Redeemable Convertible Preferred Shares were classified as temporary equity in accordance with the provisions of ASC 480-10-S99, as they included clauses that could constitute redemption clauses that were subject to the Companyâ€™s stockholder approval and outside of the Companyâ€™s control. On June 17, 2024, the Company filed a definitive Proxy Statement on Schedule 14A with respect to a meeting of stockholders to approve, among other things, the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock. In addition, the majority of the Companyâ€™s stockholders signed a binding support agreement that contained their commitment to vote in favor or deliver a written consent regarding any stockholdersâ€™ matter in the stockholdersâ€™ meeting which took place on July 9, 2024. These circumstances led the Company to determine that the Redeemable Convertible Preferred Shares meet the definition of permanent equity as the Company is able to control the redemption. Therefore, the Redeemable Convertible Preferred Shares were reclassified as equity. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Companyâ€™s Common Stock according to beneficial ownership limitations set by certain investors.Â F-8 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 1 â€“ GENERAL (Cont.) Â The Merger Warrants are classified as equity, as they are indexed to the Companyâ€™s own shares and meet the classification requirements for stockholdersâ€™ equity classification under ASC 815-40. Â Concurrently with the consummation of the Acquisition, the Company entered into a securities purchase agreement with certain investors, for aggregate gross proceeds of $50,000. See Note 10A for further information. Â Immediately following the Acquisition, and without taking into account the PIPE Preferred Shares and the Private Placement Warrants as defined and described in Note 10A, the Companyâ€™s stockholders prior to the Acquisition owned approximately 55% of the Company and APTâ€™s stockholders prior to the Acquisition owned approximately 45% of the Company on a diluted basis. Â The Acquisition was accounted for in accordance with Accounting Standards Codification (â€œASCâ€) Topic 805, â€œBusiness Combinations,â€ using the acquisition method of accounting. The Company was identified as the accounting acquirer, based on the evaluation of the following facts and circumstances: Â Â â— Pursuant to the Merger Agreement, the post-Acquisition board of directors of the Company consisted of seven directors, out of which the Company designated four board seats, with the Companyâ€™s chair of the board prior to the Acquisition continuing in his position, i.e. the majority of the post-closing board was designated by the Company. Â Â â— The Chief Executive Officer and the majority of management roles are held by individuals who were affiliated with the Company prior to the Acquisition. Â The Acquisition-related transaction costs are accounted for as expenses in the period in which the costs are incurred. The Company incurred transaction costs of $874 during the nine months ended September 30, 2024, which were included in general and administrative expenses in the condensed consolidated statements of operations. Â Purchase Price Allocation Â The following sets forth the fair value of acquired identifiable assets and assumed liabilities of APT, after consideringÂ measurement period adjustmentÂ as described below,Â which includes adjustments to reflect the fair value of intangible assets acquired as of March 15, 2024: Â Â Â AmountsÂ Cash and cash equivalentsÂ Â 509Â Restricted cashÂ Â 154Â Other current assetsÂ Â 1,780Â Property, plant and equipmentÂ Â 3,748Â Operating lease right-of-use assetÂ Â 7,953Â IPR&D assets and GoodwillÂ Â 16,088Â Total assetsÂ Â 30,232Â Â Â Â Â Â Trade accounts payableÂ Â (3,667) Other accounts payableÂ Â (2,895) Operating lease liabilityÂ Â (7,819) Total liabilitiesÂ Â (14,381) Total considerationÂ Â 15,851Â Â Â The fair value estimate for all identifiable assets and liabilities assumed is based on assumptions that market participants would use in pricing an asset, based on the most advantageous market for the asset (i.e., its highest and best use). Â The Company recognized intangible assets related to the Acquisition, which consist of IPR&D valued at $15,287 using the Multi-Period Excess Earnings Method valuation method and of goodwill valued at $501. The goodwill is primarily attributed to the expected synergies from combining the operations of APT with the Companyâ€™s operations and to the assembled workforce of APT. The IPR&D is considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon successful completion of the project, IPR&D assets are reclassified to developed technology and amortized over their estimated useful livesÂ F-9 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 1 â€“ GENERAL (Cont.) Â During the three months ended September 30, 2024, the Company made measurement period adjustment to the purchase price allocation, which resulted in an increase to goodwill of $300. The increase resulted from a provision for a contingency not provided in the initial Purchase Price Allocation,Â following a term sheet for a settlement agreement between APT and Oyster Point Pharma, Inc. (â€œOysterâ€) in connection with the Collaboration and Option Agreement signed in May 2021 as discussed in Note 7A. The fair value of assets acquired and liabilities assumed have been finalized. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information. Â These intangible assets are classified as Level 3 measurements within the fair value hierarchy. Â Â The following table summarizes the fair value of the consideration transferred to APT shareholders for the Acquisition: Â Â Â AmountsÂ Common StockÂ Â 3,041Â Redeemable Convertible Preferred SharesÂ Â 12,610Â Merger WarrantsÂ Â 200Â Â Â Â 15,851Â Â The fair value of shares of Common Stock issued by the Company was determined using the Companyâ€™s closing trading price on the Closing Date adjusted by a discount for lack of marketability (â€œDLOMâ€) of 9.4% as a registration statement was filed within 45 days. The fair value of Redeemable Convertible Preferred Shares was determined using the Companyâ€™s closing trading price on the Closing Date adjusted by a DLOM of 14.9% as the conversion of the Redeemable Convertible Preferred Shares to shares of Common Stock was subject to the stockholder approval, which was obtained on July 9, 2024. The Company determined the fair value of the Merger Warrants using the Black-Scholes model as of the Closing Date. The main assumptions used are as follows: Â Underlying value of Common Stock ($)Â Â 0.37Â Exercise price ($)Â Â 5.0Â Expected volatility (%)Â Â 117.7Â Expected terms (years)Â Â 2.87Â Risk-free interest rate (%)Â Â 4.5Â Â The actual APT net loss included in the Companyâ€™s condensed consolidated statements of operations for the nine months ended September 30, 2024, is as follows: Â Â Â SeptemberÂ 30, 2024Â Net loss attributable to APTÂ Â 5,884Â Â The unaudited pro forma financial information below summarizes the combined results of operations for BiomX Inc. (including its wholly owned subsidiaries, BiomX Ltd. and RondinX Ltd.) and APT. The unaudited pro forma financial information includes adjustments to reflect certain business combination effects, including: acquisition-related costs incurred by both parties and reversal of certain costs incurred by BiomX Inc. which would not have been incurred had the acquisition

occurred on January 1, 2023. The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the Acquisition had taken place at the beginning of fiscal 2023. Â The following unaudited table provides certain pro forma financial information for the Company as if the Acquisition occurred on January 1, 2023: Â Â Â SeptemberÂ 30, 2024*Â Net lossÂ Â 2,698Â Â * The pro forma amounts above are derived from historical numbers of the Company and APT. Â F-10 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 2 â€“ SIGNIFICANT ACCOUNTING POLICIES Â Â A. Unaudited Condensed Financial Statements Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for condensed financial information. They do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments except as otherwise discussed). Â The financial information contained in this report should be read in conjunction with the annual financial statements included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that the Company filed with the U.S. Securities and Exchange Commission (the â€œSECâ€) on April 4, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023. Â Â B. Principles of Consolidation Â The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation. Â Â C. Use of Estimates in the Preparation of Financial Statements Â The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. The most significant estimates in the Companyâ€™s financial statements relate to accruals for research and development expenses, valuation of stock-based compensation awards, purchase price allocation related to the Acquisition and the Private Placement Warrants fair value revaluation; estimates used in the IPR&D impairment assessment for calculating the fair value of the Companyâ€™s assets by using discounted cash flow incorporate the Companyâ€™s estimated post-tax weighted average cost of capital, amounts and timing of projected future cash flows that are influenced by the expected outcome of research and development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Companyâ€™s specific market share. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Â The full extent to which Israelâ€™s war with Hamas and Hezbollah may directly or indirectly impact the Companyâ€™s business, results of operations and financial condition will depend on future developments that are uncertain, as well as the economic impact on local, regional, national and international markets. Â Â D. Business Combination Â The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. The excess of the fair value of the consideration transferred over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The fair value of the consideration transferred included equity securities. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective dates of Acquisition.Â F-11 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 2 â€“ SIGNIFICANT ACCOUNTING POLICIES (Cont.) Â Â E. Financial instruments Â When the Company issues freestanding instruments, it first analyzes the provisions of ASC 480, â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the consolidated statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-10 in order to determine whether the instrument is considered indexed to the entityâ€™s own stock and qualifies for classification within equity. Â When the Company issues preferred shares, it first considers the provisions of ASC 480, in order to determine whether the preferred shares should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrumentâ€™s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. See Note 1D regarding the reclassification of the Redeemable Convertible Preferred Shares. Â When the Company issues warrants, it first considers the provisions of ASC 815-40, â€œContracts in Entityâ€™s Own Equityâ€ (â€œASC 815-40â€) in order to determine whether the warrants should be classified as equity. Equity classification is permitted when warrants are indexed to the Companyâ€™s own shares and meet the classification requirements for stockholdersâ€™ equity classification under ASC 815-40. If the warrants are not within the scope of ASC 815-40, the Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (â€œASC 815â€), â€œDerivatives and Hedgingâ€, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the Private Placement Warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the condensed consolidated statements of operations. See Note 10A for further information regarding the Private Placement Warrants. Â Â F. Basic and diluted loss (earnings) per share Â Basic loss (earnings) per share is computed by dividing net loss (income) by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Companyâ€™s Common Stock and fully vested Pre-Funded Warrants for the Companyâ€™s Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. The calculation excludes shares of Common Stock purchased by the Company and held as treasury shares. Diluted loss (income) per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period, plus the number of shares of Common Stock that would have been outstanding if all potentially dilutive shares of Common Stock had been issued, using the treasury stock and if-converted method, in accordance with ASC 260-10, â€œEarnings per Share.â€ Â The Company computes net loss (income) per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its Redeemable Convertible Preferred Shares to be participating securities as the holders of the Redeemable Convertible Preferred Shares would be entitled to dividends that would be distributed to the holders of Common Stock, on a pro-rata basis assuming conversion of all Redeemable Convertible Preferred Shares into shares of Common Stock. These participating securities do not contractually require the holders of such shares to participate in the Companyâ€™s losses. As such, net loss for the periods presented was not allocated to the Companyâ€™s participating securities. Â Â G. Intangible Assets Â Goodwill Â Goodwill reflects the excess of the consideration transferred at the business combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, â€œIntangiblesâ€”Goodwill and Otherâ€ allows an entity to first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value is less than its carrying amount. Otherwise, no further impairment testing is required.Â F-12 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 2 â€“ SIGNIFICANT ACCOUNTING POLICIES (Cont.) Â The Companyâ€™s goodwill is tested for impairment at least on an annual basis, on the last day of the third quarter of the fiscal year and whenever events or changes in circumstances indicate the carrying value of a reporting unit may not be recoverable. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount of the respective reporting unit exceeds its fair value. However, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information. Â Intangible assets Â IPR&D assets acquired in a business combination are recognized at fair value as of the acquisition date and subsequently accounted for as indefinite-lived intangible assets until completion or abandonment of the associated R&D efforts. Indefinite-lived intangible assets are reviewed for impairment at least annually, on the last day of the third quarter of the fiscal year or whenever there is an indication that the asset may be impaired.Â Â Â H. Recent Accounting Standards Â Recently issued accounting pronouncements, not yet adopted Â In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€). This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€). This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, â€œSegment Reportingâ€. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entityâ€™s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â NOTE 3 â€“ FAIR VALUE OF FINANCIAL INSTRUMENTS Â The Company accounts for financial instruments in accordance with ASC 820, â€œFair Value Measurements and Disclosuresâ€ (â€œASC 820â€). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below: Â Level 1 â€“ Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Â Level 2 â€“ Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data. Â Level 3 â€“ Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Â There were no changes in the fair value hierarchy levelling during the nine months ended September 30, 2024 and year ended December 31, 2023.Â F-13 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 3 â€“ FAIR VALUE OF FINANCIAL INSTRUMENTS (Cont.) Â The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy:Â Â Â Â September 30, 2024Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 20,325Â Â Â -Â Â Â -Â Â Â Â 20,325Â Foreign exchange contracts receivableÂ Â -Â Â Â 15Â Â Â -Â Â Â 15Â Â Â Â 20,325Â Â Â 15Â Â Â -Â Â Â 20,340Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 161Â Â Â 161Â Private Placement WarrantsÂ Â -Â Â Â -Â Â Â 4,328Â Â Â 4,328Â Â Â -Â Â Â -Â Â Â 4,489Â Â Â 4,489Â Â Â Â December 31, 2023Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 11,377Â Â Â -Â Â Â -Â Â Â Â 11,377Â Foreign exchange contracts receivableÂ Â Â Â Â Â 256Â Â Â -Â Â Â 256Â Â Â Â 11,377Â Â Â 256Â Â Â -Â Â Â 11,633Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 155Â Â Â 155Â Â Â -Â Â Â -Â Â Â 155Â Â Â 155Â Â Â The changes in the fair value of the Companyâ€™s Level 3 financial liabilities, which are measured on a recurring basis are as follows: Â Â Â Nine Months Ended SeptemberÂ 30, 2024Â Â Nine Months Ended SeptemberÂ 30, 2023Â Beginning balanceÂ -Â Â Â Â Â Â -Â Private Placement WarrantsÂ Â 28,745Â Â Â Â Â Â Â Â -Â Change in fair valueÂ Â (24,417)Â Â -Â Ending balanceÂ Â 4,328Â Â Â -Â Â Financial instruments with carrying values approximating fair value include cash and cash equivalents, restricted cash, short-term deposits, other current assets, trade accounts payable and other accounts payable, due to their short-term nature.Â F-14 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 3 â€“ FAIR VALUE OF FINANCIAL INSTRUMENTS (Cont.) Â The Company determined the fair value of the liabilities for the contingent consideration based on a probability of discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the attainment of future clinical, developmental, regulatory, commercial and strategic milestones relating to product candidates for treatment of primary sclerosing cholangitis. The discount rate applied ranged from 3.84% to 4.52%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of operations. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liability. Changes in contingent consideration for the nine and three months ended September 30, 2024 and September 30, 2023, resulted from the passage of time and discount rate revaluation. Â The Company uses foreign exchange contracts (mainly option and forward contracts) to hedge cash flows from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, the Company recognizes gains or losses that offset the revaluation of the cash flows also recorded under financial expenses (income), net in the condensed consolidated statements of operations. As of September 30, 2024, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $3,410 with a fair value asset of $15. As of December 31, 2023, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $4,136 with a fair value asset of $256. Â The Company determined the fair value of the liabilities for the Private Placement Warrants using the Black-Scholes model, a Level 3 measurement, within the fair value hierarchy. Â The main assumptions used are as follows: Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Underlying value of Common Stock ($)Â Â 1.02Â Â Â Â Â Â Â Â Â Â -Â Exercise price ($)Â Â 2.31Â Â Â Â -Â Expected volatility (%)Â Â 117.6Â Â Â Â -Â Expected terms (years)Â Â 1.75Â Â Â Â -Â Risk-free interest rate (%)Â Â 3.6Â Â Â Â -Â Â Â F-15 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 4 â€“ OTHER CURRENT ASSETS Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Government institutionsÂ Â 84Â Â Â Â 66Â Prepaid insuranceÂ Â 1,165Â Â Â 505Â Other prepaid expensesÂ Â 574Â Â Â Â 128Â Grants receivableÂ Â 950Â Â Â Â 574Â OtherÂ Â 892Â Â Â Â 495Â Other current assetsÂ Â 3,665Â Â Â Â 1,768Â Â NOTE 5 â€“ OTHER ACCOUNTS PAYABLE Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Employees and related institutionsÂ Â 956Â Â Â Â 1,852Â Accrued expensesÂ Â 3,421Â Â Â Â 1,289Â Government institutionsÂ Â 622Â Â Â Â 175Â Prepaid sublease incomeÂ Â -Â Â Â Â 28Â Severance related to former employees of APTÂ Â 70Â Â Â Â -Â Â Â Â 5,069Â Â Â Â 3,344Â Â NOTE 6 â€“ LEASES Â On August 9, 2019, APT entered into a lease agreement (the â€œLease Agreementâ€) with ARE-708 Quince Orchard, LLC (the â€œLandlordâ€), for office and lab spaces in Gaithersburg, Maryland starting on September 1, 2019. Over the course of years, APT and the Landlord amended the Lease Agreement in order to expand the square footage and to extend the lease period until November 28, 2034. The agreement included 49,625 square feet of area. The monthly lease payments under the lease agreement were approximately $255. On March 5, 2024, in connection with the Acquisition, APT and the Landlord, signed an amendment to the lease agreement. Pursuant to the amendment, the leased area will be decreased to 25,894 square feet

(the â€œRemaining Areaâ€), effective as of December 31, 2024. Following the amendment, the revised monthly lease payments are approximately $134. In exchange, APT was required to pay a relinquished premises fee in an amount equal to $1,500 within 10 business days following March 15, 2024 (the â€œAmendment Effective Dateâ€). In addition, the Company issued the Landlord warrants (the â€œLandlord Warrantsâ€) to purchase up to an aggregate of 25,000 shares of the Companyâ€™s Common Stock at an exercise price of $50.00 per share. The Landlord Warrants became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on January 28, 2027. The amendment also included a one-time option to early terminate the lease agreement on February 28, 2029 with respect to the Remaining Area under certain terms. The execution of the early termination will require APT to pay a termination fee of $3,000. Â APT accounted for the decreased leased area and the termination option as a modification as it continues to use the area for a period of time after the termination. The modification occurred before the Acquisition as APT signed the amendment before the Closing Date but was contingent upon the Acquisition. The operating lease right-of-use assets and operating lease liabilities contemplate the termination option. Â Lease expenses recorded in the condensed statements of operations were $2,543 and $995 for the nine and three months ended September 30, 2024, respectively, and $488 and $161 for the nine and three months ended September 30, 2023, respectively. Â F-16 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 7 â€“ COMMITMENTS AND CONTINGENCIES Â Â A. In May 2021, APT entered into a Collaboration and Option Agreement (the â€œOyster Agreementâ€) with Oyster, a wholly owned subsidiary of Viatris Inc., to collaborate on the use of APTâ€™s proprietary phage technology for the treatment of certain ophthalmic diseases. Upon execution of the Agreement, Oyster paid an upfront payment of $500 to APT, a portion of which APT claims it has spent in the course of performing its obligations under the Oyster Agreement. In April 2022 and September 2023, APT received letters from Oyster and Viatris Inc. raising concerns about APTâ€™s actions, including allegations that APT had breached the Oyster Agreement. APT and Oyster have agreed to settle their dispute related to the Oyster Agreement, including the allegations described in the letters, and to terminate the Oyster Agreement under a term sheet (the â€œTerm Sheetâ€). Under the terms of the Term Sheet, APT and Oyster will sign a final settlement agreement, which will include a payment of $300 from APT to Oyster. As of September 30, 2024, the final settlement agreement had not yet been signed. The Company has recorded a provision of $300 as other accounts payable in the condensed consolidated balance sheets. Â Â Â B. In August 2021, the Israeli Innovation Authority (â€œIIAâ€) approved an application that supports upgrading the Companyâ€™s manufacturing capabilities for an aggregate budget of NIS 5,737 (approximately $1,778). The IIA committed to fund 50% of the approved budget. The program was for the period beginning July 2021 through June 2022. The program does not bear royalties. Through September 30, 2024, the Company received NIS 1,912 (approximately $577) from the IIA with respect to this program. Â In March 2022, the IIA approved an application for a total budget of NIS 13,004 (approximately $4,094) in relation to the Companyâ€™s cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2022 through December 2022. Through September 30, 2024, the Company received NIS 1,365 (approximately $395) from the IIA with respect to this program. Â In March 2023, the IIA approved an application for a total budget of NIS 11,283 (approximately $3,164) in relation to the Companyâ€™s cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2023 through December 2023. Through September 30, 2024, the Company received NIS 2,783 (approximately $768) from the IIA with respect to this program. Â According to the agreement with the IIA, excluding the August 2021 program, BiomX Israel will pay royalties of 3% to 3.5% of future sales up to an amount equal to the accumulated grant received including annual interest of LIBOR linked to the USD. Starting January 2024, the IIA has notified that the interest has changed to the 12-month Secured Overnight Financing Rate (â€œSOFRâ€) as published on the first trading day of each calendar year. BiomX Israel may be required to pay additional royalties upon the occurrence of certain events as determined by the IIA, that are within the control of BiomX Israel. No such events have occurred or were probable of occurrence as of the balance sheet date with respect to these royalties. Repayment of the grant is contingent upon the successful completion of the BiomX Israelâ€™s R&D programs and generating sales. BiomX Israel has no obligation to repay these grants if the R&D program fails, is unsuccessful or aborted or if no sales are generated. The Company had not yet generated sales as of September 30, 2024; therefore, no liability was recorded in these condensed consolidated financial statements. IIA grants are recorded as a reduction of R&D expenses, net. Â Through September 30, 2024, total grants approved from the IIA aggregated to approximately $9,353 (NIS 32,068). Through September 30, 2024, the Company had received an aggregate amount of $8,003 (NIS 27,423) in the form of grants from the IIA. Total grants subject to royaltiesâ€™ payments aggregated to approximately $7,413. As of September 30, 2024, BiomX Israel had a contingent obligation to the IIA in the amount of approximately $8,250 including annual interest of SOFR applicable to dollar deposits. Â F-17 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 7 â€“ COMMITMENTS AND CONTINGENCIES (Cont.) Â Â C. On June 23, 2022, BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH (â€œBIâ€) for a collaboration to identify biomarkers for Inflammatory Bowel Disease. Under the agreement, BiomX Israel is eligible to receive fees totaling $1,411 to cover costs to be incurred by BiomX Israel in conducting the research plan under the collaboration. The fees were paid in four installments according to certain activities under the agreement. In December 2023, the Company completed its obligations with respect to this agreement and the last installment of $211 was received on January 18, 2024. The consideration was recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. Â NOTE 8 - U.S. GOVERNMENT CONTRACTS AND GRANTS Â In 2019, APT entered into a Base Agreement and Research Project Award (collectively, the â€œAgreementâ€) with the U.S. Army Medical Research Acquisition Activity (â€œUSAMRAAâ€) and the U.S. Army Medical Research & Development Command (â€œUSAMRDCâ€) to advance personalized phage therapy from niche to broad use. Awards under the Agreement are intended to lay the groundwork for rapid advancement of personalized phage therapy to commercialization for the variety of clinical indications and bacterial pathogens representing un-met needs with a focus on infections with significant military relevance. The competitive award was granted by USAMRAA and USAMRDC in collaboration with the Medical Technology Enterprise Consortium (â€œMTECâ€), a 501(c)(3) biomedical technology consortium working in partnership with the U.S. Department of Defense. Since Agreement inception, APT entered into certain modifications to the Agreement to include additional activities and perform pre-clinical activities to advance the Diabetic Foot Osteomyelitis (â€œDFOâ€) clinical program. Under the Agreement, MTEC reimburses APT for approved costs as incurred that are based upon the achievement of certain milestones up to a contract value of $36,214. In September 2024, the Agreement was amended to extend the period of performance to continue and complete the pre-clinical activities for the DFO clinical program, which increased the total contract value to $39,081. In conjunction with this Agreement, APT is subject to an assessment fee of an amount equal up to 3% of the total funded value of the research project award which should be paid by the Company upon signing the agreement or the modifications. For the period between the Acquisition and September 30, 2024, the Company received grants of $2,895 from MTEC with respect to the cost reimbursement contract. During the nine and three months ended September 30, 2024, the Company recorded $1,802 and $849 as a reduction of R&D expenses, net, respectively. The remainder of the consideration the Company is entitled to receive is recorded as other current assets in the condensed consolidated financial statements. See Note 14B for information regarding grants received subsequent to the financial statement date. Â NOTE 9 â€“ LONG-TERM DEBT Â On August 16, 2021 (the â€œClosing Dateâ€), the Company entered into a Loan and Security Agreement (the â€œLoan Agreementâ€) with Hercules Capital, Inc. (â€œHerculesâ€), with respect to a venture debt facility. Under the Loan Agreement, $15,000 was advanced to the Company on the date the Loan Agreement was executed. The Company was required to make interest only payments through March 1, 2023, and started to then repay the principal balance and interest in equal monthly installments through September 1, 2025. Â The Loan Agreement provided that the Company could prepay advances under the Loan Agreement, in whole or in part, at any time subject to a prepayment charge equal to 1.0% after 24 months but prior to 36 months following the Closing Date. Upon prepayment or repayment of all or any of the term loans under the Term Loan Facility, the Company was required to pay an end of term charge (â€œEnd of Term Chargeâ€) equal to 6.55% of the total aggregate amount of the term loans being prepaid or repaid. On March 19, 2024, the Company prepaid the entire balance under the Term Loan Facility in a total of $10,428. The prepayment included the End of Term Charge of $983 and accrued interest of $69. The Company received from Hercules a waiver regarding the prepayment charge that should have been 1% out of the prepaid principal amount that equals to $94. Â Interest expense relating to the term loan, which is included in interest expense in the condensed statements of operations was $850 for the nine months ended September 30, 2024. No interest expense was recognized in connection with the term loan for the three months ended September 30, 2024. Interest expense for the nine and three months ended September 30, 2023, was $1,884 and $574, respectively. Â F-18 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 10 â€“ STOCKHOLDERS EQUITY Â Â A. Share Capital: Â Reverse Stock Split: Â On July 9, 2024, the Companyâ€™s stockholders approved a reverse stock split at a ratio within a range ofÂ 1-for-5 andÂ 1-for-10 at such time as the Board of Directors shall determine, in its sole discretion, at any time before July 9, 2025. On August 8, 2024, the Board of Directors approved a 1-for-10 Reverse Stock Split of the Companyâ€™s shares of Common Stock (the â€œReverse Stock Splitâ€). Â On August 20, 2024, the Company filed the Certificate of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, which became effective on August 26, 2024 (the â€œEffective Dateâ€). The Companyâ€™s Common Stock began trading on a Reverse Stock Split adjusted basis on the NYSE American at the opening of the markets on the Effective Date. Â As a result of the Reverse Stock Split, the number of shares of Common Stock outstanding was reduced from 178,958,447Â shares to 18,021,173Â shares. No fractional shares of Common Stock or Units were issued in connection with the Reverse Stock Split. Stockholders of the Company who otherwise were entitled to receive fractional shares or Units, because they held a number of shares or Units, as applicable, not evenly divisible by the Reverse Stock Split ratio were automatically entitled to receive an additional fraction of a share of the Common Stock or Unit, as applicable, to round up to the next whole share. As a result, 125,328 shares of Common Stock were issued. The Reverse Stock Split did not change the par value of the Common Stock nor the authorized number of shares of Common Stock, preferred stock or any series of preferred stock. Â Unless otherwise indicated, all amounts of issued and outstanding stock contained in the accompanying condensed consolidated financial statements have been adjusted to reflect theÂ 1-for-10 Reverse Stock Split for all prior periods presented.Â Proportional adjustments were also made to shares underlying outstanding equity awards, warrants and Redeemable Convertible Preferred Shares, and to the number of shares issued and issuable under the Companyâ€™s stock incentive plans and certain existing agreements. Â Authorized shares of common stock: Â On July 9, 2024, the Companyâ€™s stockholders approved increasing the number of authorized shares of Common Stock from 120,000,000 shares, par value $0.0001 per share, to 750,000,000 shares, par value $0.0001 per share. Â Preferred Stock: Â The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Companyâ€™s Board of Directors (the â€œBoardâ€). Â On March 15, 2024, the Company issued 40,470 and 216,417 Redeemable Convertible Preferred Shares, par value $0.0001 per share, as part of the Acquisition and the March 2024 PIPE, respectively. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares were converted into 10,915,200 shares of the Companyâ€™s Common Stock. Â F-19 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 10 â€“ STOCKHOLDERS EQUITY (Cont.) Â Private Investment in Public Equity: Â On February 22, 2023, the Company entered into a Securities Purchase Agreement to issue and sell an aggregate of 1,599,746 shares of its Common Stock and 1,461,072 pre-funded warrants (the â€œPre-Funded Warrantsâ€) at a price of $2.45 per share and $2.44 per Pre-Funded Warrant in a private placement (the â€œFebruary 2023 PIPEâ€). The net proceeds from the PIPE were approximately $7,152, after deducting issuance costs of $333. During the nine months ended September 30, 2024, 533,031 Pre-Funded Warrants were exercised into 533,031 shares of Common Stock for total consideration of $6 at an exercise price of $0.01 per share of Common Stock, and 928,041 Pre-Funded Warrants were exercised into 925,607 shares of Common Stock through cashless mechanism with no consideration. As of September 30, 2024, there are no outstanding Pre-Funded Warrants. Â On March 15, 2024, in connection with the Acquisition, the Company issued to APTâ€™s former stockholders 916,497 shares of the Companyâ€™s Common Stock, 40,470 Redeemable Convertible Preferred Shares and Merger Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock. See Note 1D for further information. Â Concurrently with the consummation of the Acquisition as described in Note 1D, the Company entered into the March 2024 PIPE, pursuant to which such investors purchased an aggregate of 216,417 Redeemable Convertible Preferred Shares (â€œPIPE Preferred Sharesâ€) and Private Placement Warrants to purchase up to an aggregate of 10,820,850 shares of the Companyâ€™s Common Stock, at a combined price of $231.10 per share. The PIPE Preferred Shares and the Private Placement Warrants were issued in a private placement pursuant to an exemption from registration requirements under the Securities Act for aggregate gross proceeds of $50,000. Each Private Placement Warrantâ€™s exercise price equals to $2.31, subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on July 9, 2026. Under certain circumstances, the Company may be required to pay to each holder of the Private Placement Warrants (i) an amount in cash equal to the holderâ€™s total purchase price for the shares of Common Stock purchased (the â€œBuy-In Priceâ€) or credit such holderâ€™s balance account with the Depository Trust Company (â€œDTCâ€) for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation to deliver to such holder a certificate or certificates representing such shares of Common Stock or credit such holderâ€™s balance account with DTC, as applicable, and pay cash to such holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) Weighted Average Price (as defined in the Private Placement Warrant) on the trading day immediately preceding the exercise date. Â The Company accounted for the Private Placement Warrants as liabilities as the Private Placement Warrants are not considered indexed to the entityâ€™s own stock based on the provision of ASC 815. The Private Placement Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized in the condensed consolidated statements. Â The terms of the PIPE Preferred Shares are substantially the same as those of the Redeemable Convertible Preferred Shares issued under the Acquisition and were accounted for as temporary equity at the issuance date and were reclassified as equity. See Note 1D for further information. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Companyâ€™s Common Stock according to beneficial ownership limitations set by certain investors. Â In connection therewith, the Company issued warrants to purchase shares of the Companyâ€™s Common Stock to the Placement Agents (the â€œAgents Warrantsâ€). See Note 10B for further information. Â The Company allocated the total consideration from the issuance of the 2024 March PIPE first to the fair value of the Private Placement Warrants and then to the PIPE Preferred Shares. The Company had transaction costs of approximately $3,317 out of which $1,273 is Stock-Based Compensation due to issuance of the Agents Warrants. The transaction costs were allocated in the same manner as the consideration. Issuance costs which were allocated to the PIPE Preferred Shares were $1,410 and deducted from Redeemable Convertible Preferred Shares, and issuance costs that were allocated to the Private Placement Warrants were $1,907 and were expensed immediately. Â At-the-Market Sales Agreement:Â Â Â In December 2023, pursuant to a registration statement on Form S-3 declared effective by the SEC on January 2, 2024, the Company entered an At the Market Offering Agreement with H.C. Wainwright & Co., LLC (â€œWainwrightâ€), pursuant to which the Company may issue and sell shares of Common Stock having an aggregate offering price of up to $7,500 from time to time through Wainwright. During the nine months ended September 30, 2024, the Company sold 7,518 shares of Common Stock under this agreement, at an average price of $2.71 per share, raising aggregate net proceeds of approximately $19, after deducting an aggregate commission of $1.Â F-20 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 10 â€“ STOCKHOLDERS EQUITY (Cont.) Â Warrants: Â As of SeptemberÂ 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders: Â WarrantÂ Issuance DateÂ Expiration DateÂ Exercise Price Per ShareÂ Â Number of Shares of CommonÂ Stock Underlying WarrantsÂ Public WarrantsÂ IPO (December 13, 2018)Â October 28, 2024Â Â 115.00Â Â Â 350,000Â 2021 Registered Direct Offering WarrantsÂ SPA (July 28, 2021)Â January 28, 2027Â Â 50.00Â Â Â 281,251Â Merger WarrantsÂ March 15, 2024Â January 28, 2027Â Â 50.00Â Â Â 216,650Â Private Placement WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 10,820,850Â Agents WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 952,381Â Â Â Â Â Â Â Â Â Â Â Â Â Â 12,621,132Â Â Â B. Stock-based Compensation: Â Â On March 15, 2024, the Company issued Agents Warrants to purchase up to an aggregate of 952,381 shares of the Companyâ€™s Common Stock to the Placement Agents in connection with the March 2024 PIPE. The exercise price of the Agents Warrants is $2.31 per share and they became exercisable at any time after the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on July 9, 2026. Â The Company accounted for the Agents Warrants under the scope of ASC 718-10 â€œStock-Based Paymentâ€, (â€œASC 718-10â€), and treated them as issuance costs of the March 2024 PIPE as the Company considers these Warrants as consideration for receipt of Private Placement Services. Â The Company determined the fair value of the Agents Warrants using the

Black-Scholes model as of March 5, 2024. The main assumptions used are as follows: Â Underlying value of Common Stock ($)Â Â 2.31Â Exercise price ($)Â Â 2.31Â Expected volatility (%)Â Â 100.6Â Expected terms (years)Â Â 2.32Â Risk-free interest rate (%)Â Â 4.4Â Â On July 9, 2024, the Companyâ€™s stockholders approved increasing the number of shares of Common Stock under the Companyâ€™s 2019 Omnibus Long-Term Incentive Plan (the â€œ2019 Planâ€) to be equal to 15% of the total number of fully-diluted shares of Common Stock outstanding as of the approval date, or 7,800,000 shares. Â On September 16, 2024, the Company granted 155,429 RSUs to four senior officers and one service provider. The RSUs were fully vested and issued on the grant date and are not subject to continued service to the Company. The RSUsâ€™ fair value is the Companyâ€™s stock closing price as of the grant date, which was $0.99. As of September 30, 2024, the Company has no unvested RSUs. Â On July 11, 2024, the Board of Directors approved the grant of 1,567,795 options to 51 employees, six senior officers and seven directors under the 2019 Plan, without consideration. Options were granted at an exercise price of $3.63 per share with a vesting period of four years. Directors and senior officers are entitled to full acceleration of their unvested options upon the occurrence of both a change in control of the Company and the end of their engagement with the Company.Â F-21 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTE 10 â€“ STOCKHOLDERS EQUITY (Cont.) Â Â Â A summary of options granted to purchase the Companyâ€™s Common Stock under the Companyâ€™s share option plans is as follows: Â Â Â For the Nine Months Ended SeptemberÂ 30, 2024Â Â Â Number of OptionsÂ Â Weighted Average Exercise PriceÂ Â Aggregate Intrinsic ValueÂ Outstanding at the beginning of periodÂ Â 528,112Â Â Â 5.41Â Â Â 72Â GrantedÂ Â 1,567,795Â Â Â 3.63Â Â Â Â Â ForfeitedÂ Â (26,808)Â Â Â 3.96Â Â Â Â Â ExpiredÂ Â (6,449)Â Â Â 4.58Â Â Â Â Â ExercisedÂ Â -Â Â Â -Â Â Â Â Â Outstanding at the end of periodÂ Â 2,062,650Â Â Â 4.08Â Â Â 22Â Exercisable at the end of periodÂ Â 351,109Â Â Â 5.79Â Â Â Â Â Weighted average remaining contractual life of outstanding options â€“ years as of September 30, 2024Â Â 8.85Â Â Â Â Â Â Â Â Â Â Warrants: Â As of September 30, 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock: Â WarrantÂ Issuance DateÂ Expiration DateÂ Â Exercise Price Per ShareÂ Â Number of Shares of CommonÂ Stock Underlying WarrantsÂ Private Warrants issued to scientific foundersÂ November 27,Â 2017Â Â -Â Â Â -Â Â Â 298Â Landlord Warrants*Â March 15,Â 2024Â Â January 28, 2027Â Â Â 50.00Â Â Â 25,000Â Â Â Â Â Â Â Â Â Â Â Â Â 25,298Â Â Â (*) See Note 6. Â Â The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations: Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Â Research and development expenses, netÂ Â 273Â Â Â 31Â Â Â 336Â Â Â 202Â General and administrativeÂ Â 556Â Â Â 164Â Â Â 747Â Â Â 439Â Â Â Â 829Â Â Â 195Â Â Â 1,083Â Â Â 641Â Â F-22 Â Â BIOMX INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (USD and NIS in thousands, except share and per share data) (unaudited) Â NOTEÂ 11 â€“ BASIC AND DILUTED LOSS (EARNINGS) PER SHARE Â Basic loss (earnings) per share is computed on the basis of the net loss (income) for the period divided by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Companyâ€™s Common Stock and fully vested Pre-Funded Warrants for the Companyâ€™s Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. Â Diluted loss per share is based upon the weighted average number of shares of Common Stock and of potential shares of Common Stock outstanding when dilutive. Potential shares of Common Stock equivalents include outstanding stock options and warrants, which are included under the treasury stock method when dilutive. Â The calculation of diluted loss per share for the nine and three months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023, does not include the shares underlying the following financial instruments because their effect would be anti-dilutive: Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â Â 2024Â Â Â 2023Â Â Â 2024Â Â Â 2023Â OptionsÂ Â 2,041,139Â Â Â 591,034Â Â Â 2,062,650Â Â Â 591,034Â WarrantsÂ Â 12,646,132Â Â Â 921,251Â Â Â 1,825,281Â Â Â 921,251Â Contingent sharesÂ Â 200,000Â Â Â 400,000Â Â Â 200,000Â Â Â 400,000Â Redeemable Convertible Preferred SharesÂ Â 14,773,500Â Â Â -Â Â Â 14,773,500Â Â Â -Â Â The following table presents the computation of basic and diluted loss (earnings) per share: Â Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Basic loss (earnings) per share of common stockÂ Â Â Â Â Â Â Â Â

be administered via inhalation twice daily for a duration of 8 weeks. The study is designed to monitor the safety and tolerability of BX004 and is designed to demonstrate improvement in microbiological reduction of P.Â aeruginosa burden and evaluation of effects on clinical parameters such as lung function measured by FEV1 and patient reported outcomes. During the third quarter of 2024, we experienced manufacturing delays for BX004. As a result of these delays, study results are now expected in the first half of 2026.Â Â BX211 â€“ Treatment of Diabetic Foot Osteomyelitis, or DFO Â BX211 is a personalized phage therapy for the treatment of DFO associated with Staphylococcus aureus, or S. aureus, a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis. The personalized phage treatment tailors a specific phage selected from a proprietary phage-bank according to the specific strain of S. aureus biopsied and isolated from each patient. DFO is a bacterial infection of the bone that usually develops from an infected foot ulcer and is a leading cause of amputation in patients with diabetes. We believe that scientific literature demonstrating the potential benefit in treating osteomyelitis using phage in animal models as well as numerous successful compassionate cases using phage therapy to treat DFO patient support our approach of using phage therapy to treat DFO. Â The ongoing randomized, double-blind, placebo-controlled, multi-center Phase 2 trial investigating the safety, tolerability, and efficacy of BX211 for subjects with DFO associated with S. aureus has finished enrollment for a randomized at a 2:1 ratio to BX211 or placebo. BX211 or placebo is designed to be administered weekly, by topical and IV route at week 1 and by the topical route only at each of weeks 2-12. Over the 12-week treatment period, all subjects are expected to continue to be treated in accordance with standard of care which will include antibiotic treatment as appropriate. A first readout of study topline results is expected at week 13 evaluating healing of the wound associated with osteomyelitis, followed by a second readout at week 52 evaluating amputation rates and resolution of osteomyelitis based on X-ray, clinical assessments, and established biomarkers (Erythrocyte Sedimentation Rate and C-Reactive Protein). These readouts are expected in the first quarter of 2025 and the first quarter of 2026, respectively. Â Non-CF Bronchiectasis, or NCFB Â ChronicÂ P. aeruginosaÂ infections in NCFB patients are a main contributor to morbidity and mortality in this disease. Pending positive data of BX004 in our cystic fibrosis Phase 2B study, we expect to look to initiate studies into NCFB as an additional indication for BX004. Â National Institutes of Health, or NIH, study in Cystic Fibrosis Â We are supporting a study conducted by the NIH and The Antibacterial Resistance Leadership Group targeting P. Aeruginosa infections in CF patients under FDA emergency Investigational New Drug allowance. Phase 1b/2, multi-centered, randomized, double-blind, placebo-controlled trial is assessing the safety and microbiological activity of a single IV dose of bacteriophage therapy in cystic fibrosis subjects colonized with P. aeruginosa. Â 4 Â Â Programs on hold Â Prosthetic Joint Infections, or PJI Â Our personalized phage therapy for treating PJI targets multiple bacterial organisms such as Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. This treatment was granted Orphan-drug designation by the FDA in July 2020. As of the date of this Quarterly Report, we have paused development efforts of this program due to prioritizing resources towards our CF and DFO programs, and we cannot provide guidance on resuming its development. Â Discontinued programs Â BX005 â€“ Treatment of Atopic Dermatitis, or ADÂ Â BX005 is our topical phage product candidate targeting S. aureus. S. aureusÂ is more abundant on the skin of AD patients than on the skin of healthy individuals and on lesional skin than non-lesional skin. It also increases in abundance, becoming the dominant bacteria, when patients experience flares. By reducing the load ofÂ S. aureus, BX005 is designed to shift the skin microbiome composition to its â€˜pre-flareâ€™ state and potentially provide a clinical benefit. In preclinical in vitro studies, BX005 was shown to eradicate over 90% of strains, including antibiotic resistant strains, from a panel of S. aureus strains (120 strains isolated from skin of subjects from the U.S. and Europe). On April 8, 2022, the FDA approved the Companyâ€™s IND application for BX005. Â In 2024, we discontinued the development of BX005, choosing instead to focus our resources on our Cystic Fibrosis and DFO programs. Â Consolidated Results of OperationsÂ Â Comparison of the Three Months Ended September 30, 2024 and 2023 Â The following table summarizes our consolidated results of operations for the three months ended September 30, 2024 and 2023: Â Â Â Three Months ended September 30,Â Â Â 2024Â Â Â Â 2023Â Â Â USD in thousandsÂ Research and development (â€œR&Dâ€) expenses, netÂ Â 7,279Â Â Â 5,641Â General and administrative expensesÂ Â 3,248Â Â Â 2,154Â Goodwill impairmentÂ Â 801Â Â Â -Â Operating lossÂ Â 11,328Â Â Â 7,795Â Other incomeÂ Â (84)Â Â (89) Interest expensesÂ Â 5Â Â Â 574Â Income from change in fair value of Private Placement WarrantsÂ Â 20,559)Â Â -Â Finance income, netÂ Â (332)Â Â (382) Loss (income) before taxÂ Â 9,642)Â Â 7,898Â Tax expensesÂ Â -Â Â Â 8Â Net loss (income)Â Â 9,642Â Â Â 7,906Â Basic loss (income) per share of Common StockÂ Â (0.31)Â Â 1.30Â Diluted loss (income) per share of Common StockÂ Â (0.31)Â Â 1.30Â Weighted average number of shares of Common Stock outstanding, basicÂ Â 16,366,122Â Â Â 6,058,774Â Weighted average number of shares of Common Stock outstanding, dilutedÂ Â 16,387,633Â Â Â 6,058,774Â Â 5 Â Â R&D expenses, net (net of grants received from the Israel Innovation Authority (â€œIIAâ€) and the Medical Technology Enterprise Consortium (â€œMTECâ€), and consideration from research collaborations) were $7.3 million for the three months ended September 30, 2024, compared to $5.6 million for same period in 2023. The increase of $1.7 million, or 30%, is primarily due to the following factors: Â â—preparations for Phase 2b in the clinical trial of our CF product candidate, BX004, Â Â â— an increase in expenses relating to the clinical trial of our DFO product candidate, BX211; and Â Â â— an increase in rent and related expenses following the APT Acquisition. Â Â The increase was partly offset by higher grants received. During the three months ended September 30, 2024, the Company recorded $0.9 million of MTEC grants, compared to $0.2 million of IIA grants recorded in the same period in 2023. Â General and administrative expenses were $3.2 million for the three months ended September 30, 2024, compared to $2.2 million for the three months ended September 30, 2023. The increase of $1.0 million, or 45%, is primarily attributed to a full quarter consolidation of expenses following the Acquisition, incorporating the combined workforce, increased professional services, and additional subcontractor expenses. Â Goodwill impairment was $0.8 million for the three months ended September 30, 2024, following an impairment of the Companyâ€™s goodwill that resulted from the Acquisition. The Companyâ€™s market capitalization as of September 30, 2024, was lower in comparison to its stockholdersâ€™ equity and triggered an impairment assessment that concluded that the entire goodwill should be impaired. Â Other income was $0.1 million for each of the three months ended September 30, 2024 and September 30, 2023 and consisted proceeds from a sublease agreement for a portion of our office space in Ness Ziona, Israel. Â Interest expenses were $5,000 for the three months ended September 30, 2024, compared to $574,000 for the three months ended September 30, 2023. The decrease of $569,000, or 99%, is due to repayment of the loan under the Loan and Security Agreement, or the Hercules Loan Agreement, with Hercules Capital, Inc., or Hercules, in March 2024. Â Income from change in fair value of Private Placement Warrants reflects the revaluation that resulted from the accounting of the Private Placement Warrants issued under the March 2024 PIPE. Â There was no material change to Finance income that impacted earnings for the three months ended September 30, 2024 compared to the three months ended September 30, 2023. Â Basic and diluted earnings per share of Common Stock was $0.31 for the three months ended September 30, 2024, compared to loss per share of $1.30 for the three months ended September 30, 2023. The increase of $1.61 resulted from the revaluation of the Private Placement Warrants. Such increase was partly offset due to share issuances as part of the Acquisition and the Redeemable Convertible Preferred Sharesâ€™ conversion into shares of Common Stock. Â 6Â Â Comparison of the Nine Months Ended September 30, 2024 and 2023 Â The following table summarizes our consolidated results of operations for the nine months ended September 30, 2024 and 2023: Â Â Â Nine Months ended September 30,Â Â Â 2024Â Â 2023Â Â Â Â USD in thousandsÂ R&D expenses, net Â Â 18,281Â Â Â 14,023Â General and administrative expenses Â Â 8,756Â Â Â 6,053Â Goodwill impairment Â Â 801Â Â Â -Â Operating loss Â Â 27,838Â Â Â 20,076Â Other income Â Â (2,189)Â Â (270) Interest expenses Â Â 868Â Â Â 1,884Â Income from change in fair value of Private Placement Warrants Â Â (24,417)Â Â -Â Finance expense (income), net Â Â 1,104Â Â Â (1,034) Loss before tax Â Â 3,204Â Â Â 20,656Â Tax expenses Â Â 10Â Â Â 22Â Net loss Â Â 2,214Â Â Â 20,678Â Basic loss per share of Common Stock Â Â 0.32Â Â Â 4.29Â Diluted loss per share of Common Stock Â Â 2.45Â Â Â 4.29Â Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock Â Â 9,944,267Â Â Â 4,819,658Â Weighted average number of shares used in computing diluted loss (earnings) per share of Common Stock Â Â 11,294,880Â Â Â 4,819,658Â Â R&D expenses, net (net of grants received from IIA and MTEC, and consideration from research collaborations) were $18.3 million for the nine months ended September 30, 2024, compared to $14.0 million for the nine months ended September 30, 2023. The increase of $4.3 million, or 31%, is primarily due to the following factors: Â â—Increased expenses relating to the clinical trial of our DFO product candidate, BX211; and Â â—Increased expenses relating to the combined workforce and rent expenses following the Acquisition Â Such increase was partly offset by completing the enrollment and follow-up period of patients in the clinical trial of our CF product candidate, BX004. During the nine months ended September 30, 2024, the Company recorded $1.8 million of MTEC grants, compared to $1.3 million of IIA grants for the same period in 2023. Â General and administrative expenses were $8.8 million for the nine months ended September 30, 2024, compared to $6.1 million for the same period in 2023. The increase of $2.7 million, or 44%, is primarily due to issuance costs and legal services expenses related to the Acquisition and the March 2024 PIPE agreement. as well as due to increased salaries and related expenses resulting from the combined workforce following the Acquisition. Â Goodwill impairment was $0.8 million for the nine months ended September 30, 2024, following an impairment of the Companyâ€™s goodwill resulted from the Acquisition. The Companyâ€™s market capitalization as of September 30, 2024, was lower in comparison to its stockholdersâ€™ equity and triggered an impairment assessment that concluded that the entire goodwill should be impaired. Â Â Other income was $2.2 million for the nine months ended September 30, 2024, compared to $0.3 million for the nine months ended September 30, 2023. The increase of $1.9 million, or 633%, is primarily due to the reversion of the contract liability associated with the Companyâ€™s AD program which has been paused. Â Interest expenses were $0.9 million for the nine months ended September 30, 2024, compared to $1.9 million for the nine months ended September 30, 2023. The decrease of $1.0 million, or 53%, is due to the repayment of the loan under the Loan and Security Agreement in March 2024. Â Income from change in fair value of Private Placement Warrants reflects the revaluation that resulted from the accounting of the Private Placement Warrants issued under the March 2024 PIPE. Â 7Â Â Finance expenses, net were $1.1 million for the nine months ended September 30, 2024, compared to Finance income, net of $1.0 million for the nine months ended September 30, 2023. The increase of $2.1 million resulted mainly from the Private Placement Warrants transaction costs. Â Basic loss per share of Common Stock was $0.27 for the nine months ended September 30, 2024, compared to $4.29 for the nine months ended September 30, 2023. The decrease in loss per share of $4.02, or 94%, is primarily attributable to an increase in outstanding shares resulting from the share issuance as part of the Acquisition and the Redeemable Convertible Preferred Sharesâ€™ conversion into shares of Common Stock. In addition, the income resulting from the Private Placement Warrants revaluation has led to a decreased net loss. Â Diluted loss per share of Common Stock was $2.45 for the nine months ended September 30, 2024, compared to diluted loss per share of $4.29 for the nine months ended September 30, 2023. The decrease of $1.84 resulted from the increased number of potential shares of Common Stock that would have been issued upon exercises of the Private Placement Warrants from the March 2024 PIPE. Â Liquidity and Capital ResourcesÂ Â We believe our cash and cash equivalents and short-term deposits on hand will be sufficient to meet our working capital and capital expenditure requirements into the fourth quarter of 2025. We currently plan to continue to focus primarily on the development of BX004, our product candidate for treating CF and BX211, our product candidate for treating DFO. Although we recently completed the 2024 March PIPE, in the future we will likely require or desire additional funds to support our operating expenses and capital requirements. Accordingly, we are implementing cost cutting measures, and exploring and expect to further explore, raising such additional funds through public or private equity, debt financing, loans, government or other grants or collaborative agreements or from other sources, as well as under the 2023 ATM Agreement discussed below. If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited. If there are increases in operating costs for facilities expansion, research and development and clinical activity, we will need to use mitigating actions such as to seek additional financing or postpone expenses that are not based on firm commitments. If certain disruptions due to, for instance, the war with Hamas and Hezbollah, or Israeli political instability persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity to support our operating expenses and capital requirements. As a result of these factors, management believes that there is substantial doubt as to the Companyâ€™s ability to continue as a going concern. Â Cash Flows Â The following table summarizes our sources and uses of cash for the nine months ended September 30, 2024 and 2023: Â Â Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â Â USD in thousandsÂ Net cash used in operating activitiesÂ Â (30,690)Â Â (15,044) Net cash provided by investing activitiesÂ Â 716Â Â Â 1,957Â Net cash provided by financing activitiesÂ Â 38,772Â Â Â 4,223Â Net increase (decrease) in cash and cash equivalentsÂ Â 8,798Â Â Â (8,864) Effect of exchange rate changes on cash and cash equivalents and restricted cashÂ Â (11)Â Â (37) Â Operating Activities Â Net cash used in operating activities for the nine months ended September 30, 2024 was $30.7 million, primarily driven by our R&D, general and administrative expenses, as well as changesÂ in our operating assets and liabilities of $4.0 million, offset by non-cash charges of $23.5 million. Non-cash charges for the nine months ended September 30, 2024 consisted primarily of income from change in fair value of the Private Placement Warrants of $24.4 million and income from change in contract liability in amount of $2.0 million resulting from pausing the Companyâ€™s AD program. Additionally, there were depreciation and amortization expenses of $0.9 million, Private Placement Warrants issuance costs of $0.7 million and Goodwill impairment of $0.8 million. Net changes in our operating assets and liabilities consisted primarily of a decrease in trade account payable of $2.7 million, as well as a decrease in other accounts payable of $0.9 million and a decrease in other current and non-current assets of $0.2 million. Â Net cash used in operating activities for the nine months ended September 30, 2023 was $15.0 million primarily due to a net loss of $20.7 million, mostly due to our R&D and general and administrative expenses, and due to changes in our operating assets and liabilities of $4.2 million, offset by non-cash charges of $1.4 million. Non-cash charges for the nine months ended September 30, 2023 consisted primarily of depreciation and amortization expenses of $0.7 million, stock-based compensation expenses of $0.6 million and amortization of debt issuance costs of $0.4 million, partly offset by finance income of $0.3 million. Net changes in our operating assets and liabilities consisted primarily of an increase in other accounts payable of $3.3 million, due to expenses related to conducting the clinical trial of our CF product candidate, BX004, and an increase in trade account payables of $0.2 million, partially offset by a decrease in other current assets in the amount of $0.7 million. Â Â 8Â Â Investing Activities Â During the nine months ended September 30, 2024, net cash provided by investing activities was $0.7 million, mainly consisting of cash and restricted cash acquired from the Acquisition. Â During the nine months ended September 30, 2023, net cash provided by investing activities was $2.0 million, mainly consisting of proceeds from short-term deposits of $2.0 million. Â Â We have invested, and plan to continue to invest, our existing cash in short-term investments in accordance with our investment policy. These investments may include money market funds and investment securities consisting of U.S. Treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises. We use foreign exchange contracts (mainly options and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, we record gains or losses that offset the revaluation of the balance sheet items under financial income, net in our condensed consolidated statements of operations.Â As of September 30, 2024, we had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $3.4 million with a fair value asset of $15,000. As of September 30, 2023, we had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $3.8 million with a fair value of $33,000. Â Â Financing Activities Â During the nine months ended September 30, 2024, net cash provided by financing activities was $39.0 million, mainly consisting of the issuance of Redeemable Convertible Preferred Shares and the Private Placement Warrants in the March 2024 PIPE in the amount of $20.8 million, net of issuance costs and $28.7 million, respectively. This was partially offset by the prepayment of the long-term debt in the amount of $10.7 million under the Hercules Loan Agreement. Â During the nine months ended September 30, 2023, net cash provided by financing activities was $4.2 million, mainly consisting of the issuance of Common Stock under the Securities Purchase Agreement we entered into in February 2023, of $7.2 million net of issuance costs, partially offset by the repayment of long-term debt of $2.9 million under the Hercules Loan Agreement. Â Â Under the Hercules Loan Agreement, Hercules provided the Company with access to a term loan with an aggregate principal amount of up to $30 million, or the Term Loan Facility, available in three tranches, subject to certain terms and conditions. The first tranche of $15 million was advanced to us on the date the Hercules Loan Agreement was executed. The conditions for the second and third tranches were not reached and have expired. We were required to make interest only payments through March 1, 2023, and started to then repay the principal balance and interest in equal monthly installments. Interest on the Hercules Loan accrues at a per annum rate equal to the greater of (i) the Prime Rate as reported in The Wall Street Journal plus 5.70% and (ii) 8.95%. On March 19, 2024, the Company prepaid all the term loan under the Term Loan Facility in a total of $10,428,000. The prepayment included an end of term charge of $983,000 and accrued interest of $69,000. The Company received a waiver regarding the prepayment charge that should have been 1% out of the prepaid principal amount, equaling $94,000. Â On December 7, 2023, we filed a shelf registration statement on Form S-3, which was declared effective by the SEC on January 2, 2024. In addition, on December 7, 2023, we entered into an At the Market Offering Agreement, or the 2023 ATM Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, with Wainwright as manager, pursuant to which we may issue and sell shares of our Common Stock having an aggregate offering price of up to $7.5 million from time to time

through Wainwright. We are not obligated to make any sales of Common Stock under the 2023 ATM Agreement. From January 1, 2024 through November 12, 2024, we issued 7,518 shares of Common Stock pursuant to the 2023 ATM Agreement for aggregate gross proceeds of $19 thousand. Â On March 15, 2024, concurrently with the consummation of the Acquisition, we consummated the March 2024 PIPE with existing and new investors, resulting in aggregate gross proceeds of approximately $50 million, in which the investors purchased (i) an aggregate of 216,417 Redeemable Convertible Preferred Shares, convertible upon stockholder approval, which was obtained on July 9, 2024, into an aggregate of up to 21,641,700 shares of BiomX common stock, and (ii) the Private Placement Warrants, to purchase up to an aggregate of 10,820,850 shares of BiomX common stock, at a combined purchase price of $231.10 per share of Series X Preferred Stock and an accompanying Private Placement Warrant to purchase 50 shares of BiomX common stock. The Private Placement Warrants are exercisable at an exercise price of $2.311 per share and will expire on July 9, 2026. Â During the nine months ended September 30, 2024, 533,031 Pre-Funded Warrants were exercised into 533,031 shares of Common Stock for total consideration of $6,000 at an exercise price of $0.01 per share of Common Stock, and 928,041 Pre-Funded Warrants were exercised into 925,607 shares of Common Stock through cashless mechanism with no consideration. As of September 30, 2024, there are no outstanding Pre-Funded Warrants. Â 9 Â Â OutlookÂ Â We have accumulated a deficit of $166.2 million since our inception. To date, we have not generated revenue from our operations, and we do not expect to generate any significant revenues from sales of products in the next twelve months. Our cash needs may increase in the foreseeable future. We expect to generate revenues from the sale of licenses to use our technology or products, but in the short and medium terms any amounts generated are unlikely to exceed our costs of operations. According to our estimates and based on our current operating plans, our liquidity resources as of September 30, 2024, which consisted primarily of cash, cash equivalents, short-term deposits and restricted cash of approximately $24.7 million will be sufficient to fund our operations into the fourth quarter of 2025.Â Â Consistent with our ongoing R&D activities, we expect to continue to incur additional losses in the foreseeable future. To the extent we require funds above our existing liquidity resources in the medium and long term, we plan to fund our operations, as well as other development activities relating to additional product candidates, through future issuances of public or private equity, including under our 2023 ATM Agreement, issuance of debt securities, loans, and possibly additional grants from the IIA or other government or non-profit institutions. Our ability to raise additional capital in the equity and debt markets is dependent on a number of factors including, but not limited to, the market demand for our securities, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk Â As a smaller reporting company, we are not required to make disclosures under this Item. Â Item 4. Controls and Procedures Â We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation, as of the end of the period covered by this Quarterly Report, of the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of September 30, 2024. Â Changes in Internal Control over Financial Reporting Â There has been no change in our internal control over financial reporting, as that term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.Â Â 10 Â Â PART II - OTHER INFORMATION Â Item 1A. Risk Factors Â In addition to the other information set forth in this report, you should carefully consider the factors discussed in PartÂ I, â€œItem 1A. Risk Factorsâ€ in our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31, 2023 and in Part II, â€œItem 1A. Risk Factorsâ€ in our Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024, which could materially affect our business, financial condition or future results. Â There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023, filed with the SEC on April 4, 2024, and in our Quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 14, 2024, except as noted below. Â Risks Related to Our Operations in IsraelÂ Â Our research and development and other significant operations are located in Israel, and, therefore, our results may be adversely affected by political, economic and military instability in Israel, including the recent war with Hamas, Hezbollah and other terrorist organizations in the Middle East.Â Â Our executive offices and research and development facilities are located in Israel. In addition, the majority of our key employees and all of our officers are residents of Israel. Accordingly, political, geopolitical, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, several armed conflicts have taken place between Israel and its neighboring Arab countries, the Hamas (an Islamist terrorist militia and political group that controls the Gaza strip), the Hezbollah (an Islamist terrorist militia and political group based in Lebanon) and other terrorist organizations active in the region. These conflicts have involved missile strikes, drone strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions in Israel. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could negatively affect business conditions in Israel in general and our business in particular, and adversely affect our product development, operations and results of operations. Â In October 2023, Hamas terrorists infiltrated Israelâ€™s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israelâ€™s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israelâ€™s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, since the commencement of these events, there have been continued hostilities along Israelâ€™s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen, as described below). In April 2024 and September 2024, Israel experienced direct attacks from Iran, involving hundreds of drones and missiles launched towards various parts of the country, mostly targeting military bases. The Israeli defense systems, aided by international allies, successfully intercepted most of these attacks, minimizing physical damage and casualties. Such incidents contribute to regional instability and could potentially escalate into broader conflicts with Iran and its proxies in the Middle East, affecting Israelâ€™s political and trade relations, especially with neighboring countries and global allies. The situation remains fluid, and the potential for further escalation exists. Â In connection with the Israeli security cabinetâ€™s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service, including 6 employees, none of whom are management or key employees, who were called up for reserve service, of which 4 have since returned to work full time and their pre-war military reserve duty. So long as the war continues, our personnel may be called up for reserve service, whether for extended periods or periodically for short-term periods. Military service call ups that result in absences of personnel for extended periods of time may materially and adversely affect our business, prospects, financial condition and results of operations.Â Â Since the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our business operations. As such, our product and business development activities remain on track. However, the intensity and duration of Israelâ€™s current war against Hamas is difficult to predict at this stage, as are such warâ€™s economic implications on our business and operations and on Israelâ€™s economy in general. If the war extends for a long period of time or expands to other fronts, such as Lebanon, Syria and the West Bank, our operations may be adversely affected. Â Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our results of operations and the market price of our Common Stock, and could make it more difficult for us to raise capital. Â Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government has in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business. Â Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israelâ€™s judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects. Â 11 Â Â Â Item 6. Exhibits Â Â No. Â Description of Exhibit 3.1* Â Composite Copy of Amended and Restated Certificate of Incorporation of the Company, as amended to date (clean version). 3.2* Â Composite Copy of Amended and Restated Certificate of Incorporation of the Company, as amended to date. (marked version) 3.3 Â Amended and Restated Bylaws of the Company, as amended on April 11, 2024 (Incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed by the Company on April 11, 2024) 10.1* Â Form of Restricted Stock Unit Agreement under the Companyâ€™s 2019 Omnibus Long-Term Incentive Plan 31.1* Â Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) 31.2* Â Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) 32** Â Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 101.INS* Â Inline XBRL Instance Document. 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. 101.CAL* Â Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF* Â Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB* Â Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE* Â Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104* Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â *Filed herewith. **Furnished herewith. Â 12 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â BIOMX INC. Â Â Â Date: November 14, 2024 By: /s/ Jonathan Solomon Â Name:Â Jonathan Solomon Â Title: Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â Date: November 14, 2024 By: /s/ Marina Wolfson Â Name: Marina Wolfson Â Title: Chief Financial Officer Â Â (Principal Financial Officer and Principal Accounting Officer) Â Â 13 Â 166184000 false --12-31 Q3 0001739174 0001739174 2024-01-01 2024-09-30 0001739174 2024-11-12 0001739174 2024-09-30 0001739174 2023-12-31 0001739174 2024-07-01 2024-09-30 0001739174 2023-07-01 2023-09-30 0001739174 2023-01-01 2023-09-30 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001739174 us-gaap:CommonStockMember 2023-12-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001739174 us-gaap:RetainedEarningsMember 2023-12-31 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001739174 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001739174 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001739174 2024-01-01 2024-03-31 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001739174 us-gaap:CommonStockMember 2024-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001739174 us-gaap:RetainedEarningsMember 2024-03-31 0001739174 2024-03-31 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001739174 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001739174 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001739174 2024-04-01 2024-06-30 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001739174 us-gaap:CommonStockMember 2024-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001739174 us-gaap:RetainedEarningsMember 2024-06-30 0001739174 2024-06-30 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001739174 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001739174 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001739174 us-gaap:RedeemablePreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001739174 us-gaap:RetainedEarningsMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2022-12-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001739174 us-gaap:RetainedEarningsMember 2022-12-31 0001739174 2022-12-31 0001739174 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001739174 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001739174 2023-01-01 2023-03-31 0001739174 us-gaap:CommonStockMember 2023-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001739174 us-gaap:RetainedEarningsMember 2023-03-31 0001739174 2023-03-31 0001739174 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001739174 2023-04-01 2023-06-30 0001739174 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001739174 us-gaap:CommonStockMember 2023-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001739174 us-gaap:RetainedEarningsMember 2023-06-30 0001739174 2023-06-30 0001739174 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001739174 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001739174 us-gaap:CommonStockMember 2023-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001739174 us-gaap:RetainedEarningsMember 2023-09-30 0001739174 2023-09-30 0001739174 2024-03-15 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-03-15 2024-03-15 0001739174 phge:PrivatePlacementWarrantsMember 2024-03-15 2024-03-15 0001739174 us-gaap:CommonStockMember 2024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:RedeemableConvertiblePreferredStockMember 2024-03-15 2024-03-15 0001739174 phge:MergerWarrantsMember 2024-03-15 2024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001739174 phge:MergerWarrantsMember us-gaap:CommonStockMember 2024-03-15 0001739174 2024-03-15 2024-03-15 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-03-15 2024-03-15 0001739174 us-gaap:CommonStockMember 2024-03-15 2024-03-15 0001739174 phge:APTsStockholdersMember phge:PrivatePlacementWarrantsMember 2024-09-30 0001739174 phge:APTsStockholdersMember 2024-09-30 0001739174 phge:APTsStockholdersMember 2024-01-01 2024-09-30 0001739174 phge:MultiPeriodExcessEarningsMethodMPEEMMember 2024-07-09 2024-07-09 0001739174 phge:MultiPeriodExcessEarningsMethodMPEEMMember 2024-07-09 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember 2024-07-09 2024-07-09 0001739174 phge:PurchasePriceAllocationMember 2024-03-15 0001739174 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001739174 phge:MergerWarrantsMember 2024-01-01 2024-09-30 0001739174 phge:MergerWarrantsMember 2024-01-01 2024-09-30 0001739174 phge:MergerWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001739174 phge:MergerWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-09-30 0001739174 phge:MergerWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001739174 phge:MergerWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001739174 phge:MergerWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001739174 phge:AdaptivePhageTherapeuticsLLCMember 2024-01-01 2024-09-30 0001739174 srt:MinimumMember 2024-01-01 2024-09-30 0001739174 srt:MaximumMember 2024-01-01 2024-09-30 0001739174 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2024-01-01 2023-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001739174 us-gaap:FairValueInputsLevel3Member phge:MeasurementInputUnderlyingValueOfCommonStockMember 2024-09-30

0001739174 us-gaap:FairValueInputsLevel3Member phge:MeasurementInputUnderlyingValueOfCommonStockMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001739174 2019-08-09 0001739174 2019-08-09 2019-08-09 0001739174 phge:LeaseAgreementMember 2019-08-09 0001739174 phge:LeaseAgreementMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001739174 2021-08-31 2021-08-31 0001739174 phge:IsraelInnovationAuthorityMember 2024-09-30 0001739174 2022-03-31 2022-03-31 0001739174 2023-03-31 2023-03-31 0001739174 phge:CysticFibrosisProductMember 2024-01-01 2024-09-30 0001739174 phge:CysticFibrosisProductMember 2024-09-30 0001739174 2022-06-23 2022-06-23 0001739174 2024-01-18 2024-01-18 0001739174 phge:MTECMember 2024-09-30 0001739174 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-08-16 0001739174 phge:LoanAgreementMember 2024-09-30 0001739174 us-gaap:LineOfCreditMember 2024-01-01 2024-09-30 0001739174 2024-03-19 2024-03-19 0001739174 phge:LongTermDebtsMember 2024-03-19 2024-03-19 0001739174 phge:HerculesCapitalIncMember 2024-09-30 0001739174 srt:MaximumMember 2024-09-30 0001739174 srt:MinimumMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-07-09 0001739174 2024-07-09 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-03-15 2024-03-15 0001739174 phge:PIPEMember us-gaap:PreferredStockMember 2024-03-15 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2024-07-15 2024-07-15 0001739174 us-gaap:CommonStockMember 2024-07-15 2024-07-15 0001739174 us-gaap:PrivatePlacementMember 2023-02-22 0001739174 phge:PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2023-02-22 0001739174 srt:MaximumMember phge:PreFundedWarrantsMember 2023-02-22 0001739174 srt:MinimumMember phge:PreFundedWarrantsMember 2023-02-22 0001739174 phge:PreFundedWarrantsMember us-gaap:PrivatePlacementMember 2023-02-22 2023-02-22 0001739174 us-gaap:PrivatePlacementMember 2023-02-22 2023-02-22 0001739174 phge:PreFundedWarrantsMember 2024-09-30 0001739174 phge:PrivatePlacementWarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001739174 phge:PreFundedWarrantsMember us-gaap:CommonStockMember 2024-09-30 0001739174 phge:PreFundedWarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001739174 phge:PrivatePlacementWarrantsMember 2024-01-01 2024-09-30 0001739174 phge:PIPEMember phge:PrivatePlacementWarrantsMember 2024-09-30 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-09-30 0001739174 us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001739174 phge:March2024PIPEMember us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001739174 phge:March2024PIPEMember 2024-01-01 2024-09-30 0001739174 2023-12-31 2023-12-31 0001739174 phge:PIPEMember 2024-03-15 0001739174 phge:PIPEMember phge:AgentsWarrantsMember 2024-03-15 0001739174 2024-07-09 2024-07-09 0001739174 2024-09-16 2024-09-16 0001739174 srt:BoardOfDirectorsChairmanMember 2024-07-11 2024-07-11 0001739174 2024-07-11 2024-07-11 0001739174 phge:IPODecember132018Member phge:PublicWarrantsMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 phge:IPODecember132018Member phge:PublicWarrantsMember us-gaap:WarrantMember 2024-09-30 0001739174 phge:SPAJuly282021PMember phge:TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 phge:SPAJuly282021PMember phge:TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember us-gaap:WarrantMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:MergerWarrantsMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:MergerWarrantsMember us-gaap:WarrantMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:PrivatePlacementWarrantsMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:PrivatePlacementWarrantsMember us-gaap:WarrantMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:AgentsWarrantsMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMember phge:AgentsWarrantsMember us-gaap:WarrantMember 2024-09-30 0001739174 us-gaap:WarrantMember 2024-09-30 0001739174 us-gaap:BlackScholesMertonModelMember 2024-09-30 0001739174 us-gaap:BlackScholesMertonModelMember 2024-01-01 2024-09-30 0001739174 us-gaap:EmployeeStockMember 2023-12-31 0001739174 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001739174 us-gaap:EmployeeStockMember 2024-09-30 0001739174 us-gaap:WarrantMember phge:PrivateWarrantsIssuedToScientificFounderMember 2024-01-01 2024-09-30 0001739174 us-gaap:WarrantMember phge:PrivateWarrantsIssuedToScientificFounderMember 2024-09-30 0001739174 us-gaap:WarrantMember phge:LandlordWarrantsMember 2024-01-01 2024-09-30 0001739174 us-gaap:WarrantMember phge:LandlordWarrantsMember 2024-09-30 0001739174 us-gaap:WarrantMember 2024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001739174 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001739174 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001739174 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001739174 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001739174 phge:ContingentSharesMember 2024-07-01 2024-09-30 0001739174 phge:ContingentSharesMember 2023-07-01 2023-09-30 0001739174 phge:ContingentSharesMember 2024-01-01 2024-09-30 0001739174 phge:ContingentSharesMember 2023-01-01 2023-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-07-01 2024-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2023-07-01 2023-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-01-01 2024-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2023-01-01 2023-09-30 0001739174 us-gaap:SubsequentEventMember 2024-10-17 2024-10-17 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqm iso4217:ILS EX-3.1 2 ea022102501ex3-1_biomx.htm COMPOSITE COPY OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED TO DATE (CLEAN VERSION) Exhibit 3.1 Â BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION Â INCORPORATING: Â Amended and Restated Certificate of Incorporation filed December 13, 2018 Â Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Â Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Â Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 Â Certificate of Amendment of Certificate of Incorporation filed August 20, 2024 Â AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. Pursuant to Section 245 of the Delaware General Corporation Law Â FIRST:1 The name of the corporation is BiomX Inc. (hereinafter called the â€œCorporationâ€). Â SECOND: The registered office of the Corporation is to be located at 850 New Burton Road, Suite 201, in the City of Dover, in the County of Kent, 19904. The name of its registered agent at that address is Cogency Global Inc. Â THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (â€œGCLâ€). Â FOURTH: The name and mailing address of the incorporator is: Jaszick Maldonado, c/o Loeb & Loeb LLP, 345 Park Avenue, New York NY 10154. Â FIFTH:2 The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is 751,000,000, of which 750,000,000 shares shall be common stock, par value $.0001 per share (â€œCommon Stockâ€) and 1,000,000 shares shall be preferred stock, par value $.0001 per share (â€œPreferred Stockâ€). Subject to this Certificate of Amendment becoming effective pursuant to the General Corporation Law of the State of Delaware, at 12:01 a.m. on August 26, 2024 (the â€œEffective Timeâ€), the shares of Common Stock issued and outstanding or held in treasury immediately prior to the Effective Time (the â€œOld Common Stockâ€) shall be reclassified as and converted into a different number of shares of Common Stock (the â€œNew Common Stockâ€) such that each ten shares of Old Common Stock shall, at the Effective Time, be automatically reclassified as and converted into one share of New Common Stock (the â€œReverse Stock Splitâ€). From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of whole shares of New Common Stock into which such Old Common Stock shall have been reclassified pursuant to this Certificate of Amendment. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. Fractional share resulting from the Reverse Stock Split will be rounded up to the next whole share. Â A. Preferred Stock. The Board of Directors is expressly granted authority to issue shares of the Preferred Stock, in one or more series, and to fix for each such series such voting powers, full or limited, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issue of such series (a â€œPreferred Stock Designationâ€) and as may be permitted by the GCL. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, without a separate vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to any Preferred Stock Designation. Â B. Common Stock. Except as otherwise required by law or as otherwise provided in any Preferred Stock Designation, the holders of the Common Stock shall exclusively possess all voting power and each share of Common Stock shall have one vote. Â 1This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed October 28, 2019. 2This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed August 20, 2024. Â 1 Â Â SIXTH: This Article Sixth shall apply during the period commencing upon the filing of this Certificate of Incorporation and terminating upon the consummation of any â€œBusiness Combinationâ€ (as defined below). A â€œBusiness Combinationâ€ shall mean any merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination involving the Corporation and one or more businesses or entities (â€œTarget Businessâ€), or entering into contractual arrangements that give the Corporation control over such a Target Business, and, if the Corporation is then listed on a national securities exchange, the Target Business has a fair market value equal to at least 80% of the balance in the Trust Fund (defined below), less any taxes payable on interest earned, at the time of signing a definitive agreement in connection with the initial Business Combination. â€œIPO Sharesâ€ shall mean the shares sold pursuant to the registration statement on Form S-1 (â€œRegistration Statementâ€) filed with the Securities and Exchange Commission (â€œCommissionâ€) in connection with the Corporationâ€™s initial public offering (â€œIPOâ€). The â€œfair market valueâ€ for purposes of this Article Sixth will be determined by the Board of Directors of the Corporation based upon one or more standards generally accepted by the financial community (such as actual and potential sales, earnings, cash flow and/or book value). If the Board of Directors is unable to independently determine the fair market value of the Target Business, the Corporation will obtain an opinion from an independent investment banking firm, or another independent entity that commonly renders valuation opinions, with respect to the satisfaction of such criteria. Â A. Prior to the consummation of a Business Combination, the Corporation shall either (i) submit any Business Combination to its holders of Common Stock for approval (â€œProxy Solicitationâ€) pursuant to the proxy rules promulgated under the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€), or (ii) provide its holders of IPO Shares with the opportunity to sell their shares to the Corporation by means of a tender offer (â€œTender Offerâ€). Â B. If the Corporation engages in a Proxy Solicitation with respect to a Business Combination, the Corporation will consummate the Business Combination only if a majority of the then outstanding shares of Common Stock present and entitled to vote at the meeting to approve the Business Combination are voted for the approval of such Business Combination. Â C. In the event that a Business Combination is consummated by the Corporation or the Corporation holds a vote of its stockholders to amend its Certificate of Incorporation, any holder of IPO Shares who (i) voted on the proposal to approve such Business Combination or amend the Certificate of Incorporation, whether such holder voted in favor or against such Business Combination or amendment, and followed the procedures contained in the proxy materials to perfect the holderâ€™s right to convert the holderâ€™s IPO Shares into cash, if any, or (ii) tendered the holderâ€™s IPO Shares as specified in the tender offer materials therefore, shall be entitled to receive the Conversion Price (as defined below) in exchange for the holderâ€™s IPO Shares. The Corporation shall, promptly after consummation of the Business Combination or the filing of the amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware, convert such shares into cash at a per share price equal to the quotient determined by dividing (i) the amount then held in the Trust Fund (as defined below) less any income taxes owed on such funds but not yet paid, calculated as of two business days prior to the consummation of the Business Combination or the filing of the amendment, as applicable, by (ii) the total number of IPO Shares then outstanding (such price being referred to as the â€œConversion Priceâ€). â€œTrust Fundâ€ shall mean the trust account established by the Corporation at the consummation of its IPO and into which the amount specified in Registration Statement is deposited. Notwithstanding the foregoing, a holder of IPO Shares, together with any affiliate of his or any other person with whom he is acting in concert or as a â€œgroupâ€ (within the meaning of Section 13(d)(3) of the Exchange Act) (â€œGroupâ€) with, will be restricted from demanding conversion in connection with a proposed Business Combination with respect to 20.0% or more of the IPO Shares. Accordingly, all IPO Shares beneficially owned by such holder or any other person with whom such holder is acting in concert or as a Group with in excess of 20.0% or more of the IPO Shares will remain outstanding following consummation of such Business Combination in the name of the stockholder and not be converted. Â D. The Corporation will not consummate any Business Combination unless it has net tangible assets of at least $5,000,001 upon consummation of such Business Combination. Â 2 Â Â E. In the event that the Corporation does not consummate a Business Combination by 24 months from the consummation of the IPO (such date being referred to as the â€œTermination Dateâ€), the Corporation shall (i) cease all operations except for the purposes of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter redeem 100% of the IPO Shares for cash for a redemption price per share as described below (which redemption will completely extinguish such holdersâ€™ rights as stockholders, including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to approval of the Corporationâ€™s then stockholders and subject to the requirements of the GCL, including the adoption of a resolution by the Board of Directors pursuant to Section 275(a) of the GCL finding the dissolution of the Corporation advisable and the provision of such notices as are required by said Section 275(a) of the GCL, dissolve and liquidate the balance of the Corporationâ€™s net assets to its remaining stockholders, as part of the Corporationâ€™s plan of dissolution and liquidation, subject (in the case of (ii) and (iii) above) to the Corporationâ€™s obligations under the GCL to provide for claims of creditors and other requirements of applicable law. In such event, the per-share redemption price shall be equal to a pro rata share of the Trust Account plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Corporation for its working capital requirements or necessary to pay its taxes divided by the total number of IPO Shares then outstanding. Â F. A holder of IPO Shares shall only be entitled to receive distributions from the Trust Fund in the event (i) he demands conversion of his shares in accordance with paragraph C above or (ii) that the Corporation has not consummated a Business Combination by the Termination Date as described in paragraph E above. In no other circumstances shall a holder of IPO Shares have any right or interest of any kind in or to the Trust Fund. Â G. Prior to a Business Combination, the Board of Directors may not issue (i) any shares of Common Stock or any securities convertible into Common Stock; or (ii) any securities which participate in or are otherwise entitled in any manner to any of the proceeds in the Trust Fund or which vote as a class with the Common Stock on a Business Combination. Â SEVENTH:3 The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation, and for further definition, limitation and regulation of the powers of the Corporation and of its directors and stockholders: Â A. Election of directors need not be by ballot unless the by-laws of the Corporation so provide. Â B. The Board of Directors shall have the power, without the assent or vote of the stockholders, to make, alter, amend, change, add to or repeal the by-laws of the Corporation as provided in the by-laws of the Corporation. Â C. The directors in their discretion may submit any contract or act for approval or ratification at any annual meeting of the stockholders or at any meeting of the stockholders called for the purpose of considering any such act or contract, and any contract or act that shall be approved or be ratified by the vote of the holders of a majority of the stock of the Corporation which is represented in person or by proxy at such meeting and entitled to vote thereat (provided that a lawful quorum of stockholders be there represented in person or by proxy) shall be as valid and binding upon the Corporation and upon all the stockholders as though it

had been approved or ratified by every stockholder of the Corporation, whether or not the contract or act would otherwise be open to legal attack because of directorsâ€™ interests, or for any other reason. Â D. In addition to the powers and authorities hereinbefore or by statute expressly conferred upon them, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation; subject, nevertheless, to the provisions of the statutes of Delaware, of this Amended and Restated Certificate of Incorporation, and to any bylaws from time to time made by the stockholders; provided, however, that no bylaw so made shall invalidate any prior act of the directors which would have been valid if such bylaws had not been made. Â 3This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed October 28, 2019. Â 3 Â Â E. The Board of Directors shall be divided into three classes: Class I, Class II and Class III. The number of directors in each class shall be fixed exclusively by the Board of Directors and shall be as nearly equal as possible. Following the filing of the amendment to the certificate of incorporation including this provision, the entire Board of Directors will be elected at the first Annual Meeting of Stockholders. At such first Annual Meeting of Stockholders, the directors in Class I shall be elected for a term expiring at the second Annual Meeting of Stockholders, the directors in Class II shall be elected for a term expiring at the third Annual Meeting of Stockholders and the directors in Class III shall be elected for a term expiring at the fourth Annual Meeting of Stockholders. Commencing at the second Annual Meeting of Stockholders following the filing of the amendment to the certificate of incorporation including this provision, and at each annual meeting thereafter, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Except as the GCL may otherwise require, in the interim between annual meetings of stockholders or special meetings of stockholders called for the election of directors and/or the removal of one or more directors and the filling of any vacancy in that connection, newly created directorships and any vacancies in the Board of Directors, including unfilled vacancies resulting from the removal of directors for cause, may be filled only by the vote of a majority of the remaining directors then in office, although less than a quorum (as defined in the Corporationâ€™s bylaws), or by the sole remaining director. All directors shall hold office until the expiration of their respective terms of office and until their successors shall have been elected and qualified. A director elected to fill a vacancy resulting from the death, resignation or removal of a director shall serve for the remainder of the full term of the director whose death, resignation or removal shall have created such vacancy and until his successor shall have been elected and qualified. Â EIGHTH: Â A. A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the directorâ€™s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the GCL, or (iv) for any transaction from which the director derived an improper personal benefit. If the GCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the GCL, as so amended. Any repeal or modification of this paragraph A by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation with respect to events occurring prior to the time of such repeal or modification. Â B. The Corporation, to the full extent permitted by Section 145 of the GCL, as amended from time to time, shall indemnify all persons whom it may indemnify pursuant thereto. Expenses (including attorneysâ€™ fees) incurred by an officer or director in defending any civil, criminal, administrative, or investigative action, suit or proceeding for which such officer or director may be entitled to indemnification hereunder shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the Corporation as authorized hereby. Â C. Notwithstanding the foregoing provisions of this Article Eighth, no indemnification nor advancement of expenses will extend to any claims made by the Companyâ€™s officers and directors to cover any loss that such individuals may sustain as a result of such individualsâ€™ agreement to pay debts and obligations to target businesses or vendors or other entities that are owed money by the Corporation for services rendered or contracted for or products sold to the Corporation, as described in the Registration Statement. Â NINTH: Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this Corporation under Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under Section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this Corporation, as the case may be, and also on this Corporation. Â 4 Â Â EX-3.2 3 ea022102501ex3-2_biomx.htm COMPOSITE COPY OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED TO DATE. (MARKED VERSION) Exhibit 3.2 Â BIOMX INC. COMPOSITE CERTIFICATE OF INCORPORATION Â INCORPORATING: Â Amended and Restated Certificate of Incorporation filed December 13, 2018 Â Certificate of Amendment of Certificate of Incorporation filed October 28, 2019 Â Certificate of Amendment of Certificate of Incorporation filed August 31, 2022 Â Certificate of Amendment of Certificate of Incorporation filed July 9, 2024 Â Certificate of Amendment of Certificate of Incorporation filed August 20, 2024 Â AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMX INC. Pursuant to Section 245 of the Delaware General Corporation Law Â FIRST:1 The name of the corporation is BiomX Inc. (hereinafter called the â€œCorporationâ€). Â SECOND: The registered office of the Corporation is to be located at 850 New Burton Road, Suite 201, in the City of Dover, in the County of Kent, 19904. The name of its registered agent at that address is Cogency Global Inc. Â THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (â€œGCLâ€). Â FOURTH: The name and mailing address of the incorporator is: Jaszick Maldonado, c/o Loeb & Loeb LLP, 345 Park Avenue, New York NY 10154. Â FIFTH:2 The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is 751,000,000, of which 750,000,000 shares shall be common stock, par value $.0001 per share (â€œCommon Stockâ€) and 1,000,000 shares shall be preferred stock, par value $.0001 per share (â€œPreferred Stockâ€). Subject to this Certificate of Amendment becoming effective pursuant to the General Corporation Law of the State of Delaware, at 12:01 a.m. on August 26, 2024 (the â€œEffective Timeâ€), the shares of Common Stock issued and outstanding or held in treasury immediately prior to the Effective Time (the â€œOld Common Stockâ€) shall be reclassified as and converted into a different number of shares of Common Stock (the â€œNew Common Stockâ€) such that each ten shares of Old Common Stock shall, at the Effective Time, be automatically reclassified as and converted into one share of New Common Stock (the â€œReverse Stock Splitâ€). From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of whole shares of New Common Stock into which such Old Common Stock shall have been reclassified pursuant to this Certificate of Amendment. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. Fractional share resulting from the Reverse Stock Split will be rounded up to the next whole share. Â A. Preferred Stock. The Board of Directors is expressly granted authority to issue shares of the Preferred Stock, in one or more series, and to fix for each such series such voting powers, full or limited, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issue of such series (a â€œPreferred Stock Designationâ€) and as may be permitted by the GCL. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all of the then outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, without a separate vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to any Preferred Stock Designation. Â B. Common Stock. Except as otherwise required by law or as otherwise provided in any Preferred Stock Designation, the holders of the Common Stock shall exclusively possess all voting power and each share of Common Stock shall have one vote. Â 1This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed October 28, 2019. 2This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed JulyÂ AugustÂ 920, 2024. Â 1 Â Â SIXTH: This Article Sixth shall apply during the period commencing upon the filing of this Certificate of Incorporation and terminating upon the consummation of any â€œBusiness Combinationâ€ (as defined below). A â€œBusiness Combinationâ€ shall mean any merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination involving the Corporation and one or more businesses or entities (â€œTarget Businessâ€), or entering into contractual arrangements that give the Corporation control over such a Target Business, and, if the Corporation is then listed on a national securities exchange, the Target Business has a fair market value equal to at least 80% of the balance in the Trust Fund (defined below), less any taxes payable on interest earned, at the time of signing a definitive agreement in connection with the initial Business Combination. â€œIPO Sharesâ€ shall mean the shares sold pursuant to the registration statement on Form S-1 (â€œRegistration Statementâ€) filed with the Securities and Exchange Commission (â€œCommissionâ€) in connection with the Corporationâ€™s initial public offering (â€œIPOâ€). The â€œfair market valueâ€ for purposes of this Article Sixth will be determined by the Board of Directors of the Corporation based upon one or more standards generally accepted by the financial community (such as actual and potential sales, earnings, cash flow and/or book value). If the Board of Directors is unable to independently determine the fair market value of the Target Business, the Corporation will obtain an opinion from an independent investment banking firm, or another independent entity that commonly renders valuation opinions, with respect to the satisfaction of such criteria. Â A. Prior to the consummation of a Business Combination, the Corporation shall either (i) submit any Business Combination to its holders of Common Stock for approval (â€œProxy Solicitationâ€) pursuant to the proxy rules promulgated under the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€), or (ii) provide its holders of IPO Shares with the opportunity to sell their shares to the Corporation by means of a tender offer (â€œTender Offerâ€). Â B. If the Corporation engages in a Proxy Solicitation with respect to a Business Combination, the Corporation will consummate the Business Combination only if a majority of the then outstanding shares of Common Stock present and entitled to vote at the meeting to approve the Business Combination are voted for the approval of such Business Combination. Â C. In the event that a Business Combination is consummated by the Corporation or the Corporation holds a vote of its stockholders to amend its Certificate of Incorporation, any holder of IPO Shares who (i) voted on the proposal to approve such Business Combination or amend the Certificate of Incorporation, whether such holder voted in favor or against such Business Combination or amendment, and followed the procedures contained in the proxy materials to perfect the holderâ€™s right to convert the holderâ€™s IPO Shares into cash, if any, or (ii) tendered the holderâ€™s IPO Shares as specified in the tender offer materials therefore, shall be entitled to receive the Conversion Price (as defined below) in exchange for the holderâ€™s IPO Shares. The Corporation shall, promptly after consummation of the Business Combination or the filing of the amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware, convert such shares into cash at a per share price equal to the quotient determined by dividing (i) the amount then held in the Trust Fund (as defined below) less any income taxes owed on such funds but not yet paid, calculated as of two business days prior to the consummation of the Business Combination or the filing of the amendment, as applicable, by (ii) the total number of IPO Shares then outstanding (such price being referred to as the â€œConversion Priceâ€). â€œTrust Fundâ€ shall mean the trust account established by the Corporation at the consummation of its IPO and into which the amount specified in Registration Statement is deposited. Notwithstanding the foregoing, a holder of IPO Shares, together with any affiliate of his or any other person with whom he is acting in concert or as a â€œgroupâ€ (within the meaning of Section 13(d)(3) of the Exchange Act) (â€œGroupâ€) with, will be restricted from demanding conversion in connection with a proposed Business Combination with respect to 20.0% or more of the IPO Shares. Accordingly, all IPO Shares beneficially owned by such holder or any other person with whom such holder is acting in concert or as a Group with in excess of 20.0% or more of the IPO Shares will remain outstanding following consummation of such Business Combination in the name of the stockholder and not be converted. Â D. The Corporation will not consummate any Business Combination unless it has net tangible assets of at least $5,000,001 upon consummation of such Business Combination. Â 2 Â Â E. In the event that the Corporation does not consummate a Business Combination by 24 months from the consummation of the IPO (such date being referred to as the â€œTermination Dateâ€), the Corporation shall (i) cease all operations except for the purposes of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter redeem 100% of the IPO Shares for cash for a redemption price per share as described below (which redemption will completely extinguish such holdersâ€™ rights as stockholders, including the right to receive further liquidation distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to approval of the Corporationâ€™s then stockholders and subject to the requirements of the GCL, including the adoption of a resolution by the Board of Directors pursuant to Section 275(a) of the GCL finding the dissolution of the Corporation advisable and the provision of such notices as are required by said Section 275(a) of the GCL, dissolve and liquidate the balance of the Corporationâ€™s net assets to its remaining stockholders, as part of the Corporationâ€™s plan of dissolution and liquidation, subject (in the case of (ii) and (iii) above) to the Corporationâ€™s obligations under the GCL to provide for claims of creditors and other requirements of applicable law. In such event, the per-share redemption price shall be equal to a pro rata share of the Trust Account plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Corporation for its working capital requirements or necessary to pay its taxes divided by the total number of IPO Shares then outstanding. Â F. A holder of IPO Shares shall only be entitled to receive distributions from the Trust Fund in the event (i) he demands conversion of his shares in accordance with paragraph C above or (ii) that the Corporation has not consummated a Business Combination by the Termination Date as described in paragraph E above. In no other circumstances shall a holder of IPO Shares have any right or interest of any kind in or to the Trust Fund. Â G. Prior to a Business Combination, the Board of Directors may not issue (i) any shares of Common Stock or any securities convertible into Common Stock; or (ii) any securities which participate in or are otherwise entitled in any manner to any of the proceeds in the Trust Fund or which vote as a class with the Common Stock on a Business Combination. Â SEVENTH:3 The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation, and for further definition, limitation and regulation of the powers of the Corporation and of its directors and stockholders: Â A. Election of directors need not be by ballot unless the by-laws of the Corporation so provide. Â B. The Board of Directors shall have the power, without the assent or vote of the stockholders, to make, alter, amend, change, add to or repeal the by-laws of the Corporation as provided in the by-laws of the Corporation. Â C. The directors in their discretion may submit any contract or act for approval or ratification at any annual meeting of the stockholders or at any meeting of the stockholders called for the purpose of considering any such act or contract, and any contract or act that shall be approved or be ratified by the vote of the holders of a majority of the stock of the Corporation which is represented in person or by proxy at such meeting and entitled to vote thereat (provided that a lawful quorum of stockholders be there represented in person or by proxy) shall be as valid and binding upon the Corporation and upon all the stockholders as though it had been approved or ratified by every stockholder of the Corporation, whether or not the contract or act would otherwise be open to legal attack because of directorsâ€™ interests, or for any other reason. Â D. In addition to the powers and authorities hereinbefore or by statute expressly conferred upon them, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation; subject, nevertheless, to the provisions of the statutes of Delaware, of this Amended and Restated Certificate of Incorporation, and to any bylaws from time to time made by the stockholders; provided, however, that no bylaw so made shall invalidate any prior act of the directors which would have been valid if such bylaws had not been made. Â 3This provision has been revised to reflect changes effectuated by the Certificate of Amendment filed October 28, 2019. Â 3 Â Â E. The Board of Directors shall be divided into three classes: Class I, Class II and Class III. The number of directors in each class shall be fixed exclusively by the Board of Directors and shall be as nearly equal as possible. Following the filing of the amendment to the certificate of incorporation including this provision, the entire Board of Directors will be elected at the first Annual Meeting of Stockholders. At such first Annual Meeting of Stockholders, the directors in Class I shall be elected for a term expiring at the second Annual Meeting of Stockholders, the directors in Class II shall be elected for a term expiring at the third Annual Meeting of Stockholders and the directors in Class III shall be elected for a term expiring at the fourth Annual Meeting of Stockholders. Commencing at the second Annual Meeting of Stockholders following the filing of the amendment to the certificate of incorporation including this provision, and at each annual meeting thereafter, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Except as the GCL may otherwise require, in the interim between annual meetings of stockholders or special meetings of stockholders called for the election of directors and/or the removal of one or more directors and the filling of any vacancy in that connection, newly created

directorships and any vacancies in the Board of Directors, including unfilled vacancies resulting from the removal of directors for cause, may be filled only by the vote of a majority of the remaining directors then in office, although less than a quorum (as defined in the Corporationâ€™s bylaws), or by the sole remaining director. All directors shall hold office until the expiration of their respective terms of office and until their successors shall have been elected and qualified. A director elected to fill a vacancy resulting from the death, resignation or removal of a director shall serve for the remainder of the full term of the director whose death, resignation or removal shall have created such vacancy and until his successor shall have been elected and qualified. Â EIGHTH: Â A. A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the directorâ€™s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the GCL, or (iv) for any transaction from which the director derived an improper personal benefit. If the GCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the GCL, as so amended. Any repeal or modification of this paragraph A by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation with respect to events occurring prior to the time of such repeal or modification. Â B. The Corporation, to the full extent permitted by Section 145 of the GCL, as amended from time to time, shall indemnify all persons whom it may indemnify pursuant thereto. Expenses (including attorneysâ€™ fees) incurred by an officer or director in defending any civil, criminal, administrative, or investigative action, suit or proceeding for which such officer or director may be entitled to indemnification hereunder shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the Corporation as authorized hereby. Â C. Notwithstanding the foregoing provisions of this Article Eighth, no indemnification nor advancement of expenses will extend to any claims made by the Companyâ€™s officers and directors to cover any loss that such individuals may sustain as a result of such individualsâ€™ agreement to pay debts and obligations to target businesses or vendors or other entities that are owed money by the Corporation for services rendered or contracted for or products sold to the Corporation, as described in the Registration Statement. Â NINTH: Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this Corporation under Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under Section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this Corporation, as the case may be, and also on this Corporation. Â 4 Â Â EX-10.1 4 ea022102501ex10-1_biomx.htm FORM OF RESTRICTED STOCK UNIT AGREEMENT UNDER THE COMPANY'S 2019 OMNIBUS LONG-TERM INCENTIVE PLAN Exhibit 10.1 Â BIOMX INC. 2019 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Agreement Â This Restricted Stock Unit Agreement and the associated grant award information (theÂ â€œCustomizing Informationâ€), which Customizing Information is provided in written form or is available in electronic form from the recordkeeper for the BiomX Inc. 2019 Omnibus Long-Term Incentive Plan (including any appendices and addendums thereto), as amended and in effect from time to time (the â€œPlanâ€), is made as of the date shown as the â€œGrant Dateâ€ in the Customizing Information (the â€œGrant Dateâ€) by and between BiomX Inc., a Delaware corporation (the â€œCompanyâ€), and the individual identified in the Customizing Information (theÂ â€œRecipientâ€). This instrument and the Customizing Information are collectively referred to as the â€œRestricted Stock Unit Agreement.â€ Â WITNESSETH THAT: Â WHEREAS, the Company has instituted the Plan; and Â WHEREAS, the Administrator has authorized the grant of restricted stock units (â€œRSUsâ€) with respect to the Companyâ€™s Stock upon the terms and conditions set forth below and pursuant to the Plan, a copy of which is incorporated herein; and Â WHEREAS, the Recipient acknowledges that he or she has carefully read this Restricted Stock Unit Agreement and agrees, as provided in Section 17(a) below, that the terms and conditions of the Restricted Stock Unit Agreement reflect the entire understanding between himself or herself and the Company regarding this RSU award (and the Recipient has not relied upon any statement or promise other than the terms and conditions of the Restricted Stock Unit Agreement with respect to this RSU award); Â NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Recipient agree as follows. Â 1.Â Grant. Subject to the terms of the Plan and this Restricted Stock Unit Agreement, the Company hereby grants to the Recipient that number of RSUs equal to the corresponding number of shares of the Companyâ€™s Stock (the â€œUnderlying Sharesâ€) shown in the Customizing Information under â€œRestricted Stock Units Granted.â€ Â 2.Â Vesting. Â (a)Â In General. If the Recipient remains in an employment, contractual or other service relationship with the Company (â€œRelationshipâ€) as of a â€œVesting Date,â€ as specified in the Customizing Information, and the Recipient as of such date is not in violation of any confidentiality, inventions, non-solicitation and/or non-competition agreement with the Company (each to the extent not otherwise prohibited under applicable state law), all or a portion, as applicable (the â€œIncremental Amount,â€ as specified in the Customizing Information), of the RSUs shall vest on such date. For the avoidance of doubt, except as otherwise provided pursuant to the terms of the Plan and Section 2(c), if the Recipientâ€™s Relationship with the Company is terminated by the Company or by the Recipient for any reason, whether voluntarily or involuntarily, no RSUs granted pursuant to this Restricted Stock Unit Agreement shall vest under any circumstances on and after the date of such termination. Â 1 Â Â (b)Â Change in Control. In the event of a Change in Control, the Company, or the entity that is the surviving entity or successor to the Company following such transaction, may elect to: (i) continue this RSU subject to the terms of this Restricted Stock Unit Agreement and the Plan and subject to such adjustments, if any, by the Administrator as permitted by Section 3.2 of the Plan; or (ii) accelerate vesting of this RSU and terminate this RSU in exchange for a cash payment. In the event that the Company or its successor chooses to terminate this RSU upon a Change in Control, the Recipient shall be entitled to a payment within thirty (30) days of such Change in Control. Â (c)Â Administrator Discretion. In the event the Relationship is terminated for any reason (whether voluntary or involuntary), (i) the Recipientâ€™s right to vest in the RSU will, except as provided otherwise explicitly in this Section 2 or as provided by the Administrator, terminate as of the date of the termination of the Relationship (and will not be extended by any notice period mandated under local law) and (ii) the Administrator shall have the exclusive discretion to determine when the Relationship has terminated for purposes of this RSU (including when the Recipient is no longer considered to be providing active service while on a leave of absence). Â (d)Â Special Definitions. For purposes of this Section 2, the term â€œCompanyâ€ refers to the Company and its Related Companies. Â 3.Â Dividends. If so provided in the Customizing Information under â€œDividend Equivalent Unitsâ€, a Recipient shall be credited with dividend equivalents equal to the dividends the Recipient would have received if the Recipient had been the actual record owner of the Underlying Shares on each dividend record date on or after the Grant Date and through the date the Recipient receives a settlement pursuant to Section 4 below (the â€œDividend Equivalentâ€). If a dividend on the Stock is payable wholly or partially in Stock, the Dividend Equivalent representing that portion shall be in the form of additional RSUs, credited on a one-for-one basis. If a dividend on the Stock is payable wholly or partially in cash, the Dividend Equivalent representing that portion shall also be in the form of cash and a Recipient shall be treated as being credited with any cash dividends, without earnings, until settlement pursuant to Section 4 below. If a dividend on Stock is payable wholly or partially in other than cash or Stock, the Administrator may, in its discretion, provide for such Dividend Equivalents with respect to that portion as it deems appropriate under the circumstances. Dividend Equivalents shall be subject to the same terms and conditions as the RSUs originally awarded pursuant to this Restricted Stock Unit Agreement, and they shall vest (or, if applicable, be forfeited) as if they had been granted at the same time as the original RSU. Dividend Equivalents representing the cash portion of a dividend on Stock shall be settled in cash. Â 4.Â Delivery of Underlying Shares or Cash Settlement. With respect to any RSUs that become vested RSUs as of a Vesting Date pursuant to Section 2, the Company shall issue and deliver to the Recipient as soon as practicable following the applicable Vesting Date (a) the number of Underlying Shares equal to the number of RSUs vesting on that date or an amount of cash equal to the Fair Market Value, as defined in the Plan, of such Underlying Shares as of that date (or such later delivery date, if applicable) and (b) the amount (and in the form) due with respect to any Dividend Equivalents applicable to such Underlying Shares. Whether Underlying Shares, or the cash value thereof, shall be issued or paid at settlement shall be determined based on the â€œForm of Settlementâ€ specified in the Customizing Information. Â 2 Â Â To the extent the vesting of any RSUs occurs during a â€œblackoutâ€ period wherein certain employees, including the Recipient, are precluded from selling Stock, the Administrator retains the right, in its sole discretion, to defer the delivery of the Underlying Shares; provided, however, that the Administrator shall not exercise its right to defer the Recipientâ€™s receipt of the Underlying Shares if the Stock is specifically covered by a RuleÂ 10b5-1 trading plan of the Recipient that causes the Stock to be exempt from any applicable blackout period then in effect. In the event the receipt of any shares of Stock is deferred hereunder due to the existence of a blackout period, the shares shall be issued to the Recipient on the first day following the termination of the blackout period; provided, however, that in no event shall the issuance of the shares be deferred later than the fifteenth day of the third month following the close of the year in which the Underlying Shares otherwise would have been issued. Â Any shares issued pursuant to this Restricted Stock Unit Agreement shall be issued, without issue or transfer tax, by (i) delivering a stock certificate or certificates for such shares out of theretofore authorized but unissued shares or treasury shares of its Stock as the Company may elect or (ii) issuance of shares of its Stock in book entry form; provided, however, that the time of such delivery may be postponed by the Company for such period as may be required for it with reasonable diligence to comply with any applicable requirements of law. Notwithstanding the preceding provisions of this Section 4, delivery of Underlying Shares shall be made, or the amount of cash equivalent thereto shall be paid, only if the required purchase price designated as the â€œPurchase Priceâ€ shown in the Customizing Information per underlying RSU is paid to the Company by means of payment acceptable to the Company in accordance with the terms of the Plan. If the Recipient fails to pay for or accept delivery of all of the shares, the right to shares of Stock provided pursuant to this RSU may be terminated by the Company. Â 5.Â Withholding Taxes. The Recipient hereby agrees, as a condition of this award, to provide to the Company (or a Related Company employing the Recipient, as applicable) an amount sufficient to satisfy the Companyâ€™s and/or Related Companyâ€™s obligation to withhold any and all federal, state, local or provincial income tax, social security, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items or statutory withholdings related to the Recipientâ€™s participation in the Plan (theÂ â€œWithholding Amountâ€), if any, by (a) authorizing the Company and/or any Related Company employing the Recipient, as applicable, to withhold the Withholding Amount from the Recipientâ€™s cash compensation, (b) remitting the Withholding Amount to the Company (or a Related Company employing the Recipient, as applicable) in cash or (c) delivering to the Company stock certificates registered in his or her name representing shares of Company Stock legally and beneficially owned by him or her, fully vested and free of all liens, claims, and encumbrances of every kind, duly endorsed or accompanied by stock powers duly endorsed by the record holder of the Company Stock represented by such certificates; provided, however, that to the extent that the Withholding Amount is not provided by one or a combination of such methods, the Company may at its election withhold from the Underlying Shares and any Dividend Equivalents that would otherwise be delivered that number of shares (and/or cash) having a Fair Market Value on the date of vesting sufficient to eliminate any deficiency in the Withholding Amount. Regardless of any action that the Company and/or Related Company takes with respect to any or all federal, state, local or provincial income tax, social security, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items or statutory withholdings related to the Recipientâ€™s participation in the Plan, the Recipient acknowledges that he or she, and not the Company and/or any Related Company, has the ultimate liability for any such items. Further, if the Recipient becomes subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, the Recipient acknowledges that the Company and/or Related Company may be required to withhold or account for such tax-related items in more than one jurisdiction. Â 3 Â Â 6.Â Non-assignability of RSUs and Dividend Equivalents. RSUs and any Dividend Equivalents shall not be assignable or transferable by the Recipient except by will or by the laws of descent and distribution or as permitted by the Administrator in its discretion pursuant to the terms of the Plan. During the life of the Recipient, delivery of shares of Stock or payment of cash as settlement of RSUs and any Dividend Equivalents shall be made only to the Recipient, to a conservator or guardian duly appointed for the Recipient by reason of the Recipientâ€™s incapacity or to the person appointed by the Recipient in a durable power of attorney acceptable to the Companyâ€™s counsel. Â 7.Â Compliance with Securities Act; Lock-Up Agreement. The Company shall not be obligated to sell or issue any Underlying Shares or other securities in settlement of RSUs and any Dividend Equivalents hereunder unless the shares of Stock or other securities are at that time effectively registered or exempt from registration under the Securities Act and applicable state or provincial securities laws. In the event shares or other securities shall be issued that shall not be so registered, the Recipient hereby represents, warrants and agrees that the Recipient will receive such shares or other securities for investment and not with a view to their resale or distribution, and will execute an appropriate investment letter satisfactory to the Company and its counsel. The Recipient further hereby agrees that as a condition to the settlement of RSUs and any Dividend Equivalents, if requested by the Company, the Recipient will execute an agreement in a form acceptable to the Company to the effect that the Underlying Shares shall be subject to any underwriterâ€™s or similar lock-up agreement in connection with an offering of any securities of the Company that may from time to time apply to shares held by officers and directors of the Company, and such agreement or a successor agreement must be in full force and effect. Â 8.Â Addendum. Notwithstanding any provisions in this Restricted Stock Unit Agreement, this RSU award shall, in the case of a Recipient subject to tax, working and/or residing in Israel, also be subject to any special terms and conditions set forth in Appendix A to this Restricted Stock Unit Agreement. Â 9.Â Legends. The Recipient hereby acknowledges that the stock certificate or certificates (or entries in the case of book entry form) evidencing shares of Stock or other securities issued pursuant to any settlement of an RSU or any Dividend Equivalent hereunder may bear a legend (or provide a restriction) setting forth the restrictions on their transferability described in Section 7 hereof, if such restrictions are then in effect. Â 4 Â Â 10.Â Rights as Stockholder. The Recipient shall have no rights as a stockholder with respect to any RSUs, Dividend Equivalents or Underlying Shares until the date of issuance of a stock certificate (or appropriate entry is made in the case of book entry form) for Underlying Shares and any Dividend Equivalents. Except as provided by Section 3, no adjustment shall be made for any rights for which the record date is prior to the date such stock certificate is issued (or appropriate entry is made in the case of book entry form), except to the extent the Administrator so provides, pursuant to the terms of the Plan and upon such terms and conditions it may establish. Â 11.Â Effect Upon Employment and Performance of Services. Nothing in this Restricted Stock Unit Agreement or the Plan shall be construed to impose any obligation upon the Company or any Related Company to employ or utilize the services of the Recipient or to retain the Recipient in its employ or to engage or retain the services of the Recipient. Â 12.Â Time for Acceptance. Unless the Recipient shall evidence acceptance of this Restricted Stock Unit Agreement by electronic or other means prescribed by the Administrator within sixty (60) days after its delivery, the RSUs and any Dividend Equivalents shall be null and void (unless waived by the Administrator). Â 13.Â Section 409A of the Internal Revenue Code. The RSUs and any Dividend Equivalents granted hereunder are intended to avoid the potential adverse tax consequences to the Recipient of Section 409A of the Code and the Administrator may make such modifications to this Restricted Stock Unit Agreement as it deems necessary or advisable to avoid such adverse tax consequences. If and to the extent that the RSUs and any Dividend Equivalents are subject to Section 409A, in addition to the provisions of Section 9.13 of the Plan, any payment upon termination of the Relationship shall be made only upon a â€œseparation from serviceâ€ under Section 409A, and the Recipient may not directly or indirectly designate the calendar year of a payment. Â 14.Â Electronic Delivery. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Recipient consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company. Â 15.Â Company Policies. This RSU shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may be implemented by the Board from time to time, in accordance with applicable law. Â 16.Â Nature of Award. By accepting this RSU, the Recipient acknowledges, understands and agrees that: Â (a)Â the Plan is established voluntarily by the Company, is discretionary in nature and may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan and this Restricted Stock Unit Agreement; Â 5 Â Â (b)Â the grant of this RSU is voluntary and occasional and does not create any contractual or other right to receive future awards under the Plan or benefits in lieu of Plan awards, even if RSUs or other Plan awards have been granted in the past; Â (c)Â all

decisions with respect to future RSU awards will be at the sole discretion of the Administrator; Â (d)Â he or she is voluntarily participating in the Plan; Â (e)Â the future value of the Underlying Shares is unknown and cannot be predicted with certainty; and Â (f)Â the Company shall not be liable for any foreign exchange rate fluctuation between the Recipientâ€™s local currency and the United States dollar that may affect the value of this RSU or any amounts due pursuant to the settlement of the RSU or the subsequent sale of any Underlying Shares acquired upon settlement. Â 17.Â General Provisions. Â (a)Â Amendment; Waivers. This Restricted Stock Unit Agreement, including the Plan, contains the full and complete understanding and agreement of the parties hereto as to the subject matter hereof, and except as otherwise permitted by the express terms of the Plan and this Restricted Stock Unit Agreement and applicable law, it may not be modified or amended nor may any provision hereof be waived without a further written agreement duly signed by each of the parties; provided, however, that a modification or amendment that does not materially diminish the rights of the Recipient hereunder, as they may exist immediately before the effective date of the modification or amendment, shall be effective upon written notice of its provisions to the Recipient, to the extent permitted by applicable law. The waiver by either of the parties hereto of any provision hereof in any instance shall not operate as a waiver of any other provision hereof or in any other instance. The Recipient shall have the right to receive, upon request, a written confirmation from the Company of the Customizing Information. Â (b)Â Binding Effect. This Restricted Stock Unit Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, representatives, successors and assigns. Â (c) Fractional RSUs, Underlying Shares and Dividend Equivalents. All fractional Underlying Shares and any Dividend Equivalents settled in Stock resulting from the application of the Vesting Schedule or the adjustment provisions contained in the Plan shall be rounded down to the nearest whole share. If cash in lieu of Underlying Shares is delivered at settlement, or any Dividend Equivalents are settled in cash, the amount paid shall be rounded down to the nearest penny. Â (d)Â Governing Law. This Restricted Stock Unit Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the principles of conflicts of law. Â 6 Â Â (e)Â Construction. This Restricted Stock Unit Agreement is to be construed in accordance with the terms of the Plan. In case of any conflict between the Plan and this Restricted Stock Unit Agreement, the Plan shall control. The titles of the sections of this Restricted Stock Unit Agreement and of the Plan are included for convenience only and shall not be construed as modifying or affecting their provisions. The masculine gender shall include both sexes; the singular shall include the plural and the plural the singular unless the context otherwise requires. Capitalized terms not defined herein shall have the meanings given to them in the Plan. Â (f)Â Language. If the Recipient receives this Restricted Stock Unit Agreement, or any other document related to this RSU and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. Â (g)Â Data Privacy. Â (i)The Recipient hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Recipientâ€™s personal data as described in this Restricted Stock Unit Agreement by and among, as applicable, his or her employer, the Company and its subsidiaries for the exclusive purpose of implementing, administering and managing the Recipientâ€™s participation in the Plan. Â (ii)The Recipient understands that his or her employer, the Company and its subsidiaries, as applicable, hold certain personal information about the Recipient regarding his or her employment, the nature and amount of the Recipientâ€™s compensation and the fact and conditions of the Recipientâ€™s participation in the Plan, including, but not limited to, the Recipientâ€™s name, home address, telephone number and e-mail address, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company and its subsidiaries, details of all options, awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Recipientâ€™s favor, for the purpose of implementing, administering and managing the Plan (the â€œDataâ€). Â (iii)The Recipient understands that the Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these third parties may be located in the Recipientâ€™s country, or elsewhere, and that the third partyâ€™s country may have different data privacy laws and protections than the Recipientâ€™s country. The Recipient understands that the Recipient may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative. The Recipient authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Recipientâ€™s participation in the Plan, including any requisite transfer of such Data as may be required to a broker or other third party. The Recipient understands that the Data will be held only as long as is necessary to implement, administer and manage Recipientâ€™s participation in the Plan. The Recipient understands that he or she may, at any time, view the Data, request additional information about the storage and processing of the Data, require any necessary amendments to the Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing the Recipientâ€™s local human resources representative. The Recipient understands, however, that refusing or withdrawing his or her consent may affect the Recipientâ€™s ability to participate in the Plan. For more information on the consequences of refusal to consent or withdrawal of consent, the Recipient understands that the Recipient may contact his or her local human resources representative. Â (h)Â Notices. Any notice in connection with this Restricted Stock Unit Agreement shall be deemed to have been properly delivered if it is delivered in the form specified by the Administrator as follows: Â Â To the Recipient: Last address provided to the Company Â Â Â Â To the Company: BiomX Inc. Â Â 22 Einstein Street, 4th Floor Â Â Ness Ziona, Israel 7414003 Â Â Attn: Chief Financial Officer Â Â (i)Â Version Number. This document is Version 1 of the BiomX Inc. 2019 Omnibus Long-Term Incentive Plan Restricted Stock Unit Agreement. Â 7 Â Â APPENDIX A Â BIOMX INC. 2019 OMNIBUS LONG-TERM INCENTIVE PLAN Restricted Stock Unit Agreement Â FOR Israeli PARTICIPANTS Â Terms and Conditions Â This Appendix A includes additional terms and conditions that govern the RSU award to Recipient under the Plan if Recipient is subject to tax, works, and/or resides, in Israel. Â This Appendix A forms part of the Restricted Stock Unit Agreement. Any capitalized term used in this Appendix A without definition will have the meaning ascribed to it in the Restricted Stock Unit Agreement or the Plan, as applicable. Â If Recipient is a citizen or resident of a jurisdiction, or is considered resident of a jurisdiction, other than Israel, or Recipient transfers employment and/or residency from Israel after the Grant Date, the Company will, in its sole discretion, determine to what extent the additional terms and conditions included herein will apply to Recipient under these circumstances. Â Notifications Â This Appendix A also includes information relating to securities laws, exchange control, foreign asset/account reporting requirements, and other issues of which Recipient should be aware with respect to Recipientâ€™s participation in the Plan. The information is based on the securities, exchange control, and other laws in effect in Israel as of July 2024. Such laws are often complex and change frequently. As a result, Recipient should not rely on the information herein as the only source of information relating to the consequences of Recipientâ€™s participation in the Plan because the information may be out of date at the time that Recipient vests in the RSUs or sells Underlying Shares acquired pursuant to this RSU award. Â In addition, the information is general in nature and may not apply to Recipientâ€™s particular situation, and the Company is not in a position to assure Recipient of any particular result. Accordingly, Recipient should seek appropriate professional advice as to how the relevant laws in Israel may apply to Recipientâ€™s situation. Â Finally, if Recipient is a citizen or resident of a jurisdiction, or is considered resident of a jurisdiction, other than Israel, or Recipient transfers employment and/or residency from Israel after the Grant Date, the information contained herein may not apply to Recipient in the same manner. Â Terms and Conditions Â Nature of Award. By accepting this RSU award, Recipient understands and agrees that the RSUs are offered subject to and in accordance with the Israeli Appendix to the Plan and the RSU is intended to be a 102 Capital Gain Track Award (as defined in the Israeli Appendix). A copy of the Israeli Appendix is attached hereto as Exhibit A. Notwithstanding the foregoing, the Company does not undertake to maintain the qualified status of this RSU award and Recipient acknowledges that Recipient will not be entitled to damages of any kind if the RSU award becomes disqualified and no longer qualifies as a 102 Capital Gain Track Award. In the event of any inconsistencies between the Israeli Appendix, the Restricted Stock Unit Agreement and/or the Plan, the terms of the Israeli Appendix will govern. Â 8 Â Â Further, to the extent requested by the Company or an Affiliate, Recipient agrees to execute any letter or other agreement in connection with the grant of this RSU award or any future RSUs granted under the Israeli Appendix. If Recipient fails to comply with such request, the RSU may not qualify as a 102 Capital Gain Track Award. Â Terms of RSUs. Certain specific terms of the RSU granted under this Agreement are set forth in Exhibit B attached hereto. Notwithstanding anything to the contrary, this RSU award shall not be settled in cash nor shall the Recipient be entitled to Dividend Equivalent Units. Â Trust Arrangement. Recipient acknowledges and agrees that any Underlying Shares issued upon vesting of this RSU award will be registered under the name of the Companyâ€™s designated trustee in Israel, Altshare Trusts Ltd. (the â€œTrusteeâ€) and for the benefit of the Recipient, in accordance with the terms of the trust agreement between the Company and the Trustee (the â€œTrust Agreement,â€ a copy of which is attached hereto as Exhibit C). Recipient further agrees that such Underlying Shares will be subject to the Required Holding Period (as defined in the Israeli Appendix), which shall be 24 months from the Grant Date. The Company may, in its sole discretion, replace the Trustee from time to time and instruct the transfer of all RSUs and Underlying Shares held and/or administered by such Trustee at such time to its successor and the provisions of this Restricted Stock Unit Agreement shall apply to the new Trustee mutatis mutandis. The Company may replace, amend, cancel or renew the Trust Agreement at any time, at its sole discretion. By accepting this RSU award, the Recipient hereby confirms that he or she read the provisions of the Trust Agreement and that the terms and conditions thereof are hereby agreed and acknowledged and the Recipient hereby agrees to be bound by, and comply with, the provisions of the Trust Agreement. The Recipient hereby confirms that he or she is aware that the Underlying Shares may be held by a global stock plan administrator other than the Trustee, and that funds from the sale or other disposition of such Underlying Shares will be transferred to an account in the name of the Trustee who shall transfer the funds to the Recipient only after withholding any applicable Israeli taxes as required by law. Â Restriction on Sale. Recipient acknowledges that any Underlying Shares may not be sold prior to the expiration of the Required Holding Period in order to qualify for tax treatment under the 102 Capital Gain Track. Accordingly, Recipient shall not dispose of (or request the Trustee to dispose of) any such Underlying Shares prior to the expiration of the Required Holding Period, other than as permitted by applicable law. For purposes of Israeli tax provisions, â€œdisposeâ€ shall mean any sale, transfer or other disposal of the Underlying Shares by Recipient (including by means of an instruction by Recipient to the designated broker) or the Trustee, including a release of such Underlying Shares from the Trustee to Recipient. Â 9 Â Â Tax Obligations. The following provision supplements Section 5 of the Agreement. Â The Recipient hereby acknowledges that he or she is familiar with the provisions of Section 102 of the Israeli Income Tax Ordinance (New Version), 5721- 1961 (the â€œIsraeli Income Tax Ordinanceâ€) and the regulations and rules promulgated thereunder, including without limitation, the tax implications applicable to this RSU award. Â The fair market value of the RSUs on the Grant Date (as computed in accordance with the provisions relating to the 102 Capital Gain Track) shall be subject to taxation in Israel in accordance with ordinary income tax principles. Moreover, in the event that Recipient disposes of any Underlying Shares prior to the expiration of the Required Holding Period, Recipient acknowledges and agrees that any additional gains from the sale of such Underlying Shares will not qualify for tax treatment under the 102 Capital Gain Track and will be subject to taxation in Israel in accordance with ordinary income tax principles, and any sanctions under Section 102 with respect thereto shall be borne solely by the Recipient. Further, the Recipient acknowledges and agrees that Recipient will be liable for the Companyâ€™s or an Affiliatesâ€™ component of payments to the Israeli National Insurance Institute (to the extent such payments by the Company or Affiliate are required). Â The Recipient agrees that he or she shall not sell or release from trust any Underlying Shares issued upon vesting under Section 102, or any shares received subsequently following any realization of rights, including without limitation, bonus shares and dividend equivalents, until the lapse of the Restricted Holding Period. Â Recipient further agrees that the Trustee may act on behalf of the Company or its Affiliates, as applicable, to satisfy any obligation to withhold tax-related items applicable to the Recipient in connection with the RSUs granted under the Israeli Appendix. Â The following provisions apply if Recipient was not an Israeli tax resident when the RSUs were granted or if the RSUs do not qualify as a 102 Capital Gain Track Award â€” Â Non-Trustee Award. This RSU award is subject to the Plan and is not made pursuant to Sections 102(b)(2) and (3) of the Israeli Income Tax Ordinance and, in particular, is not eligible to benefit from the capital gains track described in subsection (b)(2) and (3) thereof. To facilitate compliance with tax requirements in Israel, the Recipient acknowledges and agrees that the Company may require that any Underlying Shares be held with the Companyâ€™s designated broker appointed under the Plan or another designee or that such Underlying Shares be sold at any such time specified by the Company. Â Notifications Â Securities Law Information. This RSU award does not constitute a public offering under the Israeli Securities Law, 1968. Â Exhibits. Exhibits Aâ€“C attached hereto shall be considered an integral part of Appendix A and the Restricted Stock Unit Agreement. Â 10 Â Â BIOMX INC. 2019 OMNIBUS LONG-TERM INCENTIVE PLAN Â EXHIBITS TO CUSTOMIZING INFORMATION FOR ISRAELI RECIPIENTS Â Exhibit A: Israeli Appendix to the BiomX Inc. 2019 Omnibus Long-Term Incentive Plan Â Â Exhibit B: Terms of RSUs Â Â Exhibit C: Trust Agreement Â Â Â Â EXHIBIT A Â ISRAELI APPENDIX TO THE BIOMX, INC., 2019 OMNIBUS LONG-TERM EQUITY INCENTIVE PLAN Â Â Â Â EXHIBIT B TERMS OF RSUs Â Recipientâ€™s Name and Address Â Â Â [FIRST NAME] [LAST NAME] Â Â [ADDRESS] Â Â [ZIP CODE] Â Â Type of Award Â RSU Designation Â â˜Â Section 102 â€“ Capital Gains Tax Track â˜Â Section 102 â€“ Non-Trustee Tax Track â˜Â Section 3(i) Number of Restricted Stock Units Â As set forth in the Customizing Information Grant Date Â As set forth in the Customizing Information Vesting Commencement Date Â As set forth in the Customizing Information Vesting Schedule Â As set forth in the Customizing Information Â Â Â Â EXHIBIT C Trust Agreement Â Â Â EX-31.1 5 ea022102501ex31-1_biomx.htm CERTIFICATION Exhibit 31.1 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Â I, Jonathan Solomon, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of BiomX Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 /s/ Jonathan Solomon Â Jonathan Solomon Â Chief Executive Officer Â (Principal executive officer) Â EX-31.2 6 ea022102501ex31-2_biomx.htm CERTIFICATION Exhibit 31.2 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Â I, Marina Wolfson, certify that: Â 1. I have reviewed this Quarterly Report on Form 10-Q of BiomX Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be

designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 /s/ Marina Wolfson Â Marina Wolfson Â Chief Financial Officer Â (Principal financial officer) Â EX-32 7 ea022102501ex32_biomx.htm CERTIFICATION Exhibit 32 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 Â In connection with the Quarterly Report of BiomX Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission (the â€œQuarterly Reportâ€), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, that, to his or her knowledge: Â 1.The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â 2.The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 14, 2024 /s/ Jonathan Solomon Â Jonathan Solomon Â Chief Executive Officer Â (Principal executive officer) Â Date: November 14, 2024 /s/ Marina Wolfson Â Marina Wolfson Â Chief Financial Officer Â (Principal financial officer) Â Â Â EX-101.SCH 8 phge-20240930.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholdersâ€™ Equity (Capital Deficiency) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholdersâ€™ Equity (Capital Deficiency) (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Other Current Assets link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Other Accounts Payable link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - U.S. Government Contracts and Grants link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Long-Term Debt link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Stockholders Equity link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Basic and Diluted Loss (Earnings) Per Share link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Goodwill link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Events During the Period link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - General (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Other Accounts Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Stockholders Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - General (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - General (Details) - Schedule of Fair Value of the Merger Warrants link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - General (Details) - Schedule of Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - General (Details) - Schedule of Pro Forma Financial Information link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilities link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement Warrants link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - U.S. Government Contracts and Grants (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Long-Term Debt (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Stockholders Equity (Details) - Part-1 link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Stockholders Equity (Details) - Part-2 link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Stockholders Equity (Details) - Schedule of Options Granted to Purchase link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Stockholders Equity (Details) - Schedule of Stock-Based Payment Expenses link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial Instruments link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per Share link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 996035 - Disclosure - Events During the Period (Details) link:presentationLink link:definitionLink link:calculationLink 996036 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 phge-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 phge-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 phge-20240930_lab.xml XBRL LABEL FILE Total current assets Total non-current assets Total Assets Total current liabilities Total non-current liabilities Total stockholdersâ€™ equity Balance Balance Total liabilities and stockholdersâ€™ equity Operating loss Loss (income) before tax Net loss (income) Net income (loss) Net loss Net loss attributable to APT Net loss (income) (in Dollars) Balance (in Shares) Balance (in Shares) Class of Stock [Axis] Equity Components [Axis] Net cash used in operating activities Net cash provided by investing activities Net cash provided by financing activities Increase (decrease) in cash and cash equivalents and restricted cash Cash and cash equivalents and restricted cash at the beginning of the period Cash and cash equivalents and restricted cash at the end of the period Total cash and cash equivalents and restricted cash General [Abstract] Total assets Total liabilities Total consideration Finite-Lived Intangible Assets by Major Class [Axis] Equity Interest Type [Axis] Class of Warrant or Right [Axis] Measurement Input Type [Axis] Consolidated Entities [Axis] Schedule of Pro Forma Financial Information [Abstract] Significant Accounting Policies [Abstract] Fair Value of Financial Instruments [Abstract] Total assets Total liabilities Fair Value Hierarchy and NAV [Axis] Beginning balance Ending balance Other Current Assets [Abstract] Schedule of Other Current Assets [Abstract] Other current assets Other current assets Other Accounts Payable [Abstract] Schedule of Other Accounts Payable [Abstract] Other accounts payable Other accounts payable Leases [Abstract] Commitments and Contingencies [Abstract] U.S. Government Contracts and Grants [Abstract] Long-Term Debt [Abstract] Stockholders Equity [Abstract] Award Type [Axis] Related Party Transaction [Axis] Derivative Instrument [Axis] Number of Options, Beginning Balance Number of Options, Ending Balance Weighted Average Exercise Price, Beginning Balance Weighted Average Exercise Price, Ending Balance Aggregate Intrinsic Value, Beginning Balance Aggregate Intrinsic Value, Ending Balance Sale of Stock [Axis] Exercise Price Range [Axis] Statement of Income Location, Balance [Axis] Basic and Diluted Loss (Earnings) Per Share [Abstract] Antidilutive Securities [Axis] Goodwill [Abstract] Events During the Period [Abstract] Subsequent Events [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Entity Central Index Key ASSETS Assets: Current assets Cash and cash equivalents Restricted cash Non-current assets Other assets Operating lease right-of-use assets Property and equipment, net In-process Research and development (â€œIPR&Dâ€) assets LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Current liabilities Trade accounts payable Current portion of lease liabilities Current portion of long-term debt Non-current liabilities Contract liability Long-term debt, net of current portion Operating lease liabilities, net of current portion Other liabilities Private Placement Warrants Commitments and Contingencies (Note 7) Stockholdersâ€™ equity Preferred Stock, $0.0001 par value; Authorized â€“ 1,000,000 shares as of September 30, 2024 and December 31, 2023. Issued and outstanding- 147,735 as of September 30, 2024. No shares issued and outstanding as of December 31, 2023. Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, $0.0001 par value; Authorized â€“ 750,000,000 shares as of September 30, 2024 and 120,000,000 shares as of December 31, 2023. Issued and outstanding- 18,176,602 shares as of September 30, 2024 and 4,723,320 shares as of December 31, 2023. Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid in capital Accumulated deficit Accumulated deficit (in Dollars) Research and development (â€œR&Dâ€) expenses, net General and administrative expenses Goodwill impairment Goodwill impairment (in Dollars) Interest expenses Income from change in fair value of Private Placement Warrants Change in fair value Change in fair value of Private Placement Warrants (in Dollars) Tax expenses Basic loss (earnings) per share of Common Stock (in Dollars per share) Basic loss (earnings) per share of common stock (in Dollars per share) Diluted loss (earnings) per share of Common Stock (in Dollars per share) Diluted net loss per share of common stock (in Dollars per share) Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock (in Shares) Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share Weighted-average number of shares of common stock outstanding Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (in Shares) Redeemable convertible preferred shares Exercise of Pre-Funded Warrants into shares of Common Stock Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares) Number of Options, Exercised Exercised shares Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (in Shares) Issuance of common stock under open market sales agreement, net of issuance costs Stock-based compensation expenses Stock-based compensation expenses (in Shares) Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (in Shares) Issuance of redeemable convertible preferred shares upon March 2024 PIPE, net of issuance costs Reclassification of Redeemable convertible preferred Shares to equity Reclassification of Redeemable convertible preferred Shares to equity (in Shares) Redeemable Convertible Preferred Shares conversion into shares of Common Stock Redeemable Convertible Preferred Shares conversion into shares of Common Stock (in Shares) Redeemable Convertible Preferred Shares conversion into shares of Common Stock Redeemable convertible preferred shares Issuance of Common Stock upon restricted stock units (â€œRSUâ€) vesting Issuance of Common Stock upon restricted stock units (â€œRSUâ€) vesting (in Shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs Aggregate offering price (in Dollars) Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs (in Shares) Aggregate shares Aggregate shares (in Shares) Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs CASH FLOWS â€“ OPERATING ACTIVITIES Adjustments required to reconcile cash flows used in operating activities: Depreciation and amortization Stock-based compensation Share based compensation (in Dollars) Amortization of debt issuance costs Revaluation of contingent consideration Private Placement Warrants issuance cost Changes in operating assets and liabilities: Trade accounts payable Other accounts payable Net change in operating leases CASH FLOWS â€“ INVESTING ACTIVITIES Proceeds from short-term deposits Proceeds from sale of property and equipment CASH FLOWS â€“ FINANCING ACTIVITIES Issuance of Private Placement Warrants under March 2024 PIPE Private Placement Warrants Private placement warrants (in Dollars) Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE Issuance of Common Stock and Warrants under February 2023 PIPE Aggregate gross proceeds (in Dollars) Pre-Funded Warrants exercise Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs Effect of exchange rate changes on cash and cash equivalents and restricted cash RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest Taxes paid SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Property and equipment purchases included in accounts payable and Trade payable Issuance cost from March 2024 PIPE Issuance of Common Stock under the APT acquisition Issuance of Redeemable Convertible Preferred Shares under the APT acquisition Issuance of Merger Warrants under the APT acquisition Redeemable Convertible Preferred Shares conversion into shares of Common Stock Other income Finance expense (income), net Finance income, net Change in contract liability Loss from sale and disposal of fixed assets, net Other current and non-current assets Cash and restricted cash acquired from the APT acquisition Purchases of property and equipment March 2024 PIPE issuance costs Net proceeds from PIPE (in Dollars) Issuance costs from February 2023 PIPE Issuance cost from the APT acquisition Repayment of long-term debt Redeemable Convertible Preferred Shares Preferred Shares [Member] Redeemable Convertible Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit GENERAL Schedule of Fair Value Acquired Identifiable Assets And Assumed Liabilities Cash and cash equivalents Restricted cash Other current assets Property, plant and equipment Operating lease right-of-use asset IPR&D assets and Goodwill Goodwill value (in Dollars) Goodwill Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition Total Schedule of Fair Value of the Merger Warrants Schedule of Fair Value of the Liabilities for the Private Placement Warrants Merger warrant measurement input Private placement warrants Schedule of Condensed Consolidated Statements of Operations Schedule of Pro Forma Financial Information Net loss SIGNIFICANT ACCOUNTING POLICIES FAIR VALUE OF FINANCIAL INSTRUMENTS Schedule of Fair Value of Our Financial Assets and Liabilities Cash equivalents: Money market funds Foreign exchange contracts receivable Fair value asset Liabilities: Contingent consideration

Schedule of Fair Value Level 3 financial liabilities OTHER CURRENT ASSETS Schedule of Other Current Assets Government institutions Prepaid insurance Other prepaid expenses Grants receivable Other OTHER ACCOUNTS PAYABLE Schedule of Other Accounts Payable Employees and related institutions Accrued expenses Government institutions Prepaid sublease income Severance related to former employees of APT LEASES COMMITMENTS AND CONTINGENCIES U.S. GOVERNMENT CONTRACTS AND GRANTS LONG-TERM DEBT STOCKHOLDERS EQUITY Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders Issuance Date Expiration Date Exercise Price Per Share Exercise price per share (in Dollars per share) Exercise price (in Dollars per share) Exercise price Number of Shares of Common Stock Underlying Warrants Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model Underlying value of Common Stock ($) Exercise price ($) Expected volatility (%) Expected terms (years) Risk-free interest rate (%) Schedule of Options Granted to Purchase Number of Options, Granted Grant of options Weighted Average Exercise Price, Granted Options granted exercise price (in Dollars per share) Weighted Average Exercise Price, Forfeited Weighted Average Exercise Price, Expired Weighted Average Exercise Price, Exercised Number of Options, Exercisable at end of period Weighted Average Exercise Price, Exercisable at the end of period Weighted average remaining contractual life of outstanding options â€“ years as of September 30, 2024 Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock Issuance Date Schedule of Stock-Based Payment Expenses Stock-based payment expenses BASIC AND DILUTED LOSS (EARNINGS) PER SHARE Schedule of Anti-dilutive Financial Instruments Anti-dilutive shares Schedule of Basic and Diluted Loss (earnings) Per Share Basic loss (earnings) per share of common stock Numerator: Net loss (income) attributable to shares of common stock (in Dollars) Denominator: Number of shares of common stock outstanding Number of shares upon Pre-Funded Warrants exercise Number of shares upon Fully vested Warrants exercise Diluted net loss per share of common stock Numerator: Diluted net loss (in Dollars) Denominator: Private Placement Warrants Options GOODWILL EVENTS DURING THE PERIOD SUBSEQUENT EVENTS Trade accounts payable Other accounts payable Operating lease liability Number of Options, Forfeited Number of Options, Expired Amount allocated to Redeemable Convertible Preferred Shares (in Dollars) Purchase Price Allocation [Member] Redeemable Convertible Preferred Stock [Member] Redeemable Convertible Preferred Shares [Member] Merger Warrants [Member] Merger Warrants Underlying value of Common Stock [Member] Exercise price [Member] Expected volatility [Member] Expected terms [Member] Risk-free interest rate [Member] Adaptive Phage therapeutics LLC [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Underlying value of Common Stock [Member] IPO (December 13, 2018) [Member] Public Warrants [Member] SPA (July 28, 2021) [Member] 2021 Registered Direct Offering Warrants [Member] March 15, 2024 [Member] Private Placement Warrants [Member] Agents Warrants [Member] Warrants [Member] Warrant [Member] Black-Scholes-Merton Model [Member] Stock Option [Member] Private Warrants issued to scientific founders [Member] Landlord Warrants [Member] Research and development expenses, net [Member] General and administrative [Member] Options [Member] Contingent shares [Member] Redeemable Convertible Preferred Shares [Member] Redeemable convertible preferred shares [Member] Business Acquisition [Axis] Related and Nonrelated Parties [Axis] Statistical Measurement [Axis] Lease Contractual Term [Axis] Loss Contingency Nature [Axis] Product and Service [Axis] Vesting [Axis] Debt Instrument [Axis] Credit Facility [Axis] Plan Name [Axis] Title and Position [Axis] Subsequent Event Type [Axis] Shares received Additional shares Conversion of stock, shares converted Converted shares of common stock Reverse stock split Expiration term Proceeds from business combination (in Dollars) Business acquisition percentage Transaction costs (in Dollars) Intangible assets (in Dollars) Increase to goodwill (in Dollars) Percentage of discount for lack of marketability Exercise price Exercise price per share (in Dollars per share) Discount rate, percentage Foreign exchange contracts Square feet of area (in Square Meters) Payments for rent Lease payments Premises fee Payment amount Warrants issued (in Shares) Termination fee Lease expenses Oyster paid upfront payment Payment from APT to Oyster Other accounts payable Manufacturing capabilities Fund approved budget Received amount Aggregate budget Percentage of approved budgets Received amount Royalties rate Total approved grants Grant receivable Received grants Royalty expense Contingent obligation Receive fees Installment amount Milestones contract value Total contract value Percentage of assessment fee Reduction expenses, net Advanced amount Prepayment charge, percentage Term loan facility Interest expense term loan amount Prepayment Accrued interest Prepaid principal amount Interest expense Aggregate warrants Issuance cost (in Dollars) Total consideration amount (in Dollars) Convertible preferred shares Combination price (in Dollars per share) Warrant exercise price (in Dollars per share) Transaction cost (in Dollars) Sale of stock Sale of stock price (in Dollars per share) Aggregate net proceeds (in Dollars) Aggregate commission (in Dollars) Total number of fully-diluted shares Restricted stock unit fair value (in Dollars per share) Contract liability Contract liability recognized Unaudited Condensed Financial Statements Principles of Consolidation Use of Estimates in the Preparation of Financial Statements Business Combination Financial instruments Basic and diluted loss (earnings) per share Intangible Assets Recent Accounting Standards Business Combination [Member] APTâ€™s Stockholders [Member] APTâ€™s stockholders [Member] Multi-Period Excess Earnings Method (â€œMPEEMâ€) [Member] Minimum [Member] Maximum [Member] Lease Agreement [Member] Israel Innovation Authority [Member] Cystic Fibrosis Product [Member] MTEC [Member] First Tranche [Member] Loan Agreement [Member] Line of Credit [Member] Long Term Debts [Member] Hercules Capital Inc [Member] March 2024 PIPE [Member] PIPE [Member] Private Placement [Member] Pre funded warrants [Member] March 2024 PIPE [Member] Board of Directors [Member] Subsequent Event [Member] Class of Stock [Domain] Equity Component [Domain] Statement [Table] Statement [Line Items] Class of Warrant or Right [Domain] General (Tables) [Table] General (Tables) [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities [Table] Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities [Line Items] Equity Interest Issued or Issuable, Type [Domain] Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items] Measurement Input Type [Domain] Fair Value Measurement Inputs and Valuation Techniques [Table] Schedule of Fair Value of Merger Warrants [Line Items] Consolidated Entities [Domain] Condensed Income Statement [Table] Schedule of Condensed Consolidated Statements of Operations [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities [Table] Schedule of Fair Value of Our Financial Assets and Liabilities [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Schedule of Fair Value Level 3 Financial Liabilities [Line Items] Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items] Award Type [Domain] Related Party Transaction [Domain] Class of Warrant or Right [Table] Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Derivative Contract [Domain] Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model [Table] Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model [Line Items] Sale of Stock [Domain] Stockholders Equity (Details) - Schedule of Options Granted to Purchase [Table] Schedule of Options Granted to Purchase [Line Items] Exercise Price Range [Domain] Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock [Table] Class of Warrant or Right [Line Items] Statement of Income Location, Balance [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Stock-Based Payment Expenses [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Security, Excluded EPS Calculation [Table] Schedule of Anti-dilutive Financial Instruments [Line Items] Business Acquisition, Acquiree [Domain] Related and Nonrelated Parties [Domain] General (Details) [Table] General [Line Items] Statistical Measurement [Domain] Fair Value of Financial Instruments (Details) [Table] Fair Value of Financial Instruments [Line Items] Lease Contractual Term [Domain] Leases (Details) [Table] Leases [Line Items] Loss Contingency, Nature [Domain] Product and Service [Domain] Commitments and Contingencies (Details) [Table] Commitments and Contingencies [Line Items] U.S. Government Contracts and Grants (Details) [Table] U.S. Government Contracts and Grants [Line Items] Credit Facility [Domain] Vesting [Domain] Debt Instrument, Name [Domain] Long-Term Debt (Details) [Table] Long-Term Debt [Line Items] Plan Name [Domain] Stockholders Equity (Details) - Part-1 [Table] Stockholders Equity [Line Items] Title and Position [Domain] Stockholders Equity (Details) - Part-2 [Table] Basic and Diluted Loss (Earnings) Per Share (Details) [Table] Basic and Diluted Loss (Earnings) Per Share [Line Items] Subsequent Event Type [Domain] Subsequent Events (Details) [Table] Subsequent Events [Line Items] Aggregate amount of budget. The amount of restricted cash. Amount of operating lease liability. The amount of Operating lease right-of-use asset. Change in contract liability. Consideration paid. Expiration date. The fund approved budget. Government institutions. The amount of installment. Issuance cost from March 2024 PIPE. Issuance cost from the APT acquisition. Issuance cost from the APT acquisition. Issuance date. Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs. Issuance of Merger Warrants under the APT acquisition. The amount of issuance of redeemable convertible preferred shares under the apt acquisition. Milestones contract value. Number of shares of common stock outstanding. Number of shares upon Fully vested Warrants exercise. Number of shares upon Pre-Funded Warrants exercise. The shares of option. Oyster paid an upfront payment. Payment from APT to oyster. Percentage of assessment fee. Percentage of discount for lack of marketability (â€œDLOMâ€). Percentage of total fund. Prepaid sublease income. Proceeds from business combination. Property and equipment purchases included in accounts payable and trade payable. Received amount. Pay based on royalties rate. Number of new stock issued during the period. Redeemable Convertible preferred shares conversion into shares of common stock. Issuance of common stock and warrants under february 2023 PIPE, net of issuance costs. Total approved grants. Amount of total contract value. Number of fully-diluted shares. Issuance date. Stockholders' Equity, Reverse Stock Split Assets [Abstract] Cash and Cash Equivalents [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Small Business Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Earnings Per Share, Diluted Liabilities, Noncurrent [Abstract] Retained Earnings [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Proceeds From Business Combination Weighted Average Number of Shares Outstanding, Basic Preferred Stock, Convertible, Shares Issuable Private Warrants Issued To Scientific Founder Member Warrants and Rights Outstanding, Maturity Date Public Warrants Member Measurement Input, Exercise Price [Member] Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Business Acquisition, Transaction Costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Long-Term Debt, Current Maturities Local Phone Number Stock Issued During Period, Shares, Acquisitions Goodwill, Other Increase (Decrease) Schedule Of Fair Value Acquired Identifiable Assets And Assumed Liabilities Abstract Fund Approved Budget Percentage Diluted Net Loss Per Share Of Common Stock Abstract Stock Issued During Period, Shares, New Issues Entity Common Stock, Shares Outstanding Goodwill and Intangible Assets, Policy [Policy Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Gain (Loss) on Contract Termination Assets, Noncurrent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Title of 12(b) Security Other Assets, Noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Additional Paid in Capital Prepayment Fees on Advances, Net Board of Directors Chairman [Member] Stock Issued During Period, Shares, Conversion of Units Issuance Date Class Of Warrant Warrants and Rights Outstanding Net Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Other Accounts Payable Increase (Decrease) in Accounts Payable, Trade Lease Agreement Member Royalty Expense Accounts Payable, Trade, Current Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Contract with Customer, Liability, Noncurrent Security Exchange Name Prepaid Insurance Schedule Of Fair Value Level3 Financial Liabilities Abstract Minimum [Member] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Common Stock, Shares, Outstanding Milestones Contract Value Liabilities, Fair Value Disclosure Percentage Of Total Fund Retained Earnings (Accumulated Deficit) Net Cash Provided by (Used in) Investing Activities Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Payments for Other Fees Aggregate Amount Of Budget Payments to Acquire Property, Plant, and Equipment Hercules Capital Inc Member Cystic Fibrosis Product Member Preferred Stock, Shares Authorized Interest Paid, Excluding Capitalized Interest, Operating Activities Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability Maximum [Member] Manufacturing Costs Entity Address, Address Line One Common Stock, Shares Authorized Entity Incorporation, State or Country Code Entity Address, Address Line Two Goodwill, Impairment Loss Operating Lease, Liability, Noncurrent Event During The Period Text Block March2024 PIPEMember Preferred Stock [Member] Contingent Consideration Classified as Equity, Fair Value Disclosure Lease, Cost Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Redeemable Preferred Stock [Member] Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Other Income Class of Warrant or Right, Number of Securities Called by Warrants or Rights Purchase Price Allocation Member Accounts Payable, Other Share-Based Payment Arrangement, Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance Of Redeemable Convertible Preferred Shares Under The APTAcquisition Stock Issued During Period, Shares, Restricted Stock Award, Gross Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Two Thousand Twenty One Registered Direct Offering Warrants Member Contract with Customer, Liability, Revenue Recognized Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Depreciation, Depletion and Amortization, Nonproduction Schedule Of Fair Value Of Our Financial Assets And Liabilities Abstract Increase (Decrease) in Other Operating Assets Significant Accounting Policies [Text Block] Goodwill Number Of Shares Upon Pre Funded Warrants Exercise Interest Expense, Long-Term Debt Unlabeled Abstract3 Unlabeled Abstract2 Unlabeled Abstract5 Unlabeled Abstract4 Schedule Of Anti Dilutive Financial Instruments Abstract Unlabeled Abstract1 Unlabeled Abstract0 Unlabeled Abstract7 Unlabeled Abstract6 Unlabeled Abstract9 Unlabeled Abstract8 Fair Value, Inputs, Level 3 [Member] Foreign Currency Contract, Asset, Fair Value Disclosure Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Net Cash Provided by (Used in) Operating Activities Issuance of Stock and Warrants for Services or Claims Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Merger Warrants Member Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability SPAJuly282021 PMember Warrant, Exercise Price, Increase Stock Issued During Period Shares Redeemable Convertible Preferred Shares Conversion Into Shares Of Common Stock Money Market Funds, at Carrying Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock Issued During Period, Shares, Other Payments of Stock Issuance Costs Fair Value, Inputs, Level 1 [Member] Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Net Of Issuance Costs Stock Issued During Period Sharess Redeemable Convertible Preferred Shares Conversion Into Shares Of Common Stock Equity, Attributable to Parent Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block] Line of Credit [Member] Asset Acquisition, Consideration Transferred Fair Value Adjustment of Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Current Fiscal Year End Date Number Of Shares Upon Fully Vested Warrants Exercise Schedule Of Outstanding Warrants To Purchase Common Stock Issued To Stockholders Abstract Entity Address, Postal Zip Code Debt Instrument, Increase, Accrued Interest Net Income (Loss) Available to Common Stockholders, Basic Schedule Of Outstanding Compensation Related Warrants To Purchase Common Stock Abstract Document Fiscal Period Focus Business Combination, Consideration Transferred March Fifteen Two Thousand Twenty Four Member Property And Equipment Purchases Included In Accounts Payable And Trade Payable Share-Based Payment Arrangement, Tranche One [Member] Royalties Rate Accounts Payable, Other, Current Equity [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Proceeds from Warrant Exercises Sale of Stock, Number of Shares Issued in Transaction Loan Agreement Member Development in Process Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Israel Innovation Authority Member Statement of Financial Position [Abstract] Cash and Cash Equivalents, at Carrying Value Other Current Assets [Text Block] Entity File Number Entity Tax Identification Number Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Document Type Stock Issued During Period, Shares, Conversion of Convertible Securities Accrued Liabilities Expiration Date Class Of Warrant Document Period End Date Proceeds from Issuance of Common Stock Entity Interactive Data Current Finite-Lived Intangible Assets Acquired Schedule of Other Current Assets [Table Text Block] Weighted Average Number of Shares Outstanding, Diluted, Adjustment Liabilities [Abstract] Debt Conversion, Converted Instrument, Warrants or Options Issued Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Share-Based Payment Arrangement, Noncash Expense Change In Contract Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Symbol Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Entity Address, City or Town Options Payments for Rent Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Income Taxes Paid, Net Warrants And Rights Outstanding Issuance Date Restricted Cash, Current Common Stock, Value, Issued City Area Code Amortization of Debt Issuance Costs Supplemental

Unemployment Benefits, Severance Benefits Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents MTECMember Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Schedule of Stock Options Roll Forward [Table Text Block] Weighted Average Number of Shares Outstanding, Basic [Abstract] Operating Lease, Payments Schedule Of Fair Value Of The Liabilities For The Private Placement Warrants Abstract PIPEMember Stock Issued During Period, Value, New Issues Statement of Stockholders' Equity [Abstract] Basis of Accounting, Policy [Policy Text Block] Increase (Decrease) in Operating Lease Liability Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Adaptive Phage Therapeutics LLCMember Proceeds from Issuance of Convertible Preferred Stock Stock Issued During Period, Value, Acquisitions Measurement Input, Share Price [Member] Income Tax Expense (Benefit) Research and Development Expense [Member] Reductions in Other Assets, Amount Payment From APTTo Oyster Income Statement [Abstract] Lessee, Operating Leases [Text Block] Convertible Preferred Stock [Member] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Consideration Paid Earnings Per Share, Basic Liabilities, Noncurrent Other Noncash Income (Expense) Business Acquisition, Pro Forma Net Income (Loss) Assets Research and Development Expense Cash, Cash Equivalents, and Short-Term Investments [Abstract] Receivables, Long-Term Contracts or Programs Entity Shell Company Subsequent Events [Text Block] Long Term Debts Member Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Assets, Fair Value Disclosure Stock Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Warrants and Rights Outstanding, Measurement Input Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Prepaid Sublease Income Conversion of Stock, Shares Converted Schedule Of Options Granted To Purchase Abstract Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Net Cash Provided by (Used in) Financing Activities Contingent Shares Member Issuance Of Merger Warrants Under The APTAcquisition Business Acquisition, Share Price Debt Instrument, Issued, Principal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Employee-related Liabilities Interest Expense, Nonoperating Subsequent Event [Member] Warrant [Member] Total Number Of Fullydiluted Shares Percentage Received Amount Amendment Flag Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Entity Address, Country Contract with Customer, Liability Sale of Stock, Consideration Received on Transaction Number Of Shares Of Common Stock Outstanding Entity Central Index Key Temporary Equity, Accretion to Redemption Value Operating Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Private Placement Warrants Member Repayments of Long-Term Debt Other Long-Term Debt Schedule Of Fair Value Of The Merger Warrants Abstract Fair Value, Concentration of Risk, Foreign Currency Contract, Asset APTs Stockholders Member Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Business Combination, Contingent Consideration, Asset Goodwill Disclosure [Text Block] Sale of Stock, Price Per Share USGovernment Contracts And Grants Text Block Schedule Of Fair Value Of The Consideration Transferred To Apt Shareholders Acquisition Abstract Common Stock [Member] Net Income (Loss) Available to Common Stockholders, Diluted Entity Registrant Name Basic Loss Earnings Per Share Of Common Stock Abstract Measurement Input, Price Volatility [Member] Statement of Cash Flows [Abstract] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Interest Expense, Operating and Nonoperating Class of Warrant or Right, Outstanding Business Combinations Policy [Policy Text Block] Other Prepaid Expense, Current Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Measurement Input, Risk Free Interest Rate [Member] Operating Lease, Liability, Current Area of Land Line of Credit Facility, Commitment Fee Percentage Long-Term Debt, Weighted Average Interest Rate, at Point in Time Other Liabilities, Noncurrent Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance Cost From The APTAcquisitions Government Assistance, Asset, Current Total Approved Grants Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Long-Term Debt, Excluding Current Maturities Total Contract Value Liabilities, Current [Abstract] Stock Issued During Period, Value, Conversion of Units Employee Stock [Member] Other Assets, Current APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Legal Fees General and Administrative Expense [Member] Fair Value Assumption, Date of Securitization or Asset-Backed Financing Arrangement, Transferor's Continuing Involvement, Servicing Assets or Liabilities, Discount Rate Fair Value of Financial Instruments, Policy [Policy Text Block] Supplemental Cash Flow Elements [Abstract] Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Rightofuse Asset Earnings Per Share [Text Block] Business Acquisition, Percentage of Voting Interests Acquired Share Price Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Conversion of Convertible Securities Landlord Warrants Member Other Deferred Costs, Net General and Administrative Expense Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Pre Funded Warrants Member Document Fiscal Year Focus Common Stock, Par or Stated Value Per Share Earnings Per Share, Policy [Policy Text Block] Entity Current Reporting Status Common Stock, Shares, Issued Proceeds from Issuance of Private Placement Entity Emerging Growth Company Payment of Financing and Stock Issuance Costs Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Redeemable Convertible Preferred Shares Member Weighted Average Number of Shares Outstanding, Diluted Business Acquisition, Pro Forma Information [Table Text Block] Percentage Of Discount For Lack Of Marketability DLOM Agents Warrants Member Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Disclosures [Text Block] IPODecember132018 Member Series of Individually Immaterial Business Acquisitions [Member] Private Placement [Member] Document Transition Report Grants Receivable, Current Net Income (Loss) Attributable to Parent Long-Term Debt [Text Block] Stock Issued During Period, Value, Restricted Stock Award, Gross Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Assets, Current [Abstract] Document Quarterly Report Oyster Paid An Upfront Payment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Proceeds from Sale of Productive Assets Liabilities, Current Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restrictedcash Proceeds from Debt, Net of Issuance Costs Condensed Income Statement [Table Text Block] Schedule Of Condensed Consolidated Statements Of Operations Abstract Consolidation, Policy [Policy Text Block] Multi Period Excess Earnings Method MPEEMMember Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] Measurement Input, Expected Term [Member] Measurement Input Underlying Value Of Common Stock Member Grants Receivable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Schedule Of Fair Value Of The Agents Warrants Using The Black Scholes Model Abstract Entity Filer Category Percentage Of Assessment Fee Warrant, Exercise Price, Decrease Preferred Stock, Value, Issued Proceeds from Sale of Short-Term Investments Liabilities and Equity Issuance Cost From The APTAcquisition Nonoperating Income (Expense) Redeemable Convertible Preferred Stock [Member] Black-Scholes-Merton Model [Member] Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Payments to Acquire Businesses, Net of Cash Acquired Assets, Noncurrent [Abstract] Issuance Of Common Stock Under Open Market Sales Agreement Net Of Issuance Costs Government Institutions Installment Amount Issuance Cost From March2024 PIPE Preferred Stock, Par or Stated Value Per Share Operating Lease, Right-of-Use Asset Excess Stock, Shares Issued Assets, Current Proceeds from Other Equity Schedule Of Stock Based Payment Expenses Abstract EX-101.PRE 12 phge-20240930_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 12, 2024 Document Information Line Items Â Â Entity Registrant Name BiomX Inc. Â Trading Symbol PHGE Â Document Type 10-Q Â Current Fiscal Year End Date --12-31 Â Entity Common Stock, Shares Outstanding Â 18,176,602 Amendment Flag false Â Entity Central Index Key 0001739174 Â Entity Current Reporting Status Yes Â Entity Filer Category Non-accelerated Filer Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Document Quarterly Report true Â Document Transition Report false Â Entity File Number 001-38762 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 82-3364020 Â Entity Address, Address Line One 22 Einstein St., Â Entity Address, Address Line Two Floor 4 Â Entity Address, City or Town Ness Ziona Â Entity Address, Country IL Â Entity Address, Postal Zip Code 7414003 Â City Area Code +972 Â Local Phone Number 723942377 Â Title of 12(b) Security Common stock, $0.0001 par value Â Security Exchange Name NYSE Â Entity Interactive Data Current Yes Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 23,537 $ 14,907 Restricted cash 1,114 957 Other current assets 3,665 1,768 Total current assets 28,316 17,632 Non-current assets Â Â Other assets 96 Operating lease right-of-use assets 9,700 3,495 Property and equipment, net 6,581 3,902 In-process Research and development (â€œIPR&Dâ€) assets 15,287 Total non-current assets 31,664 7,397 Total Assets 59,980 25,029 Current liabilities Â Â Trade accounts payable 2,779 1,381 Current portion of lease liabilities 1,096 666 Other accounts payable 5,069 3,344 Current portion of long-term debt 5,785 Total current liabilities 8,944 11,176 Non-current liabilities Â Â Contract liability 1,976 Long-term debt, net of current portion 5,402 Operating lease liabilities, net of current portion 8,651 3,239 Other liabilities 161 155 Private Placement Warrants 4,328 Total non-current liabilities 13,140 10,772 Commitments and Contingencies (Note 7) Stockholdersâ€™ equity Â Â Preferred Stock, $0.0001 par value; Authorized â€” 1,000,000 shares as of September 30, 2024 and December 31, 2023. Issued and outstanding- 147,735 as of September 30, 2024. No shares issued and outstanding as of December 31, 2023. 18,645 Common Stock, $0.0001 par value; Authorized â€“ 750,000,000 shares as of September 30, 2024 and 120,000,000 shares as of December 31, 2023. Issued and outstanding- 18,176,602 shares as of September 30, 2024 and 4,723,320 shares as of December 31, 2023. [1] 6 3 Additional paid in capital 185,429 166,048 Accumulated deficit (166,184) (162,970) Total stockholdersâ€™ equity 37,896 3,081 Total liabilities and stockholdersâ€™ equity $ 59,980 $ 25,029 [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe current amount of expenditures for a real estate project that has not yet been completed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_DevelopmentInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized 1,000,000 1,000,000 Preferred stock, shares issued 147,735 Preferred stock, shares outstanding 147,735 Common stock, par value (in Dollars per share) [1] $ 0.0001 $ 0.0001 Common stock, shares authorized [1] 750,000,000 120,000,000 Common stock, shares issued [1] 18,176,602 4,723,320 Common stock, shares outstanding [1] 18,176,602 4,723,320 [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Research and development (â€œR&Dâ€) expenses, net $ 7,279 $ 5,641 $ 18,281 $ 14,023 General and administrative expenses 3,248 2,154 8,756 6,053 Goodwill impairment 801 801 Operating loss 11,328 7,795 27,838 20,076 Other income (84) (89) (2,189) (270) Interest expenses 5 574 868 1,884 Income from change in fair value of Private Placement Warrants (20,559) (24,417) Finance expense (income), net (332) (382) 1,104 (1,034) Loss (income) before tax (9,642) 7,898 3,204 20,656 Tax expenses 8 10 22 Net loss (income) $ (9,642) $ 7,906 $ 3,214 $ 20,678 Basic loss (earnings) per share of Common Stock (in Dollars per share) [1] $ (0.31) $ 1.3 $ 0.32 $ 4.29 Diluted loss (earnings) per share of Common Stock (in Dollars per share) [1] $ (0.31) $ 1.3 $ 2.45 $ 4.29 Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock (in Shares) 16,366,122 6,058,774 9,944,267 4,819,658 Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) 16,387,633 6,058,774 11,294,880 4,819,658 [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue and income classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_OtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -

Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholdersâ€™ Equity (Capital Deficiency) (Unaudited) - USD ($) $ in Thousands Preferred Shares Redeemable Convertible Preferred Shares Redeemable Convertible Common Stock Additional Paid-in Capital Accumulated Deficit Total Balance at Dec. 31, 2022 Â Â $ 2 [1] $ 157,838 $ (136,801) $ 21,039 Balance (in Shares) at Dec. 31, 2022 [1] Â Â 3,122,987 Â Â Â Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs [3] Â Â [1],[2] 1,293 1,293 Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs (in Shares) [1],[3] Â Â 319,950 Â Â Â Stock-based compensation expenses Â Â [1] 175 175 Stock-based compensation expenses (in Shares) [1] Â Â Â Â Â Net income (loss) Â Â (6,361) (6,361) Balance at Mar. 31, 2023 Â Â $ 2 [1] 159,306 (143,162) 16,146 Balance (in Shares) at Mar. 31, 2023 [1] Â Â 3,442,937 Â Â Â Balance at Dec. 31, 2022 Â Â $ 2 [1] 157,838 (136,801) 21,039 Balance (in Shares) at Dec. 31, 2022 [1] Â Â 3,122,987 Â Â Â Net income (loss) Â Â Â Â Â (20,678) Balance at Sep. 30, 2023 Â Â $ 3 [1] 165,630 (157,479) 8,154 Balance (in Shares) at Sep. 30, 2023 [1] Â Â 4,722,733 Â Â Â Balance at Mar. 31, 2023 Â Â $ 2 [1] 159,306 (143,162) 16,146 Balance (in Shares) at Mar. 31, 2023 [1] Â Â 3,442,937 Â Â Â Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs [3] Â Â $ 1 [1] 5,858 Â 5,859 Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs (in Shares) [1],[3] Â Â 1,279,796 Â Â Â Stock-based compensation expenses Â Â [1] 271 Â 271 Stock-based compensation expenses (in Shares) [1] Â Â Â Â Â Net income (loss) Â Â Â Â (6,411) (6,411) Balance at Jun. 30, 2023 Â Â $ 3 [1] 165,435 (149,573) 15,865 Balance (in Shares) at Jun. 30, 2023 [1] Â Â 4,722,733 Â Â Â Stock-based compensation expenses Â Â [1] 195 195 Stock-based compensation expenses (in Shares) [1] Â Â Â Â Â Net income (loss) Â Â Â (7,906) (7,906) Balance at Sep. 30, 2023 Â Â $ 3 [1] 165,630 (157,479) 8,154 Balance (in Shares) at Sep. 30, 2023 [1] Â Â 4,722,733 Â Â Â Balance at Dec. 31, 2023 $ 3 [1] 166,048 (162,970) 3,081 Balance (in Shares) at Dec. 31, 2023 4,723,320 [1] Â Â Â Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost [4] $ 12,561 $ 1 [1] 3,227 3,228 Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (in Shares) [4] 40,470 916,497 [1] Â Â Â Exercise of Pre-Funded Warrants into shares of Common Stock [3] [1],[2] 5 5 Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares) [3] Â 477,827 [1] Â Â Â Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs [3] [1],[2] 19 19 Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (in Shares) [3] Â 7,518 [1] Â Â Â Stock-based compensation expenses Â [1] 909 909 Stock-based compensation expenses (in Shares) Â Â Â Â Â Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs [3] $ 19,859 [1] 541 Â 541 Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (in Shares) [3] 216,417 [1] Â Â Â Net income (loss) Â Â (17,327) (17,327) Balance at Mar. 31, 2024 $ 32,420 $ 4 [1] 170,749 (180,297) (9,544) Balance (in Shares) at Mar. 31, 2024 256,887 6,125,162 [1] Â Â Â Balance at Dec. 31, 2023 $ 3 [1] 166,048 (162,970) 3,081 Balance (in Shares) at Dec. 31, 2023 4,723,320 [1] Â Â Â Net income (loss) Â Â Â Â Â (3,214) Balance at Sep. 30, 2024 $ 18,645 $ 6 [1] 185,429 (166,184) 37,896 Balance (in Shares) at Sep. 30, 2024 147,735 18,176,602 [1] Â Â Â Balance at Mar. 31, 2024 $ 32,420 $ 4 [1] 170,749 (180,297) (9,544) Balance (in Shares) at Mar. 31, 2024 256,887 6,125,162 [1] Â Â Â Exercise of Pre-Funded Warrants into shares of Common Stock [3] $ 1 [1] 1 Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares) [3] Â 980,811 [1] Â Â Â Reclassification of Redeemable convertible preferred Shares to equity $ (32,420) $ 32,420 [1] 32,420 Reclassification of Redeemable convertible preferred Shares to equity (in Shares) (256,887) 256,887 [1] Â Â Â Stock-based compensation expenses Â Â 77 77 Stock-based compensation expenses (in Shares) Â Â Â Â Â Net income (loss) Â Â Â 4,471 4,471 Balance at Jun. 30, 2024 $ 32,420 $ 5 [1] 170,826 (175,826) 27,425 Balance (in Shares) at Jun. 30, 2024 256,887 7,105,973 [1] Â Â Â Redeemable Convertible Preferred Shares conversion into shares of Common Stock Â $ (13,775) $ 1 [1] 13,774 Â Redeemable Convertible Preferred Shares conversion into shares of Common Stock (in Shares) Â (109,152) 10,915,200 [1] Â Â Â Issuance of Common Stock upon restricted stock units (â€œRSUâ€) vesting Â [1],[2] [2] Issuance of Common Stock upon restricted stock units (â€œRSUâ€) vesting (in Shares) Â 155,429 [1] Â Â Â Stock-based compensation expenses Â [1] 829 829 Stock-based compensation expenses (in Shares) Â [1] Â Â Â Net income (loss) Â 9,642 9,642 Balance at Sep. 30, 2024 $ 18,645 $ 6 [1] $ 185,429 $ (166,184) $ 37,896 Balance (in Shares) at Sep. 30, 2024 147,735 18,176,602 [1] Â Â Â [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. [2] Less than $1. [3] See Note 10A. [4] See Note 1D. X - DefinitionNumber of new stock issued during the period. + ReferencesNo definition available. + Details Name: phge_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRedeemable Convertible preferred shares conversion into shares of common stock. + ReferencesNo definition available. + Details Name: phge_StockIssuedDuringPeriodSharessRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued attributable to transactions classified as other. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholdersâ€™ Equity (Capital Deficiency) (Unaudited) (Parentheticals) - USD ($) $ in Thousands 3 Months Ended Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Statement of Stockholders' Equity [Abstract] Â Â Â Issuance of common stock under open market sales agreement, net of issuance costs [1] $ 1 Â Â Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs [1] Â $ 157 $ 176 [1] See Note 10A. X - DefinitionIssuance of common stock and warrants under february 2023 PIPE, net of issuance costs. + ReferencesNo definition available. + Details Name: phge_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderNetOfIssuanceCosts Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of

Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS â€“ OPERATING ACTIVITIES Â Â Net loss $ (3,214) $ (20,678) Adjustments required to reconcile cash flows used in operating activities: Â Â Depreciation and amortization 882 659 Stock-based compensation 1,083 641 Amortization of debt issuance costs 453 Finance income, net (478) (293) Revaluation of contingent consideration 6 (40) Income from change in fair value of Private Placement Warrants (24,417) Private Placement Warrants issuance cost 732 Change in contract liability (1,976) Loss from sale and disposal of fixed assets, net 145 Goodwill impairment 801 Changes in operating assets and liabilities: Â Â Other current and non-current assets (213) 679 Trade accounts payable (2,691) 241 Other accounts payable (1,169) 3,354 Net change in operating leases (181) (60) Net cash used in operating activities (30,690) (15,044) CASH FLOWS â€“ INVESTING ACTIVITIES Â Â Cash and restricted cash acquired from the APT acquisition 663 Proceeds from short-term deposits 2,000 Proceeds from sale of property and equipment 72 Purchases of property and equipment (19) (43) Net cash provided by investing activities 716 1,957 CASH FLOWS â€“ FINANCING ACTIVITIES Â Â Issuance of Private Placement Warrants under March 2024 PIPE 28,745 Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE 21,269 March 2024 PIPE issuance costs (507) Issuance costs from February 2023 PIPE (333) Issuance of Common Stock and Warrants under February 2023 PIPE 7,485 Pre-Funded Warrants exercise 6 Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs 19 Issuance cost from the APT acquisition (13) Repayment of long-term debt (10,747) (2,929) Net cash provided by financing activities 38,772 4,223 Increase (decrease) in cash and cash equivalents and restricted cash 8,798 (8,864) Effect of exchange rate changes on cash and cash equivalents and restricted cash (11) (37) Cash and cash equivalents and restricted cash at the beginning of the period 15,864 32,294 Cash and cash equivalents and restricted cash at the end of the period 24,651 23,393 RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS Â Â Cash and cash equivalents 23,537 22,450 Restricted cash 1,114 943 Total cash and cash equivalents and restricted cash 24,651 23,393 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Â Â Cash paid for interest 1,437 1,455 Taxes paid 10 50 SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Property and equipment purchases included in accounts payable and Trade payable 11 5 Issuance cost from March 2024 PIPE 1,685 Issuance of Common Stock under the APT acquisition 3,041 Issuance of Redeemable Convertible Preferred Shares under the APT acquisition 12,610 Issuance of Merger Warrants under the APT acquisition 200 Redeemable Convertible Preferred Shares conversion into shares of Common Stock $ 13,774 X - DefinitionChange in contract liability. + ReferencesNo definition available. + Details Name: phge_ChangeInContractLiability Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance cost from March 2024 PIPE. + ReferencesNo definition available. + Details Name: phge_IssuanceCostFromMarch2024PIPE Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance cost from the APT acquisition. + ReferencesNo definition available. + Details Name: phge_IssuanceCostFromTheAPTAcquisition Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance cost from the APT acquisition. + ReferencesNo definition available. + Details Name: phge_IssuanceCostFromTheAPTAcquisitions Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of Common Stock under Open Market Sales Agreement, net of issuance costs. + ReferencesNo definition available. + Details Name: phge_IssuanceOfCommonStockUnderOpenMarketSalesAgreementNetOfIssuanceCosts Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of Merger Warrants under the APT acquisition. + ReferencesNo definition available. + Details Name: phge_IssuanceOfMergerWarrantsUnderTheAPTAcquisition Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of issuance of redeemable convertible preferred shares under the apt acquisition. + ReferencesNo definition available. + Details Name: phge_IssuanceOfRedeemableConvertiblePreferredSharesUnderTheAPTAcquisition Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProperty and equipment purchases included in accounts payable and trade payable. + ReferencesNo definition available. + Details Name: phge_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndTradePayable Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_GainLossOnDispositionOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name

Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.24.3 General 9 Months Ended Sep. 30, 2024 General [Abstract] Â GENERAL NOTE 1 â€" GENERAL Â Â A. General information Â BiomX Inc. (individually, and together with its subsidiaries, BiomX Ltd. (â€œBiomX Israelâ€), RondinX Ltd. and Adaptive Phage Therapeutics LLC, (â€œAPTâ€), the â€œCompanyâ€ or â€œBiomXâ€) was incorporated in 2017. The Companyâ€™s shares of Common Stock are traded on the NYSE American under the symbol PHGE. The Companyâ€™s units, consisting of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (â€œUnitsâ€), were traded on the NYSE American under the symbol PHGE.U until a mandatory unit separation of the units became effective on October 25, 2024. Certain warrants were quoted on OTC Pink under the symbol â€œPHGEWâ€ and expired on October 28, 2024. Â Â BiomX is developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, focusing its efforts, at this point, on cystic fibrosis and on diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The Companyâ€™s headquarters are located in Ness Ziona, Israel. Â On March 6, 2024, the Company entered into an agreement and plan of merger (the â€œMerger Agreementâ€) with APT and certain other parties, as a result of which APT became a wholly-owned subsidiary of the Company (the â€œAcquisitionâ€), as further described below. Additionally, on March 15, 2024, concurrently with the consummation of the Acquisition, the Company consummated a private placement (the â€œMarch 2024 PIPEâ€) with certain investors pursuant to which such investors purchased an aggregate of 216,417 shares of the Companyâ€™s Series X non-voting convertible preferred share, par value $0.0001 per share (the â€œRedeemable Convertible Preferred Sharesâ€), with each share of Redeemable Convertible Preferred Shares being convertible into 100 shares of the Companyâ€™s Common Stock, after giving effect to the Reverse Split (as defined below), and warrants (the â€œPrivate Placement Warrantsâ€) to purchase up to an aggregate of 10,820,850 shares of the Companyâ€™s Common Stock, for aggregate gross proceeds of approximately $50,000. See Note 1D for further information regarding the Acquisition and the conversion of the Redeemable Convertible Preferred Shares. Â On August 8, 2024, the Board of Directors approved a 1-for-10 reverse stock split of the Companyâ€™s shares of Common Stock (the â€œReverse Splitâ€), effective on August 26, 2024. See Note 10A for further information. Â Â B. The war with Hamas and Hezbollah Â On October 7, 2023, an unprecedented attack was launched against Israel by terrorists from the Hamas terrorist organization that infiltrated Israelâ€™s southern border from the Gaza Strip and in other areas within the state of Israel attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, has attacked military and civilian targets in Northern Israel, to which Israel has responded. Moreover, Iran recently launched a direct attack on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. Such clashes may escalate in the future into a greater regional conflict. Â To date, the State of Israel continues to be at war with Hamas and Hezbollah and in an armed conflict with Iran and its rebel militia groups. Â BiomX headquarters are located in Ness Ziona, Israel; as well as most of its operations. In addition, most of the key employees and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect its business. Â While a few employees of the Company were called to reserve duty in the Israel Defense Forces, the ongoing war with Hamas and Hezbollah has not, since its inception, materially impacted BiomXâ€™s business or operations. Furthermore, BiomX does not expect any delays to its programs as a result of the situation. However, at this time, it is not possible to predict the intensity or duration of Israelâ€™s war against Hamas and Hezbollah, nor predict how this war will ultimately affect BiomX business and operations or Israelâ€™s economy in general.Â Â C. Going concern Â As of September 30, 2024, the Company has an accumulated deficit of $166,184 and has incurred significant losses and negative cash flows from operations. These are expected to continue in the foreseeable future. The Company plans to continue to fund its ongoing operations, as well as other development activities relating to additional product candidates, through issuance of debt and/or equity securities, loans, and government grants. Management believes that its current funds are not sufficient to fund its operations for at least one year from the issuance date of these financial statements. Increased research and development, clinical, or operating expenses may require additional funding or expense postponement. The Companyâ€™s ability to raise capital is subject to market conditions and other aspects, which may affect the terms and availability of such funding. These factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of such circumstances. Â Â D. Merger Agreement Â On March 6, 2024, the Company, entered into the Merger Agreement with BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (â€œFirst Merger Subâ€), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (â€œSecond Merger Subâ€), and APT. Pursuant to the Merger Agreement, First Merger Sub merged with and into APT, with APT being the surviving corporation and becoming a wholly owned subsidiary of the Company (the â€œFirst Mergerâ€). Immediately following the First Merger, APT merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. APT was a U.S.-based privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infection. As a result of the Acquisition, the Company is expected to have a pipeline that includes two Phase 2 assets each aimed at treating serious infections with unmet medical needs. Â On March 15, 2024, the effective date of the Acquisition (the â€œClosing Dateâ€), APTâ€™s former stockholders were issued an aggregate of 916,497 shares of the Companyâ€™s Common Stock, 40,470 Redeemable Convertible Preferred Shares and Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock (â€œMerger Warrantsâ€). Each share of Redeemable Convertible Preferred Shares is convertible into an aggregate of 100 shares, after giving effect to the Reverse Split of Common Stock.Â The Merger Warrants will be exercisable at any time after the date of the receipt of BiomX stockholder approval at an exercise price of $50.00 per share and will expire on January 28, 2027. In the event the Redeemable Convertible Preferred Shares are not converted by the earlier to occur of (i) the time that meeting of BiomX stockholders is ultimately concluded or (ii) five months after the initial issuance of the Redeemable Convertible Preferred Shares, the Company may be required to pay to each holder of the Redeemable Convertible Preferred Shares an amount in cash equal to the fair value of the Redeemable Convertible Preferred Shares. On July 9, 2024, the Companyâ€™s stockholders approved the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock and the issuance of shares of Common Stock upon the exercise of the Merger Warrants. Â The Redeemable Convertible Preferred Shares are entitled to receive dividends on shares of the Redeemable Convertible Preferred Shares equal to, on an as-if-converted-to Common-Stock basis, and in the same form as, dividends actually paid on shares of the Common Stock. Except as otherwise required by law or with respect to the Redeemable Convertible Preferred Shares protective provisions set forth in the Companyâ€™s Certificate of Designations, the Redeemable Convertible Preferred Shares does not have voting rights. Â At the Closing Date, the Redeemable Convertible Preferred Shares were classified as temporary equity in accordance with the provisions of ASC 480-10-S99, as they included clauses that could constitute redemption clauses that were subject to the Companyâ€™s stockholder approval and outside of the Companyâ€™s control. On June 17, 2024, the Company filed a definitive Proxy Statement on Schedule 14A with respect to a meeting of stockholders to approve, among other things, the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock. In addition, the majority of the Companyâ€™s stockholders signed a binding support agreement that contained their commitment to vote in favor or deliver a written consent regarding any stockholdersâ€™ matter in the stockholdersâ€™ meeting which took place on July 9, 2024. These circumstances led the Company to determine that the Redeemable Convertible Preferred Shares meet the definition of permanent equity as the Company is able to control the redemption. Therefore, the Redeemable Convertible Preferred Shares were reclassified as equity. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Companyâ€™s Common Stock according to beneficial ownership limitations set by certain investors.Â The Merger Warrants are classified as equity, as they are indexed to the Companyâ€™s own shares and meet the classification requirements for stockholdersâ€™ equity classification under ASC 815-40. Â Concurrently with the consummation of the Acquisition, the Company entered into a securities purchase agreement with certain investors, for aggregate gross proceeds of $50,000. See Note 10A for further information. Â Immediately following the Acquisition, and without taking into account the PIPE Preferred Shares and the Private Placement Warrants as defined and described in Note 10A, the Companyâ€™s stockholders prior to the Acquisition owned approximately 55% of the Company and APTâ€™s stockholders prior to the Acquisition owned approximately 45% of the Company on a diluted basis. Â The Acquisition was accounted for in accordance with Accounting Standards Codification (â€œASCâ€) Topic 805, â€œBusiness Combinations,â€ using the acquisition method of accounting. The Company was identified as the accounting acquirer, based on the evaluation of the following facts and circumstances: Â Â â— Pursuant to the Merger Agreement, the post-Acquisition board of directors of the Company consisted of seven directors, out of which the Company designated four board seats, with the Companyâ€™s chair of the board prior to the Acquisition continuing in his position, i.e. the majority of the post-closing board was designated by the Company. Â Â â— The Chief Executive Officer and the majority of management roles are held by individuals who were affiliated with the Company prior to the Acquisition. Â The Acquisition-related transaction costs are accounted for as expenses in the period in which the costs are incurred. The Company incurred transaction costs of $874 during the nine months ended September 30, 2024, which were included in general and administrative expenses in the condensed consolidated statements of operations. Â Purchase Price Allocation Â The following sets forth the fair value of acquired identifiable assets and assumed liabilities of APT, after consideringÂ measurement period adjustmentÂ as described below,Â which includes adjustments to reflect the fair value of intangible assets acquired as of March 15, 2024: Â Â Â AmountsÂ Cash and cash equivalentsÂ Â 509Â Restricted cashÂ Â 154Â Other current assetsÂ Â 1,780Â Property, plant and equipmentÂ Â 3,748Â Operating lease right-of-use assetÂ Â 7,953Â IPR&D assets and GoodwillÂ Â 16,088Â Total assetsÂ Â 30,232Â Â Â Â Â Â Trade accounts payableÂ Â (3,667) Other accounts payableÂ Â (2,895) Operating lease liabilityÂ Â (7,819) Total liabilitiesÂ Â (14,381) Total considerationÂ Â 15,851Â Â Â The fair value estimate for all identifiable assets and liabilities assumed is based on assumptions that market participants would use in pricing an asset, based on the most advantageous market for the asset (i.e., its highest and best use). Â The Company recognized intangible assets related to the Acquisition, which consist of IPR&D valued at $15,287 using the Multi-Period Excess Earnings Method valuation method and of goodwill valued at $501. The goodwill is primarily attributed to the expected synergies from combining the operations of APT with the Companyâ€™s operations and to the assembled workforce of APT. The IPR&D is considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon successful completion of the project, IPR&D assets are reclassified to developed technology and amortized over their estimated useful livesÂ During the three months ended September 30, 2024, the Company made measurement period adjustment to the purchase price allocation, which resulted in an increase to goodwill of $300. The increase resulted from a provision for a contingency not provided in the initial Purchase Price Allocation,Â following a term sheet for a settlement agreement between APT and Oyster Point Pharma, Inc. (â€œOysterâ€) in connection with the Collaboration and Option Agreement signed in May 2021 as discussed in Note 7A. The fair value of assets acquired and liabilities assumed have been finalized. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information. Â These intangible assets are classified as Level 3 measurements within the fair value hierarchy. Â Â The following table summarizes the fair value of the consideration transferred to APT shareholders for the Acquisition: Â Â Â AmountsÂ Common StockÂ Â 3,041Â Redeemable Convertible Preferred SharesÂ Â 12,610Â Merger WarrantsÂ Â 200Â Â Â Â 15,851Â Â The fair value of shares of Common Stock issued by the Company was determined using the Companyâ€™s closing trading price on the Closing Date adjusted by a discount for lack of marketability (â€œDLOMâ€) of 9.4% as a registration statement was filed within 45 days. The fair value of Redeemable Convertible Preferred Shares was determined using the Companyâ€™s closing trading price on the Closing Date adjusted by a DLOM of 14.9% as the conversion of the Redeemable Convertible Preferred Shares to shares of Common Stock was subject to the stockholder approval, which was obtained on July 9, 2024. The Company determined the fair value of the Merger Warrants using the Black-Scholes model as of the Closing Date. The main assumptions used are as follows: Â Underlying value of Common Stock ($)Â Â 0.37Â Exercise price ($)Â Â 5.0Â Expected volatility (%)Â Â 117.7Â Expected terms (years)Â Â 2.87Â Risk-free interest rate (%)Â Â 4.5Â Â The actual APT net loss included in the Companyâ€™s condensed consolidated statements of operations for the nine months ended September 30, 2024, is as follows: Â Â Â SeptemberÂ 30, 2024Â Net loss attributable to APTÂ Â 5,884Â Â The unaudited pro forma financial information below summarizes the combined results of operations for BiomX Inc. (including its wholly owned subsidiaries, BiomX Ltd. and RondinX Ltd.) and APT. The unaudited pro forma financial information includes adjustments to reflect certain business combination effects, including: acquisition-related costs incurred by both parties and reversal of certain costs incurred by BiomX Inc. which would not have been incurred had the acquisition occurred on January 1, 2023. The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the Acquisition had taken place at the beginning of fiscal 2023. Â The following unaudited table provides certain pro forma financial information for the Company as if the Acquisition occurred on January 1, 2023: Â Â Â SeptemberÂ 30, 2024*Â Net lossÂ Â 2,698Â Â * The pro forma amounts above are derived from historical numbers of the Company and APT. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Significant Accounting Policies [Abstract] Â SIGNIFICANT ACCOUNTING POLICIES NOTE 2 â€" SIGNIFICANT ACCOUNTING POLICIES Â Â A. Unaudited Condensed Financial Statements Â The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for condensed

financial information. They do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments except as otherwise discussed). Â The financial information contained in this report should be read in conjunction with the annual financial statements included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that the Company filed with the U.S. Securities and Exchange Commission (the â€œSECâ€) on April 4, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023. Â Â B. Principles of Consolidation Â The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation. Â Â C. Use of Estimates in the Preparation of Financial Statements Â The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. The most significant estimates in the Companyâ€™s financial statements relate to accruals for research and development expenses, valuation of stock-based compensation awards, purchase price allocation related to the Acquisition and the Private Placement Warrants fair value revaluation; estimates used in the IPR&D impairment assessment for calculating the fair value of the Companyâ€™s assets by using discounted cash flow incorporate the Companyâ€™s estimated post-tax weighted average cost of capital, amounts and timing of projected future cash flows that are influenced by the expected outcome of research and development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Companyâ€™s specific market share. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. Â The full extent to which Israelâ€™s war with Hamas and Hezbollah may directly or indirectly impact the Companyâ€™s business, results of operations and financial condition will depend on future developments that are uncertain, as well as the economic impact on local, regional, national and international markets. Â Â D. Business Combination Â The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. The excess of the fair value of the consideration transferred over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The fair value of the consideration transferred included equity securities. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective dates of Acquisition.Â Â E. Financial instruments Â When the Company issues freestanding instruments, it first analyzes the provisions of ASC 480, â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the consolidated statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-10 in order to determine whether the instrument is considered indexed to the entityâ€™s own stock and qualifies for classification within equity. Â When the Company issues preferred shares, it first considers the provisions of ASC 480, in order to determine whether the preferred shares should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrumentâ€™s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. See Note 1D regarding the reclassification of the Redeemable Convertible Preferred Shares. Â When the Company issues warrants, it first considers the provisions of ASC 815-40, â€œContracts in Entityâ€™s Own Equityâ€ (â€œASC 815-40â€) in order to determine whether the warrants should be classified as equity. Equity classification is permitted when warrants are indexed to the Companyâ€™s own shares and meet the classification requirements for stockholdersâ€™ equity classification under ASC 815-40. If the warrants are not within the scope of ASC 815-40, the Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (â€œASC 815â€), â€œDerivatives and Hedgingâ€, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the Private Placement Warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the condensed consolidated statements of operations. See Note 10A for further information regarding the Private Placement Warrants. Â Â F. Basic and diluted loss (earnings) per share Â Basic loss (earnings) per share is computed by dividing net loss (income) by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Companyâ€™s Common Stock and fully vested Pre-Funded Warrants for the Companyâ€™s Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. The calculation excludes shares of Common Stock purchased by the Company and held as treasury shares. Diluted loss (income) per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period, plus the number of shares of Common Stock that would have been outstanding if all potentially dilutive shares of Common Stock had been issued, using the treasury stock and if-converted method, in accordance with ASC 260-10, â€œEarnings per Share.â€ Â The Company computes net loss (income) per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its Redeemable Convertible Preferred Shares to be participating securities as the holders of the Redeemable Convertible Preferred Shares would be entitled to dividends that would be distributed to the holders of Common Stock, on a pro-rata basis assuming conversion of all Redeemable Convertible Preferred Shares into shares of Common Stock. These participating securities do not contractually require the holders of such shares to participate in the Companyâ€™s losses. As such, net loss for the periods presented was not allocated to the Companyâ€™s participating securities. Â Â G. Intangible Assets Â Goodwill Â Goodwill reflects the excess of the consideration transferred at the business combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, â€œIntangiblesâ€”Goodwill and Otherâ€ allows an entity to first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value is less than its carrying amount. Otherwise, no further impairment testing is required.Â The Companyâ€™s goodwill is tested for impairment at least on an annual basis, on the last day of the third quarter of the fiscal year and whenever events or changes in circumstances indicate the carrying value of a reporting unit may not be recoverable. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount of the respective reporting unit exceeds its fair value. However, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information. Â Intangible assets Â IPR&D assets acquired in a business combination are recognized at fair value as of the acquisition date and subsequently accounted for as indefinite-lived intangible assets until completion or abandonment of the associated R&D efforts. Indefinite-lived intangible assets are reviewed for impairment at least annually, on the last day of the third quarter of the fiscal year or whenever there is an indication that the asset may be impaired.Â Â Â H. Recent Accounting Standards Â Recently issued accounting pronouncements, not yet adopted Â In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€). This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. Â In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€). This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, â€œSegment Reportingâ€. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entityâ€™s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value of Financial Instruments [Abstract] Â FAIR VALUE OF FINANCIAL INSTRUMENTS NOTE 3 â€“ FAIR VALUE OF FINANCIAL INSTRUMENTS Â The Company accounts for financial instruments in accordance with ASC 820, â€œFair Value Measurements and Disclosuresâ€ (â€œASC 820â€). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below: Â Level 1 â€“ Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Â Level 2 â€“ Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data. Â Level 3 â€“ Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Â There were no changes in the fair value hierarchy levelling during the nine months ended September 30, 2024 and year ended December 31, 2023.Â The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy:Â Â Â Â September 30, 2024Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 20,325Â Â -Â Â Â -Â Â Â 20,325Â Foreign exchange contracts receivableÂ Â -Â Â Â 15Â Â Â -Â Â 15Â Â Â Â 20,325Â Â Â 15Â Â Â -Â Â Â 20,340Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 161Â Â Â 161Â Private Placement WarrantsÂ Â -Â Â Â -Â Â Â 4,328Â Â Â 4,328Â Â Â Â -Â Â Â -Â Â Â 4,489Â Â Â 4,489Â Â Â Â December 31, 2023Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 11,377Â Â Â -Â Â Â -Â Â Â 11,377Â Foreign exchange contracts receivableÂ Â Â Â Â Â 256Â Â Â -Â Â Â 256Â Â Â Â 11,377Â Â Â 256Â Â Â -Â Â Â 11,633Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 155Â Â Â 155Â Â Â Â -Â Â Â -Â Â Â 155Â Â Â 155Â Â The changes in the fair value of the Companyâ€™s Level 3 financial liabilities, which are measured on a recurring basis are as follows: Â Â Â Nine Months Ended SeptemberÂ 30, 2024Â Â Nine Months Ended SeptemberÂ 30, 2023Â Beginning balanceÂ -Â Â Â Â Â -Â Private Placement WarrantsÂ Â 28,745Â Â Â Â Â Â Â Â -Â Change in fair valueÂ Â (24,417)Â Â -Â Ending balanceÂ Â 4,328Â Â Â -Â Â Financial instruments with carrying values approximating fair value include cash and cash equivalents, restricted cash, short-term deposits, other current assets, trade accounts payable and other accounts payable, due to their short-term nature.Â The Company determined the fair value of the liabilities for the contingent consideration based on a probability of discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the attainment of future clinical, developmental, regulatory, commercial and strategic milestones relating to product candidates for treatment of primary sclerosing cholangitis. The discount rate applied ranged from 3.84% to 4.52%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of operations. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liability. Changes in contingent consideration for the nine and three months ended September 30, 2024 and September 30, 2023, resulted from the passage of time and discount rate revaluation. Â The Company uses foreign exchange contracts (mainly option and forward contracts) to hedge cash flows from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, the Company recognizes gains or losses that offset the revaluation of the cash flows also recorded under financial expenses (income), net in the condensed consolidated statements of operations. As of September 30, 2024, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $3,410 with a fair value asset of $15. As of December 31, 2023, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $4,136 with a fair value asset of $256. Â The Company determined the fair value of the liabilities for the Private Placement Warrants using the Black-Scholes model, a Level 3 measurement, within the fair value hierarchy. Â The main assumptions used are as follows: Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Underlying value of Common Stock ($)Â Â 1.02Â Â Â Â Â Â Â Â Â Â -Â Exercise price ($)Â Â 2.31Â Â Â -Â Expected volatility (%)Â Â 117.6Â Â Â -Â Expected terms (years)Â Â 1.75Â Â Â -Â Risk-free interest rate (%)Â Â 3.6Â Â Â -Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Other Current Assets 9 Months Ended Sep. 30, 2024 Other Current Assets [Abstract] Â OTHER CURRENT ASSETS NOTE 4 â€“ OTHER CURRENT ASSETS Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Government institutionsÂ Â 84Â Â Â 66Â Prepaid insuranceÂ Â 1,165Â Â Â 505Â Other prepaid expensesÂ Â 574Â Â Â 128Â Grants receivableÂ Â 950Â Â Â 574Â OtherÂ Â 892Â Â Â 495Â Other current assetsÂ Â 3,665Â Â Â 1,768Â X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable 9 Months Ended Sep. 30, 2024 Other Accounts Payable [Abstract] Â OTHER ACCOUNTS PAYABLE NOTE 5 â€“ OTHER ACCOUNTS PAYABLE Â Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Employees and related institutionsÂ Â 956Â Â Â 1,852Â Accrued expensesÂ Â 3,421Â Â Â 1,289Â Government institutionsÂ Â 622Â Â Â 175Â Prepaid sublease incomeÂ Â -Â Â Â 28Â Severance related to former employees of APTÂ Â 70Â Â Â -Â Â Â Â 5,069Â Â Â 3,344Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â LEASES NOTE 6 â€“ LEASES Â On August 9, 2019, APT entered into a lease agreement (the â€œLease Agreementâ€) with ARE-708 Quince Orchard, LLC (the â€œLandlordâ€), for office and lab spaces in Gaithersburg, Maryland starting on September 1, 2019. Over the course of years, APT and the Landlord amended the Lease Agreement in order to expand the square footage and to extend the lease period until November 28, 2034. The agreement included 49,625 square feet of area. The monthly lease payments under the lease agreement were approximately $255. On March 5, 2024, in connection with the Acquisition, APT and the Landlord, signed an amendment to the lease agreement. Pursuant to the amendment, the leased area will be decreased to 25,894 square feet (the â€œRemaining Areaâ€), effective as of December 31, 2024. Following the amendment, the revised monthly lease payments are approximately $134. In exchange, APT was required to pay a relinquished premises fee in an amount equal to $1,500 within 10 business days following March 15, 2024 (the â€œAmendment Effective Dateâ€). In addition, the Company issued the Landlord warrants (the â€œLandlord Warrantsâ€) to purchase up to an aggregate of 25,000 shares of the Companyâ€™s Common Stock at an exercise price of $50.00 per share. The Landlord Warrants became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on January 28, 2027. The amendment also included a one-time option to early terminate the lease agreement on February 28, 2029 with respect to the Remaining Area under certain terms. The execution of the early termination will require APT to pay a termination fee of $3,000. Â APT accounted for the decreased leased area and the termination option as a modification as it continues to use the area for a period of time after the termination. The modification occurred before the Acquisition as APT signed the amendment before the Closing Date but was contingent upon the Acquisition. The operating lease right-of-use assets and operating lease liabilities contemplate the termination option. Â Lease expenses recorded in the condensed statements of operations were $2,543 and $995 for the nine and three months ended September 30, 2024, respectively, and $488 and $161 for the nine and three months ended September 30, 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies [Abstract] Â COMMITMENTS AND CONTINGENCIES NOTE 7 â€“ COMMITMENTS AND CONTINGENCIES Â Â A. In May 2021, APT entered into a Collaboration and Option Agreement (the â€œOyster Agreementâ€) with Oyster, a wholly owned subsidiary of Viatris Inc., to collaborate on the use of APTâ€™s proprietary phage technology for the treatment of certain ophthalmic diseases. Upon execution of the Agreement, Oyster paid an upfront payment of $500 to APT, a portion of which APT claims it has spent in the course of performing its obligations under the Oyster Agreement. In April 2022 and September 2023, APT received letters from Oyster and Viatris Inc. raising concerns about APTâ€™s actions, including allegations that APT had breached the Oyster Agreement. APT and Oyster have agreed to settle their dispute related to the Oyster Agreement, including the allegations described in the letters, and to terminate the Oyster Agreement under a term sheet (the â€œTerm Sheetâ€). Under the terms of the Term Sheet, APT and Oyster will sign a final settlement agreement, which will include a payment of $300 from APT to Oyster. As of September 30, 2024, the final settlement agreement had not yet been signed. The Company has recorded a provision of $300 as other accounts payable in the condensed consolidated balance sheets. Â Â Â Â B. In August 2021, the Israeli Innovation Authority (â€œIIAâ€) approved an application that supports upgrading the Companyâ€™s manufacturing capabilities for an aggregate budget of NIS 5,737 (approximately $1,778). The IIA committed to fund 50% of the approved budget. The program was for the period beginning July 2021 through June 2022. The program does not bear royalties. Through September 30, 2024, the Company received NIS 1,912 (approximately $577) from the IIA with respect to this program. Â In March 2022, the IIA approved an application for a total budget of NIS 13,004 (approximately $4,094) in relation to the Companyâ€™s cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2022 through December 2022. Through September 30, 2024, the Company received NIS 1,365 (approximately $395) from the IIA with respect to this program. Â In March 2023, the IIA approved an application for a total budget of NIS 11,283 (approximately $3,164) in relation to the Companyâ€™s cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2023 through December 2023. Through September 30, 2024, the Company received NIS 2,783 (approximately $768) from the IIA with respect to this program. Â According to the agreement with the IIA, excluding the August 2021 program, BiomX Israel will pay royalties of 3% to 3.5% of future sales up to an amount equal to the accumulated grant received including annual interest of LIBOR linked to the USD. Starting January 2024, the IIA has notified that the interest has changed to the 12-month Secured Overnight Financing Rate (â€œSOFRâ€) as published on the first trading day of each calendar year. BiomX Israel may be required to pay additional royalties upon the occurrence of certain events as determined by the IIA, that are within the control of BiomX Israel. No such events have occurred or were probable of occurrence as of the balance sheet date with respect to these royalties. Repayment of the grant is contingent upon the successful completion of the BiomX Israelâ€™s R&D programs and generating sales. BiomX Israel has no obligation to repay these grants if the R&D program fails, is unsuccessful or aborted or if no sales are generated. The Company had not yet generated sales as of September 30, 2024; therefore, no liability was recorded in these condensed consolidated financial statements. IIA grants are recorded as a reduction of R&D expenses, net. Â Through September 30, 2024, total grants approved from the IIA aggregated to approximately $9,353 (NIS 32,068). Through September 30, 2024, the Company had received an aggregate amount of $8,003 (NIS 27,423) in the form of grants from the IIA. Total grants subject to royaltiesâ€™ payments aggregated to approximately $7,413. As of September 30, 2024, BiomX Israel had a contingent obligation to the IIA in the amount of approximately $8,250 including annual interest of SOFR applicable to dollar deposits. Â Â C. On June 23, 2022, BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH (â€œBIâ€) for a collaboration to identify biomarkers for Inflammatory Bowel Disease. Under the agreement, BiomX Israel is eligible to receive fees totaling $1,411 to cover costs to be incurred by BiomX Israel in conducting the research plan under the collaboration. The fees were paid in four installments according to certain activities under the agreement. In December 2023, the Company completed its obligations with respect to this agreement and the last installment of $211 was received on January 18, 2024. The consideration was recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.24.3 U.S. Government Contracts and Grants 9 Months Ended Sep. 30, 2024 U.S. Government Contracts and Grants [Abstract] Â U.S. GOVERNMENT CONTRACTS AND GRANTS NOTE 8 - U.S. GOVERNMENT CONTRACTS AND GRANTS Â In 2019, APT entered into a Base Agreement and Research Project Award (collectively, the â€œAgreementâ€) with the U.S. Army Medical Research Acquisition Activity (â€œUSAMRAAâ€) and the U.S. Army Medical Research & Development Command (â€œUSAMRDCâ€) to advance personalized phage therapy from niche to broad use. Awards under the Agreement are intended to lay the groundwork for rapid advancement of personalized phage therapy to commercialization for the variety of clinical indications and bacterial pathogens representing un-met needs with a focus on infections with significant military relevance. The competitive award was granted by USAMRAA and USAMRDC in collaboration with the Medical Technology Enterprise Consortium (â€œMTECâ€), a 501(c)(3) biomedical technology consortium working in partnership with the U.S. Department of Defense. Since Agreement inception, APT entered into certain modifications to the Agreement to include additional activities and perform pre-clinical activities to advance the Diabetic Foot Osteomyelitis (â€œDFOâ€) clinical program. Under the Agreement, MTEC reimburses APT for approved costs as incurred that are based upon the achievement of certain milestones up to a contract value of $36,214. In September 2024, the Agreement was amended to extend the period of performance to continue and complete the pre-clinical activities for the DFO clinical program, which increased the total contract value to $39,081. In conjunction with this Agreement, APT is subject to an assessment fee of an amount equal up to 3% of the total funded value of the research project award which should be paid by the Company upon signing the agreement or the modifications. For the period between the Acquisition and September 30, 2024, the Company received grants of $2,895 from MTEC with respect to the cost reimbursement contract. During the nine and three months ended September 30, 2024, the Company recorded $1,802 and $849 as a reduction of R&D expenses, net, respectively. The remainder of the consideration the Company is entitled to receive is recorded as other current assets in the condensed consolidated financial statements. See Note 14B for information regarding grants received subsequent to the financial statement date. X - ReferencesNo definition available. + Details Name: phge_USGovernmentContractsAndGrantsAbstract Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phge_USGovernmentContractsAndGrantsTextBlock Namespace Prefix: phge_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt 9 Months Ended Sep. 30, 2024 Long-Term Debt [Abstract] Â LONG-TERM DEBT NOTE 9 â€“ LONG-TERM DEBT Â On August 16, 2021 (the â€œClosing Dateâ€), the Company entered into a Loan and Security Agreement (the â€œLoan Agreementâ€) with Hercules Capital, Inc. (â€œHerculesâ€), with respect to a venture debt facility. Under the Loan Agreement, $15,000 was advanced to the Company on the date the Loan Agreement was executed. The Company was required to make interest only payments through March 1, 2023, and started to then repay the principal balance and interest in equal monthly installments through September 1, 2025. Â The Loan Agreement provided that the Company could prepay advances under the Loan Agreement, in whole or in part, at any time subject to a prepayment charge equal to 1.0% after 24 months but prior to 36 months following the Closing Date. Upon prepayment or repayment of all or any of the term loans under the Term Loan Facility, the Company was required to pay an end of term charge (â€œEnd of Term Chargeâ€) equal to 6.55% of the total aggregate amount of the term loans being prepaid or repaid. On March 19, 2024, the Company prepaid the entire balance under the Term Loan Facility in a total of $10,428. The prepayment included the End of Term Charge of $983 and accrued interest of $69. The Company received from Hercules a waiver regarding the prepayment charge that should have been 1% out of the prepaid principal amount that equals to $94. Â Interest expense relating to the term loan, which is included in interest expense in the condensed statements of operations was $850 for the nine months ended September 30, 2024. No interest expense was recognized in connection with the term loan for the three months ended September 30, 2024. Interest expense for the nine and three months ended September 30, 2023, was $1,884 and $574, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity 9 Months Ended Sep. 30, 2024 Stockholders Equity [Abstract] Â STOCKHOLDERS EQUITY NOTE 10 â€“ STOCKHOLDERS EQUITY Â Â A. Share Capital: Â Reverse Stock Split: Â On July 9, 2024, the Companyâ€™s stockholders approved a reverse stock split at a ratio within a range ofÂ 1-for-5 andÂ 1-for-10 at such time as the Board of Directors shall determine, in its sole discretion, at any time before July 9, 2025. On August 8, 2024, the Board of Directors approved a 1-for-10 Reverse Stock Split of the Companyâ€™s shares of Common Stock (the â€œReverse Stock Splitâ€). Â On August 20, 2024, the Company filed the Certificate of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, which became effective on August 26, 2024 (the â€œEffective Dateâ€). The Companyâ€™s Common Stock began trading on a Reverse Stock Split adjusted basis on the NYSE American at the opening of the markets on the Effective Date. Â As a result of the Reverse Stock Split, the number of shares of Common Stock outstanding was reduced from 178,958,447Â shares to 18,021,173Â shares. No fractional shares of Common Stock or Units were issued in connection with the Reverse Stock Split. Stockholders of the Company who otherwise were entitled to receive fractional shares or Units, because they held a number of shares or Units, as applicable, not evenly divisible by the Reverse Stock Split ratio were

automatically entitled to receive an additional fraction of a share of the Common Stock or Unit, as applicable, to round up to the next whole share. As a result, 125,328 shares of Common Stock were issued. The Reverse Stock Split did not change the par value of the Common Stock nor the authorized number of shares of Common Stock, preferred stock or any series of preferred stock. Â Unless otherwise indicated, all amounts of issued and outstanding stock contained in the accompanying condensed consolidated financial statements have been adjusted to reflect theÂ 1-for-10 Reverse Stock Split for all prior periods presented.Â Proportional adjustments were also made to shares underlying outstanding equity awards, warrants and Redeemable Convertible Preferred Shares, and to the number of shares issued and issuable under the Companyâ€™s stock incentive plans and certain existing agreements. Â Authorized shares of common stock: Â On July 9, 2024, the Companyâ€™s stockholders approved increasing the number of authorized shares of Common Stock from 120,000,000 shares, par value $0.0001 per share, to 750,000,000 shares, par value $0.0001 per share. Â Preferred Stock: Â The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Companyâ€™s Board of Directors (the â€œBoardâ€). Â On March 15, 2024, the Company issued 40,470 and 216,417 Redeemable Convertible Preferred Shares, par value $0.0001 per share, as part of the Acquisition and the March 2024 PIPE, respectively. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares were converted into 10,915,200 shares of the Companyâ€™s Common Stock. Â Private Investment in Public Equity: Â On February 22, 2023, the Company entered into a Securities Purchase Agreement to issue and sell an aggregate of 1,599,746 shares of its Common Stock and 1,461,072 pre-funded warrants (the â€œPre-Funded Warrantsâ€) at a price of $2.45 per share and $2.44 per Pre-Funded Warrant in a private placement (the â€œFebruary 2023 PIPEâ€). The net proceeds from the PIPE were approximately $7,152, after deducting issuance costs of $333. During the nine months ended September 30, 2024, 533,031 Pre-Funded Warrants were exercised into 533,031 shares of Common Stock for total consideration of $6 at an exercise price of $0.01 per share of Common Stock, and 928,041 Pre-Funded Warrants were exercised into 925,607 shares of Common Stock through cashless mechanism with no consideration. As of September 30, 2024, there are no outstanding Pre-Funded Warrants. Â On March 15, 2024, in connection with the Acquisition, the Company issued to APTâ€™s former stockholders 916,497 shares of the Companyâ€™s Common Stock, 40,470 Redeemable Convertible Preferred Shares and Merger Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock. See Note 1D for further information. Â Concurrently with the consummation of the Acquisition as described in Note 1D, the Company entered into the March 2024 PIPE, pursuant to which such investors purchased an aggregate of 216,417 Redeemable Convertible Preferred Shares (â€œPIPE Preferred Sharesâ€) and Private Placement Warrants to purchase up to an aggregate of 10,820,850 shares of the Companyâ€™s Common Stock, at a combined price of $231.10 per share. The PIPE Preferred Shares and the Private Placement Warrants were issued in a private placement pursuant to an exemption from registration requirements under the Securities Act for aggregate gross proceeds of $50,000. Each Private Placement Warrantâ€™s exercise price equals to $2.31, subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on July 9, 2026. Under certain circumstances, the Company may be required to pay to each holder of the Private Placement Warrants (i) an amount in cash equal to the holderâ€™s total purchase price for the shares of Common Stock purchased (the â€œBuy-In Priceâ€) or credit such holderâ€™s balance account with the Depository Trust Company (â€œDTCâ€) for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation to deliver to such holder a certificate or certificates representing such shares of Common Stock or credit such holderâ€™s balance account with DTC, as applicable, and pay cash to such holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) Weighted Average Price (as defined in the Private Placement Warrant) on the trading day immediately preceding the exercise date. Â The Company accounted for the Private Placement Warrants as liabilities as the Private Placement Warrants are not considered indexed to the entityâ€™s own stock based on the provision of ASC 815. The Private Placement Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized in the condensed consolidated statements. Â The terms of the PIPE Preferred Shares are substantially the same as those of the Redeemable Convertible Preferred Shares issued under the Acquisition and were accounted for as temporary equity at the issuance date and were reclassified as equity. See Note 1D for further information. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Companyâ€™s Common Stock according to beneficial ownership limitations set by certain investors. Â In connection therewith, the Company issued warrants to purchase shares of the Companyâ€™s Common Stock to the Placement Agents (the â€œAgents Warrantsâ€). See Note 10B for further information. Â The Company allocated the total consideration from the issuance of the 2024 March PIPE first to the fair value of the Private Placement Warrants and then to the PIPE Preferred Shares. The Company had transaction costs of approximately $3,317 out of which $1,273 is Stock-Based Compensation due to issuance of the Agents Warrants. The transaction costs were allocated in the same manner as the consideration. Issuance costs which were allocated to the PIPE Preferred Shares were $1,410 and deducted from Redeemable Convertible Preferred Shares, and issuance costs that were allocated to the Private Placement Warrants were $1,907 and were expensed immediately. Â At-the-Market Sales Agreement:Â Â Â In December 2023, pursuant to a registration statement on Form S-3 declared effective by the SEC on January 2, 2024, the Company entered an At the Market Offering Agreement with H.C. Wainwright & Co., LLC (â€œWainwrightâ€), pursuant to which the Company may issue and sell shares of Common Stock having an aggregate offering price of up to $7,500 from time to time through Wainwright. During the nine months ended September 30, 2024, the Company sold 7,518 shares of Common Stock under this agreement, at an average price of $2.71 per share, raising aggregate net proceeds of approximately $19, after deducting an aggregate commission of $1.Â Warrants: Â As of SeptemberÂ 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders: Â WarrantÂ Issuance DateÂ Expiration DateÂ Exercise Price Per ShareÂ Â Number of Shares of CommonÂ Stock Underlying WarrantsÂ Public WarrantsÂ IPO (December 13, 2018)Â October 28, 2024Â Â 115.00Â Â Â 350,000Â 2021 Registered Direct Offering WarrantsÂ SPA (July 28, 2021)Â January 28, 2027Â Â 50.00Â Â Â 281,251Â Merger WarrantsÂ March 15, 2024Â January 28, 2027Â Â 50.00Â Â Â 216,650Â Private Placement WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 10,820,850Â Agents WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 952,381Â Â Â

Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill 9 Months Ended Sep. 30, 2024 Goodwill [Abstract] Â GOODWILL NOTEÂ 12 â€“ GOODWILL Â Following the APT Acquisition, the Company recognized goodwill valued at $801 after adjustment made during the measurement period as described in Note 1D above. In the third quarter of 2024, the Company experienced a decline in its stock price resulting in its market capitalization being less than the Companyâ€™s stockholdersâ€™ equity. Thus, the Company performed quantitative assessments of the Companyâ€™s goodwill. The assessments utilizes the Companyâ€™s market capitalization plus an appropriate control premium. Market capitalization is determined by multiplying the outstanding number of shares of Common Stock by the Companyâ€™s stock price. The control premium is determined by utilizing publicly available data from studies for similar transactions of public companies. As a result of this assessment, the Company recorded a goodwill impairment of $801 during the three and nine months ended September 30, 2024.Â X - DefinitionThe entire disclosure for goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillImpairedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Events During the Period 9 Months Ended Sep. 30, 2024 Events During the Period [Abstract] Â EVENTS DURING THE PERIOD NOTEÂ 13 â€“ EVENTS DURING THE PERIOD Â In October 2021, the Company entered into a Stock Purchase Agreement with a subsidiary of Maruho Co. Ltd., (â€œMaruhoâ€), pursuant to which the Company issued to Maruho shares of Common Stock of the Company and granted Maruho a right of first offer to license its atopic dermatitis product candidate, BX005, in Japan. The right of first offer was supposed to commence following the availability of results from the Phase 1/2 study which were expected in 2022. Part of the consideration paid under the agreements, equal to the grant date fair value of the shares issued to Maruho was attributed to the issuance of shares. The remainder of $1,976 was attributed to a contract liability, to be recognized as other income, at a point in time, once the clinical trials related to the product candidate are completed. In April 2024, following the Acquisition, the Company decided to pause the development of BX005. As a result, the parties agreed that the right of first offer to license BX005 is no longer applicable. As a result, the Company reversed the full amount of the contract liability and recognized $1,976 as Other Income in the condensed consolidated statements of operations. X - ReferencesNo definition available. + Details Name: phge_EventDuringThePeriodAbstract Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: phge_EventDuringThePeriodTextBlock Namespace Prefix: phge_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â SUBSEQUENT EVENTS NOTE 14 â€“ SUBSEQUENT EVENTS Â a.On October 15, 2024, the Company announced that effective October 25, 2024, the Companyâ€™s Units will be mandatorily separated and the Units will no longer trade on the NYSE American. In the separation, Unit-holders received shares of Common Stock and warrants underlying their units, which warrants expired on October 28, 2024. The Common Stock continues to trade on the NYSE American under the symbol â€œPHGEâ€ with the other existing shares of the Companyâ€™s Common Stock. Â b.On October 17, 2024, the Company received a payment of $600 from MTEC in connection with the Agreement for reimbursement of approved costs. See Note 8 for further information. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Accounting Policies, by Policy (Policies) 9 Months Ended Sep. 30, 2024 Significant Accounting Policies [Abstract] Â Unaudited Condensed Financial Statements Â A. Unaudited Condensed Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for condensed financial information. They do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments except as otherwise discussed).The financial information contained in this report should be read in conjunction with the annual financial statements included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that the Company filed with the U.S. Securities and Exchange Commission (the â€œSECâ€) on April 4, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023. Principles of Consolidation Â B. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation. Use of Estimates in the Preparation of Financial Statements Â C. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. The most significant estimates in the Companyâ€™s financial statements relate to accruals for research and development expenses, valuation of stock-based compensation awards, purchase price allocation related to the Acquisition and the Private Placement Warrants fair value revaluation; estimates used in the IPR&D impairment assessment for calculating the fair value of the Companyâ€™s assets by using discounted cash flow incorporate the Companyâ€™s estimated post-tax weighted average cost of capital, amounts and timing of projected future cash flows that are influenced by the expected outcome of research and development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Companyâ€™s specific market share. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.The full extent to which Israelâ€™s war with Hamas and Hezbollah may directly or indirectly impact the Companyâ€™s business, results of operations and financial condition will depend on future developments that are uncertain, as well as the economic impact on local, regional, national and international markets. Business Combination Â D. Business Combination The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. The excess of the fair value of the consideration transferred over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The fair value of the consideration transferred included equity securities. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective dates of Acquisition.Â Financial instruments Â E. Financial instruments When the Company issues freestanding instruments, it first analyzes the provisions of ASC 480, â€œDistinguishing Liabilities From Equityâ€ (â€œASC 480â€) in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the consolidated statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-10 in order to determine whether the instrument is considered indexed to the entityâ€™s own stock and qualifies for classification within equity.When the Company issues preferred shares, it first considers the provisions of ASC 480, in order to determine whether the preferred shares should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrumentâ€™s characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. See Note 1D regarding the reclassification of the Redeemable Convertible Preferred Shares.When the Company issues warrants, it first considers the provisions of ASC 815-40, â€œContracts in Entityâ€™s Own Equityâ€ (â€œASC 815-40â€) in order to determine whether the warrants should be classified as equity. Equity classification is permitted when warrants are indexed to the Companyâ€™s own shares and meet the classification requirements for stockholdersâ€™ equity classification under ASC 815-40. If the warrants are not within the scope of ASC 815-40, the Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 (â€œASC 815â€), â€œDerivatives and Hedgingâ€, under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the Private Placement Warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the condensed consolidated statements of operations. See Note 10A for further information regarding the Private Placement Warrants. Basic and diluted loss (earnings) per share Â F. Basic and diluted loss (earnings) per share Basic loss (earnings) per share is computed by dividing net loss (income) by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Companyâ€™s Common Stock and fully vested Pre-Funded Warrants for the Companyâ€™s Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. The calculation excludes shares of Common Stock purchased by the Company and held as treasury shares. Diluted loss (income) per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period, plus the number of shares of Common Stock that would have been outstanding if all potentially dilutive shares of Common Stock had been issued, using the treasury stock and if-converted method, in accordance with ASC 260-10, â€œEarnings per Share.â€The Company computes net loss (income) per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its Redeemable Convertible Preferred Shares to be participating securities as the holders of the Redeemable Convertible Preferred Shares would be entitled to dividends that would be distributed to the holders of Common Stock, on a pro-rata basis assuming conversion of all Redeemable Convertible Preferred Shares into shares of Common Stock. These participating securities do not contractually require the holders of such shares to participate in the Companyâ€™s losses. As such, net loss for the periods presented was not allocated to the Companyâ€™s participating securities. Intangible Assets Â G. Intangible Assets GoodwillGoodwill reflects the excess of the consideration transferred at the business combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, â€œIntangiblesâ€”Goodwill and Otherâ€ allows an entity to first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value is less than its carrying amount. Otherwise, no further impairment testing is required.Â The Companyâ€™s goodwill is tested for impairment at least on an annual basis, on the last day of the third quarter of the fiscal year and whenever events or changes in circumstances indicate the carrying value of a reporting unit may not be recoverable. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount of the respective reporting unit exceeds its fair value. However, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information.Intangible assetsIPR&D assets acquired in a business combination are recognized at fair value as of the acquisition date and subsequently accounted for as indefinite-lived intangible assets until completion or abandonment of the associated R&D efforts. Indefinite-lived intangible assets are reviewed for impairment at least annually, on the last day of the third quarter of the fiscal year or whenever there is an indication that the asset may be impaired.Â Recent Accounting Standards Â H. Recent Accounting Standards Recently issued accounting pronouncements, not yet adoptedIn December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09 â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€). This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.In November 2023, the FASB issued ASU 2023-07 â€œSegment Reporting: Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€). This guidance expands public entitiesâ€™ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segmentâ€™s profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, â€œSegment Reportingâ€. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entityâ€™s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4 + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.3 General (Tables) 9 Months Ended Sep. 30, 2024 General (Tables) [Line Items] Â Schedule of Fair Value Acquired Identifiable Assets And Assumed Liabilities The following sets forth the fair value of acquired identifiable assets and assumed liabilities of APT, after consideringÂ measurement period adjustmentÂ as described below,Â which includes adjustments to reflect the fair value of intangible assets acquired as of March 15, 2024: Â Â AmountsÂ Cash and cash equivalentsÂ Â 509Â Restricted cashÂ Â 154Â Other current assetsÂ Â 1,780Â Property, plant and equipmentÂ Â 3,748Â Operating lease right-of-use assetÂ Â 7,953Â IPR&D assets and GoodwillÂ Â 16,088Â Total assetsÂ Â 30,232Â Â Â Â Â Â Trade accounts payableÂ Â (3,667) Other accounts payableÂ Â (2,895) Operating lease liabilityÂ Â (7,819) Total liabilitiesÂ Â (14,381) Total considerationÂ Â 15,851Â Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition The following table summarizes the fair value of the consideration transferred to APT shareholders for the Acquisition: Â Â AmountsÂ Common StockÂ Â 3,041Â Redeemable Convertible Preferred SharesÂ Â 12,610Â Merger WarrantsÂ Â 200Â Â Â Â 15,851Â Schedule of Fair Value of the Merger Warrants The main assumptions used are as follows: Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Underlying value of Common Stock ($)Â Â 1.02Â Â Â Â Â Â Â Â Â Â -Â Exercise price ($)Â Â 2.31Â Â Â -Â Expected volatility (%)Â Â 117.6Â Â Â -Â Expected terms (years)Â Â 1.75Â Â Â -Â Risk-free interest rate (%)Â Â 3.6Â Â Â -Â Schedule of Condensed Consolidated Statements of Operations The actual APT net loss included in the Companyâ€™s condensed consolidated statements of operations for the nine months ended September 30, 2024, is as follows: Â Â SeptemberÂ 30, 2024Â Net loss attributable to APTÂ Â 5,884Â Schedule of Pro Forma Financial Information The following unaudited table provides certain pro forma financial information for the Company as if the Acquisition occurred on January 1, 2023: Â Â SeptemberÂ 30, 2024*Â Net lossÂ Â 2,698Â * The pro forma amounts above are derived from historical numbers of the Company and APT. Merger Warrants Â General (Tables) [Line Items] Â Schedule of Fair Value of the Merger Warrants The Company determined the fair value of the Merger Warrants using the Black-Scholes model as of the Closing Date. The main assumptions used are as follows: Underlying value of Common Stock ($)Â Â 0.37Â Exercise price ($)Â Â 5.0Â Expected volatility (%)Â Â 117.7Â Expected terms (years)Â Â 2.87Â Risk-free interest rate (%)Â Â 4.5Â X - ReferencesNo definition available. + Details Name: phge_GeneralTablesLineItems Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: srt_ScheduleOfCondensedIncomeStatementTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_MergerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value of Financial Instruments [Abstract] Â Schedule of Fair Value of Our Financial Assets and Liabilities The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy: Â Â September 30, 2024Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 20,325Â Â Â -Â Â Â -Â Â Â 20,325Â Â Foreign exchange contracts receivableÂ Â -Â Â Â 15Â Â Â -Â Â Â 15Â Â Â Â 20,325Â Â Â 15Â Â Â -Â Â Â 20,340Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 161Â Â Â 161Â Private Placement WarrantsÂ Â -Â Â Â -Â Â Â 4,328Â Â Â 4,328Â Â Â Â -Â Â Â -Â Â Â 4,489Â Â Â 4,489Â Â Â December 31, 2023Â Â Â Level 1Â Â Level 2Â Â Level 3Â Â Â Â Fair ValueÂ Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Money market fundsÂ Â 11,377Â Â Â -Â Â Â -Â Â Â 11,377Â Foreign exchange contracts receivableÂ Â Â Â Â 256Â Â Â -Â Â Â 256Â Â Â 11,377Â Â Â 256Â Â Â -Â Â Â 11,633Â Liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent considerationÂ Â -Â Â Â -Â Â Â 155Â Â Â 155Â Â Â Â -Â Â Â -Â Â Â 155Â Â Â 155Â Schedule of Fair Value Level 3 financial liabilities The changes in the fair value of the Companyâ€™s Level 3 financial liabilities, which are measured on a recurring basis are as follows: Â Â Nine Months Ended SeptemberÂ 30, 2024Â Â Nine Months Ended SeptemberÂ 30, 2023Â Beginning balanceÂ -Â Â Â Â Â Â -Â Private Placement WarrantsÂ Â 28,745Â Â Â Â Â Â Â Â -Â Change in fair valueÂ Â (24,417)Â Â -Â Ending balanceÂ Â 4,328Â Â Â -Â Schedule of Fair Value of the Liabilities for the Private Placement Warrants The main assumptions used are as follows: Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Underlying value of Common Stock ($)Â Â 1.02Â Â Â Â Â Â Â Â Â Â -Â Exercise price ($)Â Â 2.31Â Â Â -Â Expected volatility (%)Â Â 117.6Â Â Â -Â Expected terms (years)Â Â 1.75Â Â Â -Â Risk-free interest rate (%)Â Â 3.6Â Â Â -Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Other Current Assets (Tables) 9 Months Ended Sep. 30, 2024 Other Current Assets [Abstract] Â Schedule of Other Current Assets Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Government institutionsÂ Â 84Â Â Â 66Â Prepaid insuranceÂ Â 1,165Â Â Â 505Â Other prepaid expensesÂ Â 574Â Â Â 128Â Grants receivableÂ Â 950Â Â Â 574Â OtherÂ Â 892Â Â Â 495Â Other current assetsÂ Â 3,665Â Â Â 1,768Â X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-

gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable (Tables) 9 Months Ended Sep. 30, 2024 Other Accounts Payable [Abstract] Â Schedule of Other Accounts Payable Â Â SeptemberÂ 30, 2024Â Â DecemberÂ 31, 2023Â Employees and related institutionsÂ Â 956Â Â Â 1,852Â Accrued expensesÂ Â 3,421Â Â Â 1,289Â Government institutionsÂ Â 622Â Â Â 175Â Prepaid sublease incomeÂ Â -Â Â Â 28Â Severance related to former employees of APTÂ Â 70Â Â Â -Â Â Â Â 5,069Â Â Â 3,344Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Tables) 9 Months Ended Sep. 30, 2024 Stockholders Equity [Abstract] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders As of SeptemberÂ 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders: WarrantÂ Issuance DateÂ Expiration DateÂ Exercise Price Per ShareÂ Â Number of Shares of CommonÂ Stock Underlying WarrantsÂ Public WarrantsÂ IPO (December 13, 2018)Â October 28, 2024Â Â 115.00Â Â Â 350,000Â 2021 Registered Direct Offering WarrantsÂ SPA (July 28, 2021)Â January 28, 2027Â Â 50.00Â Â Â 281,251Â Merger WarrantsÂ March 15, 2024Â January 28, 2027Â Â 50.00Â Â Â 216,650Â Private Placement WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 10,820,850Â Agents WarrantsÂ March 15, 2024Â July 9, 2026Â Â 2.31Â Â Â 952,381Â Â Â Â Â Â Â Â Â Â Â Â 12,621,132Â Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows: Underlying value of Common Stock ($)Â Â 2.31Â Exercise price ($)Â Â 2.31Â Expected volatility (%)Â Â 100.6Â Expected terms (years)Â Â 2.32Â Risk-free interest rate (%)Â Â 4.4Â Schedule of Options Granted to Purchase A summary of options granted to purchase the Companyâ€™s Common Stock under the Companyâ€™s share option plans is as follows: Â Â For the Nine Months Ended SeptemberÂ 30, 2024Â Â Â Number of OptionsÂ Â Weighted Average Exercise PriceÂ Â Aggregate Intrinsic ValueÂ Outstanding at the beginning of periodÂ Â 528,112Â Â Â 5.41Â Â Â 72Â GrantedÂ Â 1,567,795Â Â Â 3.63Â Â Â Â Â ForfeitedÂ Â (26,808)Â Â 3.96Â Â Â Â Â ExpiredÂ Â (6,449)Â Â 4.58Â Â Â Â Â ExercisedÂ Â -Â Â Â -Â Â Â Â Â Outstanding at the end of periodÂ Â 2,062,650Â Â Â 4.08Â Â Â 22Â Exercisable at the end of periodÂ Â 351,109Â Â Â 5.79Â Â Â Â Â Weighted average remaining contractual life of outstanding options â€“ years as of September 30, 2024Â Â 8.85Â Â Â Â Â Â Â Â Â Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock As of September 30, 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock: WarrantÂ Issuance DateÂ Expiration DateÂ Â Exercise Price Per ShareÂ Â Number of Shares of CommonÂ Stock Underlying WarrantsÂ Private Warrants issued to scientific foundersÂ November 27,Â 2017Â Â -Â Â Â -Â Â Â 298Â Landlord Warrants*Â March 15,Â 2024Â Â January 28, 2027Â Â Â 50.00Â Â Â 25,000Â Â Â Â Â Â Â Â Â Â Â Â Â 25,298Â (*) See Note 6. Schedule of Stock-Based Payment Expenses The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations: Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Research and development expenses, netÂ Â 273Â Â Â 31Â Â Â 336Â Â Â 202Â General and administrativeÂ Â 556Â Â Â 164Â Â Â 747Â Â Â 439Â Â Â Â 829Â Â Â 195Â Â Â 1,083Â Â Â 641Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in common stock outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in stock options. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Basic and Diluted Loss (Earnings) Per Share (Tables) 9 Months Ended Sep. 30, 2024 Basic and Diluted Loss (Earnings) Per Share [Abstract] Â Schedule of Anti-dilutive Financial Instruments The calculation of diluted loss per share for the nine and three months ended SeptemberÂ 30, 2024 and SeptemberÂ 30, 2023, does not include the shares underlying the following financial instruments because their effect would be anti-dilutive: Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â OptionsÂ Â 2,041,139Â Â Â 591,034Â Â Â 2,062,650Â Â Â 591,034Â WarrantsÂ Â 12,646,132Â Â Â 921,251Â Â Â 1,825,281Â Â Â 921,251Â Contingent sharesÂ Â 200,000Â Â Â 400,000Â Â Â 200,000Â Â Â 400,000Â Redeemable Convertible Preferred SharesÂ Â 14,773,500Â Â Â -Â Â Â 14,773,500Â Â Â -Â Schedule of Basic and Diluted Loss (earnings) Per Share The following table presents the computation of basic and diluted loss (earnings) per share: Â Â Three Months Ended September 30,Â Â Nine Months Ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Basic loss (earnings) per share of common stockÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator:Â Â Â Â Â Â Â Â Â Â Â Â Net loss (income)Â Â (9,642)Â Â 7,906Â Â Â 3,214Â Â Â 20,678Â Amount allocated to Redeemable Convertible Preferred SharesÂ Â (4,575)Â Â -Â Â Â -Â Â Â -Â Net loss (income) attributable to shares of common stockÂ Â (5,067)Â Â 7,906Â Â Â 3,214Â Â Â 20,678Â Denominator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of shares of common stock outstandingÂ Â 16,365,824Â Â Â 4,597,403Â Â Â 9,943,968Â Â Â 3,951,624Â Number of shares upon Pre-Funded Warrants exerciseÂ Â -Â Â Â 1,461,073Â Â Â -Â Â Â 867,736Â Number of shares upon Fully vested Warrants exerciseÂ Â 298Â Â Â 298Â Â Â 298Â Â Â 298Â Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per shareÂ Â 16,366,122Â Â Â 6,058,774Â Â Â 9,944,267Â Â Â 4,819,658Â Basic loss (earnings) per share of common stockÂ Â (0.31)Â Â 1.30Â Â Â 0.32Â Â Â 4.29Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Diluted net loss per share of common stockÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Numerator:Â Â Â Â Â Â Â Â Â Â Â Â Net loss (income)Â Â (9,642)Â Â 7,906Â Â Â 3,214Â Â Â 20,678Â Change in fair value of Private Placement WarrantsÂ Â -Â Â Â -Â Â Â 24,417Â Â Â -Â Diluted net lossÂ Â (9,642)Â Â 7,906Â Â Â 27,631Â Â Â 20,678Â Denominator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average number of shares of common stock outstandingÂ Â 16,366,122Â Â Â 6,058,774Â Â Â 9,944,267Â Â Â 4,819,658Â Private Placement WarrantsÂ Â -Â Â Â -Â Â Â 1,350,613Â Â Â -Â OptionsÂ Â 21,511Â Â Â -Â Â Â -Â Â Â -Â Total weighted-average number of shares of common stock outstanding, after givingÂ effect to dilutive securitiesÂ Â 16,387,633Â Â Â 6,058,774Â Â Â 11,294,880Â Â Â 4,819,658Â Diluted net loss per share of common stockÂ Â (0.31)Â Â 1.30Â Â Â 2.45Â Â Â 4.29Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R29.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - USD ($) 3 Months Ended 9 Months Ended Jul. 15, 2024 Jul. 09, 2024 Mar. 15, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Shares received Â Â 216,417Â Â Â Â Â Â Â Â Preferred stock, par value (in Dollars per share) Â Â Â $ 0.0001Â Â Â Â $ 0.0001Â Â $ 0.0001 Aggregate gross proceeds (in Dollars) Â Â Â Â Â Â Â Â $ 7,485,000Â Reverse stock split Â Â Â Â Â Â Â 1-for-10 Â Â Accumulated deficit (in Dollars) Â Â Â $ (166,184,000) Â Â Â $ (166,184,000) Â $ (162,970,000) Expiration term Â Â Â Jan. 28, 2027 Â Â Â Â Â Â Â Â Proceeds from business combination (in Dollars) Â Â Â Â Â Â Â Â 50,000,000 Â Â Goodwill value (in Dollars) Â Â Â 801,000 Â Â Increase to goodwill (in Dollars) Â Â Â Â Â Â Â 300 Â Â Goodwill impairment (in Dollars) Â Â Â $ 801,000 Â Â $ 801,000 Â Percentage of discount for lack of marketability Â Â Â Â Â Â Â 9.40% Â Â Merger Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate shares Â Â 216,650 Â Â Â Â Â Â Â Â Multi-Period Excess Earnings Method (â€œMPEEMâ€) [Member] Â Â Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Intangible assets (in Dollars) Â $ 15,287,000 Â Â Â Â Â Â Â Â Goodwill value (in Dollars) Â $ 501,000 Â Â Â Â Â Â Â Â Business Combination [Member] Â Â Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Conversion of stock, shares converted Â Â 100 Â Â Â Â Â Â Â Â APTâ€™s stockholders [Member] Â Â Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Business acquisition percentage Â Â Â 45.00% Â Â Â 45.00% Â Â Transaction costs (in Dollars) Â Â Â Â Â Â Â $ 874,000 Â Â APTâ€™s stockholders [Member] | Private Placement Warrants [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Business acquisition percentage Â Â Â 55.00% Â Â Â 55.00% Â Â Redeemable convertible preferred shares [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Preferred stock, par value (in Dollars per share) Â Â $ 0.0001 Â Â Â Â Â Â Â Â Redeemable Convertible Preferred Shares [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Percentage of discount for lack of marketability Â 14.90% Â Â Â Â Â Â Â Â Redeemable Convertible Preferred Shares [Member] | Business Combination [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Conversion of stock, shares converted Â Â 40,470 Â Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Shares received Â Â 916,497 Â Â Â Â Â Â Â Â Aggregate shares [1],[2] Â Â Â Â Â Â 1,279,796 319,950 Â Â Â Exercise price per share (in Dollars per share) Â Â Â $ 0.001 Â Â Â $ 0.001 Â Â Redeemable Convertible Preferred Shares conversion into shares of Common Stock 10,915,200 Â 10,915,200 10,915,200 [2] Â Â Â Â Â Â Â Common Stock [Member] | Merger Warrants [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Exercise price per share (in Dollars per share) Â Â Â $ 50 Â Â Â Â Â Â Â Â Common Stock [Member] | Business Combination [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Conversion of stock, shares converted Â Â 100 Â Â Â Â Â Â Â Â Preferred Shares [Member] | Redeemable Convertible Preferred Shares [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Redeemable Convertible Preferred Shares conversion into shares of Common Stock 109,152 Â 109,152 Â Â Â Â Â Â Â Private Placement Warrants [Member] Â Â Â Â Â Â Â Â Â Â General [Line Items] Â Â Â Â Â Â Â Â Â Â Aggregate shares Â Â 10,820,850 Â Â Â Â Â Â Â Aggregate gross proceeds (in Dollars) Â Â $ 50,000,000 Â Â Â Â Â Â Â [1] See Note 10A. [2] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionExpiration date. + ReferencesNo definition available. + Details Name: phge_ExpirationDateClassOfWarrant Namespace Prefix: phge_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionPercentage of discount for lack of marketability (â€œDLOMâ€). + ReferencesNo definition available. + Details Name: phge_PercentageOfDiscountForLackOfMarketabilityDLOM Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionProceeds from business combination. + ReferencesNo definition available. + Details Name: phge_ProceedsFromBusinessCombination Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRedeemable Convertible preferred shares conversion into shares of common stock. + ReferencesNo definition available. + Details Name: phge_StockIssuedDuringPeriodSharessRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments

in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. + ReferencesNo definition available. + Details Name: us-gaap_ExcessStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details Name: us-gaap_FinitelivedIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillOtherIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phge_MergerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phge_MultiPeriodExcessEarningsMethodMPEEMMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=phge_APTsStockholdersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phge_PrivatePlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phge_RedeemableConvertiblePreferredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=phge_PrivatePlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities - Purchase Price Allocation [Member] $ in Thousands Mar. 15, 2024 USD ($) Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities [Line Items] Â Cash and cash equivalents $ 509 Restricted cash 154 Other current assets 1,780 Property, plant and equipment 3,748 Operating lease right-of-use asset 7,953 IPR&D assets and Goodwill 16,088 Total assets 30,232 Trade accounts payable (3,667) Other accounts payable (2,895) Operating lease liability (7,819) Total liabilities (14,381) Total consideration $ 15,851 X - DefinitionThe amount of restricted cash. + ReferencesNo definition available. + Details Name: phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedcash Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating lease liability. + ReferencesNo definition available. + Details Name: phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of Operating lease right-of-use asset. + ReferencesNo definition available. + Details Name: phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightofuseAsset Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=phge_PurchasePriceAllocationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R31.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items] Â Total $ 15,851 Common Stock [Member] Â Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items] Â Total 3,041 Redeemable Convertible Preferred Stock [Member] Â Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items] Â Total 12,610 Merger Warrants [Member] Â Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items] Â Total $ 200 X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_RedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=phge_MergerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R32.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Fair Value of the Merger Warrants - Merger Warrants [Member] Sep. 30, 2024 Underlying value of Common Stock [Member] Â Schedule of Fair Value of Merger Warrants [Line Items] Â Merger warrant measurement input 0.37 Exercise price [Member] Â Schedule of Fair Value of Merger Warrants [Line Items] Â Merger warrant measurement input 5 Expected volatility [Member] Â Schedule of Fair Value of Merger Warrants [Line Items] Â Merger warrant measurement input 117.7 Expected terms [Member] Â Schedule of Fair Value of Merger Warrants [Line Items] Â Merger warrant measurement input 2.87 Risk-free interest rate [Member] Â Schedule of Fair Value of Merger Warrants [Line Items] Â Merger warrant measurement input 4.5 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_MergerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R33.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Condensed Consolidated Statements of Operations $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Adaptive Phage therapeutics LLC [Member] Â Schedule of Condensed Consolidated Statements of Operations [Line Items] Â Net loss attributable to APT $ 5,884 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11 + Details Name: srt_CondensedStatementOfIncomeCaptionsLineItems Namespace Prefix: srt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidatedEntitiesAxis=phge_AdaptivePhageTherapeuticsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R34.htm IDEA: XBRL DOCUMENT v3.24.3 General (Details) - Schedule of Pro Forma Financial Information $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Schedule of Pro Forma Financial Information [Abstract] Â Net loss $ 2,698 [1] [1] The pro forma amounts above are derived from historical numbers of the Company and APT. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionProFormaInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Significant Accounting Policies [Abstract] Â Â Â Exercise price Â Â $ 0.001 Â Goodwill impairment $ 801 $ 801 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceIncrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration XML 49 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Fair Value of Financial Instruments [Line Items] Â Foreign exchange contracts $ 3,410 $ 4,136 Fair value asset $ 15 $ 256 Minimum [Member] Â Â Fair Value of Financial Instruments [Line Items] Â Â Discount rate, percentage 3.84% Â Maximum [Member] Â Â Fair Value of Financial Instruments [Line Items] Â Â Discount rate, percentage 4.52% Â X - DefinitionDiscount rate which is used to value residual cash flows generated by financial assets of the securitization, asset-backed financing arrangement, or similar transfer for initial fair value measurement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 860 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-3 + Details Name: us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value of derivative asset for foreign currency contract subject to concentration of credit or market risk or both. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23 + Details Name: us-gaap_FairValueConcentrationOfRiskForeignCurrencyContractAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-31Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32 + Details Name: us-gaap_FairValueOptionQuantitativeDisclosuresLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash equivalents: Â Â Money market funds $ 20,325 $ 11,377 Foreign exchange contracts receivable 15 256 Total assets 20,340 11,633 Liabilities: Â Â Contingent consideration 161 155 Private Placement Warrants 4,328 Total liabilities 4,489 155 Level 1 [Member] Â Â Cash equivalents: Â Â Money market funds 20,325 11,377 Foreign exchange contracts receivable Â Total assets 20,325 11,377 Liabilities: Â Â Contingent consideration Private Placement Warrants Â Total liabilities Level 2 [Member] Â Â Cash equivalents: Â Â Money market funds Foreign exchange contracts receivable 15 256 Total assets 15 256 Liabilities: Â Â Contingent consideration Private Placement Warrants Â Total liabilities Level 3 [Member] Â Â Cash equivalents: Â Â Money market funds Foreign exchange contracts receivable Total assets Liabilities: Â Â Contingent consideration 161 155 Private Placement Warrants 4,328 Â Total liabilities $ 4,489 $ 155 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of contingent consideration in a business combination that is classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesNo definition available. + Details Name: us-gaap_MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilities - Level 3 [Member] - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Schedule of Fair Value Level 3 Financial Liabilities [Line Items] Â Â Beginning balance Private Placement Warrants 28,745 Change in fair value (24,417) Ending balance $ 4,328 X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement Warrants - Fair Value, Inputs, Level 3 [Member] Sep. 30, 2024 Dec. 31, 2023 Underlying value of Common Stock [Member] Â Â Schedule of Fair Value of the Liabilities for the Private

Placement Warrants [Line Items] Â Â Private placement warrants 1.02 Exercise price [Member] Â Â Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items] Â Â Private placement warrants 2.31 Expected volatility [Member] Â Â Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items] Â Â Private placement warrants 117.6 Expected terms [Member] Â Â Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items] Â Â Private placement warrants 1.75 Risk-free interest rate [Member] Â Â Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items] Â Â Private placement warrants 3.6 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_MeasurementInputTypeAxis=phge_MeasurementInputUnderlyingValueOfCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Other Current Assets (Details) - Schedule of Other Current Assets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Other Current Assets [Abstract] Â Â Government institutions $ 84 $ 66 Prepaid insurance 1,165 505 Other prepaid expenses 574 128 Grants receivable 950 574 Other 892 495 Other current assets $ 3,665 $ 1,768 X - DefinitionAmount of asset from government assistance, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3 + Details Name: us-gaap_GovernmentAssistanceAmountCumulativeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_GrantsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherDeferredCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule of Other Accounts Payable [Abstract] Â Â Employees and related institutions $ 956 $ 1,852 Accrued expenses 3,421 1,289 Government institutions 622 175 Prepaid sublease income 28 Severance related to former employees of APT 70 Other accounts payable $ 5,069 $ 3,344 X - DefinitionGovernment institutions. + ReferencesNo definition available. + Details Name: phge_GovernmentInstitutions Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPrepaid sublease income. + ReferencesNo definition available. + Details Name: phge_PrepaidSubleaseIncome Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLiability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment. + ReferencesNo definition available. + Details Name: us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) $ in Thousands 3 Months Ended 9 Months Ended Mar. 15, 2024 USD ($) Aug. 09, 2019 USD ($) mÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) Leases [Line Items] Â Â Â Â Â Â Square feet of area (in Square Meters) | mÂ² Â 49,625 Â Â Â Â Payments for rent Â $ 255 Â Â Â Â Lease payments Â Â Â Â $ 134 Â Premises fee $ 1,500 Â Â Â Â Â Warrants issued (in Shares) | shares Â Â Â Â 25,000 Â Termination fee Â Â Â Â $ 3,000 Â Lease expenses Â Â $ 995 $ 161 $ 2,543 $ 488 Lease Agreement [Member] Â Â Â Â Â Â Leases [Line Items] Â Â Â Â Â Â Square feet of area (in Square Meters) | mÂ² Â 25,894 Â Â Â Â Common Stock [Member] | Lease Agreement [Member] Â Â Â Â Â Â Leases [Line Items] Â Â Â Â Â Â Aggregate shares (in Shares) | shares Â Â Â Â 50 Â X - DefinitionArea of land held. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfLand Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionThe number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnContractTermination Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OperatingLeasedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for fees classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash payments to lessor's for use of assets under operating leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForRent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=phge_LeaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) â‚¬ in Thousands, $ in Thousands 9 Months Ended Jan. 18, 2024 USD ($) Mar. 31, 2023 USD ($) Mar. 31, 2023 ILS (â‚ª) Jun. 23, 2022 USD ($) Mar. 31, 2022 USD ($) Mar. 31, 2022 ILS (â‚ª) Aug. 31, 2021 USD ($) Aug. 31, 2021 ILS (â‚ª) Sep. 30, 2024 USD ($) Sep. 30, 2024 ILS (â‚ª) Sep. 30, 2024 ILS (â‚ª) Commitments and Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Oyster paid upfront payment Â Â Â Â Â Â Â Â Â Â $ 500 Â Â Payment from APT to Oyster Â Â Â Â Â Â Â Â Â Â 300 Â Â Other accounts payable Â Â Â Â Â Â Â Â Â Â 300 Â Â Manufacturing capabilities Â Â Â Â Â Â Â $ 1,778 â‚ª 5,737 Â Â Â Fund approved budget Â Â Â Â Â Â 50.00% 50.00% Â Â Â Received amount Â Â Â Â Â Â Â Â Â

395 Â â,ª 1,365 Aggregate budget Â $ 3,164 â,ª 11,283 Â $ 4,094 â,ª 13,004 Â Â Â Â Â Percentage of approved budgets Â 30.00% 30.00% Â 30.00% 30.00% Â Â Â Â Â Total approved grants Â Â Â Â Â Â Â Â 9,353 â,ª 32,068 Â Royalty expense Â Â Â Â Â Â Â Â 7,413 Â Â Contingent obligation Â Â Â Â Â Â Â Â 8,250 Â Â Receive fees Â Â Â $ 1,411 Â Â Â Â Â Â Â Installment amount $ 211 Â Â Â Â Â Â Â Â Â Â Cystic Fibrosis Product [Member] Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Received amount Â Â Â Â Â Â Â Â 768 â,ª 2,783 Â Grant receivable Â Â Â Â Â Â Â Â 8,003 Â 27,423 Israel Innovation Authority [Member] Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Received amount Â Â Â Â Â Â Â Â $ 577 Â â,ª 1,912 Minimum [Member] Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Royalties rate Â Â Â Â Â Â Â 3.00% 3.00% Â Maximum [Member] Â Â Â Â Â Â Â Â Â Â Commitments and Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Royalties rate Â Â Â Â Â Â Â 3.50% 3.50% Â X - DefinitionAggregate amount of budget. + ReferencesNo definition available. + Details Name: phge_AggregateAmountOfBudget Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fund approved budget. + ReferencesNo definition available. + Details Name: phge_FundApprovedBudgetPercentage Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of installment. + ReferencesNo definition available. + Details Name: phge_InstallmentAmount Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOyster paid an upfront payment. + ReferencesNo definition available. + Details Name: phge_OysterPaidAnUpfrontPayment Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment from APT to oyster. + ReferencesNo definition available. + Details Name: phge_PaymentFromAPTToOyster Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of total fund. + ReferencesNo definition available. + Details Name: phge_PercentageOfTotalFund Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionReceived amount. + ReferencesNo definition available. + Details Name: phge_ReceivedAmount Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPay based on royalties rate. + ReferencesNo definition available. + Details Name: phge_RoyaltiesRate Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionTotal approved grants. + ReferencesNo definition available. + Details Name: phge_TotalApprovedGrants Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of obligations incurred and payable classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-7 + Details Name: us-gaap_BusinessCombinationContingentConsiderationAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_GrantsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs incurred in the production of goods for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ManufacturingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ReceivablesLongTermContractsOrPrograms Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RoyaltyExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=phge_CysticFibrosisProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=phge_IsraelInnovationAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R44.htm IDEA: XBRL DOCUMENT v3.24.3 U.S. Government Contracts and Grants (Details) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2024 USD ($) U.S. Government Contracts and Grants [Line Items] Â Â Milestones contract value Â $ 36,214 Total contract value Â $ 39,081 Percentage of assessment fee Â 3.00% Reduction expenses, net $ 849 $ 1,802 MTEC [Member] Â Â U.S. Government Contracts and Grants [Line Items] Â Â Received grants $ 2,895 $ 2,895 X - DefinitionMilestones contract value. + ReferencesNo definition available. + Details Name: phge_MilestonesContractValue Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of assessment fee. + ReferencesNo definition available. + Details Name: phge_PercentageOfAssessmentFee Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of total contract value. + ReferencesNo definition available. + Details Name: phge_TotalContractValue Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: phge_USGovernmentContractsAndGrantsLineItems Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_GrantsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of significant reductions in the period of other assets (current, noncurrent, or unclassified). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ReductionsInOtherAssetsAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionAxis=phge_MTECMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Long-Term Debt (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Mar. 19, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Aug. 16, 2021 Long-Term Debt [Line Items] Â Â Â Â Â Interest expense term loan amount $ 10,428 Â Â Â Â Prepayment 983 Â Â Â Â Prepaid principal amount 94 Â Â Â Â Interest expense Â $ 574 $ 850 $ 1,884 Â Loan Agreement [Member] Â Â Â Â Â Long-Term Debt [Line Items] Â Â Â Â Â Prepayment charge, percentage Â Â 1.00% Â Â Long Term Debts [Member] Â Â Â Â Â Long-Term Debt [Line Items] Â Â Â Â Â Accrued interest $ 69 Â Â Â Â Hercules Capital Inc [Member] Â Â Â Â Â Long-Term Debt [Line Items] Â Â Â Â Â Prepayment charge, percentage Â Â 1.00% Â Â Line of Credit [Member] Â Â Â Â Â Long-Term Debt [Line Items] Â Â Â Â Â Term loan facility Â Â 6.55% Â Â First Tranche [Member] Â Â Â Â Â Long-Term Debt [Line Items] Â Â Â Â Â Advanced amount Â Â Â Â $ 15,000 X - DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of principal of debt issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentIssuedPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate amount of interest paid or due on all long-term debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SECReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SECReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestExpenseLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionWeighted average interest rate of long-term debt outstanding calculated at point in time. + ReferencesNo definition available. + Details Name: us-gaap_LongtermDebtWeightedAverageInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of long-term debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal Home Loan Bank (FHLBank) advances before original maturity. + ReferencesNo definition available. + Details Name: us-gaap_PrepaymentFeesOnAdvancesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCapitalizationLongtermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=phge_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=phge_LongTermDebtsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=phge_HerculesCapitalIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Part-1 - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Jul. 15, 2024 Mar. 15, 2024 Dec. 31, 2023 Feb. 22, 2023 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep.

30, 2023 Jul. 09, 2024 Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares outstanding Â Â 4,723,320 [1] Â 18,176,602 [1] Â Â Â Â 18,176,602 [1] Â 7,800,000 Common stock, shares issued [1] Â Â 4,723,320 Â 18,176,602 Â Â Â Â 18,176,602 Â Â Common stock, shares authorized Â Â 120,000,000 [1] Â 750,000,000 [1] Â Â Â Â 750,000,000 [1] Â 750,000,000 Common stock, par value (in Dollars per share) Â Â $ 0.0001 [1] Â $ 0.0001 [1] Â Â Â Â $ 0.0001 [1] Â $ 0.0001 Preferred stock, shares authorized Â Â 1,000,000 Â 1,000,000 Â Â Â Â 1,000,000 Â Â Preferred stock, par value (in Dollars per share) Â Â $ 0.0001 Â $ 0.0001 Â Â Â Â $ 0.0001 Â Â Additional shares Â 216,417 Â Â Â Â Â Â Â Â Â Â Net proceeds from PIPE (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 507 Â Total consideration amount (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 6 Â Â Exercise price per share (in Dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.001 Â Â Private placement warrants (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 28,745 Â Warrant exercise price (in Dollars per share) Â Â Â Â Â Â Â Â Â Â $ 2.31 Â Â Share based compensation (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 1,083 $ 641 Â Aggregate offering price (in Dollars) Â Â $ 7,500 Â Â Â Â $ 5,859 [2] $ 1,293 [2] Â Â Â Â Sale of stock Â Â Â Â Â Â Â Â Â Â 7,518 Â Â Sale of stock price (in Dollars per share) Â Â Â Â $ 2.71 Â Â Â Â $ 2.71 Â Â Aggregate net proceeds (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 19 Â Â Aggregate commission (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 1 Â Â Pre funded warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate warrants Â Â Â Â 533,031 Â Â Â Â 533,031 Â Â Private Placement Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Issuance of redeemable convertible preferred shares upon March 2024 PIPE, net of issuance costs Â Â Â Â Â Â Â Â Â Â 216,417 Â Â Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares outstanding Â Â Â Â 178,958,447 Â Â Â Â 178,958,447 Â Â Maximum [Member] | Pre funded warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Exercise price (in Dollars per share) Â Â Â $ 2.45 Â Â Â Â Â Â Â Â Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares outstanding Â Â Â Â 18,021,173 Â Â Â Â 18,021,173 Â Â Minimum [Member] | Pre funded warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Exercise price (in Dollars per share) Â Â Â $ 2.44 Â Â Â Â Â Â Â Â March 2024 PIPE [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Converted shares of common stock Â Â Â Â Â Â Â Â 1,410,000 Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares issued Â 40,470 Â Â 125,328 Â Â Â Â 125,328 Â Â Redeemable convertible preferred shares [3],[4] Â Â Â Â Â Â Â Â 916,497 Â Â Â Â Â Â Issuance of redeemable convertible preferred shares upon March 2024 PIPE, net of issuance costs [2],[4] Â Â Â Â Â Â Â Â Â Â Redeemable convertible preferred shares 10,915,200 10,915,200 Â Â 10,915,200 [4] Â Â Â Â Â Â Additional shares Â 916,497 Â Â Â Â Â Â Â Â Â Â Exercise price (in Dollars per share) Â Â Â Â $ 0.001 Â Â Â Â $ 0.001 Â Â Exercised shares [2],[4] Â Â Â Â Â Â 980,811 477,827 Â Â Â Â Â Total consideration amount (in Dollars) Â Â Â Â Â Â Â Â Â Â Exercise price per share (in Dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.01 Â Â Convertible preferred shares Â 216,650 Â Â Â Â Â Â Â Â Â Â Aggregate offering price (in Dollars) [2],[4] Â Â Â Â Â Â Â $ 1 [5] Â Â Â Â Common Stock [Member] | Pre funded warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate warrants Â Â Â Â 928,041 Â Â Â Â 928,041 Â Â Exercised shares Â Â Â Â Â Â Â Â 925,607 Â Â March 2024 PIPE [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate warrants Â 952,381 Â Â Â Â Â Â Â Â March 2024 PIPE [Member] | Private Placement Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate warrants Â Â Â Â 10,820,850 Â Â Â Â 10,820,850 Â Â March 2024 PIPE [Member] | Preferred Shares [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Preferred stock, par value (in Dollars per share) Â $ 0.0001 Â Â Â Â Â Â Â Â Â Â Business Combination [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Combination price (in Dollars per share) Â Â Â Â $ 231.1 Â Â Â Â $ 231.1 Â Â Transaction cost (in Dollars) Â Â Â Â $ 3,317 Â Â Â Â $ 3,317 Â Â Converted shares of common stock Â 100 Â Â Â Â Â Â Â Â Â Â Business Combination [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Redeemable convertible preferred shares Â 916,497 Â Â Â Â Â Â Â Â Â Â Converted shares of common stock Â 100 Â Â Â Â Â Â Â Â Â Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares authorized Â Â Â Â Â Â Â Â Â Â 120,000,000 Common Stock [Member] | Private Placement Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Exercised shares Â Â Â Â Â Â Â Â 533,031 Â Â Redeemable Convertible Preferred Shares [Member] Â Â Â Â Â Â Â Â Â Â Â Â Preferred Shares [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Redeemable convertible preferred shares Â 40,470 Â Â Â Â Â Â Â Â Â Â Redeemable convertible preferred shares 109,152 109,152 Â Â Â Â Â Â Â Â Â Â Redeemable Convertible Preferred Shares [Member] | Business Combination [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Converted shares of common stock Â 40,470 Â Â Â Â Â Â Â Â Â Â Redeemable convertible preferred shares [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Preferred stock, par value (in Dollars per share) Â $ 0.0001 Â Â Â Â Â Â Â Â Â Â Issuance of redeemable convertible preferred shares upon March 2024 PIPE, net of issuance costs Â 216,417 Â Â Â Â Â Â Â Â Â Â Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Additional shares Â Â Â 1,599,746 Â Â Â Â Â Â Â Â Â Â Issuance cost (in Dollars) Â Â Â $ 333 Â Â Â Â Â Â Â Â Â Â Private placement warrants (in Dollars) Â Â Â Â Â Â Â Â $ 50,000 Â Â Private Placement [Member] | Pre funded warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Aggregate warrants Â Â Â 1,461,072 Â Â Â Â Â Â Â Â Â Â Net proceeds from PIPE (in Dollars) Â Â Â $ 7,152 Â Â Â Â Â Â Â Â Â Â Private Placement [Member] | March 2024 PIPE [Member] Â Â Â Â Â Â Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Â Â Â Â Private placement warrants (in Dollars) Â Â Â Â Â Â Â Â Â Â 1,907 Â Â Share based compensation (in Dollars) Â Â Â Â Â Â Â Â Â Â $ 1,273 Â Â [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. [2] See Note 10A. [3] See Note 1D. [4] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. [5] Less than $1. X - DefinitionConsideration paid. + ReferencesNo definition available. + Details Name: phge_ConsiderationPaid Namespace Prefix: phge_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRedeemable Convertible preferred shares conversion into shares of common stock. + ReferencesNo definition available. + Details Name: phge_StockIssuedDuringPeriodSharessRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_ConversionOfStockSharesConverted1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. + ReferencesNo definition available. + Details Name: us-gaap_ExcessStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of common shares issuable upon conversion of preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockConvertibleSharesIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the issuance of equity classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromOtherEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIntrinsic value of vested award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share decrease in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceDecrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_WarrantExercisePriceIncrease Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_PrivatePlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=phge_March2024PIPEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=phge_PIPEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=phge_RedeemableConvertiblePreferredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Part-2 - $ / shares Sep. 16, 2024 Jul. 11, 2024 Jul. 09, 2024 Sep. 30, 2024 [1] Mar. 15, 2024 Dec. 31, 2023 [1] Stockholders Equity [Line Items] Â Â Â Â Â Â Â Total number of fully-diluted shares Â Â 15.00% Â Â Â Common stock, shares outstanding Â Â 7,800,000 18,176,602 Â 4,723,320 Stock Issued During Period, Shares, Restricted Stock Award, Gross 155,429 Â Â Â Â Â Restricted stock unit fair value (in Dollars per share) $ 0.99 Â Â Â Â Â Options granted exercise price (in Dollars per share) Â $ 3.63 Â Â Â Â PIPE [Member] Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Aggregate warrants Â Â Â Â 952,381 Â Agents Warrants [Member] | PIPE [Member] Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Exercise price (in Dollars per share) Â Â Â Â $ 2.31 Â Board of Directors [Member] Â Â Â Â Â Â Stockholders Equity [Line Items] Â Â Â Â Â Â Grant of options Â 1,567,795 Â Â Â Â [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionNumber of fully-diluted shares. + ReferencesNo definition available. + Details Name: phge_TotalNumberOfFullydilutedSharesPercentage Namespace Prefix: phge_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=phge_PIPEMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_AgentsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders - Warrants [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Number of Shares of Common Stock Underlying Warrants 12,621,132 Public Warrants [Member] | IPO (December 13, 2018) [Member] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Issuance Date IPO (December 13, 2018) Expiration Date Oct. 28, 2024 Exercise Price Per Share | $ / shares $ 115 Number of Shares of Common Stock Underlying Warrants 350,000 2021 Registered Direct Offering Warrants [Member] | SPA (July 28, 2021) [Member] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Issuance Date SPA (July 28, 2021) Expiration Date Jan. 28, 2027 Exercise Price Per Share | $ / shares $ 50 Number of Shares of Common Stock Underlying Warrants 281,251 Merger Warrants [Member] | March 15, 2024 [Member] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Issuance Date March 15, 2024 Expiration Date Jan. 28, 2027 Exercise Price Per Share | $ / shares $ 50 Number of Shares of Common Stock Underlying Warrants 216,650 Private Placement Warrants [Member] | March 15, 2024 [Member] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Issuance Date March 15, 2024 Expiration Date Jul. 09, 2026 Exercise Price Per Share | $ / shares $ 2.31 Number of Shares of Common Stock Underlying Warrants 10,820,850 Agents Warrants [Member] | March 15, 2024 [Member] Â Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items] Â Issuance Date March 15, 2024 Expiration Date Jul. 09, 2026 Exercise Price Per Share | $ / shares $ 2.31 Number of Shares of Common Stock Underlying Warrants 952,381 X - DefinitionIssuance date. + ReferencesNo definition available. + Details Name: phge_IssuanceDateClassOfWarrant Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_PublicWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=phge_IPODecember132018Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=phge_SPAJuly282021PMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_MergerWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=phge_MarchFifteenTwoThousandTwentyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_PrivatePlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=phge_AgentsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model - Black-Scholes-Merton Model [Member] 9 Months Ended Sep. 30, 2024 $ / shares Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model [Line Items] Â Underlying value of Common Stock ($) $ 2.31 Exercise price ($) $ 2.31 Expected volatility (%) 100.60% Expected terms (years) 2 years 3 months 25 days Risk-free interest rate (%) 4.40% X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_BlackScholesMertonModelMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Schedule of Options Granted to Purchase - Stock Option [Member] $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Schedule of Options Granted to Purchase [Line Items] Â Number of Options, Beginning Balance | shares 528,112 Weighted Average Exercise Price, Beginning Balance | $ / shares $ 5.41 Aggregate Intrinsic Value, Beginning Balance | $ $ 72 Number of Options, Granted | shares 1,567,795 Weighted Average Exercise Price, Granted | $ / shares $ 3.63 Number of Options, Forfeited | shares (26,808) Weighted Average Exercise Price, Forfeited | $ / shares $ 3.96 Number of Options, Expired | shares (6,449) Weighted Average Exercise Price, Expired | $ / shares $ 4.58 Number of Options, Exercised | shares Weighted Average Exercise Price, Exercised | $ / shares Number of Options, Ending Balance | shares 2,062,650 Weighted Average Exercise Price, Ending Balance | $ / shares $ 4.08 Aggregate Intrinsic Value, Ending Balance | $ $ 22 Number of Options, Exercisable at end of period | shares 351,109 Weighted Average Exercise Price, Exercisable at the end of period | $ / shares $ 5.79 Weighted average remaining contractual life of outstanding options â€” years as of September 30, 2024 8 years 10 months 6 days X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock - Warrant [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Class of Warrant or Right [Line Items] Â Number of Shares of Common Stock Underlying Warrants 25,298 Private Warrants issued to scientific founders [Member] Â Class of Warrant or Right [Line Items] Â Issuance Date Nov. 27, 2017 Expiration Date Exercise Price Per Share | $ / shares Number of Shares of Common Stock Underlying Warrants 298 Landlord Warrants [Member] Â Class of Warrant or Right [Line Items] Â Issuance Date Mar. 15, 2024 [1] Expiration Date Jan. 28, 2027 [1] Exercise Price Per Share | $ / shares $ 50 [1] Number of Shares of Common Stock Underlying Warrants 25,000 [1] [1] See Note 6. X - DefinitionIssuance date. + ReferencesNo definition available. + Details Name: phge_WarrantsAndRightsOutstandingIssuanceDate Namespace Prefix: phge_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExpiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=phge_PrivateWarrantsIssuedToScientificFounderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=phge_LandlordWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity (Details) - Schedule of Stock-Based Payment Expenses - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Schedule of Stock-Based Payment Expenses [Line Items] Â Â Â Â Stock-based payment expenses $ 829 $ 195 $ 1,083 $ 641 Research and development expenses, net [Member] Â Â Â Â Schedule of Stock-Based Payment Expenses [Line Items] Â Â Â Â Stock-based payment expenses 273 31 336 202 General and administrative [Member] Â Â Â Â Schedule of Stock-Based Payment Expenses [Line Items] Â Â Â Â Stock-based payment expenses $ 556 $ 164 $ 747 $ 439 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Basic and Diluted Loss (Earnings) Per Share (Details) Sep. 30, 2024 $ / shares Common Stock [Member] Â Basic and Diluted Loss (Earnings) Per Share [Line Items] Â Exercise price $ 0.001 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial Instruments - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Options [Member] Â Â Â Â Schedule of Anti-dilutive Financial Instruments [Line Items] Â Â Â Â Anti-dilutive shares 2,041,139 591,034 2,062,650 591,034 Warrants [Member] Â Â Â Â Schedule of Anti-dilutive Financial Instruments [Line Items] Â Â Â Â Anti-dilutive shares 12,646,132 921,251 1,825,281 921,251 Contingent shares [Member] Â Â Â Â Schedule of Anti-dilutive Financial Instruments [Line Items] Â Â Â Â Anti-dilutive shares 200,000 400,000 200,000 400,000 Redeemable Convertible Preferred Shares [Member] Â Â Â Â Schedule of Anti-dilutive Financial Instruments [Line Items] Â Â Â Â Anti-dilutive shares 14,773,500 14,773,500 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phge_ContingentSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=phge_RedeemableConvertiblePreferredSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per Share - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Â Â Â Â Net loss (income) (in Dollars) $ (9,642) $ (4,471) $ 17,327 $ 7,906 $ 6,411 $ 6,361 $ 3,214 $ 20,678 Change in fair value of Private Placement Warrants (in Dollars) 20,559 Â Â Â Â 24,417 Diluted net loss (in Dollars) (9,642) Â Â 7,906 Â Â 27,631 20,678 Amount allocated to Redeemable Convertible Preferred Shares (in Dollars) (4,575) Â Â Â Â Net loss (income) attributable to shares of common stock (in Dollars) $ (5,067) Â Â $ 7,906 Â Â $ 3,214 $ 20,678 Denominator: Â Â Â Â Â Â Â Â Weighted-average number of shares of common stock outstanding 16,366,122 Â Â 6,058,774 Â Â 9,944,267 4,819,658 Private Placement Warrants Â Â Â Â 1,350,613 Options 21,511 Â Â Â Â Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities 16,387,633 Â Â 6,058,774 Â Â 11,294,880 4,819,658 Diluted net loss per share of common stock (in Dollars per share) [1] $ (0.31) Â Â $ 1.3 Â Â $ 2.45 $ 4.29 Denominator: Â Â Â Â Â Â Â Â Number of shares of common stock outstanding 16,365,824 Â Â 4,597,403 Â Â 9,943,968 3,951,624 Number of shares upon Pre-Funded Warrants exercise Â Â 1,461,073 Â Â 867,736 Number of shares upon Fully vested Warrants exercise 298 Â Â 298 Â Â 298 298 Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share 16,366,122 Â Â 6,058,774 Â Â 9,944,267 4,819,658 Basic loss (earnings) per share of common stock (in Dollars per share) [1] $ (0.31) Â Â $ 1.3 Â Â $ 0.32 $ 4.29 [1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share splitÂ as discussed in Note 10A. X - DefinitionNumber of shares of common stock outstanding. + ReferencesNo definition available. + Details Name: phge_NumberOfSharesOfCommonStockOutstanding Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares upon Fully vested Warrants exercise. + ReferencesNo definition available. + Details Name: phge_NumberOfSharesUponFullyVestedWarrantsExercise Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares upon Pre-Funded Warrants exercise. + ReferencesNo definition available. + Details Name: phge_NumberOfSharesUponPreFundedWarrantsExercise Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe shares of option. + ReferencesNo definition available. + Details Name: phge_Options Namespace Prefix: phge_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of accretion of temporary equity to its redemption value during the period. + ReferencesNo definition available. + Details Name: us-gaap_TemporaryEquityAccretionToRedemptionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill [Abstract] Â Â Â Â Goodwill $ 801 Â $ 801 Â Goodwill impairment $ 801 $ 801 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillImpairedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 70 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Events During the Period (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Events During the Period [Abstract] Â Contract liability $ 1,976 Contract liability recognized $ 1,976 X - ReferencesNo definition available. + Details Name: phge_EventDuringThePeriodAbstract Namespace Prefix: phge_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 71 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) Oct. 17, 2024 USD ($) Subsequent Event [Member] Â Subsequent Events [Line Items] Â Payment amount $ 600 X - DefinitionAmount of cash outflow for fees classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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p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l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

*TI09:I >*N2^/'(E564ND!% MKKL0;E+=:Y;45"M2(VLI-DD&/; +!6UY]I #;\|5AE(PB.<>NNW' 6TL+'F^ MSB7^###X[3=_7:]+/A$MK)]WXM$DZ"[1)>5\47W=T2!<6#@)OD9GJMH1 PCBD M:MV]U72C@V]RGVI&[IWQ_F:O{"Y2WD8. ![@) _5 IB_?W9[%CJ]8KKJ9-] MY=2(1QV1#)I&=6R@Q^WS&B&;T%XO0I/")5Q\<)>#^.!!?5CP M1:UMI[6NC'7W CF\XLTYIJXK4D\RG,_5F6$;^0WJ!5;I^*+4#U>1!+=X:O7;" M[?)A\5YJ'MSWW.2G/)>:KJYQR5I: H7WT$#CG3]Q]&=D(@[1]/LI,HM,CV_I M#KT:>5:XSM_674_$&SK)EJ.W[P>.GTBP4XQOS2,D*&1]*6\1DL?SG[SC('59*:?U1W=4?U<-PB8 M3\[FCVW]/KTKJ6LIN*?U;)^\|>Z[/V6Y!>_A%_2M5Q"1\QP4B:NBWEUM>*O MV<*42_"%BFSCKM%DW#<>[/*U&LP ZUI7I3HX\GCQNGDCPICL?H*"Z7ZX2'Q$X 0X7W88F"\=U\FPB MN###^?]P !W.*(-4&=F(9R*^RBG#2"Z4N%7Z%?QG@6'7[(DW96RB^7X>D3 0E"DL3<7WB-2"G"8@\/B),&5(NT;_<-$S=#+KQM]F4$U32.%M'=*PNRX^_M-)TF*"V)B7+W5MPMWCK2M?XR$<-[VVC.\3%61EUL3A+E4 J%42Z]Z_M'NLG. M~WLC]. =/Q"\M]P1'A8\Z^9+ (EI^&]f..KY=Y.[S0MROFY"\%HAS6#_ZI]SE MZ3YWT?2705VZ3II\7<&XNNXP.77#K%HDV%T%U[NL5?]=NN(T9WX?TD]R_ZR37 MS\BF?(:1#X5]?6T]4*7ZO3^H'+HR'+/0@59W/18 YDZ\3BE M%!/.Z20P"OG8K#6 .[!DQ.AE4[N@2.!W%[#<=)OG3X9[0:8[K6A MAAI)XR_&Z?CF4H!P$IH=/HQ-T^NOQ<2E5$HU2*%W+.P4[N:A(E)4+ATIO1X) MS]*X7P%$WP]R# 3)-.Y+V.=*OX.03DFTF->MV2*5B/-C'2;N"P3>,OH>63&E48L.TK4[:FW#-<76Z?S.'T[\#++$E_O%BVWTQ M.2:V7;_X.8I^]56BAN3?H]'$\'SYT5;X-OSD[5Q^Z34,E]_+-1/UAZDL4K8% M7IU-GSXYD!Z8_Z.K&_[=%T):5Y?| <.45H$@#\\O^Y>%4U.;6C'O8 M-D:T&@P^.Q(*/BGG-%F#$;*F8;1(0%2KP+5A&/CC(9&4;(2O4UDV6%KVSY=G-D4U2:1EHV'YG2N.VDWZVJ+U-9NBSH@4L6\LCM25%$+N ME$5(W''9B.@=%K2$8D8A2[T. D9;^8T3Z]6S+2[VQ].# H$B_0?BL+7F)G MG!H$S0P,<(§Z]5$*TA!]V[8)*A;Z# MN7%I0Q19IX4((DH2^==*ZW;KJW^U<&[6 HZ_{Z MOKFM"L%#=X%W-BOAH?MRO":%(P LIJ7%%; M(LY$*:DDG^*F65&X[0MYF];FI842NG[<\FD4U;D)'- MU!D "}<.@]1!=?!F.D4=X2T.:)?Y;X6"S)O9O4*XTZUZ *"B'C!;/90[DZO] MMBB4KZ,-MB4TC6P+H.A% %UR2+VFTKIQJ43^1!!Y&:KWCJ.HE:N<@OB\4A1NS\HOVN7VXVD$'.LF_H=KO..!*5] $KC#Y>#"F8H$MN4D4JM7&EWM^4"EO$FN ME#D'=/4AYF5;N4ZAYM%$#T3AC%JX52$ #DAF8NQ- "CVWNV+?]4%3(UQ=8>K&H)&[YHAQ=OYOP5&3=Z;W)^3!4Z3DL+.#\UQM&ULE51 ;]! $+WS*T:.E!.*/[=DX.E(#3|(0D"TAZJ M^A9[P*O8N^{N&M)_WUW:N%0B2+W@C9UY.] [L,#.Z8\/86Z(M(Q?+.:?5 MI33 T_.1_4M=NZYE0R3.>/Z=IBH;6Y$%*6Y)E:LE/SQA6T]@^'!*>R_H7#DWL MP+,@|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|GB]OI T23R>$!OP=}SQ12Z<'[69]Y_#MW6[KA:4TF0XX[@WL5EUP%5MXHZ,+%[:+F4ALQ>35/[K]AL NVO M!#3[P|!0].OP+U1Y<1<& #3+0 &0 'AL+W=O MO(-R@V #'=^?27 G2[<. M:9,EW3I@V ,M'5M$*5$E]3CY]_L.*2EVZN9A+[9(GN:TH]|\&9l:"X)EG8U<*4EF0:E7 _&P^:!()>]Z)Z?:MAKU;>WYJ*]I50;=6N"K/I7VZ(&W69]U1M|FX4ZO.\\;@ _+24* [HG_V=Y.[$: MM%92E5/AE"F$I>59=SYZ=S%E^2#PEZ*UVW@6',G"F*^|^)">=8<,B#0EGBU(-M_#W0)6G-A@#C6VVSV[IDQ*N@Y\^O"2&YTX&'+=X9)+7>1=0; M_T#O6'PTA<^&_'TU?L3=K)L'> MY-7 Q#_SA2.6M2]W5XS1Q'2W"0Z'=ZZ4"9UUT?"[-US]^<-A'1T,3UX\.&T! M3E^S?GY)_-G8AM^)M48EZMT" .BF%XPN-[MJK.@PI.E5*C"FXX4FI.BY.H28;"\^.EG%"R:ARO N(HY.2T8\^$ _[MJ_W#X9'XHU)%0N+&)IFT.4]<7U)N&Y%%JHU-&^V> &\(LUP|:.&=T'+1"3EU MP"1^E3!.UBTJN^})CV %S4+.2^M5L1(86_2%IWQ!5HQB8'UQ\X 5.TU,98'9 M+,432>MBR&R 7S90A$0X&2U+N1D!Q&@PN:,H,>R T??*ED?)V(T',T63+_'I M%HB)+,DJDX]J\$]+3^8AXAP?,=#)M"(^9YO)1N9TQ4"FQ[V#|:QU@M'M(0\ MRZB2\V3II\,)?&)U!S=I'??+,JY18R'+TI!:,(BZ.Z-9[, ^=P62FF1B%N>] MQTE/3%'4G!AJRQ;GR;=*.<6;OI2R6>! M5[/W+)^&B %:[$@,&EBXS9TQK/>T?&TLY&AK2Z(SYNN$'FT'GN.5HN*,"\ MD(Z[XA=*8DDEHQA_7[PW&N<0[^[9>E!.8*M G3; LCOLSSB.G\HT!H8B&)% ML077<&\)&:4Q^%@@$CL894YSAET02JZ8H! <%R6DU:"3!/2D9[V|46\V'(8; M|:(S&H|%Y< %SHE4/D&OC226>%37>"M3\[945VUN<$Y0Df_ 7[9IK'O(P[?) M,0=/0CE7T8M16DMK45.7V37SXDO]MJ4.#KUBJD!W5"4O.PM %#U+WQ#I3 M2=;A@IN%1U,B8X#Z>X7F.&YFCFX# E3AL%E.I63D#ON!4P,H#NO"0&2+ZGA=UT=1R"NDNT0_-@&Y/ M5$TU"5D.*?AP$2'2EE0!09VF,1214[3NU-T?I]$=@$TI;GNNVH3KWX_$G20\ M (B?SXQ0CY83(F-T F,TU+1IKDX+RB QO;G">2,;'>69\G">5&@Q@*D"%G M8^Q*. D3,.7&2Y=+73+OAH^'F9^.=DR25Y1E?$,S02R9EYQO8S0Q3;A+.'!/""G%HE7)%=-Y'=':@;FXEBJ65MWP'W32+28Y1.D2.6DA7*U=3 MM59RH30.4715>;GK'M]1UGY1;*)] <41GXK;$3TV^5M3G,/JEX +AY/84V1+) MK-V.PL4C.F_]>&LK3.;KSYD.W1NI%\GXJG]?/XWE\->TfP@_.T4 MQVMO>G04'T8'H\[_LCO9MMO?=<4,.%RT<[*K\#G!*43? OCMWN]M^L=E;7E^U(/)"N1<[-51Z@PLE ZYQ:O>MDSI18|=8ORK#'L]X][.9=% MY^+.,??NL+!Y493-9B,^:F2K/N=YM[!$R"1 MB<22!(Y_C^)*9!D) HQO06:GV9(6M!|KZ1^=[M!ESHVX4ME? 96!7YVV3#DO% M@E>.9O5/KHT309TSR8[49]Y>M_=.P1=DP8U4>.%,IEX7_S[\.]06G/1?6#_.M"X8.M],(H;FSEE^<:,,5FFF9#&CTX5=U|(@),.>7>:HQ*K+,.75RK/4865K6&\-M2-F5*]PLE]) (I#!G/8LM;&(O">(NO:CA"^:+>L4\0L#+L0Y&*=='#] :,;.- MW^7PH.!|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f8:_^#IV;S:<.-O"2.PN4XGC.9^%4NC$U54E8C#9M%2LB)A(\A)F7%)DS:MT*9R':F,W:!Q.X@E![4!\E^A?!$CS MYT$TF9R\\88%5AB"ZF& (^@7"D(WIQ]2OU<@)2M5^ 3 .5N?C 6$8]3!+ M610$(/C<&8/M.Y)/F\|%/@<]:NLH#NE>@-2;J#[.*D4 @.!:5C'!<2;J W$R062LM"SK4R'). 7#*K&]=>B1\P? $D8@ .*HNN#M2^O(:- ZU(P_&%7QNBQ>Z*OY!5PVCR1[33(Y/_B-731.B;L=SWH);^G<++@Y0{G5.[RK9H MN)85L4N!\K)%0O:%"DR_90^R9?P+[1-WQ\ZRBPH,"H;GF2#&I2$*C9S*!!/? M*L1#C2!|KSRC0 VPW!CBVWYYT5!2Z3K=XT+HK_+F_O&/KLK]L.XLO]=9?= MHZVT3_PSVH8J537PGUQ(U\[@.M!((YF&DQ7'":61.AB^S>F0!2G^]N/=MBK!)Q7.0$.]4^B)%U)C+QOJ4.I=.TWM M%<(W$T4*:MZ G[N[AL\Q)%HV]&'%Z[$N)K<1WD51.67RG]8U>4=."%E5RF, NK MRH5&&!Z5?%/+_WG<[Q_^H"252Z5K4>53,.VDG&96Z8M&S%#3,E+95>QT15 MV]M9"DW.C1#'1,/4)-+YP_#*]2H5^VIY;M'<.T4)LG(N4/G.B2B%?D);)&C%,[>9#X93-X0^4[']2.!FZ;"SD_LN*/@G$;3LFN!H S04NE)L^5 M%0)$BPQQXL;WR8R.&E1NO(TL%2;+\ Z4';)BXV+<81DM[NR-]+1VW3:HGR&]B-5L^,YB*3&"O4H^>T:657 M2DNf8:_^#IV;S:<.-O"2.PN4XGC.9^%4NC$U54E8C#9M%2LB)A(\A)F7%)DS:MT*9R':F,W:!Q.X@E![4!\E^A?!$CS MYT$TF9R\\88%5AB"ZF& (^@7"D(WIQ]2OU<@)2M5^ 3 .5N?C 6$8]3!+ M610$(/C<&8/M.Y)/F\|%/@<]:NLH#NE>@-2;J#[.*D4 @.!:5C'!<2;J W$R062LM"SK4R'). 7#*K&]=>B1\P? $D8@ .*HNN#M2^O(:- ZU(P_&%7QNBQ>Z*OY15PVCR1[33(Y/_B-731.B;L=SWH);^G<++@Y0{G5.[RK9H MN)85L4N!\K)%0O:%"DR_90^R9?P+[1-WQ\ZRBPH,"H;GF2#&I2$*C9S*!!/? M*L1#C2!|KSRC0 VPW!CBVWYYT5!2Z3K=XT+HK_+F_O&/KLK]L.XLO]=9?= MHZVT3_PSVH8J537PGUQ(U\[@.M!((YF&DQ7'":61.AB^S>F0!2G^]N/=MBK!)Q7.0$.]4^B)%U)C+QOJ4.I=.TWM M%<(W$T4*:MZ G[N[AL\Q)%HV]&'%Z[$N)K<1WD51.67RG]8U>4=."%E5RF, NK MRH5&&!Z5?%/+_WG<[Q_^H"252Z5K4>53,.VDG&96Z8M&S%#3,E+95>QT15 MV]M9"DW.C1#'1,/4)-+YP_#*]2H5^VIY;M'<.T4)LG(N4/G.B2B%?D);)&C%,[>9#X93-X0^4[']2.!FZ;"SD_LN*/@G$;3LFN!H S04NE)L^5 M%0)$BPQQXL;WR8R.&E1NO(TL%2;+\ Z4';)BXV+<81DM[NR-]+1VW3:HGR&]B-5L^,YB*3&"O4H^>T:657 M2DNf8:_^#IV;S:<.-O"2.PN4XGC.9^%4NC$U54E8C#9M%2LB)A(\A)F7%)DS:MT*9R':F,W:!Q.X@E![4!\E^A?!$CS MYT$TF9R\\88%5AB"ZF& (^@7"D(WIQ]2OU<@)2M5^ 3 .5N?C 6$8]3!+ M610$(/C<&8/M.Y)/F\|%/@<]:NLH#NE>@-2;J#[.*D4 @.!:5C'!<2;J W$R062LM"SK4R'). 7#*K&]=>B1\P? $D8@ .*HNN#M2^O(:- ZU(P_&%7QNBQ>Z*OY15PVCR1[33(Y/_B-731.B;L=SWH);^G<++@Y0{G5.[RK9H MN)85L4N!\K)%0O:%"DR_90^R9?P+[1-WQ\ZRBPH,"H;GF2#&I2$*C9S*!!/? M*L1#C2!|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|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` YC@NXP,!\#Z"NVW?F #S9?>:,]0 M2P,$% @ $X9N66 ^6^P-!0 J0L /D !X,"]W;W)K&ULC5;,,MLX$'W75PS4=.$%?%N2+W6:Q$*2IML'O:%)=Q\6^T!+ M8XE:BE1)*D[VZW=(2HJ=I$%?:/$R.^?.C7.\5?]f]1 MW-1"Fl.XLK9Y/9F8 MQ.*:F:%J4 -)1NE:65KJ^Z-6O:JW@$K]H M.&U=.WU[ADJM3<]Tf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|@7EFD)@\\" 1+V.&,W>8)%?0HN!:90^4 ^CS?.5^9@ 41UE<>>&^>1V%TT>>C64Y3@6@_8A"""K?]YVX>=/MX$9 5C9W.;K'PYI:TW&M8C;L)$%HW145TI-51+ "W M1$MP&3P/FW%^L+QYBFE6+'6RRD++E7*[=HS]S+P2EM4$9IOP"? %1\RV;KIA5 MD2LQNW]_5(+D7)) =]ND)S?PQR"!<,VCF/=<.|#U!^,N"]H+1OX@&#O>[SWO M_<^:$EO% 2K+SR+$FTY,J9D9%)Z1/^A. M_6#8>VU\&DR(S!/LSL0 NOX4, 8:MF_3MNO.Y&7) U&ZCYC.0 Y!Y?UN&O$IM8)Q2"@OZ*$Q!EW.90"*>YW4 :J9$$KPIMV5U!8 M*O64<-D^*JU>6CP.^<#KUQX.1LQ=B*$U0Y^+ 'XS6[.,>N>/YDG HKC#/<]T[M2CS_U=$PIXO? M08:9]L^!\Z^7= K6 J,#R3UC*3%&BQLM191J =.03.2N%&B P81,]6&/X>$ MV=O#AE:,@CBS^Z]58%*KC3:KI]PI8==T :],A[0?20]TJX8RW+,O.5EJXT!\VV M9=P.0KH?H02JH^$1K- G#F+E$C:4*Z04W[K+.74[$#FHSW47HIT. !\Q /BG@ MX%?-02Y"24/K+OMJ)31&?HKR9&$X'BTC@IM6<#(.T K0V"O%#D.3]5PY]24. MBI2/2FW$#45X5A' [/(\=1^6>$2QO7^V1B08I83F^PI1CMC'|$/TL$$+&5R MS$1'?(>1$#QPK8<@<4^T Q=>C)UQ*?]CUXCD.Q>AV7?Z_:;$-/UR0&'C9- M-CFC(S:.4!NO.$UB.$1NB3I34?83)PG- (DO!*Q6MA2]G29/0ED*!D5IZA$B*\[K3%- MQ"%*0ZU-IP9:K96:)M^E7_57C"CL?%7RB*TGT&>N6:<%^>M5HC_Z8*.I<5A M6C9MJ.6@%K9N4OLLFP1X3)"SY8|MDLN|!T94N|&D);N/DCS:::@ZB8A:.1[H M6<9HK<=PN.4E.BZ1!:OT=@?/-_!?!+J-(&F8&L$$@RV M5E3,$ZM2('LK$T]%\F*9@ICF7&G6XA,LN#W#W&U!*+2I;RW++M 8Q;"4+11&OH]QS M.CLS*[STK589]S6=$=:,2'7?GR(A/<5AEX.,[%4VVC>0J2# >JXG3*KB"/LD23.[$ M750H#C=[PD(S8'YPD.XIRNE: $RAN,/(.$*ZGBH%IC?S\0I4PH[57!6QYY M.A9#:NOC*!'Y&!PTOYK=O:.C:0/L&43:C\@IDP7U"-PFS5Z6?7GL=-CS^O/ MT?'!:.. W _NI.OX\\5!DKE\Y6N3?3%>.C251OF\VF"EMZ)>Q+ (!.F11@H5A?.OC93GZ[>]K7HU!=61VLJ@AH' MDW-[\@L]P.4@1^$3*=|F-K]*$O6H.DFPTC)94K<-<8K#EPV4H/?YM24?Y3Y*.M$L)783VWYFR^&Z!]UMIN";.YS!|@>>MU4E//^L U]AZN_G\XA. M7&BDF5BF!),&F4W9N#'KT<%7W-4[TY6D>2AAYURM&>0%9'ZKW]%7]+1YM.O- MF0GGVZ8 .,?!S2&F?E 1%)-2/7;ZS- 1[,L=ZNK5.$EWQ?$W_&ZR M4"M *V.,T8*|.6_ 8MZU> ^6)*VBTSLW!J UF5^1T^.R"X= ?]*:BR_P.@^Q2 M!0!0.J/3(6! <('<5"H*C$<.3S?M$6C2GN>AH4OR>5N"""DCG7(:\%L\UZR+ M]K)9X .G%37N:$BYE(5H*W.]H#6<6W$E^KCGB"A5NB. M3IKF2O8>@26:[[= MZ,3S.IH#P[GI==PNLOLG\9R&0O#4L^%KL[.15#0L<]H\|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|YQBT*Z4MP?V(T MS7C;CT ^5<6=&U%]\KZ ;K(^3*_]0:9]VO#2Y]*=FG6@?7W^B(9Y?Y49UDY-MXHS!*VWC!\QD.!PAR0 $>#6@ [4FR"=!PC,P.|.^F*$N&W[3 M],LDXKY@]^;G.I75ZL=/, .;G IQ\LIF!? H44JEQC;[8R')^9\7OFE4%O^ M:!*@N% ; KB6(?R('L#|l8*1[1=:H/|V(? !5!+ P04 " 3AFY9;C)^ M*2L& !8$ &0 'AL+W=O-Z^'@O.Q-CFW?3$Z.1;5S7K*9!%45!95WIRP7FY.> MU]MV7/-5IDW'8"%!BLV9_K+>B;Q-6A14EZP4G%)=F3+D/[I4.S7@IX& _M-]KS+B;2A1#?3..R/>FYQB&6LT0:/(@6/W;&\MP H1O?&\Q>.:)\.|+YOT= 9 MV#&&!57L3.1?>;JSD\ZH!RE;TBK7UV+S@37Q1 8O$;FR:V%3CXVB'B25T]H MJ[.'!2_K)-W1\"9.'), ,L%O)OC6[!]0]?*<.CHYEF(#THQ&-/B0[6ST3>.MFD69.XE?. <[3DU,]> *T3.&;#'1H M(@V2!ORT!O=_CZ&3Z+4F8*+,.F7|[OP!.MIZZV^\/)62?]RS=1\"EX#O^N&3 M>$$;?6#Q@C^'/OZ9+I26[*)_]Q%1VPGWVS&9=:36-&$G/4P=O>0MZTU>O)B M]^T3481M%,%3Z)/3Z?SR#*97YW!.^^?'+S<4Y?/PV,4T^NKRZOWK9O,2|[U@=.,)?$(.+%%)^RU%NL+BSO1N;F-BF MMTQBG8&R^A9H#>&L00M%)HH^C ++*L_OX)8I M M[JA4M)2*TO;G4$I@/U>N$*ATN>L-8W-+"FY9TE;/A6[1HT MQ!G4EV^:*XR M20-?&P/.RY T@CWT >/[R^\fKG?,&>&]NFB0"*RS#9.V%V0E#3[K<99=>]N[FXBJ90K47[_-X"&;ZP;RTT*S5' MT\|O)&PR5|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|-V'L. ^/G>T6UQY) M_H>4.,LHUB##PY)B& <4MJ;+H.U3.D\9R/%L9@KN/8.F 2R0A X0^\"1CP^. M^4.2@VS!//U5Y2]L>2)AC/.1.*1+G/-3V2:'W2(3'SSK3?U.C76?O.134 M.'B%1T=TO=FKL$9L.RA0+,&3H.:F>F-@(\ :T G,PSUCC#&-W$YD+|?'KL+| M?AA9A<&^V\&@<|M#4:WLG58A'):_^N+7|K;7YFE]6[P?7M^Y/U&YPBT;&PO=V!K-H965T2DX9?OT>R$Q(PV9?&NGS?^(?^2WUK.97N6+A0}!TP&BPNILE\=`8Q#O?C*

MA7\$KMW>_P1/"F,>PN;3Y,L"$*)I0\,C'Y6>(E2!B*2\=AQ)CN3 ;C_O65__M%WTG7PKF\-+(KX+/:.I[<)L!QP1KI/YOUWlCY\S+PE4;Z^!?6[=T\2Z!LG#>] M Y,")73[RYZZ,.P!3O\$R#M 'G6WA]+**^.9;&+ &FRX36SA{{H;T21.Z)"4 M.V_I5!#.SIX.P!="RDG]B2WLI66'O&B1^1^0;.^"CT:YR\9SY(2XE%3LI.1; M*1?Y4<([K(=PDKV /.O'1_A_=]Z=1+/Z3_W$-OLT+YRWE_WN? ERW)N\)D!,29 M[UF)TX2*W]%=83)[_FST*CL_(G&\DS@^OCY[?W-S]?7ZPX<^74>1 ,H^W=R_MA5$.SY^=Y]/1.6SIX9V1U'U"+\%7"//;>YB7CXUP(G3&B[AY.53-I&9@L31+ M+7X@4^A"V=U&W^=9B@^]X\6&/^7RI/ZTU,|<&=$D'0[^UDN.PDVW%)W'\8A41>ZHJ5^!DH@ M6LO!:.FIZ NZAR1Y@WMBLI& Z=(BTU?Z%@eJ!)75WSP892OIV. 5\%.8I#6'U MX3>?IV/XDU#*C M2> H[DD-OPIRUX=[).74]?0!*[']WUWQ:[FG51/ND0T\%)70B^"TICF,@QU5F+ |%@V*.A+(57- M#$W5-M2-0I8{IH*XR@Z#VO&1;"$SWY;&+H3+> <.VF*Y;.X5S<*!DO,:A>92@.;)B$;PFE^NIM7<&7SAV>F_M-I)4RB<{`90O@L@\BVMX_[XE?ZGKUB29G& M:UE]Y.DI%\$L@!P+UE:FL^P^8A_/F>5ELM+N"9VWC3\$D+7;R+IW)@4U%_[-M7OH\[#.HI\XQ+U#{'3[C9S*/YAAR[F2'2AK330[<*$Z.Q+'A3V4Q"CZRLG/ M+).VU? BM16%@\TO//0\.8>W',.L1;X^(?X+X #=2F%+#1N28?^\2DIQ!4_R] M;1T'?!2;8C.$T.H$XB]='>*=#C*>._=_JK,<*_]U0;17_$?X?"|,3I89]MDDO=_ML P7 96!1O6,P? +IN\EY=.5C-]OB4^N_/9RMQ<2V M 2,+7Z*'9^!U"|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`OSJE9K M?:/;+_5U_W^=12JY*77EC*UDHU>O3R[//2WY[3@OHC7\;O77)9XE'65K[#?_X ME+|\^62!'NM!9BR04_'>KKW11("7@XW=/|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|["K)[#M;@.4IN01.@ 3AR8'6-+5U#5,/] MP.50CZO#D\Z/ -23"%!/C@+4=>]TL.559-7.IX9)1XE-8-!.N3RR"\FN=^MQ M88A#*V(1.GH0U53A]%$#7[MN"5YG5 JGLM/5:L.CW=!2ZQ!"IZ54V3**.#1 MPD-D)U:ZVE8)&"+6')'^TRC]l\?# _@EL/X>7!O\3[O@&=>$!"P?>`[?B'%T MLPGM7$'$^.^Y(.W5P_Q^4K04H_::EC@RACI2# MA+1F%9&]J4*.D.BE#$*PTD9[0'>URTO+8O:F[)W=H3"PKJNH7.CY & XL2\ M1NRO\?(8]TTT'S3%?F=]5Z,Q@+1W@.i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lL:YM!Q?-UPC? TV#%WY!"!A@6&'^3 M&:HV&BSRP(JYGT2'X'NC80(TFM1/W'),94,IZBTN29TA-*8W=D,XG.ZS'NLV MO=09]XOCW0:E3.9;Z$6'S!<6RMH'4"-A5] 1(4P%HSEXA>)3^3A'^,R#^SJ MWYU^;IS YC9166+CZ=-.0[^HP_5Z%7=X2@KYQJ1YT<*N.+N&P0\[81S=;90F] MN*$,SW9MJ /2P!G^)3;,=A+<(B*:&:$,96-IN:,[&9]B%WL"'UNA*[&.1. M/W1T/=!WV8]2$IX2 L0^#W"^/R_FB\5Y+!99:(1%-$@CH]-`Q0f=T'F0 ' M:0NZKH@CJIS[CC6V3*5[.3&@^3W$WE07'H7N $%H1SB(.# MXA.9W0 4^A*V=Q]C>4E..2.Y? +RNIBXXES(3$-"%*K84]?N;RY2ZE=$T0FS(.M%SOV(3Z"9H;E? L1!,R%@IV^%<'@WXLPVIY9G6:<8FF,_NT&#$ 20C'T73S% M-#&AO??>14GDE)'-0S[TZ\"\2 ?NT$U%[!]11]EN[2G%\]-/^!!E@KB!V9 MJ?E^.:+|-,66.GIXI.)NE2DHRQ03SEAJ:28C@J? Y$@W!0.B3HES;+8IV0O0H MT"D.?H[QQJ[<8LT=[G M>QH(#H[UQX^2.U:E]W\Q>1P/(EYP]\W<__%MR'2IUBXX/^W/G/C%4]<-'$[Y& M3[9_3##E]+"[/ZTP=D-NLSA=B]RSY;N0C%6%/? FUU2P<=2Z2/<,UUV3DO(3 M3:&.ZLB+O67N\Q0$DT_S3U!.# -P(]B(]!XMGO9L]822#D[3M2B.M"!+ MO6%[L>X'F$EW.Y*/G" _Z] !3HTCLRCPZ"9-;O,.DL)\G#&Y*\,SEDB;'!,./"3Z!F&!!(O? 6.OSP]=T$GX5@B%COH3 M:(B$.*[($:HHQMJ54)8:!*7Z?P=\H:] HVVZAM%V.Z. M'6$QN#0C8\4HN7@!IO[7'U9UX$(Z2H&C9^?RH!VB?&,4 MK2!(32\8N5F#A^3U!+'C;XJUOW#@RO >UJMUC M+9/!%L-XW&$2.:[.91R1L< MN:5L,LOFCPD/7NP-JC>A<(!8V?KS\\4YEZ@5E;@74O7J $<-]D/13//=`EN'M MK%#MH#40X7'_BH(!)MY8%+`OX}-!NJO_?E @OJTH!G.?;=UOC/@1X(I^,/* M)9"V%8!\%>R-C.DHW! O8)=6AH _.$N?:1,H[>>N3&?9N_%?LRAYXI[2>/LE MLK/CHK8T!X&W#)'Y%F1V$Z6/!._E)P G1X,TOG'@XTA\;.*A_ ^BU_MB3#^ ~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}$PFIR/V]\MZ *.C!UP.0AW0L=Z M*\SIV5H#G2ON &.9ILP10D+V1P^PWVJ$"M .U^X9YGY ?$ 4K#8=Y85OI)ZV M^W.T/[=8D@9 2=9H.D!6(=._^O?.3]RK75]V4Q2;. #7/LBD'3!OR^5LH>)N2@ MZ, ??P)022P,$% @ $X9N6:.!%.Ol -@ @04 !0 `IS; !W;W)K&ULE53+.MLP$+[S*Q8]4+2 $;T5.[4%%$F;+]A4+B/LX M%+#W0TMHB(i$[?2=GIWWX M4[",]F+]]Q)++9@[OG/<>.2[PM@-_YW5;(=K-%_KE;*5.[#DQ$*AN12@<+#MW-M%Ol_K+Q;< WC@=],@=;,R4;*)[OXE,|=SPK"$C-C&1@->[S%LK1$)-.7S^D. M*2WP='YD_]#63K5LF.9.67[GN2GFSL2!'+>L*3@HJ+,F3/_3V< ",>"X"@!P2MIBY1]_*.&9,.E#R LM'$9B=M MJ2V:Q^%AV5M%)URPIGTLRE0P6VC% H#"ZW1.'CSA6U*U&]GKj$4 M#->KIE M1Q>\0#>%!RE.H>&IR#' %^-^2M$%?<-2W#"X2KK&^@M ;0^ %T06^<*W;/G" M_ZGWQV*%^$D/LQ:. _=-U'X#.U$XT:XNL(& RNJ=X M>@!%R? G>_G0PC3UI%e.GTP"BZ9$FZVMGW:,%XX2R^,/K9 +G[MH]L46%;M>: M7T.F&V$ZAPR[0W]9=+,Z&]XUIP>F=E0>E+@E]'=U'3N@.L-W"R/KUF0:. 5 @]@4 M !D !X,"]W,W)K&ULE533:,]HP$'[GKSAETK1) MM$E,H-!!).B/,0_54.FVAVD)/CE{U,3.,*>T__W.3LBH1)'V@NWS?9^_N_#= M="?5H\X0#3R7A= S+5.FNO1]C618 ^WV;&!OQX6O$MKM!\ MKY:*3G['DN8E'U1+ 0HW.V\>7BXBF^\2?N2XTP=[)6LI7RTAZ_IS NL("PP M.9:IT_*$5U@4EHAD_&DYO>]Y'5S<[)EO7>U4RYIKO)+\9SSPUVY#BAM>.% MN9>[+]C6. [1\B2RT^X5=DSL8>I#4VLBR!9.",A?-RI_;/AP QL$;_8"F,/= M/.147G/#XZF2.U VF]CLQ7]T"0N% .:CK(RBVYOP)OYF.E0P3Q)9"Z-AR5_X MND#X\& 7_7']&WK$!OI)2[AH" D;A!.XD\)D&FY$BNEKO$_B.H5LKW#!3A*N ML#]'0=_%K#H!-^@]WC@^;_5_&O^5H;17>2\W\=[;BBCXY36.)>ZX@G./*& M1O6$7OS^73@*/IT0"6"HU/L\8],F- 8D46[@N\ACBDIR'E=,.539KNF!?,OA M&I,V$O9[-V55R!=$#58RY,B"&TPA%]KDIK8>TS 9CB#LCX>L1QI53=?X3/-# M$Y.0CUA(EVP\Z7V63Z@$>=N\AH\8@_!BV%LJK'B>TJB@ZLASEJ7(\$N$,V+BW M0@)SD6 GP4BPXXED8B>1FC5?/L.!% &>]83\834C ((K@V ?Q#_Q#+%LW)32X M)C=6ZJ+= (-)HW_ON7WDRQ.ZZV5!{4N"%H<'Y!OE?.9&@.1E;.C6M!R-MNF]$P-M1643Z'XCI=D?[/=_E!+ P04 " 3AFY93S=1% H& #;#P &0 M 'AL+W=QUF)MC"1M'X8]T!)E'Y%$E;2R'OU(IS#0]Y5]BSP4KK\F0T4M&*YTP-1%2D4!DB=G@W/GY"*D]6;!UY3?]\XD"8+6>[HXT\ M-K")$,]XI F!X6/-+WF6$1#2^-Y@#MHM2;# [OD% 9W1'719,\4N1?4MCO3H; MA .(><*!3%^-+ ^S]XHX|/>)'(E/F%^V:M/8"H4EKDC3 RR-.B?K*Q@[/$7 ; M =?PKC/N]2O4C'-ZR1<,5T>E{XPZT;A0U:!,PK/T)F+3UW M0^ "W0MXPL)A+!8%$KNV-]^!YK;]>P?/^A;I_G2^4EA@>?_8Y@:#>A6/:ZK<9]^>QGTZW>NB!"Z1O-\P67K M'POTRO H6?%XL&*Q^4YAIE/M5'A?N."F6O"FFK@=NJH<+)1WJCD%H@#QCV' MMP]E*IE])1+Y.*K"YPE21<{CCF9GX.AQ^K{'$# MY1S1U046/H;.P;.JG@8C5U'P$X X!QS;"EW\1YCS)2>1Y\M.?=2R0L1PK=87 M\WLW[X_YVVUD8]%FV,MYDV $\$U3Q NKJ'8&4(Z[(YD00F$FGVM*-H8=& M& ^JI.(O]LJ3)ASSUK5A4_[ZW+P7^(G2MCF=T':BV6ZYW:XM M59U*[ )%Z#]3UVK7ZA6Y17>96I$+.W H,X8[I&K'I7C>,)*?D?).1 ^V4M&_F MO(%#Y\NEY$NR>K=%,&T0%EBKBL(4WP1*\%(B!4]+B..XX _'#DS$!3AVYQ?*.2SU4>!%W M-2+B6'.BFO2+>#[6%WN^O"23K?ILS26>'O& 2.E"^T5H,&KG M%N. M8P.B5K_L\'WQOG__Z-K1UVNL\'ZRU:>Tf_ T:Z.9M9.H7.6B%*LK6F"W3P1 M)L<4?!:.K6B5W8AKYQ(2@.PWA3 ^2=",FUYZOGME6 [O> ^13"'KX[0<.A0(*E@ MN" <8PC88PF<'@{'-]\06CW)FS1!.\]>@6BO>>V/8B/[V|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s&AR-9^D&VB7+=1^(s$H*7R4M5EH>% GF;#^U M'0^B#C;?PK[F1QW>X,(/H<^ ^SPZXB_L: B=O _H.&/ZDVBN3TYSXBVCC1 M_CBVQ.[U4F1XV;.,T]A6V!O_^$.0^#\=R2+]LHB,>1_?4=HQ1ST$#*TF2M&1;18*$;I6&VBU .2S'|LIL,W=7K?RQ73(()>HH98&BCHK MFQR=;Q=)0T/.5/F-]LZSLS. 94ONA)YAU3!2/3. 4.]%HYZ%0@+!.9-0W])TV9 MTRL"L./EN7?O4.\[&C[9C'9G(?\!Z&4L- "FH\26LTAY0'C<0 !& &8\5&PG?%N*#1E1{EL":."NS'S? MAVCS^ ^S9^XPY4G^G@@8R7J$RA1U{"FB4G8CC6I!OL;#D.5D)>O:TX8A@XTZP M9L%>Z@$1>64[A/NT4"A?LH#_+X&\M[58UF:R6C7&%]#@CAM$/X1-\["$CJ M+?_ 0B0M#P<]6ZH(%]4.T.&0?? $^D825,%*=>Y H$&\ ]2)DA:=PDI!X.)S" MD*5^ B'C@0W#DN(\NZID0WH11$ F:#9&PEM5<1*O>!B3WS[;T]@88P]IDU+ M*CG>]#(9>#B)2?C#_?C>82WIQ-NDUKCB) L#GNC"H0WMC=W* (&%A$E.11$ X MTR&+_!!2ED8A2Y,114GC@"4\>NFU69)#RO;LMG%,UE4A?D65%=0AJ A8E%"_M#D.;CY(A&X,) 4>W35E^@Q5]L]<53T>[?]Z]-.26UNXB@?F9(/KI7@3U*ZFS M5\%,R;Z"A9I? 3AUO(WE+XO05`3[2J2]O#@GSOX/UALB1*%.6QIO44#BBT??.M*V@X\?MA0)((^]$/.80!7G[..M"O=7._U-2.PM13=3R.!-T#]Q$V3CO$U6L_MJ$!4E(+L2?&(X.V `C$HF!(=? "XI-@:2@RFV? P!^^=]M?*OXMF_%*)@$+.M8P(7D+8?3ZN Q4&PJ?1_]_%=L S$S #B>,&RT#>'\?6((K;B.6M480I[_%!B M(\M;N)-80(=>2CF-_)W.WJZ/PKC_2AV"MM[H UVKM8DJKG[@-#DCEIG>\ON M9KMOE*OVZO/W ^2C4G.X<4.*,3/W^D(XLU7XTM`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{3X]=Q,2X_ R27,HWFOIM+F4?Q M//O%>&?
\=GUIO/G/+V3%!^6LGDPISGC#K%;QKB&29WV6&O9S*;0====>=T_(OH,%#PPOEXOLCX:ENGA2>LU*N0D_S5;11'XX*K;1F4P? MY-YSS^9@\|[IE6;Q&P2B_!ZNGT\^N[|$"+_M' M9FODL4;NS;837N_%]HIVN:)Q&P2=3L=4P^F2N]EFV!W].8-M36(.B:DDY\83V+!#V!&TX;FR1ELK/#WJA?K/-JS2T\$!^AB_Y&6KS\T4^MR#233UL0(UO-X[P!+5J;D:5I(S"8QA1<$0-(S"Q0+!^F>]ND_2=V6C*![D8 M L*4$(U0C32;X0FD_O%_;S8"DW++@\SQ,[W;G^T8MM$D9A 8LYHY]_=^9@ M8{YZ. _NN2\'HGY)!8<_HJ$Y+RB<5YK/.OLSJNL_N.7U7^L?2WM[ZLXC=;G M;7*9+IK6=BW0=FTG,5O_U/OH>6Q8H[=&>>APV+2"DPOCDIA'8CZ}!206DIB M,"5&9[<^=]/9\;.^>O-RFR8+X^8^*WY>O*>9)(N;>/D4L'V,%?T;,9.&.C:] M.:CFH]['<CZ]96V>9RR? $_2V=W\H/,*2E.SM7%>U-1FZW.23! C^7SW.%ES MCK1:ZOR1FHU]3[5MK6-]B,XJ*$W-AU7GP]+FUJ.FUNM. M4AEETL@38_;YND,@!!:.6I0;]f M .;V#&F]H8D7JRA.%W*$Y_V" GFR=({0]@&I,I0WV.FU^8.;F@[>NO@^]@4'.MOA@A]6((:O'5:.-1GHW]Z?TKF4Z*.$0S:22WQC3.)LE]D8[.)#7FT>1;^> B M2K_)/+])YW^"5V-4T-(JMFHY]":BVH>JOFH%E1;.^7YC\U3CN+>=*K0(0&E] MM.HJ@*CO @B9SF1J_!ZE:,3,.^.KD(L;F3;6TO14ZPBA)_U1S4$U%\4\5/-1 M+4"U$.4$I:E!J_L&YM/IV`;.331@&&JV:CFH)]+.AZ]^.O6LBVM98\#03@*!V96VU04=]+=V!UT5A?5/%3S42U-M1#5!*6I MT:FK"*:^BR#NYWG\KGBG%2=3P_X^*\(V5&ZC)>SS! RORL>?O/S3R/+ZKP7-M5[8MUE^;[W-1{S*B=054LU'-0347U3Q4\U$M0+40U02EJ9&LZQ'FF-EE1%L2-MJ&,CFH-]+JIYJ..C6H!J(:H)2E, _&%IW)RQ]=\);YM%R%M_,I1%EF!]5<5/-0S4>U`-5"5!.4ID:IKDI8:%5"KI7. MD;F3HW[#.1$;G=5! 1?5/%3S42U M1#5!*6I*.H+ %9;^4/'IN:YWL5'?TW' MTGNMG.[-] !W11S4,U']4"5 M135";&];ZL6'&OL?KWXM#[V; MP_?94Y3NDOFT2)=^`Q&M;]";C6H,JKFHY]&;CVH\]H6H)BA-35Q=W;"9ZH.% M0C=0S48U\]5<6/-0S4&U`-5"5!.4IH;LKFY8^NK&RV&/;/+G? 9S%Z\>]Y?B M:V/>T"8'|MFHYE2;=6[L;'.>_VM\CLZJ8=\/JH%A[T@(3]IH#0U(75#P(W M-'Y-HV46/5WG>))DAYRI0ML7[&:CFH-]+JIYJ.:C6F#M7MUA-&RXH@0ZJZ T M-4AUK\+27YQA[SLHXV_C*HT?RA[AU;Q8CO5GL0ZJR.MG;!TXM(]!:@ZJN:CF MH9]/.@&JA:@F*$V],')=Q>AVD/=97,;2 @6HVJCFHY]*:AVH^`]@6H%*:H#0U M9'5)HZLO:?S ^RRIV#IOZ#4M4.VIM*VW>?WM|\UGHI:ZJ^.@6'/"A.BD@M+4 MA-0%C*Z^@%%3J5<1&4CL#HYM6X'KNJKC^=N=+M/.IZ:T9M0.!:@ZJN:CF MH0]/.@&JA:@F*$T-X,9=.J#;9+#WR6!OE,'>*8.]509[KSV9AGLW3+8VV6P M\\OX?W0RNG4CHZOO9%P1-P'0S]$Z@6@_H]+V7:S>06=U4@FH_]+JIYJ.:C6H!J(:H)2E,#6E=(NLRE.;IH'P35;%1S M4,U%-0_5?

%0+4"U$-4%IZCU]ZSY(3W]ICA_^V)C>,9LZ5+-[N[?1Z'5ZP^T/-MC]&3N]CFH9]/:@&JA:@F*$V-4]W\Z.F;\6.X;(TO7ZCHVZ/4.]TSH^:-\#*

*MU1O4VA!!-1O5'%1S4V0=$RR&H9E2:YC[@V!STOL/MG4"T]H%]-M'JXJ!:-@6HAJ@M+14Y-2UCYZ^)G'`%;(-[2&^FG^\-6HU:)30/@BJV:CFH)]+-M:EZE*5Q>MC293J)-ML{(>'$!D79=]4.+2S]-Z-&C3-]6<2BMOM*9TLK8J62XZJX=J/JH%!]XB(3]K-MH#0U.W4[HZ<],7WPV:U)??PO7N:,\)Z&-Y,:8//31&*G:I[K^-G;'9M[8-V'JI-M7]36<3ET7N?@W-R\Y\5LWA*[Z//R4,U'M0#50E03E*8&K6YH]/0-C<8C?L>-?-M1IN;?NFG:-+UU0B^R@6H,JKFHYJ&:CVH!]H6H)BA-#6#=X^B-F(.:!<#U6Q4-MX;Z>=IF']5L5'-0W4A+MJ0U6E]*U[]OJ'D__VTX460I^_0-5;%2\0+4"U$-M-4%I2I(&9>E#?:0^-3W07S3@[-F'<2VE\=^DB)G9^-7C<-,])=B=E?AGET?G9-MHNP67|CYO#S<,:_RU5YXU$CE;?%K,:I)^OH9.=QOSSUS8;'-_,T;'KI>]:&ULK59;C],Z$/XK5@Y"*

*(+&,2YM+E[;27@1G)=*I=H'S@'APDVECX<3!-M=EKVWY^QTTU[B:!OQP$MKQY[YOIG)?)GY7LCO]@30Y&?%:[7P2]V;*]]7>0D5-M59>B@1I/-D)65.-6;GW52*'%-*

,JX'P5!XE>4U=YR;I^MY'(N6LU9#2M)5%M5-M5#[=.!?[A1=2SSP>V+,4YH&,GH=-T"X^@=S=7AU-M$?TZ-@:WQA<%>G:R)64MQ>>3C@\&4_W9P'YP;3\CCO\&IUV,:.MP]/UL_=W-G@.9DT5W-K^+RMTN?-RCQ2PH2W7#V+__OP"BHV_7'!E?\G^<+#?P-M2-X]+:J#.3*H6-WITY^:'1)P81-$9@^A@$%G>'9!E>435'6C*N'!-+L@CEKYH.1"O(>\HD^0+Y2V0-MZ_O'RR04Y+Z-6K-HVN\RDBS'-M'^?RS+]U\1>DL]T^D6KTV:-^DH#,_3_!#$31=$=":(CU\>DC[T:-M0Z(@FI+/CW?DU8O7-W2C8U[ZY$1]$'9.I-MFXGIS2O5T:P6'G:?-KD#:_GKS

*)WH[$.>GCG(OY7]Y255KBN5D-1K>C'$-S-MEJ)SE5A7IN=WRSB8S?V=-W_XT]\1]-,7PY-'0.7*B=@-@$-8RG:M2X1XU'-M4?_1/64L2DQ5$)M^5S0\1-ZS0(W=MJC)Z/8*XFZ*O73&I)P:MQ^2:O#0[>-M=!%(!B0FZ31SDTA[$NEX[-"=F*)1Q,@TJC8!=B<]'BON:#Q20=,$EG\<3-M).N99*.,[E"3(7@XG63A&?2C!#L(CMBAYP('GL(F01_,-E-?\,XBW^:%]T]&-C->*

*MX2=RRV!%Z=V@77'98@"RFUBZC1-.G1+60N/,89&PO=V]R:W-H965T-MO**,&4R',^Q>P:_-2]+LV$6&/YXK1-M*'<=9)ZF1/P<(N/KON.*

[FX4;NDB467##WI(L<(KJ;CD1>N96+#%,9.49R!P-MWG<&_N70;QB-W7%/<2UWQF!2F7'^9":?XK[C&47(,%&@NB_%8Z0,<.D=3R7-MI$X5TP!WQOOV:YN\3F9&)*

(XX>Z"Q2OI.QX$8YR1GZH:OOY*94.OP19Q)^POK-M\)R-M.U.)PHCK(XDUR%.U5!!.SE$(C$%Q&$QON89H0@0EG>H^$022<4TGMWA,@&I#P-M7)(LECU7.?U&A1N56H>%UN"

UBZ_>.82"Q^S&./?\:[.NTH^V"0_#&H)I[@\]MAX.W 0(O:.,+=]_3.\)Y]>1M541N6MW&(IY4^/A=!P*]-M_]I6O4-7WC+%6'!1!6PMH69.\0!]%=*

*MEM]S5WNBM:IHK=IH(YZFNB!3Q:.G>!QC.D.QMR2U-$>6I%V),+!)&[1?(>>+-M*N>+XVQ0P%H[-FAXS0,NZ%3!.K7!,C!&?4G-F*WF"H6B9CS1'_:BDO_V1VV*

M(VO5K>1WWZ0_N]^0L^]M+QSO.(>4N%V+^$*;]_9IQ-'YX?S;@&,4"O3P0(2N-MH9*U=]BG.K8VP59]\"8=4[,[##1O3-*LT$_GM.N-A,3H.]NPU]02P,$%-@-$X9N6='+E:$-_P-M&0T-!D

IX,"]W-W0&KULO5==:JHP%/TK&5]-M5M#[=.!?[A1=2SSP>V+,4YH&,GH=-T"X^@=S=7AU-M$?TZ-@:WQA<%>G:R)64MQ>>3C@\&4_W9P'YP;3\CCO\&IUV,:.MP]/UL_=W-G@.9DT5W-K^+RMTN?-RCQ2PH2W7#V+__OP"BHV_7'!E?\G^<+#?P-M2-X]+:J#.3*H6-WITY^:'1)P81-$9@^A@$%G>'9!E>435'6C*N'!-+L@CEKYH.1"O(>\HD^0+Y2V0-MZ_O'RR04Y+Z-6K-HVN\RDBS'-M'^?RS+]U\1>DL]T^D6KTV:-^DH#,_3_!#$31=$=":(CU\>DC[T:-M0Z(@FI+/CW?DU8O7-W2C8U[ZY$1]$'9.I-MFXGIS2O5T:P6'G:?-KD#:_GKS

*)WH[$.>GCG(OY7]Y255KBN5D-1K>C'$-S-MEJ)SE5A7IN=WRSB8S?V=-W_XT]\1]-,7PY-'0.7*B=@-@$-8RG:M2X1XU'-M4?_1/64L2DQ5$)M^5S0\1-ZS0(W=MJC)Z/8*XFZ*O73&I)P:M*

*Q

M\KB.!MI0+42U"4$]L6HE]"\1#6%;G]G'\1[7_W*^O+[.5]/%S?%!N[Z T<09]H4[[7#;X-ZE3>RT3$%-M]L6HE]":K-FZ_5% ;&_=3R?^[CX'=;DL56/[P;A26#^]R-;H5DA1S5";W07* M])GOSI]9;+9M
(^YEMIJ1W-EJ!:B6H1J M5B5$M03:*:0C7M'T?5AGU_5#U<-MHT$U2K,KNHRJ^>ZLFE71[:_#T90;JH6H%]&:V&GV%>"PEF9#QTO03:*:0C7=-M:.NFZ)B&TNR93\\(6W-BTO9T>KXX#;&
<.CEWJVWK%]5"5(M03:!:C&H]JDE4 M4ZBF=YIU$5"YO$C1$0VEV55>!MP"=\"MK/*KY7P^7:,^,W$%SFZUK'(VWH5]$ M:@+58E1+4$VBFD(U"1S'VZH'#,@$7#/CS-M>33\AFHAJD6H]E
M1K4$U22]*533]:BFJ$TNQ3+!\(6W-BTO9T>KXX#;&<,CEWJVWK%]5"5(M03:!:C&H]JDE4 M4ZBF=YIU$5"YO$C1$0VEV55>!MP"=\"MK/*KY7P^7:,^,W$%SFZUK'(VWH5]$ M:@+58E1+4$VBFD(U"1S'VZH'#,@$7#/CS-M>33\AFHAJD6H]E
M1K4$U22]*533]:BFJ$TJQ,,RR3@L(:?#@S11""JA:@6H9I M1C5$E23 MJ*903:-:BFJ&TNQF4"8"A^[!^@(/!MI.W>FF6S<%:!F(:A&JB9TV/KC>",K^_MZ^JG=M!!$U23]F90333;O"DZJ*$TNXS++-
_PQ&O^]VROS]X>RGCIG(V3<_BY-MO=:UB\[AAVH1]HFF==CAW1;?K#ZNEBX;Z4$VBFD(UW6CKINB8AM+LRBW#>L-3 MS\]YM_XQL-]FZ>+LU;YM69^%^AXQ03:!:C&H]JDE44ZBF42U%-4-
I=HV7*:NA-M.[CCOO2E-=_K /OL]SBM"Y_40E2+4$V@6HQU"-D5%.HIE$M135#:7:'**-W MPSY_3PX-XJ%:B&H1]@6HOVRX&9:!0^1CC2 ^J,,V5:\M]RZ
M)S1[U&N(CAJAFD"U&_425).HIE!-HU]*:H;2[&HOTWE#]^-M7W0# $WG[;03-M P#0T!VJ"52+42U!-8E]"M4T]J6H9BC-KO$R=##=TA^Z;7^"CP3I4"U$M0C6!
M:C&J):@F44VAFD:U%-4,I=D=H(S?#B^_#P>G]]_UI?W;_N5VNIO_()W6]P"VV[06H%J): MA&H"U6)42U!-HII"-8U]*,J9G69=_0:=O_^>KH'M0B_3=:.3Z;IG'I,QHFEX MW*.U;@)HX
[5(E03]!:C6H]J$M44JFE42U'-4)K=)\KXWBC KPY&:((U4)4 MBU!-H%],,@Fj2513]*91+44U0VEV,R@3@:-FC^)UQ<_G)EH7/SHA'ZI%]"90 M+4;U!-4D]BE4TZ/CQO&-Y_V^UTJQ%]=%1#;799ER' D3-
"=/BN_N&#=_5S4_2T-MG;{'/7SKED!J(:I%["90+4;U!-4D]BE4TZB6HIJA-+MOE-G $9\-'*90%0+_M42U"-8%J,:HE]"913;&:1K44U0REV\&E?^OINMRKT/KH
MCB8'42U"-8%J,:HE]"913;&:1K44U0REV%OC*6^2;+3+=@IO9 M@VO?472O4>LNT3NZC1#X@UYUKM<0'35"-8%],:HE]"913;&:1K44U0REV5VB M3 Z.W0_T/?Z8H?,.
9H91+40U2)4$Z@6HU"-A+5%*II5$M1S5":W0;*5.U-]1:B6H1] M5B5$M03:*:0C6-:BFJ&4]SFT&@*1R[.X7O]/I-DR4 MS1SI0;?:6HOVRX&9:!0^1CC2 ^J,,V5:\M]RZ
MS

.0"0*9'!'R[P1 I@AD>A3(=8,3?@H@,P0R.R+DH"=$ M!#(_)F0*(&<{Y.R8D!F /$,@SV@AET(+RQ6_^8# ?*'%6"RR ;;A1BI71LSW?8L15_XBW "QVFDIC8)3>"N\%@ MBS%GQ.32["KIFTJ. <=VN)!L\;Z,.&L2&>@R9VK4.[9:V-B0Z3&YA54F*KH)C#' SFF)38.3@FS!VDF&/2MW+.*:,.']1H M2HM8.3AF#C$QY.3$RD$S"\,QB4DG)98.+O#!V,2DDQ)+.!| <P?'G$%,S$(IL87&H[9_ISW,7F.6RMXD[_4Z;GL&A9B8A3)B"W5) MIM%8(\.TDY%OI"#1)G8",3'M9,3.01 .@_4\0_=2B+4S3#B WVW, QFQ;T:? M'EY.#C$OWV3'>,CI.8=W&__1NP;'!/:.|\DU'OLJ"8T-X9YIN,V#'[YX_W)";=O)7. MI` GJ11;J47Y9VC>A?*'JV)E6?/1;<]F>,/!LJV5N@AE7 6-X67_"E7_^M?G M?P!02P,$% @ $X9N61,G[+KO 0 I2(!H !X,"|?) .',|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|+ 0(4 Q0 (!.&;EEX\B=3XP4 +\? 8 " M@0X(!X;"]W;W)K&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N6.1E9VRU P Q@P !@ M ("!D!4 'AL+W=O?,_(08 , 8 8 " @7L9 !X;"]W;W)K&PO=V]R:W-H965T&UL4$!.! A0# M% @ $X9N68",+*YF P " H !@ ("!(# 'AL+W=O M&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N6.%;8],D M&P %#@ !@ ("!H58 'AL+W=O&UL4$!.! A0#% @ $X9N M60<)S1:. @ D 4 !D ("!57, 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N67QDOO.:"0 /!D M !D ("!2\ 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N66:PIM9=$@ 'C8 !D M ("!X)0 'AL+W=O&PO=V]R:W-H965T M&UL4$!.! A0# M% @ $X9N654.;XUB! <0D !D ("!T+$ 'AL+W=O M&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N666/ M+UX6!@ 2A$!D ("!U\T 'AL+W=O&PO=V]R:W-H965TP(($% 9 " @<+8 !X;"]W;W)K&UL4$!.! A0#% @ $X9N62T7U'>5 @ J@4 !D M ("!=-L 'AL+W=O&PO M=V]R:W-H965T(P4 M ,4 -9 " @8'D !X;"]W;W)K&UL4$!.! A0#% @ $X9N6?]87 P>#@ @L< !D ("! MV^D 'AL+W=OH$# !#"@ &0 @($P^ >&PO=V]R:W-H965TC[!X;"]W;W)K&UL4$!.! A0#% M @ $X9N6=+'E:$ P &0T !D ("!O\ 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N6:E&5V+M @ L@@ !D M ("!EA.! 'AL+W=O&PO=V]R:W-H965T&UL M4$!.! A0#% @ $X9N68CROEOW @ Q @ !D ("!?QT! M 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ M$X9N63@TPG80 P ^PH !D ("!GRX! 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N60<3?N$Y!@ MQRD !D ("!&5$! 'AL+W=O&PO=V]R:W-H965TK0ZP('P' 9 " @8A< 0!X;"]W;W)K&UL4$!.! A0#% @ $X9N66UTBZY ! K@\ !D M ("]E\! 'AL+W=O&PO=V]R:W-H M965T&UL4$!.! M A0#% @ $X9N69)OS#0@ @ X@0 !D ("!&L! 'AL M+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N M69(:?]/ @ &0D !D ("!.GH! 'AL+W=O&PO=V]R:W-H965T&UL4$!.! A0#% @ $X9N6394GNEH P S!8 M T (!WX$! 'AL+W T>6QEZ7=O'4$ "")@ #P @ %:A@$ M>&PO=V]R:V)O:VLN>&UL4$!.! A0#% @ $X9N61,G[+KO 0 I2(!H M (!_8H! 'AL+U]R96QS+W=O XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2213061true660false6 falsefalseR1.htm000 - Document - Document And Entity InformationSheethttp://www.biomx.com/role/DocumentAndEntityInformationDocument And Entity InformationCover1 falsefalseR2.htm001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)Sheethttp://www.biomx.com/role/CondensedConsolidatedBalanceSheetCondensed Consolidated Balance Sheets (Unaudited)Statements2 falsefalseR3.htm002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)Sheethttp://www.biomx.com/role/ConsolidatedBalanceSheet_ParentheticalsCondensed Consolidated Balance Sheets (Unaudited) (Parentheticals)Statements3 falsefalseR4.htm003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://www.biomx.com/role/ConsolidatedIncomeStatementCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm004 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders??? Equity (Capital Deficiency) (Unaudited)Sheethttp://www.biomx.com/role/ShareholdersEquityType2or3Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders??? Equity (Capital Deficiency) (Unaudited)Statements5 falsefalseR6.htm005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders??? Equity (Capital Deficiency) (Unaudited) (Parentheticals)Sheethttp://www.biomx.com/role/ShareholdersEquityType2or3_ParentheticalsCondensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders??? Equity (Capital Deficiency) (Unaudited) (Parentheticals)Statements6 falsefalseR7.htm006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.biomx.com/role/CondensedConsolidatedCashFlowCondensed Consolidated Statements of Cash Flows (Unaudited)Statements7 falsefalseR8.htm007 - Disclosure - GeneralSheethttp://www.biomx.com/role/GeneralGeneralNotes8 falsefalseR9.htm008 - Disclosure - Significant Accounting PoliciesSheethttp://www.biomx.com/role/SignificantAccountingPoliciesSignificant Accounting PoliciesNotes9 falsefalseR10.htm009 - Disclosure - Fair Value of Financial InstrumentsSheethttp://www.biomx.com/role/FairValueofFinancialInstrumentsFair Value of Financial InstrumentsNotes10 falsefalseR11.htm010 - Disclosure - Other Current AssetsSheethttp://www.biomx.com/role/OtherCurrentAssetsOther Current AssetsNotes11 falsefalseR12.htm011 - Disclosure - Other Accounts PayableSheethttp://www.biomx.com/role/OtherAccountsPayableOther Accounts PayableNotes12 falsefalseR13.htm012 - Disclosure - LeasesSheethttp://www.biomx.com/role/LeasesLeasesNotes13 falsefalseR14.htm013 - Disclosure - Commitments and ContingenciesSheethttp://www.biomx.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes14 falsefalseR15.htm014 - Disclosure - U.S. Government Contracts and GrantsSheethttp://www.biomx.com/role/USGovernmentContractsandGrantsU.S. Government Contracts and GrantsNotes15 falsefalseR16.htm015 - Disclosure - Long-Term DebtSheethttp://www.biomx.com/role/LongTermDebtLong-Term DebtNotes16 falsefalseR17.htm016 - Disclosure - Stockholders EquitySheethttp://www.biomx.com/role/StockholdersEquityStockholders EquityNotes17 falsefalseR18.htm017 - Disclosure - Basic and Diluted Loss (Earnings) Per ShareSheethttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareBasic and Diluted Loss (Earnings) Per ShareNotes18 falsefalseR19.htm018 - Disclosure - GoodwillSheethttp://www.biomx.com/role/GoodwillGoodwillNotes19 falsefalseR20.htm019 - Disclosure - Events During the PeriodSheethttp://www.biomx.com/role/EventsDuringthePeriodEvents During the PeriodNotes20 falsefalseR21.htm020 - Disclosure - Subsequent EventsSheethttp://www.biomx.com/role/SubsequentEventsSubsequent EventsNotes21 falsefalseR22.htm996000 - Disclosure - Accounting Policies, by Policy (Policies)Sheethttp://www.biomx.com/role/AccountingPoliciesByPolicyAccounting Policies, by Policy (Policies)Policiesshttp://www.biomx.com/role/SignificantAccountingPolicies22 falsefalseR23.htm996001 - Disclosure - General (Tables)Sheethttp://www.biomx.com/role/GeneralTablesGeneral (Tables)Tableshttp://www.biomx.com/role/General23 falsefalseR24.htm996002 - Disclosure - Fair Value of Financial Instruments (Tables)Sheethttp://www.biomx.com/role/FairValueofFinancialInstrumentsTablesFair Value of Financial Instruments (Tables)Tableshttp://www.biomx.com/role/FairValueofFinancialInstruments24 falsefalseR25.htm996003 - Disclosure - Other Current Assets (Tables)Sheethttp://www.biomx.com/role/OtherCurrentAssetsTablesOther Current Assets (Tables)Tableshttp://www.biomx.com/role/OtherCurrentAssets25 falsefalseR26.htm996004 - Disclosure - Other Accounts Payable (Tables)Sheethttp://www.biomx.com/role/OtherAccountsPayableTablesOther Accounts Payable (Tables)Tableshttp://www.biomx.com/role/OtherAccountsPayable26 falsefalseR27.htm996005 - Disclosure - Stockholders Equity (Tables)Sheethttp://www.biomx.com/role/StockholdersEquityTablesStockholders Equity (Tables)Tableshttp://www.biomx.com/role/StockholdersEquity27 falsefalseR28.htm996006 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Tables)Sheethttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTablesBasic and Diluted Loss (Earnings) Per Share (Tables)Tableshttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShare28 falsefalseR29.htm996007 - Disclosure - General (Details)Sheethttp://www.biomx.com/role/GeneralDetailsGeneral (Details)Tableshttp://www.biomx.com/role/GeneralTables29 falsefalseR30.htm996008 - Disclosure - General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed LiabilitiesSheethttp://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTableGeneral (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed LiabilitiesDetailshttp://www.biomx.com/role/GeneralTables30 falsefalseR31.htm996009 - Disclosure - General (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders AcquisitionSheethttp://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTableGeneral (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders AcquisitionDetailshttp://www.biomx.com/role/GeneralTables31 falsefalseR32.htm996010 - Disclosure - General (Details) - Schedule of Fair Value of the Merger WarrantsSheethttp://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTableGeneral (Details) - Schedule of Fair Value of the Merger WarrantsDetailshttp://www.biomx.com/role/GeneralTables32 falsefalseR33.htm996011 - Disclosure - General (Details) - Schedule of Condensed Consolidated Statements of OperationsSheethttp://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTableGeneral (Details) - Schedule of Condensed Consolidated Statements of OperationsDetailshttp://www.biomx.com/role/GeneralTables33 falsefalseR34.htm996012 - Disclosure - General (Details) - Schedule of Pro Forma Financial InformationSheethttp://www.biomx.com/role/ScheduleofProFormaFinancialInformationTableGeneral (Details) - Schedule of Pro Forma Financial InformationDetailshttp://www.biomx.com/role/GeneralTables34 falsefalseR35.htm996013 - Disclosure - Significant Accounting Policies (Details)Sheethttp://www.biomx.com/role/SignificantAccountingPoliciesDetailsSignificant Accounting Policies (Details)Details35 falsefalseR36.htm996014 - Disclosure - Fair Value of Financial Instruments (Details)Sheethttp://www.biomx.com/role/FairValueofFinancialInstrumentsDetailsFair Value of Financial Instruments (Details)Detailshttp://www.biomx.com/role/FairValueofFinancialInstrumentsTables36 falsefalseR37.htm996015 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and LiabilitiesSheethttp://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTableFair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and LiabilitiesDetailshttp://www.biomx.com/role/FairValueofFinancialInstrumentsTables37 falsefalseR38.htm996016 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilitiesSheethttp://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTableFair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilitiesDetailshttp://www.biomx.com/role/FairValueofFinancialInstrumentsTables38 falsefalseR39.htm996017 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement WarrantsSheethttp://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTableFair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement WarrantsDetailshttp://www.biomx.com/role/FairValueofFinancialInstrumentsTables39 falsefalseR40.htm996018 - Disclosure - Other Current Assets (Details) - Schedule of Other Current AssetsSheethttp://www.biomx.com/role/ScheduleofOtherCurrentAssetsTableOther Current Assets (Details) - Schedule of Other Current AssetsDetailshttp://www.biomx.com/role/OtherCurrentAssetsTables40 falsefalseR41.htm996019 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts PayableSheethttp://www.biomx.com/role/ScheduleofOtherAccountsPayableTableOther Accounts Payable (Details) - Schedule of Other Accounts PayableDetailshttp://www.biomx.com/role/OtherAccountsPayableTables41 falsefalseR42.htm996020 - Disclosure - Leases (Details)Sheethttp://www.biomx.com/role/LeasesDetailsLeases (Details)Detailshttp://www.biomx.com/role/Leases42 falsefalseR43.htm996021 - Disclosure - Commitments and Contingencies (Details)Sheethttp://www.biomx.com/role/CommitmentsandContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://www.biomx.com/role/CommitmentsandContingencies43 falsefalseR44.htm996022 - Disclosure - U.S. Government Contracts and Grants (Details)Sheethttp://www.biomx.com/role/USGovernmentContractsandGrantsDetailsU.S. Government Contracts and Grants (Details)Detailshttp://www.biomx.com/role/USGovernmentContractsandGrants44 falsefalseR45.htm996023 - Disclosure - Long-Term Debt (Details)Sheethttp://www.biomx.com/role/LongTermDebtDetailsLong-Term Debt (Details)Detailshttp://www.biomx.com/role/LongTermDebt45 falsefalseR46.htm996024 - Disclosure - Stockholders Equity (Details) - Part 1Sheethttp://www.biomx.com/role/StockholdersEquityDetailsPart1Stockholders Equity (Details) - Part 1Detailshttp://www.biomx.com/role/StockholdersEquityTables46 falsefalseR47.htm996025 - Disclosure - Stockholders Equity (Details) - Part 2Sheethttp://www.biomx.com/role/StockholdersEquityDetailsPart2Stockholders Equity (Details) - Part 2Detailshttp://www.biomx.com/role/StockholdersEquityTables47 falsefalseR48.htm996026 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to StockholdersSheethttp://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTableStockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to StockholdersDetailshttp://www.biomx.com/role/StockholdersEquityTables48 falsefalseR49.htm996027 - Disclosure - Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes ModelSheethttp://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTableStockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes ModelDetailshttp://www.biomx.com/role/StockholdersEquityTables49 falsefalseR50.htm996028 - Disclosure - Stockholders Equity (Details) - Schedule of Options Granted to PurchaseSheethttp://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTableStockholders Equity (Details) - Schedule of Options Granted to PurchaseDetailshttp://www.biomx.com/role/StockholdersEquityTables50 falsefalseR51.htm996029 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common StockSheethttp://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTableStockholders Equity (Details) -

Schedule of Outstanding Compensation Related Warrants to Purchase Common StockDetailshttp://www.biomx.com/role/StockholdersEquityTables51 falsefalseR52.htm996030 - Disclosure - Stockholders Equity (Details) - Schedule of Stock-Based Payment ExpensesSheethttp://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTableStockholders Equity (Details) - Schedule of Stock-Based Payment ExpensesDetailshttp://www.biomx.com/role/StockholdersEquityTables52 falsefalseR53.htm996031 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details)Sheethttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetailsBasic and Diluted Loss (Earnings) Per Share (Details)Detailshttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables53 falsefalseR54.htm996032 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial InstrumentsSheethttp://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTableBasic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial InstrumentsDetailshttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables54 falsefalseR55.htm996033 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per ShareSheethttp://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTableBasic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per ShareDetailshttp://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables55 falsefalseR56.htm996034 - Disclosure - Goodwill (Details)Sheethttp://www.biomx.com/role/GoodwillDetailsGoodwill (Details)Detailshttp://www.biomx.com/role/Goodwill56 falsefalseR57.htm996035 - Disclosure - Events During the Period (Details)Sheethttp://www.biomx.com/role/EventsDuringthePeriodDetailsEvents During the Period (Details)Detailshttp://www.biomx.com/role/EventsDuringthePeriod57 falsefalseR58.htm996036 - Disclosure - Subsequent Events (Details)Sheethttp://www.biomx.com/role/SubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.biomx.com/role/SubsequentEvents58 falsefalseAll ReportsBookAll Reports ea0221025-10q_biomxinc.htmphge-20240930.xsdphge-20240930_cal.xmlphge-20240930_def.xmlphge-20240930_lab.xmlphge-20240930_pre.xml http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024truetrue JSON 79 MetaLinks,json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0221025-10q_biomxinc.htm": { "nsprefix": "phge", "nsuri": "http://www.biomx.com/20240930", "dts": { "inline": { "local": ["ea0221025-10q_biomxinc.htm"] }, "schema": { "local": ["phge-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["phge-20240930_cal.xml"] }, "definitionLink": { "local": ["phge-20240930_def.xml"] }, "labelLink": { "local": ["phge-20240930_lab.xml"] }, "presentationLink": { "local": ["phge-20240930_pre.xml"] } }, "keyStandard": 265, "keyCustom": 41, "axisStandard": 27, "axisCustom": 0, "memberStandard": 29, "memberCustom": 27, "hidden": { "total": 168, "http://www.biomx.com/20240930": 15, "http://fasb.org/us-gaap/2024": 149, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 221, "entityCount": 1, "segmentCount": 66, "elementCount": 508, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 761, "http://xbrl.sec.gov/dei/2024": 30, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.biomx.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.biomx.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R3": { "role": "http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R4": { "role": "http://www.biomx.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.biomx.com/role/ShareholdersEquityType2or3", "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders\u2019 Equity (Capital Deficiency) (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders\u2019 Equity (Capital Deficiency) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c46", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c51", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R6": { "role": "http://www.biomx.com/role/ShareholdersEquityType2or3_Parentheticals", "longName": "005 - Statement - Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders\u2019 Equity (Capital Deficiency) (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and in Stockholders\u2019 Equity (Capital Deficiency) (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c17", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c17", "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.biomx.com/role/ConsolidatedCashFlow", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R8": { "role": "http://www.biomx.com/role/General", "longName": "007 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.biomx.com/role/SignificantAccountingPolicies", "longName": "008 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.biomx.com/role/FairValueofFinancialInstruments", "longName": "009 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.biomx.com/role/OtherCurrentAssets", "longName": "010 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.biomx.com/role/OtherAccountsPayable", "longName": "011 - Disclosure - Other Accounts Payable", "shortName": "Other Accounts Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.biomx.com/role/Leases", "longName": "012 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.biomx.com/role/CommitmentsandContingencies", "longName": "013 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.biomx.com/role/USGovernmentContractsandGrants", "longName": "014 - Disclosure - U.S. Government Contracts and Grants", "shortName": "U.S. Government Contracts and Grants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "phge:USGovernmentContractsAndGrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "phge:USGovernmentContractsAndGrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.biomx.com/role/LongTermDebt", "longName": "015 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.biomx.com/role/StockholdersEquity", "longName": "016 - Disclosure - Stockholders Equity", "shortName": "Stockholders Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShare", "longName": "017 - Disclosure - Basic and Diluted Loss (Earnings) Per Share", "shortName": "Basic and Diluted Loss (Earnings) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.biomx.com/role/Goodwill", "longName": "018 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-

10q_biomxinc.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.biomx.com/role/EventsDuringthePeriod", "longName": "019 - Disclosure - Events During the Period", "shortName": "Events During the Period", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "phge:EventDuringThePeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "phge:EventDuringThePeriodTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.biomx.com/role/SubsequentEvents", "longName": "020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.biomx.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.biomx.com/role/GeneralTables", "longName": "996001 - Disclosure - General (Tables)", "shortName": "General (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.biomx.com/role/FairValueofFinancialInstrumentsTables", "longName": "996002 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.biomx.com/role/OtherCurrentAssetsTables", "longName": "996003 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.biomx.com/role/OtherAccountsPayableTables", "longName": "996004 - Disclosure - Other Accounts Payable (Tables)", "shortName": "Other Accounts Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.biomx.com/role/StockholdersEquityTables", "longName": "996005 - Disclosure - Stockholders Equity (Tables)", "shortName": "Stockholders Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables", "longName": "996006 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Tables)", "shortName": "Basic and Diluted Loss (Earnings) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.biomx.com/role/GeneralDetails", "longName": "996007 - Disclosure - General (Details)", "shortName": "General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c73", "name": "us-gaap:ExcessStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R30": { "role": "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable", "longName": "996008 - Disclosure - General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities", "shortName": "General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c91", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c91", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable", "longName": "996009 - Disclosure - General (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition", "shortName": "General (Details) - Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable", "longName": "996010 - Disclosure - General (Details) - Schedule of Fair Value of the Merger Warrants", "shortName": "General (Details) - Schedule of Fair Value of the Merger Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c96", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c96", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable", "longName": "996011 - Disclosure - General (Details) - Schedule of Condensed Consolidated Statements of Operations", "shortName": "General (Details) - Schedule of Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c101", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c101", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.biomx.com/role/ScheduleofProFormaFinancialInformationTable", "longName": "996012 - Disclosure - General (Details) - Schedule of Pro Forma Financial Information", "shortName": "General (Details) - Schedule of Pro Forma Financial Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.biomx.com/role/SignificantAccountingPoliciesDetails", "longName": "996013 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:WarrantExercisePriceIncrease", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails", "longName": "996014 - Disclosure - Fair Value of Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FairValueConcentrationOfRiskForeignCurrencyContractAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FairValueConcentrationOfRiskForeignCurrencyContractAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable", "longName": "996015 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities", "shortName": "Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable", "longName": "996016 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilities", "shortName": "Fair Value of Financial Instruments (Details) - Schedule of Fair Value Level 3 financial liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c111", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c111", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "longName": "996017 - Disclosure - Fair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement Warrants", "shortName": "Fair Value of Financial Instruments (Details) - Schedule of Fair Value of the Liabilities for the Private Placement Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c114", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c114", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable", "longName": "996018 - Disclosure - Other Current Assets (Details) - Schedule of Other Current Assets", "shortName": "Other Current Assets (Details) - Schedule of Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:GovernmentAssistanceAmountCumulativeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:GovernmentAssistanceAmountCumulativeCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3",

```
"ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable", "longName": "996019 - Disclosure - Other Accounts Payable (Details) - Schedule of Other Accounts Payable", "shortName": "Other Accounts Payable (Details) - Schedule of Other Accounts Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.biomx.com/role/LeasesDetails", "longName": "996020 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c124", "name": "us-gaap:AreaOfLand", "unitRef": "sqm", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c124", "name": "us-gaap:AreaOfLand", "unitRef": "sqm", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.biomx.com/role/CommitmentsandContingenciesDetails", "longName": "996021 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c0", "name": "phge:OysterPaidAnUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "phge:OysterPaidAnUpfrontPayment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails", "longName": "996022 - Disclosure - U.S. Government Contracts and Grants (Details)", "shortName": "U.S. Government Contracts and Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c0", "name": "phge:MilestonesContractValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "phge:USGovernmentContractsAndGrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "phge:MilestonesContractValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "phge:USGovernmentContractsAndGrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.biomx.com/role/LongTermDebtDetails", "longName": "996023 - Disclosure - Long-Term Debt (Details)", "shortName": "Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c140", "name": "us-gaap:InterestExpenseLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c140", "name": "us-gaap:InterestExpenseLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "longName": "996024 - Disclosure - Stockholders Equity (Details) - Part 1", "shortName": "Stockholders Equity (Details) - Part 1", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:CommonStockSharesIssued", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c146", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R47": { "role": "http://www.biomx.com/role/StockholdersEquityDetailsPart2", "longName": "996025 - Disclosure - Stockholders Equity (Details) - Part 2", "shortName": "Stockholders Equity (Details) - Part 2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c171", "name": "phge:TotalNumberOfFullydilutedSharesPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c171", "name": "phge:TotalNumberOfFullydilutedSharesPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "longName": "996026 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders", "shortName": "Stockholders Equity (Details) - Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c185", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c185", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable", "longName": "996027 - Disclosure - Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model", "shortName": "Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c186", "name": "us-gaap:SharePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c186", "name": "us-gaap:SharePrice", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "longName": "996028 - Disclosure - Stockholders Equity (Details) - Schedule of Options Granted to Purchase", "shortName": "Stockholders Equity (Details) - Schedule of Options Granted to Purchase", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "longName": "996029 - Disclosure - Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock", "shortName": "Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c195", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c195", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable", "longName": "996030 - Disclosure - Stockholders Equity (Details) - Schedule of Stock-Based Payment Expenses", "shortName": "Stockholders Equity (Details) - Schedule of Stock-Based Payment Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails", "longName": "996031 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details)", "shortName": "Basic and Diluted Loss (Earnings) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c43", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable", "longName": "996032 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial Instruments", "shortName": "Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Anti-dilutive Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c204", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c204", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable", "longName": "996033 - Disclosure - Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per Share", "shortName": "Basic and Diluted Loss (Earnings) Per Share (Details) - Schedule of Basic and Diluted Loss (earnings) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "unique": true } }, "R56": { "role": "http://www.biomx.com/role/GoodwillDetails", "longName": "996034 - Disclosure - Goodwill (Details)", "shortName": "Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://www.biomx.com/role/EventsDuringthePeriodDetails", "longName": "996035 - Disclosure - Events During the Period (Details)", "shortName": "Events During the Period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "phge:EventDuringThePeriodTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "phge:EventDuringThePeriodTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.biomx.com/role/SubsequentEventsDetails", "longName": "996036 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c220", "name": "us-gaap:PaymentsForFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c220", "name": "us-gaap:PaymentsForFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0221025-10q_biomxinc.htm", "first": true, "unique": true } } }, "tag": { "phge_APTsStockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "APTsStockholdersMember", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APT\u2019s Stockholders [Member]", "verboseLabel": "APT\u2019s stockholders [Member]", "label": "APTs Stockholders Member" } } } }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.biomx.com/role/OtherAccountsPayable" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER ACCOUNTS PAYABLE", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r331" ] }, "us-gaap_AccountsPayableCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Accounts Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Accounts Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "totalLabel": "Other accounts payable", "terseLabel": "Other accounts payable", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or
```

```
the normal operating cycle, if longer." } } }, "auth_ref": [ "r48" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accounts payable", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r98" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r48" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r98" ] }, "phge_AdaptivePhageTherapeuticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "AdaptivePhageTherapeuticsLLCMember", "presentation": [ "http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Adaptive Phage therapeutics LLC [Member]", "label": "Adaptive Phage Therapeutics LLC Member" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r58", "r603", "r786" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r474", "r652", "r653", "r654", "r655", "r721", "r787" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments required to reconcile cash flows used in operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation expenses", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r11", "r81" ] }, "phge_AgentsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "AgentsWarrantsMember", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "terseLabel": "Agents Warrants [Member]", "label": "Agents Warrants Member" } } }, "auth_ref": [] }, "phge_AggregateAmountOfBudget": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "AggregateAmountOfBudget", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate budget", "documentation": "Aggregate amount of budget.", "label": "Aggregate Amount Of Budget" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based payment expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r328", "r329" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r69", "r267", "r646", "r738" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r193" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails", "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Anti-dilutive Financial Instruments [Line Items]", "terseLabel": "Basic and Diluted Loss (Earnings) Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfLand", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Square feet of area (in Square Meters)", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r593", "r718", "r719", "r720" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r96", "r106", "r138", "r162", "r198", "r202", "r206", "r207", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r353", "r355", "r389", "r434", "r508", "r572", "r573", "r603", "r619", "r685", "r686", "r742" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r133", "r145", "r162", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r353", "r355", "r389", "r603", "r685", "r686", "r742" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r368", "r369", "r594" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r162", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r353", "r355", "r389", "r685", "r686", "r742" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssumptionForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesDiscountRate", "presentation": [ "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate, percentage", "label": "Fair Value Assumption, Date of Securitization or Asset-Backed Financing Arrangement, Transferor's Continuing Involvement, Servicing Assets or Liabilities, Discount Rate", "documentation": "Discount rate which is used to value residual cash flows generated by financial assets of the securitization, asset-backed financing arrangement, or similar transfer for initial fair value measurement." } } }, "auth_ref": [ "r423" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ] }, "phge_BasicandDilutedLossEarningsPerShareDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "BasicandDilutedLossEarningsPerShareDetailsTable", "presentation": [ "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss (Earnings) Per Share (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Condensed Financial Statements", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BlackScholesMertonModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BlackScholesMertonModelMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Black-Scholes-Merton Model [Member]", "label": "Black-Scholes-Merton Model [Member]", "documentation": "Black-Scholes-Merton model used to estimate fair value of award under share-based payment arrangement." } } }, "auth_ref": [ "r591", "r712" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors [Member]", "label": "Board of Directors Chairman [Member]", "documentation": "Leader of board of directors." } } }, "auth_ref": [ "r663" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r347", "r588", "r589" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r36", "r38", "r222", "r223", "r224", "r225", "r226", "r347", "r588", "r589" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction cost (in Dollars)", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal,
```

accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r347"] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition percentage", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": ["r37"] }, "us-gaap_BusinessAcquisitionProFormaInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Pro Forma Financial Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.biomx.com/role/GeneralTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pro Forma Financial Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r628", "r629"] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Combination price (in Dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ScheduleofProFormaFinancialInformationTable"], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r345", "r346"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs (in Dollars)", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r10"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Revaluation of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r349", "r645"] }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationAsset", "crdr": "debit", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent obligation", "label": "Business Combination, Contingent Consideration, Asset", "documentation": "Amount of asset recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r41", "r90", "r348"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r40"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r40"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r40"] }, "phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedcash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedcash", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "documentation": "The amount of restricted cash." "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Restrictedcash" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": ["r40"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Other accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r40"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r40"] }, "phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease liability", "documentation": "Amount of operating lease liability." "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Liability" } } }, "auth_ref": [] }, "phge_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightofuseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightofuseAsset", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "documentation": "The amount of Operating lease right-of-use asset." "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Rightofuse Asset" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r39", "r40"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable"], "lang": { "en-us": { "role": { "totalLabel": "Total consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r40"] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://www.biomx.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r85", "r86", "r87", "r88"] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash

equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r135", "r566"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS", "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents and restricted cash at the beginning of the period", "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the period", "totalLabel": "Total cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r73", "r159"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Increase (decrease) in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r73"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "phge_ChangeInContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ChangeInContractLiability", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Change in contract liability", "documentation": "Change in contract liability.", "label": "Change In Contract Liability" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.biomx.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/LeasesDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r113", "r141", "r142", "r143", "r162", "r182", "r183", "r190", "r192", "r200", "r201", "r210", "r243", "r245", "r246", "r247", "r250", "r251", "r269", "r270", "r274", "r277", "r284", "r389", "r469", "r470", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r496", "r517", "r536", "r554", "r555", "r556", "r557", "r558", "r626", "r648", "r656"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r141", "r142", "r143", "r200", "r269", "r270", "r272", "r274", "r277", "r282", "r284", "r469", "r470", "r471", "r472", "r583", "r626", "r648"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.biomx.com/role/GeneralTables", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable", "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r31"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.biomx.com/role/GeneralTables", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails", "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Per Share", "verboseLabel": "Exercise price per share (in Dollars per share)", "netLabel": "Exercise price (in Dollars per share)", "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r285"] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate warrants", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r285"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares of Common Stock Underlying Warrants", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r31"] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "General [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r352"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r54", "r100", "r436", "r495"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.biomx.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r78", "r234", "r235", "r560", "r672", "r677"] }, "phge_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails", "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/LeasesDetails", "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r609", "r610", "r611", "r613", "r614", "r615", "r616", "r652", "r653", "r655", "r721", "r785", "r787"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r57", "r496"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r57"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r11", "r57", "r496", "r514", "r787", "r788"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, $0.0001 par value; Authorized \u2013 750,000,000 shares as of September 30, 2024 and 120,000,000 shares as of December 31, 2023; Issued and outstanding- 18,176,602 shares as of September 30, 2024 and 4,723,320 shares as of December 31, 2023.", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r57", "r438", "r603"] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":

```
"CondensedIncomeStatementTable", "presentation": [ "http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table]", "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r115", "r163", "r627" ] }, "srt_CondensedStatementOfIncomeCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CondensedStatementOfIncomeCaptionsLineItems", "presentation": [
"http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Condensed Consolidated Statements of Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r115", "r163", "r627" ] }, "phge_ConsiderationPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ConsiderationPaid", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration amount (in Dollars)", "documentation": "Consideration paid.", "label": "Consideration Paid" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r115", "r127", "r163", "r353", "r354", "r355", "r356", "r416", "r561", "r634", "r635", "r636", "r684", "r687", "r688" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r42", "r569" ] }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "crdr": "credit", "calculation": {
"http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure", "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity." } } }, "auth_ref": [ "r722", "r723", "r733" ] }, "phge_ContingentSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ContingentSharesMember", "presentation": [ "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent shares [Member]", "label": "Contingent Shares Member" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/EventsDuringthePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r287", "r288", "r289" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liability", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r287", "r288", "r289" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/EventsDuringthePeriodDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liability recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r290" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of stock, shares converted", "verboseLabel": "Converted shares of common stock", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r269", "r270", "r274", "r613", "r614", "r615", "r616" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r242", "r682" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r242", "r682", "r683" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "phge_CysticFibrosisProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "CysticFibrosisProductMember", "presentation": [
"http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cystic Fibrosis Product [Member]", "label": "Cystic Fibrosis Product Member" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued (in Shares)", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r20", "r22" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Debt [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r49", "r50", "r97", "r99", "r163", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r578", "r579", "r580", "r581", "r582", "r601", "r649", "r673", "r674", "r675", "r737", "r739" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r649" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [
"http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r469" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r163", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r578", "r579", "r580", "r581", "r582", "r601", "r649", "r673", "r674", "r675", "r737", "r739" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r7", "r28" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r43", "r44", "r45", "r93", "r486", "r488", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r524", "r525", "r526", "r527", "r530", "r531", "r532", "r533", "r546", "r547", "r548", "r549", "r568", "r609", "r611", "r727", "r728", "r729", "r730", "r731", "r732", "r734", "r735" ] }, "us-gaap_DevelopmentInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopmentInProcess", "crdr": "debit", "calculation": {
"http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "In-process Research and development (\u201cIPR&D\u201d) assets", "label": "Development in Process", "documentation": "The current amount of expenditures for a real estate project that has not yet been completed." } } }, "auth_ref": [ "r751", "r752" ] },
"phge_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [
"http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r623" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [
"r624" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss (Earnings) Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement",
"http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss (earnings) per share of Common Stock (in Dollars per share)", "verboseLabel": "Basic loss (earnings) per share of common stock (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r151", "r169", "r170", "r171", "r172", "r173", "r174", "r179", "r182", "r190", "r191", "r192", "r197", "r343", "r351", "r365", "r366", "r431", "r446", "r570" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement",
"http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss (earnings) per share of Common Stock (in Dollars per share)", "verboseLabel": "Diluted net loss per share of common stock (in Dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance
```

```
of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r151", "r169", "r170", "r171", "r172", "r173", "r174", "r182", "r190", "r191", "r192", "r197", "r343", "r351", "r365", "r366", "r431", "r446", "r570" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted loss (earnings) per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r23", "r24", "r194" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "BASIC AND DILUTED LOSS (EARNINGS) PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r178", "r193", "r195", "r196" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r393" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Employees and related institutions", "label": "Employee-related Liabilities", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r98", "r753" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options [Member]", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r621" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r621" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r621" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r625" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r621" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r621" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r621" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r621" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r131", "r148", "r149", "r150", "r164", "r165", "r166", "r168", "r173", "r175", "r177", "r199", "r211", "r212", "r230", "r286", "r337", "r338", "r340", "r341", "r342", "r344", "r350", "r351", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r394", "r395", "r396", "r397", "r398", "r399", "r403", "r405", "r413", "r445", "r460", "r461", "r462", "r474", "r536" ] }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcequisitionTable" ], "lang": { "en-us": { "role": { "label": "Equity Interest Type [Axis]", "documentation": "Information by type of equity interests that are issued or issuable in a business combination." } } }, "auth_ref": [] }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableTypeDomain", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcequisitionTable" ], "lang": { "en-us": { "role": { "label": "Equity Interest Issued or Issuable, Type [Domain]", "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination." } } }, "auth_ref": [ "r91" ] }, "phge_EventDuringThePeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "EventDuringThePeriodAbstract", "lang": { "en-us": { "role": { "label": "Events During the Period [Abstract]" } } }, "auth_ref": [] }, "phge_EventDuringThePeriodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "EventDuringThePeriodTextBlock", "presentation": [ "http://www.biomx.com/role/EventsDuringthePeriod" ], "lang": { "en-us": { "role": { "terseLabel": "EVENTS DURING THE PERIOD", "label": "Event During The Period Text Block" } } }, "auth_ref": [] }, "us-gaap_ExcessStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesIssued", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Shares received", "verboseLabel": "Additional shares", "label": "Excess Stock, Shares Issued", "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }, "auth_ref": [] }, "phge_ExpirationDateClassOfWarrant": { "xbrltype": "dateItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ExpirationDateClassOfWarrant", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration term", "documentation": "Expiration date.", "label": "Expiration Date Class Of Warrant" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 }, "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/ConsolidatedIncomeStatement", "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable", "http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Income from change in fair value of Private Placement Warrants", "verboseLabel": "Change in fair value", "negatedLabel": "Change in fair value of Private Placement Warrants (in Dollars)", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r7" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Our Financial Assets and Liabilities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r368", "r369", "r382", "r594" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Merger Warrants [Line Items]", "terseLabel": "Schedule of Fair Value of the Liabilities for the Private Placement Warrants [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r370", "r371", "r372", "r597" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
```

```
"documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r370", "r371", "r372", "r597" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [
"http://www.biomx.com/role/FairValueofFinancialInstrumentsTables", "http://www.biomx.com/role/GeneralTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Merger Warrants", "verboseLabel": "Schedule of Fair Value of the Liabilities for the Private Placement Warrants", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r370", "r371", "r597" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable", "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable",
"http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r260", "r292", "r293", "r294", "r295", "r296", "r297", "r367", "r369", "r370", "r371", "r372", "r381", "r382", "r384", "r420", "r421", "r422", "r579", "r580", "r585", "r586", "r587", "r594", "r597" ] }, "us-gaap_FairValueConcentrationOfRiskForeignCurrencyContractAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueConcentrationOfRiskForeignCurrencyContractAsset", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Fair Value, Concentration of Risk, Foreign Currency Contract, Asset", "documentation": "Fair value of derivative asset for foreign currency contract subject to concentration of credit or market risk or both." } } }, "auth_ref": [ "r94", "r95" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://www.biomx.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate), (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement, and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r377", "r379", "r380", "r381", "r384", "r385", "r386", "r387", "r388", "r429", "r594", "r598" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r260", "r292", "r297", "r369", "r382", "r420", "r585", "r586", "r587", "r594" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r260", "r292", "r297", "r369", "r370", "r382", "r421", "r579", "r580", "r585", "r586", "r587", "r594" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable", "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable",
"http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "verboseLabel": "Fair Value, Inputs, Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r260", "r292", "r293", "r294", "r295", "r296", "r297", "r369", "r370", "r371", "r372", "r382", "r422", "r579", "r580", "r585", "r586", "r587", "r594", "r597" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Level 3 Financial Liabilities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r383" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.biomx.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Level 3 financial liabilities", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r373", "r378", "r383" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r373", "r383" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r260", "r292", "r293", "r294", "r295", "r296", "r297", "r367", "r369", "r370", "r371", "r372", "r381", "r382", "r384", "r420", "r421", "r422", "r579", "r580", "r585", "r586", "r587", "r594", "r597" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r9" ] }, "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionQuantitativeDisclosuresLineItems", "presentation": [ "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r390", "r391", "r392" ] },
"phge_FairValueofFinancialInstrumentsDetailsScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "FairValueofFinancialInstrumentsDetailsScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments (Details) - Schedule of Fair Value of Our Financial Assets and Liabilities [Table]" } } }, "auth_ref": [] }, "phge_FairValueofFinancialInstrumentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "FairValueofFinancialInstrumentsDetailsTable", "presentation": [ "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r221", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r427", "r428", "r564" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets (in Dollars)", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r222" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails",
"http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts receivable", "verboseLabel": "Fair value asset", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [ "r368", "r369" ] }, "phge_FundApprovedBudgetPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "FundApprovedBudgetPercentage", "presentation": [
"http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fund approved budget", "documentation": "The fund approved budget.", "label": "Fund Approved Budget Percentage" } } }, "auth_ref": [] }, "us-gaap_GainLossOnContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnContractTermination", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "label": "Gain (Loss) on Contract Termination", "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform." } } }, "auth_ref": [ "r75" ] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": {
"http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [
"http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss from sale and disposal of fixed assets, net", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r646", "r670", "r671" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r67", "r520" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r67" ] },
"phge_GeneralDetailsScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "GeneralDetailsScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "General (Details) - Schedule of Fair Value Acquired Identifiable Assets and Assumed Liabilities [Table]" } } }, "auth_ref": [] }, "phge_GeneralDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "GeneralDetailsTable", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "General (Details) [Table]" } } }, "auth_ref": [] }, "phge_GeneralTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "GeneralTablesLineItems", "presentation": [
"http://www.biomx.com/role/GeneralTables" ], "lang": { "en-us": { "role": { "label": "General (Tables) [Line Items]" } } }, "auth_ref": [] }, "phge_GeneralTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "GeneralTablesTable", "presentation": [ "http://www.biomx.com/role/GeneralTables" ], "lang": { "en-us": { "role": {
```

```
"label": "General (Tables) [Table]" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/GoodwillDetails", "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D assets and Goodwill", "verboseLabel": "Goodwill value (in Dollars)", "netLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r136", "r214", "r430", "r573", "r576", "r595", "r603", "r667", "r668" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r666", "r669" ] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.biomx.com/role/Goodwill" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL", "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r213", "r216", "r219", "r576" ] }, "us-gaap_GoodwillImpairedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAbstract", "lang": { "en-us": { "role": { "label": "Goodwill [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/ConsolidatedIncomeStatement", "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/GoodwillDetails", "http://www.biomx.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "verboseLabel": "Goodwill impairment (in Dollars)", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r7", "r215", "r217", "r220", "r576", "r595" ] }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase to goodwill (in Dollars)", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }, "auth_ref": [ "r218" ] }, "us-gaap_GovernmentAssistanceAmountCumulativeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentAssistanceAmountCumulativeCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Government institutions", "label": "Government Assistance, Asset, Current", "documentation": "Amount of asset from government assistance, classified as current." } } }, "auth_ref": [ "r401" ] }, "phge_GovernmentInstitutions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "GovernmentInstitutions", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Government institutions", "documentation": "Government institutions.", "label": "Government Institutions" } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails", "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant receivable", "verboseLabel": "Received grants", "label": "Grants Receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": [ "r640" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Grants receivable", "label": "Grants Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r640" ] }, "phge_HerculesCapitalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "HerculesCapitalIncMember", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hercules Capital Inc [Member]", "label": "Hercules Capital Inc Member" } } }, "auth_ref": [] }, "phge_IPODecember132018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IPODecember132018Member", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "IPO (December 13, 2018) [Member]", "label": "IPODecember132018 Member" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Loss (income) before tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r63", "r102", "r105", "r432", "r443", "r571", "r572", "r658", "r659", "r660", "r661", "r662" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r231", "r232", "r233", "r374", "r378", "r383", "r457", "r459", "r521", "r564", "r596", "r756" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r232", "r233", "r374", "r378", "r383", "r457", "r459", "r521", "r564", "r596", "r756" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expenses", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r107", "r112", "r176", "r177", "r198", "r204", "r207", "r333", "r334", "r339", "r448", "r592" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes paid", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r19", "r158", "r335", "r336" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net change in operating leases", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r631", "r645" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayable", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other accounts payable", "label": "Increase (Decrease) in Other Accounts Payable", "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current and non-current assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "phge_InstallmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "InstallmentAmount", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Installment amount", "documentation": "The amount of installment.", "label": "Installment Amount" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r198", "r202", "r203", "r205", "r207", "r402", "r572", "r573" ] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense term loan amount", "label": "Interest Expense, Long-Term Debt", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": [ "r104", "r113", "r114" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r203", "r643" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r154", "r156", "r157" ] }, "phge_IsraelInnovationAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IsraelInnovationAuthorityMember", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Israel Innovation Authority [Member]", "label": "Israel Innovation Authority Member" } } }, "auth_ref": [] }, "phge_IssuanceCostFromMarch2024PIPE": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceCostFromMarch2024PIPE", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance cost from March 2024 PIPE", "documentation": "Issuance cost from March 2024 PIPE.", "label": "Issuance Cost From March2024 PIPE" } } }, "auth_ref": [] }, "phge_IssuanceCostFromTheAPTAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceCostFromTheAPTAcquisition", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Shares conversion into shares of Common Stock", "documentation": "Issuance cost from the APT acquisition.", "label": "Issuance Cost From The APTAcquisition" } } }, "auth_ref": [] }, "phge_IssuanceCostFromTheAPTAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceCostFromTheAPTAcquisitions", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance cost from the APT acquisition", "documentation": "Issuance cost from the APT acquisition.", "label": "Issuance Cost From The APTAcquisitions" } } }, "auth_ref": [] }, "phge_IssuanceDateClassOfWarrant": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceDateClassOfWarrant", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance Date", "documentation": "Issuance date.", "label": "Issuance Date Class Of Warrant" } } }, "auth_ref": [] }, "phge_IssuanceOfCommonStockUnderOpenMarketSalesAgreementNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceOfCommonStockUnderOpenMarketSalesAgreementNetOfIssuanceCosts", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs", "documentation": "Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs.", "label": "Issuance Of Common Stock Under Open Market Sales Agreement Net Of Issuance Costs" } } }, "auth_ref": [] }, "phge_IssuanceOfMergerWarrantsUnderTheAPTAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceOfMergerWarrantsUnderTheAPTAcquisition", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel":
```

```
"Issuance of Merger Warrants under the APT acquisition", "documentation": "Issuance of Merger Warrants under the APT acquisition.", "label": "Issuance Of Merger Warrants Under The APTAcquisition" } } }, "auth_ref": [] }, "phge_IssuanceOfRedeemableConvertiblePreferredSharesUnderTheAPTAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "IssuanceOfRedeemableConvertiblePreferredSharesUnderTheAPTAcquisition", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Redeemable Convertible Preferred Shares under the APT acquisition", "documentation": "The amount of issuance of redeemable convertible preferred shares under the apt acquisition.", "label": "Issuance Of Redeemable Convertible Preferred Shares Under The APTAcquisition" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants issuance cost", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r7" ] }, "phge_LandlordWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LandlordWarrantsMember", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable" ], "lang": { "en-us": { "role": { "terseLabel": "Landlord Warrants [Member]", "label": "Landlord Warrants Member" } } }, "auth_ref": [] }, "phge_LeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LeaseAgreementMember", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Agreement [Member]", "label": "Lease Agreement Member" } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r412", "r630" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r412", "r630" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease expenses", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r409", "r602" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "phge_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LeasesDetailsTable", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receive fees", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r632" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.biomx.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r404" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r62", "r101", "r440", "r603", "r650", "r664", "r736" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r51", "r134", "r162", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r354", "r355", "r356", "r389", "r603", "r685", "r742", "r743" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r369", "r722" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r52", "r53", "r54", "r55", "r162", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r354", "r355", "r356", "r389", "r685", "r742", "r743" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan facility", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit [Member]", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "phge_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LoanAgreementMember", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Agreement [Member]", "label": "Loan Agreement Member" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.biomx.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r139" ] }, "phge_LongTermDebtDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LongTermDebtDetailsTable", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r140" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.biomx.com/role/LongTermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM DEBT", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r79" ] }, "phge_LongTermDebtsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "LongTermDebtsMember", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Term Debts [Member]", "label": "Long Term Debts Member" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtWeightedAverageInterestRate", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment charge, percentage", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r236", "r237", "r238", "r241", "r330", "r465", "r577", "r678", "r679" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r236", "r237", "r238", "r241", "r330", "r577", "r678", "r679" ] }, "us-gaap_LossContingencyNatureDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r236", "r237", "r238", "r241", "r330", "r465", "r577", "r678", "r679" ] }, "phge_MTECMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MTECMember", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MTEC [Member]", "label": "MTECMember" } } }, "auth_ref": [] }, "us-gaap_ManufacturingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManufacturingCosts", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing capabilities", "label": "Manufacturing Costs", "documentation": "The aggregate costs incurred in the production of goods for sale." } } }, "auth_ref": [ "r64" ] }, "phge_March2024PIPEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "March2024PIPEMember", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 PIPE [Member]", "label": "March2024 PIPEMember" } } }, "auth_ref": [] }, "phge_MarchFifteenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MarchFifteenTwoThousandTwentyFourMember", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "March 15, 2024 [Member]", "label": "March Fifteen Two Thousand Twenty Four Member" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails", "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r129", "r130", "r237", "r238", "r239", "r240", "r299", "r330", "r372", "r425", "r456", "r458", "r465", "r487", "r488", "r542", "r543", "r544", "r545", "r550", "r562", "r563", "r574", "r583", "r590", "r597", "r598", "r599", "r600", "r605", "r689", "r744", "r745", "r746", "r747", "r748", "r749" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price [Member]", "label": "Measurement Input, Exercise Price [Member]", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected terms [Member]", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility [Member]", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r597", "r724", "r725", "r726" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate [Member]", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "us-
```

gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Underlying value of Common Stock [Member]", "label": "Measurement Input, Share Price [Member]", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": ["r724", "r725", "r726"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r370", "r371", "r372", "r597"] }, "phge_MeasurementInputUnderlyingValueOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MeasurementInputUnderlyingValueOfCommonStockMember", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable"], "lang": { "en-us": { "role": { "terseLabel": "Underlying value of Common Stock [Member]", "label": "Measurement Input Underlying Value Of Common Stock Member" } } }, "auth_ref": [] }, "phge_MergerWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MergerWarrantsMember", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/GeneralTables", "http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "terseLabel": "Merger Warrants [Member]", "verboseLabel": "Merger Warrants", "label": "Merger Warrants Member" } } }, "auth_ref": [] }, "phge_MilestonesContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MilestonesContractValue", "crdr": "credit", "presentation": ["http://www.biomx.com/role/USGovernmentContractsandGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestones contract value", "documentation": "Milestones contract value.", "label": "Milestones Contract Value" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails", "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r116", "r117", "r118", "r119", "r120", "r129", "r130", "r237", "r238", "r239", "r240", "r299", "r330", "r372", "r425", "r456", "r458", "r465", "r487", "r488", "r542", "r543", "r544", "r545", "r550", "r562", "r563", "r574", "r583", "r590", "r597", "r598", "r599", "r605", "r689", "r744", "r745", "r746", "r747", "r748", "r749"] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "phge_MultiPeriodExcessEarningsMethodMPEEMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "MultiPeriodExcessEarningsMethodMPEEMMember", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Multi-Period Excess Earnings Method (\u201cMPEEM\u201d) [Member]", "label": "Multi Period Excess Earnings Method MPEEMMember" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r155"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS \u2013 FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r155"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS \u2013 INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r73", "r74", "r75"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS \u2013 OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/ConsolidatedIncomeStatement", "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable", "http://www.biomx.com/role/ScheduleofCondensedConsolidatedStatementsofOperationsTable", "http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net loss (income)", "terseLabel": "Net income (loss)", "verboseLabel": "Net loss", "netLabel": "Net loss attributable to APT", "negatedLabel": "Net loss (income) (in Dollars)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r65", "r75", "r103", "r132", "r146", "r147", "r150", "r162", "r167", "r169", "r170", "r171", "r172", "r173", "r176", "r177", "r188", "r210", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r343", "r351", "r366", "r389", "r444", "r516", "r534", "r535", "r617", "r685"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Net loss (income) attributable to shares of common stock (in Dollars)", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r152", "r169", "r170", "r171", "r172", "r179", "r180", "r189", "r192", "r351"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss (in Dollars)", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": ["r152", "r181", "r184", "r185", "r186", "r187", "r189", "r192"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.biomx.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedLabel": "Finance expense (income), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r68"] }, "phge_NumberOfSharesOfCommonStockOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "NumberOfSharesOfCommonStockOutstanding", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of common stock outstanding", "documentation": "Number of shares of common stock outstanding.", "label": "Number Of Shares Of Common Stock Outstanding" } } }, "auth_ref": [] }, "phge_NumberOfSharesUponFullyVestedWarrantsExercise": { "xbrltype": "sharesItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "NumberOfSharesUponFullyVestedWarrantsExercise", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares upon Fully vested Warrants exercise", "documentation": "Number of shares upon Fully vested Warrants exercise.", "label": "Number Of Shares Upon Fully Vested Warrants Exercise" } } }, "auth_ref": [] }, "phge_NumberOfSharesUponPreFundedWarrantsExercise": { "xbrltype": "sharesItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "NumberOfSharesUponPreFundedWarrantsExercise", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares upon Pre-Funded Warrants exercise", "documentation": "Number of shares upon Pre-Funded Warrants exercise.", "label": "Number Of Shares Upon Pre Funded Warrants Exercise" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r105", "r571", "r658", "r659", "r660", "r661", "r662"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r407"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r407"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.biomx.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r408", "r410"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r406"] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": ["http://www.biomx.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with

```
domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "phge_Options": { "xbrltype": "sharesItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "Options", "presentation": [ "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "documentation": "The shares of option.", "label": "Options" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.biomx.com/role/General" ], "lang": { "en-us": { "role": { "terseLabel": "GENERAL", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r46", "r92", "r466", "r467" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Other current assets", "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r144", "r603" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.biomx.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER CURRENT ASSETS", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherDeferredCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDeferredCostsNet", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Deferred Costs, Net", "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies." } } }, "auth_ref": [ "r639" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Other income", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r447", "r518", "r551", "r552", "r553" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r53" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced amount", "label": "Other Long-Term Debt", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r12", "r99", "r754" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance income, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r75" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid expenses", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r642", "r665" ] }, "phge_OysterPaidAnUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "OysterPaidAnUpfrontPayment", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oyster paid upfront payment", "documentation": "Oyster paid an upfront payment.", "label": "Oyster Paid An Upfront Payment" } } }, "auth_ref": [] }, "phge_PIPEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PIPEMember", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1", "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 PIPE [Member]", "verboseLabel": "PIPE [Member]", "label": "PIPEMember" } } }, "auth_ref": [] }, "phge_PaymentFromAPTToOyster": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PaymentFromAPTToOyster", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment from APT to Oyster", "documentation": "Payment from APT to oyster.", "label": "Payment From APTTo Oyster" } } }, "auth_ref": [] }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentOfFinancingAndStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Issuance costs from February 2023 PIPE", "label": "Payment of Financing and Stock Issuance Costs", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LeasesDetails", "http://www.biomx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premises fee", "verboseLabel": "Payment amount", "label": "Payments for Other Fees", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for rent", "label": "Payments for Rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "negatedLabel": "March 2024 PIPE issuance costs", "terseLabel": "Net proceeds from PIPE (in Dollars)", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash and restricted cash acquired from the APT acquisition", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r71" ] }, "phge_PercentageOfAssessmentFee": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PercentageOfAssessmentFee", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of assessment fee", "documentation": "Percentage of assessment fee.", "label": "Percentage Of Assessment Fee" } } }, "auth_ref": [] }, "phge_PercentageOfDiscountForLackOfMarketabilityDLOM": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PercentageOfDiscountForLackOfMarketabilityDLOM", "presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of discount for lack of marketability", "documentation": "Percentage of discount for lack of marketability (\u201cDLOM\u201d).", "label": "Percentage Of Discount For Lack Of Marketability DLOM" } } }, "auth_ref": [] }, "phge_PercentageOfTotalFund": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PercentageOfTotalFund", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of approved budgets", "documentation": "Percentage of total fund.", "label": "Percentage Of Total Fund" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717" ] }, "phge_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Pre funded warrants [Member]", "label": "Pre Funded Warrants Member" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible preferred shares", "label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r271" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Shares", "verboseLabel": "Preferred Shares [Member]", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r609", "r610", "r613", "r614", "r615", "r616", "r785", "r787" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r56", "r269" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r56", "r496" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r56", "r269" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r56", "r496", "r514", "r787", "r788" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, $0.0001 par value; Authorized \u2013 1,000,000 shares as of September 30, 2024 and December 31, 2023. Issued and outstanding- 147,735 as of September 30, 2024. No shares issued and outstanding as of December 31, 2023.", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r56", "r437", "r603" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit",
```

```
"calculation": { "http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.biomx.com/role/ScheduleofOtherCurrentAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance", "documentation": "Amount of
asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [
"r567", "r575", "r665" ] }, "phge_PrepaidSubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PrepaidSubleaseIncome", "crdr":
"credit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid sublease income", "documentation": "Prepaid
sublease income.", "label": "Prepaid Sublease Income" } } }, "auth_ref": [] }, "us-gaap_PrepaymentFeesOnAdvancesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PrepaymentFeesOnAdvancesNet", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Prepayment", "label": "Prepayment Fees on Advances, Net", "documentation": "Amount of income earned, after hedging basis adjustments, from fees charged for prepayment of certain Federal
Home Loan Bank (FHLBank) advances before original maturity." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Private
Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as
insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "phge_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.biomx.com/20240930", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.biomx.com/role/GeneralDetails",
"http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-
us": { "role": { "terseLabel": "Private Placement Warrants [Member]", "label": "Private Placement Warrants Member" } } }, "auth_ref": [] },
"phge_PrivateWarrantsIssuedToScientificFounderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname":
"PrivateWarrantsIssuedToScientificFounderMember", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable" ],
"lang": { "en-us": { "role": { "terseLabel": "Private Warrants issued to scientific founders [Member]", "label": "Private Warrants Issued To Scientific Founder Member" } } }, "auth_ref": [] },
"phge_ProceedsFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ProceedsFromBusinessCombination", "crdr": "debit",
"presentation": [ "http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from business combination (in Dollars)", "documentation": "Proceeds from
business combination.", "label": "Proceeds From Business Combination" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.biomx.com/role/ShareholdersEquityType2or3_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under open market sales agreement, net of
issuance costs", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt
origination." } } }, "auth_ref": [ "r153" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow",
"http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock and Warrants under February 2023 PIPE", "verboseLabel": "Aggregate
gross proceeds (in Dollars)", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [
"r4" ] }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfConvertiblePreferredStock", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": {
"terseLabel": "Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE", "label": "Proceeds from Issuance of Convertible Preferred Stock", "documentation": "The cash
inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r4" ] }, "us-
gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr":
"debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/ScheduleofFairValueLevel3financialliabilitiesTable",
"http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Private Placement Warrants under March 2024 PIPE", "verboseLabel":
"Private Placement Warrants", "netLabel": "Private placement warrants (in Dollars)", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with
the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromOtherEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromOtherEquity", "crdr": "debit", "presentation": [
"http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance cost (in Dollars)", "label": "Proceeds from Other Equity", "documentation":
"Amount of cash inflow from the issuance of equity classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and
equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ProceedsFromSaleOfShortTermInvestments": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfShortTermInvestments", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": {
"role": { "terseLabel": "Proceeds from short-term deposits", "label": "Proceeds from Sale of Short-Term Investments", "documentation": "The cash inflow from sales of all investments, including
securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities
classified as trading securities that were acquired for reasons other than sale in the short term." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": {
"http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrants exercise", "label": "Proceeds from Warrant Exercises", "documentation":
"The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r644" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": {
"label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r121", "r122", "r123", "r124",
"r125", "r126", "r128", "r208", "r426", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r565", "r584", "r604", "r605", "r606", "r607", "r608", "r637", "r680", "r681", "r690", "r755", "r757",
"r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782",
"r783", "r784" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of
similar products or similar services." } } }, "auth_ref": [ "r121", "r122", "r123", "r124", "r125", "r126", "r128", "r208", "r426", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r565",
"r584", "r604", "r605", "r606", "r607", "r608", "r637", "r680", "r681", "r690", "r755", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770",
"r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784" ] },
"phge_PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndTradePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname":
"PropertyAndEquipmentPurchasesIncludedInAccountsPayableAndTradePayable", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": {
"role": { "terseLabel": "Property and equipment purchases included in accounts payable and Trade payable", "documentation": "Property and equipment purchases included in accounts payable
and trade payable.", "label": "Property And Equipment Purchases Included In Accounts Payable And Trade Payable" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {
"http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.biomx.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Net",
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended
for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r411", "r433", "r442",
"r603" ] }, "phge_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "PublicWarrantsMember", "presentation": [
"http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "Public Warrants [Member]",
"label": "Public Warrants Member" } } }, "auth_ref": [] }, "phge_PurchasePriceAllocationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname":
"PurchasePriceAllocationMember", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueAcquiredIdentifiableAssetsandAssumedLiabilitiesTable" ], "lang": { "en-us": { "role": {
"terseLabel": "Purchase Price Allocation [Member]", "label": "Purchase Price Allocation Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails",
"http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Statistical
Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } },
"auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r129", "r130", "r237", "r238", "r239", "r240", "r291", "r299", "r324", "r325", "r326", "r330", "r372", "r423", "r424", "r425", "r456", "r458",
"r465", "r487", "r488", "r542", "r543", "r544", "r545", "r550", "r562", "r563", "r574", "r583", "r590", "r597", "r598", "r599", "r600", "r605", "r611", "r676", "r689", "r725", "r745", "r746", "r747",
"r748", "r749" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.biomx.com/role/CommitmentsandContingenciesDetails", "http://www.biomx.com/role/FairValueofFinancialInstrumentsDetails",
"http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes,
but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r129", "r130", "r237", "r238", "r239",
"r240", "r291", "r299", "r324", "r325", "r326", "r330", "r372", "r423", "r424", "r425", "r456", "r458", "r465", "r487", "r488", "r542", "r543", "r544", "r545", "r550", "r562", "r563", "r574", "r583",
"r590", "r597", "r598", "r599", "r600", "r605", "r611", "r676", "r689", "r725", "r745", "r746", "r747", "r748", "r749" ] }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesLongTermContractsOrPrograms", "crdr": "debit", "presentation": [
"http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received amount", "label": "Receivables, Long-Term Contracts or Programs",
"documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term
contracts or programs including amounts billed and unbilled as of the balance sheet date." } } }, "auth_ref": [ "r641" ] }, "phge_ReceivedAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.biomx.com/20240930", "localname": "ReceivedAmount", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Received amount", "documentation": "Received amount." "label": "Received Amount" } } }, "auth_ref": [] }, "phge_RedeemableConvertiblePreferredSharesMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "RedeemableConvertiblePreferredSharesMember", "presentation": [
"http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ],
"lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Shares [Member]", "verboseLabel": "Redeemable convertible preferred shares [Member]", "label": "Redeemable
Convertible Preferred Shares Member" } } }, "auth_ref": [] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.biomx.com/role/GeneralDetails",
"http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": {
"en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Stock [Member]", "verboseLabel": "Redeemable Convertible Preferred Shares [Member]", "label": "Redeemable Convertible
Preferred Stock [Member]", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and
redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_RedeemablePreferredStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemablePreferredStockMember", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ],
"lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible", "label": "Redeemable Preferred Stock [Member]", "documentation": "Description of type or class of redeemable preferred
stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series." } } }, "auth_ref": [ "r13", "r29", "r162", "r210", "r243", "r245", "r246", "r247", "r250",
"r251", "r389" ] }, "us-gaap_ReductionsInOtherAssetsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReductionsInOtherAssetsAmount",
"crdr": "credit", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction expenses, net", "label":
"Reductions in Other Assets, Amount", "documentation": "Amount of significant reductions in the period of other assets (current, noncurrent, or unclassified)." } } }, "auth_ref": [ "r47" ] }, "us-
gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.biomx.com/role/GeneralDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party
includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r209", "r298",
"r414", "r415", "r435", "r441", "r490", "r491", "r492", "r493", "r494", "r513", "r515", "r541" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable", "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ],
"lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r414", "r415", "r741" ] }, "us-
```

gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.biomx.com/role/USGovernmentContractsandGrantsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r209", "r298", "r414", "r415", "r435", "r441", "r490", "r491", "r492", "r493", "r494", "r513", "r515", "r541", "r741"] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r72", "r472"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Research and development (\u201cR&D\u201d) expenses, net", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r332", "r564", "r572", "r750"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses, net [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r638", "r647"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "verboseLabel": "Accumulated deficit (in Dollars)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r59", "r81", "r439", "r463", "r464", "r473", "r497", "r603"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r131", "r164", "r165", "r166", "r168", "r173", "r175", "r177", "r211", "r212", "r230", "r337", "r338", "r340", "r341", "r342", "r344", "r350", "r351", "r357", "r359", "r360", "r362", "r364", "r403", "r405", "r460", "r462", "r474", "r787"] }, "phge_RoyaltiesRate": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "RoyaltiesRate", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties rate", "documentation": "Pay based on royalties rate." , "label": "Royalties Rate" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalty expense", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": ["r66"] }, "phge_SPAJuly282021PMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "SPAJuly282021PMember", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "terseLabel": "SPA (July 28, 2021) [Member]", "label": "SPAJuly282021PMember" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate net proceeds (in Dollars)", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock price (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.biomx.com/role/OtherAccountsPayableTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accounts Payable", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "phge_ScheduleOfAntiDilutiveFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfAntiDilutiveFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Anti Dilutive Financial Instruments Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Anti-dilutive Financial Instruments", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r23"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheConsiderationTransferredtoAPTShareholdersAcquisitionTable"], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]", "documentation": "Disclosure of information about equity interest issued or issuable to acquire entity in business combination." } } }, "auth_ref": ["r91"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock", "presentation": ["http://www.biomx.com/role/GeneralTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Consideration Transferred to APT Shareholders Acquisition", "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]", "documentation": "Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period." } } }, "auth_ref": ["r91"] }, "us-gaap_ScheduleOfCapitalizationLongtermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalizationLongtermDebtLineItems", "presentation": ["http://www.biomx.com/role/LongTermDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "phge_ScheduleOfCondensedConsolidatedStatementsOfOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfCondensedConsolidatedStatementsOfOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Consolidated Statements Of Operations Abstract" } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "presentation": ["http://www.biomx.com/role/GeneralTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Condensed Consolidated Statements of Operations", "label": "Condensed Income Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": ["r633", "r651"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Loss (earnings) Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r657"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Payment Expenses", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r35"] }, "phge_ScheduleOfFairValueAcquiredIdentifiableAssetsAndAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueAcquiredIdentifiableAssetsAndAssumedLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Acquired Identifiable Assets And Assumed Liabilities Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.biomx.com/role/FairValueofFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Our Financial Assets and Liabilities", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r722", "r723"] }, "phge_ScheduleOfFairValueLevel3FinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueLevel3FinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Level3 Financial Liabilities Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfFairValueOfOurFinancialAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueOfOurFinancialAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Our Financial Assets And Liabilities Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfFairValueOfTheAgentsWarrantsUsingTheBlackScholesModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueOfTheAgentsWarrantsUsingTheBlackScholesModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of The Agents Warrants Using The

Black Scholes Model Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfFairValueOfTheConsiderationTransferredToAptShareholdersAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueOfTheConsiderationTransferredToAptShareholdersAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of The Consideration Transferred To Apt Shareholders Acquisition Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfFairValueOfTheLiabilitiesForThePrivatePlacementWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueOfTheLiabilitiesForThePrivatePlacementWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of The Liabilities For The Private Placement Warrants Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfFairValueOfTheMergerWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfFairValueOfTheMergerWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of The Merger Warrants Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfOptionsGrantedToPurchaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfOptionsGrantedToPurchaseAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Options Granted To Purchase Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": ["http://www.biomx.com/role/OtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "phge_ScheduleOfOutstandingCompensationRelatedWarrantsToPurchaseCommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfOutstandingCompensationRelatedWarrantsToPurchaseCommonStockAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Compensation Related Warrants To Purchase Common Stock Abstract" } } }, "auth_ref": [] }, "phge_ScheduleOfOutstandingWarrantsToPurchaseCommonStockIssuedToStockholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfOutstandingWarrantsToPurchaseCommonStockIssuedToStockholdersAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Outstanding Warrants To Purchase Common Stock Issued To Stockholders Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.biomx.com/role/GeneralTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Acquired Identifiable Assets And Assumed Liabilities", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r89"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Of The Agents Warrants Using The Black-Scholes Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r84"] }, "phge_ScheduleOfStockBasedPaymentExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "ScheduleOfStockBasedPaymentExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Based Payment Expenses Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Options Granted to Purchase", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r31"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.biomx.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r620"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.biomx.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r622"] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination [Member]", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": ["r38"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.biomx.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "verboseLabel": "Share based compensation (in Dollars)", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock unit fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price ($)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (%)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r324"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (%)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable", "http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "http://www.biomx.com/role/ScheduleofStockBasedPaymentExpensesTable"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model [Line Items]", "terseLabel": "Schedule of Options Granted to Purchase [Line Items]", "verboseLabel": "Schedule of Stock-Based Payment Expenses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Exercisable at end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercisable at the end of period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options, Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r312"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r697"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r311"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Granted", "verboseLabel": "Grant of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance", "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"],

```
"lang": { "en-us": { "role": { "periodStartLabel": "Number of Options, Beginning Balance", "periodEndLabel": "Number of Options, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } },
"auth_ref": [ "r305", "r306" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r305", "r306" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Expired", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r312" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Granted", "verboseLabel": "Options granted exercise price (in Dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Tranche [Member]", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [
"http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [
"http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r34" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying value of Common Stock ($)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate commission (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected terms (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r323" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life of outstanding options \u2013 years as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r83" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.biomx.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r76", "r160" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/LeasesDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3",
"http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r113", "r141", "r142", "r143", "r162", "r182", "r183", "r190", "r192", "r200", "r201", "r210", "r243", "r245", "r246", "r247", "r250", "r251", "r269", "r270", "r274", "r277", "r284", "r389", "r469", "r470", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r496", "r517", "r536", "r554", "r555", "r556", "r557", "r558", "r626", "r648", "r656" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.biomx.com/role/BasicandDilutedLossEarningsPerShareDetails", "http://www.biomx.com/role/GeneralDetails",
"http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r57", "r60", "r61", "r131", "r148", "r149", "r150", "r164", "r165", "r166", "r168", "r173", "r175", "r177", "r199", "r211", "r212", "r230", "r286", "r337", "r338", "r340", "r341", "r342", "r344", "r350", "r351", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r394", "r395", "r396", "r397", "r398", "r399", "r403", "r405", "r413", "r445", "r460", "r461", "r462", "r474", "r536" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r164", "r165", "r166", "r199", "r405", "r426", "r468", "r485", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r513", "r515", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r536", "r612" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r164", "r165", "r166", "r199", "r200", "r405", "r426", "r468", "r485", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r513", "r515", "r519", "r520", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r536", "r612" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock under the APT acquisition", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (in Shares)", "verboseLabel": "Redeemable convertible preferred shares", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r56", "r57", "r81" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of Redeemable convertible preferred Shares to equity (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r11", "r30", "r57", "r60", "r81", "r262" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3",
"http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (in Shares)", "verboseLabel": "Issuance of redeemable convertible preferred shares upon March 2024 PIPE, net of issuance costs", "label": "Stock Issued During Period, Shares, Conversion of Units", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r11", "r30", "r56", "r57", "r81" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.biomx.com/role/GeneralDetails",
"http://www.biomx.com/role/LeasesDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs (in Shares)", "verboseLabel": "Aggregate shares", "netLabel": "Aggregate shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r56", "r57", "r81", "r469", "r536", "r555" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [
"http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "phgc_StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockIssuedDuringPeriodSharesRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock", "crdr": "credit", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Shares conversion into shares of Common Stock", "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares Redeemable Convertible Preferred Shares Conversion Into Shares Of Common Stock" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.biomx.com/role/ShareholdersEquityType2or3",
"http://www.biomx.com/role/StockholdersEquityDetailsPart2" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock upon restricted stock units (\u201cRSU\u201d) vesting (in Shares)", "verboseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r11", "r81" ] }, "us-
```

gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expenses (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r11", "r56", "r57", "r81"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of Pre-Funded Warrants into shares of Common Stock (in Shares)", "verboseLabel": "Number of Options, Exercised", "netLabel": "Exercised shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r11", "r56", "r57", "r81", "r310"] }, "phgc_StockIssuedDuringPeriodSharessRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockIssuedDuringPeriodSharessRedeemableConvertiblePreferredSharesConversionIntoSharesOfCommonStock", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Shares conversion into shares of Common Stock (in Shares)", "verboseLabel": "Redeemable Convertible Preferred Shares conversion into shares of Common Stock", "netLabel": "Redeemable convertible preferred shares", "documentation": "Redeemable Convertible preferred shares conversion into shares of common stock.", "label": "Stock Issued During Period Sharess Redeemable Convertible Preferred Shares Conversion Into Shares Of Common Stock" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": ["r11", "r57", "r60", "r61", "r81"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of Redeemable convertible preferred Shares to equity", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r11", "r57", "r60", "r61", "r81"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs", "label": "Stock Issued During Period, Value, Conversion of Units", "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": ["r11", "r57", "r60", "r61", "r81"] }, "phgc_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs", "documentation": "Issuance of common stock and warrants under february 2023 PIPE, net of issuance costs.", "label": "Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Net Of Issuance Costs" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock and warrants under February 2023 PIPE, net of issuance costs", "verboseLabel": "Aggregate offering price (in Dollars)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r11", "r56", "r57", "r81", "r474", "r536", "r555", "r618"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock upon restricted stock units (\u201cRSU\u201d) vesting", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r11", "r56", "r57", "r81"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of Pre-Funded Warrants into shares of Common Stock", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r11", "r57", "r60", "r61", "r81"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r57", "r60", "r61", "r77", "r408", "r514", "r537", "r538", "r603", "r619", "r650", "r664", "r736", "r787"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "phgc_StockholdersEquityDetailsPart1Table": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockholdersEquityDetailsPart1Table", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "label": "Stockholders Equity (Details) - Part 1 [Table]" } } }, "auth_ref": [] }, "phgc_StockholdersEquityDetailsPart2Table": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockholdersEquityDetailsPart2Table", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Stockholders Equity (Details) - Part 2 [Table]" } } }, "auth_ref": [] }, "phgc_StockholdersEquityDetailsScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockholdersEquityDetailsScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable", "presentation": ["http://www.biomx.com/role/ScheduleofFairValueoftheAgentsWarrantsUsingtheBlackScholesModelTable"], "lang": { "en-us": { "role": { "label": "Stockholders Equity (Details) - Schedule of Fair Value of the Agents Warrants Using the Black-Scholes Model [Table]" } } }, "auth_ref": [] }, "phgc_StockholdersEquityDetailsScheduleofOptionsGrantedtoPurchaseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockholdersEquityDetailsScheduleofOptionsGrantedtoPurchaseTable", "presentation": ["http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable"], "lang": { "en-us": { "role": { "label": "Stockholders Equity (Details) - Schedule of Options Granted to Purchase [Table]" } } }, "auth_ref": [] }, "phgc_StockholdersEquityDetailsScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "StockholdersEquityDetailsScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable"], "lang": { "en-us": { "role": { "label": "Stockholders Equity (Details) - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.biomx.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r80", "r161", "r268", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r286", "r363", "r539", "r540", "r559"] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": ["http://www.biomx.com/role/GeneralDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reverse stock split", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": ["r82"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.biomx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r400", "r418"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.biomx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r400", "r418"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.biomx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r400", "r418"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "phgc_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "SubsequentEventsDetailsTable", "presentation": ["http://www.biomx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.biomx.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r417", "r419"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.biomx.com/role/GeneralDetails", "http://www.biomx.com/role/ScheduleofOptionsGrantedtoPurchaseTable", "http://www.biomx.com/role/StockholdersEquityDetailsPart1"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.biomx.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable": { "parentTag": "us-gaap_AccountsPayableOtherCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.biomx.com/role/ScheduleofOtherAccountsPayableTable"], "lang": { "en-us": { "role": { "terseLabel": "Severance related to former employees of APT", "label": "Supplemental Unemployment Benefits, Severance Benefits", "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityAccretionToRedemptionValue", "crdr": "credit", "presentation": ["http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable"], "lang": { "en-us": { "role": { "negatedLabel": "Amount allocated to Redeemable Convertible Preferred Shares (in Dollars)", "label": "Temporary Equity, Accretion to Redemption Value", "documentation": "Value of accretion of temporary equity to its redemption value during the period." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": ["r663", "r740"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "phgc_TotalApprovedGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "TotalApprovedGrants", "crdr": "debit", "presentation": ["http://www.biomx.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total approved grants", "documentation": "Total approved grants.", "label": "Total Approved Grants" } } }, "auth_ref": [] }, "phgc_TotalContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "TotalContractValue", "crdr": "debit", "presentation": ["http://www.biomx.com/role/USGovernmentContractsandGrantsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total contract value", "documentation": "Amount of total contract value.", "label": "Total Contract Value" } } }, "auth_ref": [] }, "phgc_TotalNumberOfFullydilutedSharesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "TotalNumberOfFullydilutedSharesPercentage", "presentation": ["http://www.biomx.com/role/StockholdersEquityDetailsPart2"], "lang": { "en-us": { "role": { "terseLabel": "Total number of fully-diluted shares", "documentation": "Number of fully-diluted shares.", "label": "Total Number Of Fullydiluted Shares Percentage" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.biomx.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "phgc_TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember", "presentation": ["http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable"], "lang": { "en-us": { "role": { "terseLabel": "2021 Registered Direct Offering Warrants [Member]", "label": "Two Thousand Twenty One Registered Direct Offering Warrants Member" } } }, "auth_ref": [] }, "phgc_USGovernmentContractsAndGrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "USGovernmentContractsAndGrantsAbstract", "lang": { "en-us": { "role": { "label": "U.S. Government Contracts and Grants [Abstract]" } } }, "auth_ref": [] }, "phgc_USGovernmentContractsAndGrantsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname":

```
"USGovernmentContractsAndGrantsLineItems", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "label": "U.S. Government Contracts and Grants [Line Items]" } } }, "auth_ref": [] }, "phge_USGovernmentContractsAndGrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "USGovernmentContractsAndGrantsTextBlock", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrants" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. GOVERNMENT CONTRACTS AND GRANTS", "label": "USGovernment Contracts And Grants Text Block" } } }, "auth_ref": [] }, "phge_USGovernmentContractsandGrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "USGovernmentContractsandGrantsDetailsTable", "presentation": [ "http://www.biomx.com/role/USGovernmentContractsandGrantsDetails" ], "lang": { "en-us": { "role": { "label": "U.S. Government Contracts and Grants (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.biomx.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates in the Preparation of Financial Statements", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r108", "r109", "r110", "r111" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://www.biomx.com/role/LongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r713", "r714", "r715", "r716", "r717" ] }, "us-gaap_WarrantExercisePriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceDecrease", "presentation": [ "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price (in Dollars per share)", "label": "Warrant, Exercise Price, Decrease", "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r285" ] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://www.biomx.com/role/SignificantAccountingPoliciesDetails", "http://www.biomx.com/role/StockholdersEquityDetailsPart1" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "verboseLabel": "Exercise price per share (in Dollars per share)", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r285" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.biomx.com/role/ScheduleofAntidilutiveFinancialInstrumentsTable", "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "verboseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r609", "r610", "r613", "r614", "r615", "r616" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.biomx.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.biomx.com/role/ConsolidatedBalanceSheet", "http://www.biomx.com/role/ScheduleofFairValueofOurFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "phge_WarrantsAndRightsOutstandingIssuanceDate": { "xbrltype": "dateItemType", "nsuri": "http://www.biomx.com/20240930", "localname": "WarrantsAndRightsOutstandingIssuanceDate", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance Date", "documentation": "Issuance date.", "label": "Warrants And Rights Outstanding Issuance Date" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://www.biomx.com/role/ScheduleofOutstandingCompensationRelatedWarrantstoPurchaseCommonStockTable", "http://www.biomx.com/role/ScheduleofOutstandingWarrantstoPurchaseCommonStockIssuedtoStockholdersTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.biomx.com/role/ScheduleofFairValueoftheLiabilitiesforthePrivatePlacementWarrantsTable", "http://www.biomx.com/role/ScheduleofFairValueoftheMergerWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Merger warrant measurement input", "verboseLabel": "Private placement warrants", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r724", "r725", "r726" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r657" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement", "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares)", "verboseLabel": "Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r181", "r192" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.biomx.com/role/ConsolidatedIncomeStatement", "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock (in Shares)", "verboseLabel": "Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share", "netLabel": "Weighted-average number of shares of common stock outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r179", "r192" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.biomx.com/role/ScheduleofBasicandDilutedLossearningsPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role":
```

```
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r37": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic":
"10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-
10-55-37" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7" }, "r42": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "915", "SubTopic":
"10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r44": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "915", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "915",
"SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r46": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r47": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-
02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r71": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r73": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r75": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r78": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r79": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r80": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r81": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name":
"Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r84": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r86": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r88": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r90": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r92": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r93": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r95": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-23" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic":
"210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r103": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-
04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic":
"220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role":
"http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" },
"r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic":
"275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" },
"r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification",
"Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r112": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic":
"235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)",
```

```
"Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482680/260-10-45-60B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r197": { "role":
```

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r274": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" },
"r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r279": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" },
"r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r286": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-
04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r290": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r292": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)
(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-
1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)"
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r299": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)
(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)"
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)
(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
}, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)"
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-
50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r333": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r335": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r337": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)"
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r339":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)"
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
}, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r347": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r349":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)
(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" },
```

```
"r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-31" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards
```

Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480397/718-10-55-16" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147470589/842-20-55-53" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r626": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph", "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2" "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2" "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification" "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "718", "SubTopic", "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI", "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)" "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic", "820", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "50", "Paragraph", "2", "Subparagraph": "(c)(1)", "Publisher", "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r732": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 80 0001213900-24-098523-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-098523-xbrl.zip M4$L#!!0 (`!&;EE[%5LMSX! $VB# : 06$P,C(Q.#(U+3$P<5]B M.6]M>&EN8RYH=&WLO6MWXDB2,/R=7Y'+3N]6[2M=,EP%=.N.6<8^?_]^/DN,:`MMO7+?ZI7^?]DW:K;NF$]__*?SXHWE<9[TIN[9`MXT]?8%U'L)R!I8S8!V_TD>78T!/&GS]]>GU!O>K#`6[?<+AK3YP^=_$+ELO)MQUT!`!_VF76'$W9OOS"UQ.KJVV+U<{'$OG>O62%?* (G+AQXL$A9JN9_E,W_)-MRO=$O2,KK]7Y[+H?/<>\3YP<\0!\N.I_+%W)I(?20'&QZ[D$^$-8)1RWG\K709N'%/L;%'_N-M;2[W+Q\G_G7?IZ_=M=IS_D(RVWM!+7-MV/ZNU>M!QLTB_W-,V08_N\GS_!.WF_?Q)_9#(_C[BGL;YM>=P"8O#X#^\3 MW4BR\.?_G!@OOV2OQ>^Y+F.P^PF>^4D\].>>K4\,/^O&*W.]J0ET:X.K/S.U M/_98UQAQE]WS5_9DCS1+$5\HK.,=8Y"ENW`!G_#?G\:./N +&VG.LV%]9GAI.M'IW:,SP3!1TMP8W0>]2>,/,8`^4_.J6$LT?RNU=# M]X;X]/Q\;7=YESC?QQ^Q.M[M]:S1SSMJZGU_V.%)QKFX8>_.@_6?RN^K\G.M&__Q[VHE_T6N? 6D'GY;V<$C@^>]>!.`:]X 4;2SG&8:S['$/E 6=P"PO<,W.M^W:W=<,ZW6:WU?GY4R\"]2=>4;=U_?VIW6VW.JOY?!,:OU__UKS_M<6N'[Y].M;W3SC=V':RR4!`TS]%^ROH^77$TM5[(_M-9_[Z\^? Y][42,$LP?SAF^,\P1XL_O\(.F_;%P(6:]SP/C!]=SGC/A453P.MUXGFP!/-Z1,?VXXW1Q!5!`V]6J]\6.0)!N#XZ_?F4[?U=/=W]M1Z?`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`CBN!.T;ST;GB642K7PH?'(]%9&A)74SZ0&G+M?Z0]4W-=0]V$9KCP$0$P.+1T."89W]J&>:.M`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`.^H;.*^"V.M<]\D;8$X>N'7B6M8W.UIC.IA.`>+@%L7X1!<.B(+K.TE6U@R(P^XKE;T^;$. ML)=24P6T.??]2]^[%F\+0;UV4$?'HC!8#?5C6*BG5ZH&;[07C&*W(5(.(7@7E"=]E3O'EKP;\&F4["W9D(S^.M&Y)+$NS^H9FXN&(D56.KV!1H*XYNLLP?1.;52'P23!ZP3'Z9HC1R*.3NX]"6N!X-(75F.F47B("(JZ5\\R$BG+0G'1@==MYBR"7?>VR^B>$.M.M**.T'6O.*?))\O-V2/0]WSV%.50)-]`TX.-U?LNW[VWE$PHISNNWEY"413A=.M$2VE0\M\F&T)-/B^AD.#ZIB.J40O%)N9PSN(>[6FJ-6*4LD'\5!.M8TC&*9K.MD/ISKW&4S/2$5.@&%;PK*GR#"N"$5?A&P!#?.07N.W/"+8O9J.%4/6XN&$% M;-5"!`K(9@M%#/!PEG9T/Y"]YY;<.#]54OI.5S!(!?CP'ZP\C'M)+R\2L3] M<.F[OSR.NHNIRU[K^BMQV!KVU?X7.PK&5%^]X;!T6U^O6MAE=GUPWVW==\|=.W)\29S9!@9DH+C.MEUPN=;S;SW4V^0!>7E]-=)8GH.P23>.:\S5P]+%TU>]0Z;66TKZ,\30$%K1"+O MN.A05R!A.V3S5X6R8<6.XT$]!VV/CX!60W"D,@4*6283C(>CY4(U(.9U\"X>.M-B4%WX0.OB+I./Y-[!)K8+8F.W9%PF]N1FD.PW5I0.ME$X \!F5HVGY:..BY"91H"\FA0.,ZB&.A9!K\M&XY.+A.NYJ!.!CH[RT!>MP^.!.M4\.BX5%SA^S6M%\3O5B5I\#!6I.Q.P^N!VRV.C.11WR2L%(!LMYTT.EZ4V%.M*.9.LT#U1E@&&KLP;P^U/1*L#E$E.2S.GKD'L,$,!XDA$%?":)^Y.S,6CZ+SX.M*!R=1V(CKGYPQ!6OV%\QZ&(.(V!6%^(.OC#]SXA"TW8G>*XT>._;$8]@TBWOL.MR7#._.+.:G#\NFQ0/6A1/T"Y=(;E[CFV*4_K1L?M<1^.F%)3',)?7@?

P(EC&8 MQ@\4,DN.67QDN_BPI0/"+FY>$<>S6ZWOVL)6-H M] S/O3HS1%<=<@?AZH.;L9*K@:T[S-2X#TC#9/3Y1@$B,P5O@"RA1[4|_Q M/3*YX@0[7ZS],4O<,!DA JX'ZX64G0.(#XHO#)ND?F9W]BMWZ-%?J#&2 _F] MC8 PYB)E_]T$HC2R=[H8SW7S.I8=:#[!]7217_M;Z[[*GU]_-IYQV_:\8! L; M_)Ef>WCX'_B<:=]GC*S9/7R'XP2$Q[(=AODKT 8PU00LJJ#K*Q.%,5CZ>.O-M3@:#A@]3!3>+!5_D%[Y3Y0\GE0+2OF]/G3-O^]4W, ^]O/+,@7JE>5H(LKT*U&5'C."MM*BJ8^)\ MBGEHP6[F+Q6U2,$3U=.:,]JE,]&H]\M'AU"CQ8 &IR)T]R]1>W2N&>3XS&%&N MC4895WU)S!I'M;<3DEU8BJ[/. +U"AT*>F8)LI;MAKF5XC#%;_Y]-H J9DL#9GL$E\9[4 M9D\E99C4$'*)#/#SS;5:(%YTV(%8*M%NBZCN>]YD) Z*%*9Q M+YC;SFP2; !:(;SV;S8F] $,QT '<[DK:FJT@+1O6K1O.R:%+ M9]];G.OB.ZUGF!A.@+7?YG$K2E!$;9>"[/G>L* 8;]%LO6(@UM2=8H3{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l\3PS5F(61XH#A,1*-A$2,A=2S>0U(.23GD[!PRYF#?!^0Y$@GP:)[HCO:*.MYLR"2PUUGXD5(@R V($P1M(AL'(.],<>')P$4[%KDKB;E/#[CIPA-&C@.G MB2,&9J4O YW)!%A0VF<\UK^>)&C(F2THY#FH M.9@W-9B8 ?7.WX =\OAK*L!3 7YVNI=*S.P/9TWF6$AV!]F&MD,9>QATF(N+ MG_3LREW*48-13$MEX@NETCK)2ZH%WJ.K>[+U#Z,8;&\Y!Y!D6=,.R$&*^> METD1?=!MX3K3#,*F*0=[C5;*R>S67(&O0+T^V6,2.]*W9L(' M1WL TIV%%O!LVCT@87*^[3AK]C&R'3[+N1*FIX,6)?V@ M#8#N=5'2 =2L59;L[2P\62HY(L!#YJ94.9CPN;>LE+)24EF)RGI'@$!]US.O M!MJ+ {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}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|^64X|S<4#"G MOKYU30U1NWZ_=42D,1=SS9*>,:54C4@=GN6R9M8FL*-D"U!6,D+R MJFMV4591B9U4'5VC*'1X9C' (U@F*!;7K;&.7[7!%"EP%8 KN7/3W0U=6WE MP!95 0OIN%=*]G9G2D9EQ26[*\$GA#M]PQ5-D\$4\$%F.G\i5TZH4D(:8N&6-Z M#P4P,R'))M+A7[#Z\$)_C/QG+9@SAH%B?{0]0"&&BL!TF3#CR'@9R=P_.\$[9C M;LD%/.+[@Q]=-':L;C9U5-3.U-F;/7T5A:58R0PHCE:4[]*5NRZ7NL:P281T M#+M@#G#?%.5V;YM:4DN/67"-M%GZ..W/K?D8K;QWYHU0.5%L96%T.X ME!U")\\+ 7%6INQCEL6<= /U?7*G%%\E:.8!A*/S>Q^:?^(@ZC\8*X53 VE+ M&/" <^Y71(A8^=T@"7X=BYN@BH/:*&=N!1\&S:GA&\$ZC<\$*F"2D[/BT@#&VOD)D&]*B.)?KLWD&P;87]H][F54]0T/RF2#33#KRB+ M^>" +*)e@H.'\]P1@58\PUF8)M6\$8!Q4>Y5ND.S-K*[IEWD^82LN'0REJFS M@=2=B*W2*6(@4?]+V:KQH(!%B6_H!, +Z;5LHZA42[5+X_V@1]\$V5>('8SE[D)NW5CW\$Z%-H.*%\$0P,@. M043%GO8X\$.WOB*.KE8H(DPDH]N_WX]!_.:/SE)FPX_FK:.A:BQM*\$-MUZJ/FQ3O^%KE=D\ZNBCR012+(("IP1%24?\$VSN%AA;R1+BG1M;%26:@Z!R\"7MO"*%*AP<>8#V&2EV_]]&H,\$R_D\]MLU=,/. +.0R=00)M)+N MA#(5"M&D]'8;J1?Z)A.989>EDE*L+4^]/AV=`4<"EF9TV \G&6S:5VD7.H2; MJ*>PR?9)Y<{H3[2LI\$..R%]V4T&#Y84.M;GB&*=/L1F.3BS) D&\$]>)M=[:NU.8Z MAFP^+],VH3AN9+9H0+!=]V]?<25WN3]AZH.+2U?UAY[3 M4FJS5I3"/6)\<]P;D[%N&+\719FA!L;KRP]D!<6=4GJ,8/_ D!B<6E98G,(SS,%QF8|(7K<>\(7)3*CRHF'![F+J85_YH@[V%]R0 ME&)B2U 3+*X(RH(-PH8E)DF\$2Z).4^O)X2-D;SR0\$1T:#R,[,AHXBF&=-*92 MQP#@CHGKAKH\$5)L"FO-)YTN9YBML^=GP*9Q 9:,)B>]6)R0K!MZA5>K@A3,, M!'XP'.J5O)CL\GR4[AF+U-L.WGYGN_%)H95LHQ9I6F'3#(MZ.O3"/3.R1^B9 ML=6.P]U/F1/Z+?0#@C]*\$!QB.P /34[I[+ M*!R*Z#;A?IV&/K6HPY#?;T+TBWQP\-)];X<.]>8YK]PNE@^)DA%]^-2 Y^)6 M^)GE)O%S3G]1ZBB;M8@O44)Q)1=N%^[\$T&%)/4)*\$?2? \$!M-F\|4\UPE}MLSE"&*M\$YRT5X(1:LEY\$54UA#(7*2).4OEI5!!O+]ZG"B4D*H2,6Q81'V\8G3H!?IM9C.^WROQ[&-R'I0VU)US(;8BCS79\$\$=4<\$^>\|1 Q6BDCVLK+5O[S+9=D0R8Y M#D(/19.7ND7)/DY@5U!O>CG/S5]:Y"(]@.)5&GER4"7,H.%!9\$L -=S#7P9^TMZ_N4;NX>O@4>]4TC^^;H=YM^HZ\$^A#=R,;>VQA\"Z\+EQ.K)6%9+60; M]:OE"M*?O AUAS_+BH8? W&KR#HQ906:?67RDS7IFZ4GRONY(;CHQ.!@L[8 M]0=/HI"#R1.E_Y^]-]MN6TG2A>_Q%/CUIS[+[@6O. ~>2;26+\$N[=(YMJ26Y MJONJ%DB"\$G]# N#9.,3GXC(-8F!)\$EPDGG1O=LB"61&1L8<7]28=:6 "53!MI225%.ZH8(#0#*&_AC;!R(!R&RAGSD3&:LRZ*XR*"3#HS< . =0@!I7FB0* MU;ZO;.IX#HO=(A\#H/!"%[Y[KBW]^1JC.OXDZD2=,Z]O_C*P@C6DQZ)0*EXD M 8GS,B>KAY3KD 4M4=#[)&!M?&E(S9X_CEX(%&SJC2V'8YD07*UR2]B=G2*D-MLEHJ%F\$\$F[%_8_G(>,>[)SSCD*,)1-HPMC%S\)0RJR9[(-(SDO.O?VCWT<1-M8]@ \$EA<+^ 9-GGU+@H1@/ %L< K]U9U&8FW/+R/7.V46]UEK>FK35,,/% M=7+ K7*2>PD<)-#]&GL ^(<1EKQU7Y. ,#I27"KYZ#@@9R9[(-(SDO.O?VCWT<1-M8]@ \$EA<+^ 9-GGU+@H1@/ %L

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|S))/LKV-@N;AK1K,0D"ENGZ[QM;&;_QZ[0=7&[8?5+>2 M.Y? 7,;4.7NF1L#=3;0U@6UF40QPE^QN2P=_/GO6"56A@QM[" SHOECV%_X(G M.8L0#+4 IL_ RICS%/;ICU0/(>'Y>6QSASL MR9^$2YP#"Un1<5C0D$UOAOU&/@&DFX[# ,3$U.2#"FKC65U;@&65/AM!^$IFX ML/.8X+(B:D.B=RD4.R0 H(";.8-076493W^=YFZ*<=S&[RF?!&OVP7'..UT> MVV-!"P48!M$7(%Q/+ (<.U?)>&#)"Z2$0%"- 4SG0NRW5D4(@ "!L8ML#MH MV29O)!C Y_C_],$9V$%-5^5@R@O[2TI)\5VGK6K.%6$UZ=! ,/..H\;),!30L M"Z+D=2[V6]6"-.;U<_U'!,&F_W'WM^N'[VB,D!WR<'G%K9(_'B(} MWR-++#M-X*.M,A'W 0V^YS$FT0)\" $W+WO43S!\LWTQ_H'%' Q)(6*3I,?B4>9+*3P MI3^=Z]^L,9H@\=-52)E+)N_B"OH?CY??'BYE%,TF)-.*Y]$M!,$(R_-F)+70 M>_.?)4ZY4K%.3/'KY2K@0L,H*X%93\6K7TO<&EG^6#) MZ!@SPL;".#),__V='T58S2;>J?>.^##Z^*'UD;PC_E2EBW.D'Z'C,5&;H0O4 M\D.7SN7%G5X>XM%GXFSPX&Q+O+&* (\'0|CBNZ$02.%_F$@JEKX(P!4(|O#P5 M>G'S6IPI52P%[IM2O!B.!%OR0?P=36%Y?/H7VQO:6 YUXWFA?A>$EG>=6]A: M$LA;\^7F3MX8^4A12*(8CDK?*A(=&,&>#K%KD)%%D;'*.QD:. [T0Q4K873)/M.R1D+)C]-$V"A?!B;8$AD;ZZYM\M]!<6%'DL-M9;9@0437:#8*$#(3/:DL:/%'(W1X(%)^1'8ZOOS@#LA#T)/D#,(>Q"!L\ M#!U'U8:#LF>,V-9)":#06'5;,XL3XDUJP8OY4+ M0RI7]}}JY!?G\#("=]I8)0C'+*)4T@'B]@&7Z0.P8L7.5A&R%P>7HHA/!.Z MUJ0V1,NQE)"<(1)"$!%$4)6)X1LVJF8@Z=Q\%*W<&=Q%*&W(%@=Y0V5I6?>0CRJ7*0V5I6;29XR6O\$VAO9LS+C"A MYS7I)I"O+&TM$T2,C?G>V*\(DR?.Y0M#Y&'Q"VK](\$RL)>19HYM[*ZH SNDB M&]H"$1))02%N>6RN<$%"&R?120'B;7)WBB-H?LF!6$\!3F@"?^=$3RLR8 [#*

M2!+'+UQ\WM0<)XV1;324^0+;S@YBN66[\047#!@XZ<78_Z"/MQ?A2. M)?UY!? MR2.1RG7.I$UQMGX.),QVQP"LLU8<;M3+KG0_J/YE'+&=OG:U,OC6]0P^KPR^ M?

RJ#WSN!+SS94^7\I?)^.Y?S^.,^L8E3 8SP@+!{C^9P0.9[9=YAH>G^>N,&LI28===U 68VV3A,O]$EJV* M\^ .2:RP@1Y(;)9O=8SH<^:!#[+ 40[!D,MR MXTI(L/(:(+9GV/O@2C\!7"]?&6+K>$GXFSPX&Q+O+&

(

*M@S@%(8#,W[4&BQl;,"4WF)R^LF,?*3LZPVKU3ALP_\SQTNOE%;+G0_PW>#2-M2[WVAAQ*D \CQIQ(U;]^=[%T 38&6!L\}2, C9;Z5,O%VZ[B<3Z?,UO'}8*

>6DTHMXJY(Y%V5/T"HK;FL(!HEPS/#+EP0=\421. M+2G9\7*#X2QSS)R$N4[C=\B*8(?\DQ@%7G=PEE#.6'&Z05@08][5CV4_:U!B M!ZZ%LP=.M";XWLJS?Z_V0:9Z4Z.5E7;N@B[*.W)^-

**OX(C=Q4;<>=4!5]W0-MRUKS@D9V0\P8]5$@/$M.EYCC%8+$(V47TEP]_J.Pv%!3;=_\@6P,FGYJ[5 NNQUUYX=#) A<4GU2#HAB&\L5TV#=$V M-$(P"1(:V G],PRX(6\(X,1Q)WQ\C]9 8D)_ONB?MQ=WNOTFMT>8=* M4"YI2XDMFUX%*DDT\JR8>G\DNLG5D!40 NF G)H>BAK]#U8+OTOF"3=9 M(YK+A\ .;3083BAGdc#0 ZR_]Y}-(Y!0*ZQSMV_R^IDI:UV _:L=3 MXL?$R!X*0^ >#.W1,2.!R1"_M@WJ50-,*G0I8*!,:\BAZ.IBDDXA!?O0,%G M56$! A(A/IC#7>>>TO2TG_/5>.=W.)+!4.&WG=_I IV@2R"H(E^O@38;1C3(^+M.&/'LIRC[3N3C8C$AKD>5-M)!?.XCQ/C5_F,IA1)HZHH51@F:GP_@E2F.=22*XRZ0BL"P>G.(OVEW!/U0A-MQ)P?S4_87![5<7AA#^\;I>"[P/!5 [$QL"B^0HZ[T+^>A14;(V^>6<>6,UN-MVP26-5_3*$&_6Y!T>Y#_5?(9BCP7)REK $E%4[$L*ND9*4ET@,'G14|U M9%, _\|3VR !15LZ/HDV8W&D./TG,0 _+),. 'HOY)6[Z&P0L2;6B=%X:6L$C MO":B O_T508/RDHRH+Z]8^R,2.8RWQ%;B.6F;WY$P*99^?S4W#@6#DV T^9' M^CXCBL#WV2T6@'%;2&WD@=A=(VO^99;&"]IFL[5,/5M4\/Q(/NI$"_%1F"23T96];AA^(M5'H0$2NX/D?T#IS7'HK\!+*5TI9<)6)?193ZE*W M,.<;^ X0S&>G_()V7CB<(!+X+4?

_E5HJ!+TSEp\."HT*XX45MU5$Y&6Z'$=_MR<_PW.9]Y!T$,H!^@U!TSC:94Q:5*B_0$M1.$6M>1KH1+O&K6N:/KM.% 1Y?(.TC%F\IVQ4ZL#]dVV'WO:R5[7TN. MPX;[?P5 KK#IL$&\0\VC5&%IOK;ZS)7$R-4=@;2=@3_I8 MY8B&...A;D?;5'6G^)^Z&"0CT3';Y..)^"3[QXA1C=]!(_ MJ4D4OM<8B/C?7OSC ,Y9TSP1'7)[S!41>^-5%AL\(XK13Q@^%W3G5*!

MDNPTI37[@Q _UP+\C Q& ?1_63C@%T!$/""QSR^9 MY$ T/YW%>%,4HAG/>W.[V6OS _>;G=ZV3W-E;?ESK;0+XRTH5<].CN1],09G MP3,;'O@;HE_)P]C+ ^'05T+;,$1A(I,# QZ;.

4G<^Z,8IB7@$#MJ^5 YB 3>GIQ8>5+H;&\0D+YCP(S M#)?7#9KBND$]!^AFH>V8CO(-%8?W6U!@*PV34?%H&B:3468#P>.PZ1*^CN%P&.B

F<7&S=._=OF1"[ZSBQ5]NDB2H_F4M^O;M{RQ;GD:=,I2 S\;FDI_@R=&_M-MF%UZ]HA0K;36=0[2-/RV92F(19,,CQA5@4)]E92+?E:EB?PKY6]R!AQ1PT M%0-"]FG3>YV/GZA7%@[5,[]$$"\T>C43+% M;Q+ 169C=X0-] BZ"" ,,S>Z]U>],A!U6]_73V^RL!N5K$K[%R14D\]?-9 =<+ MW)PEOA,=Q<>PB_$OCH(R^(DG"AB3V-1 4#N3(S*\8AR/Q\VAR>LFO%IMMC"><80PT^1"P*(MG&OP':/(:O,..1)9B_5,LNRP%9MPMSS)4DH6K.EG080\B4X%TWFM4RBE0A&A M17C^+EL36Y=2HB">USZ-LE;Z8DOM!H1S25F45>R@W=0$*B&+2V>V45EK&OL3LW%@&[(H1S>LW M/]B.6'B+7M*Y&+2 0<8^?P13MD6" Q&V$+U>},]:#N:B'8R%TLSKX@RJLZ M<Y+LMU7L.5U1Q.!)DRF:Z,]+7CPVB3*WKMA\6M7]+8$$*RH)ATPL/&$T &U2 M,SKO3YA5F,PK-JEN>E9ETZ5PD<1SMB/ 6[@A+!LI&+M22),.1@FWO-Y]-9UY 7D!/!9=-ML5NP,T"4RC^LPDX\+.7]#27!/ENQ2]2TI[%(V2M&WY!RH?[!]F1Y.'][-R< MHW.?+ ^MWAMP(5AT2 (-)ST&!C7+<_,/+T.1R_N<3.&UHWO/=BD_%C3'@V?$ MCK%OZA{AV)^@N\IG4)# ^9.4]E7D1TC0R.$GUJ?@TLI8@T^.,VBMCA+2#EF?C M=<,<.U]>W4I6]HO*&F/!-7!31%R.P5]9:6ZJAB\VN%IEQF@!3;8;.^" Q".[SG7M,1.!0R?.?7 %,>4SK& M-Y!$RVZL>F4XF:V,\>+(:9-TU"(T@9)..SB<(:%*AI!R]B\WU[7;*74[SQ-M%)#2.VJP]OW1[_#N(1F6??.M%FXWV\/AJV6]>K]V/8B)L,XEW+O5Y R)^YTO_/3G%%BP]S"IH\|OC]F&%#VSD&D M2?]\'N\\,T7WUO@74&W2&U]!:LB#\"]IH14H]&,#[.*/W/WFN_^U=-)]P[0W# MF]_1]TE(;ACPP0&65K2&G5;S.RD4^CB^G\'T(A<\&&0 &D)[QPD"I(0?C>_M3ST_FZ+X]F[MV,Q[NZ;WZ]#KQF$-V_:0**WKH]'>"0N6 B9QCm,C$W2HM/YE.YOWM[.CM'A%!{%1N&?C)L.23 3%& M}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|BO>1*@\V6,+5,#OB_0=[YK]!D;OWFM5;>5-,.RM?(]%P=X ,SH\ M1X'Y!<"GN_4R4UIN'!Q:,.W/DJ]YB,'S9_)2V'RW)3GMN>@HW#>5\" SV\@5J[-MXX(R]4;!9W%O|&?OX!RW 5N9;$U_@B6R_B&W<6WR;BK'>U<M92M\|V@6W8;-M NJW&(.DX|/Bj="W=D6K6!E'2:>.[FEA)U!+M ME7R=V*;+TZW^V1QTDVITTVI4SZG^0=E#EMG?NT]$H'==%-ZJ9A[A*EZV3(=-MHS/=2S>BEXK&7KJLGB;&2TB=$U.#[.8-,.Z*8_U4BKV4BKVM(F7V0]$L8 MN//]D!NZGI.^GI.^G!.^4',]/;CCC)SO>W':2"0$['01,(,"TMJ>C03&4XS,[2T M)_5'U!$_CUT6FF3XL(QM$K%1)R;X?7M_^L997 ,,E=S>-M9;BOM_!G9A;GQ MP=H)8[1*WZ-Q===\"RX'_R)>EGIGB]MA9'^]\0U%0Z,O]$GXT;&4W #,G>/TA! MZY5.5X5)R$W&F-/"LL",5R\7GZR"%NWZT2+#%ZND1:=NM.A(%V_UM.C6@A9Y M,3,HDICIU8^$G;>0L+,.^$O9K2<+EE=T;23C8!@E3TK,C"!|BO>1*@\V6,+5,#OB_0=[YK]!D;OWFM5;>5-,.RM?(]%P=X ,SH\ M1X'Y!<"GN_4R4UIN'!Q:,.W/DJ]YB,'S9_)2V'RW)3GMN>@HW#>5\" SV\@5J[-MXX(RJ4;!9W%O|&?OX!RW 5N9;$U_@B6R_B&W<6WR;BK'>U<M92M\|V@6W8;-M NJW&(.DX|/Bj="W=D6K6!E'2:>.[FEA)U!+M ME7R=V*;+TZW^V1QTDVITTVI4SZG^0=E#EMG?NT]$H'==%-Z]9A[A*EZV3(=-MHS/=2S>BEXK&7KJLGB;&2TB=$U.#[.8-,.Z*8_U4BKV4BKVM(F7V0]$L8 MN//]D!NZGI.^GI.^G!.^4',]/;CCC)SO>W':2"0$['01,(,"TMJ>C03&4XS,[2T M)_5'U!$_CUT6FF3XL(QM$K%1)R;X?7M_^L997 ,,E=S>-M9;BOM_!G9A;GQ MP=H)8[1*WZ-Q===\"RX'_R)>EGIGB]MA9'^]\0U%0Z,O]$GXT;&4W #,G>/TA! MZY5.5X5)R$W&F-/"LL",5R\7GZR"%NWZT2+#%ZND1:=NM.A(%V_UM.C6@A9Y M,3,HDICIU8^$G;>0L+,.^$O9K2<+EE=T;23C8!@E3TK,C"!|BO>1*@\V6,+5,#OB_0=[YK]!D;OWFM5;>5-,.RM?(]%P=X ,SH\ M1X'Y!<"GN_4R4UIN'!Q:,.W/DJ]YB,'S9_)2V'RW)3GMN>@HW#>5\" SV\@5J[-MXX(RJ4;!9W%O|&?OX!RW 5N9;$U_@B6R_B&W<6WR;BK'>U<M92M\|V@6W8;-M NJW&(.DX|/Bj="W=D6K6!E'2:>.[FEA)U!+M ME7R=V*;+TZW^V1QTDVITTVI4SZG^0=E#EMG?NT]$H'==%-ZJ9A[A*EZV3(=-MHS/=2S>BEXK&7KJLGB;&2TB=$U.#[.8-,.Z*8_U4BKV4BKVM(F7V0]$L8 MN//]D!NZGI.^GI.^G!.^4',]/;CCC)SO>W':2"0$['01,(,"TMJ>C03&4XS,[2T M)_5'U!$_CUT6FF3XL(QM$K%1)R;X?7M_^L997 ,,E=S>-M9;BOM_!G9A;GQ MP=H)8[1*WZ-Q===\"RX'_R)>EGIGB]MA9'^]\0U%0Z,O]$GXT;&4W #,G>/TA! MZY5.5X5)R$W&F-/"LL",5R\7GZR"%NWZT2+#%ZND1:=NM.A(%V_UM.C6@A9Y M,3,HDICIU8^$G;>0L+,.^$O9K2<+EE=T;23C8!@E3TK,C"!|BO>1*@\V6,+5,#OB_0=[YK]!D;OWFM5;>5-,.RM?(]%P=X ,SH\ M1X'Y!<"GN_4R4UIN'!Q:,.W/DJ]YB,'S9_)2V'RW)3GMN>@HW#>5\" SV\@5J[-MXX(RJ4;!9W%O|&?OX!RW 5N9;$U_@B6R_B&W<6WR;BK'>U<M92M\|V@6W8;-M NJW&(.DX|/Bj="W=D6K6!E'2:>.[FEA)U!+M ME7R=V*;+TZW^V1QTDVITTVI4SZG^0=E#EMG?NT]$H'==%-Z]9A[A*EZV3(=-MHS/=2S>BEXK&7KJLGB;&2TB=$U.#[.8-,.Z*8_U4BKV4BKVM(F7V0]$L8 MN//]D!NZGI.^GI.^G!.^4',]/;CCC)SO>W':2"0$['01,(,"TMJ>C03&4XS,[2T M)_5'U!$_CUT6FF3XL(QM$K%1)R;X?7M_^L997 ,,E=S>-M9;BOM_!G9A;GQ MP=H)8[1*WZ-Q===\"RX'_R)>EGIGB]MA9'^]\0U%0Z,O]$GXT;&4W #,G>/TA! MZY5.5X5)R$W&F-/"LL",5R\7GZR"%NWZT2+#%ZND1:=NM.A(%V_UM.C6@A9Y M,3,HDICIU8^$G;>0L+,.^$O9K2<+EE=T;23C8!@E3TK,C"!|BO>1*@\V6,+5,#OB_0=[YK]!D;OWFM5;>5-,.RM?(]%P=X ,SH\ M1X'Y!<"GN_4R4UIN'!Q:,.W/DJ]YB,'S9_)2V'RW)3GMN>@HW#>5\" SV\@5J[-MXX(RJ4;!9W%O|&?OX!RW 5N9;$U_@B6R_B&W<6WR;BK'>U<M92M\|V@6W8;-M NJW&(.DX|/Bj="W=D6K6!E'2:>.[FEA)U!+M ME7R=V*;+TZW^V1QTDVITTVI4SZG^0=E#EMG?NT]$H'==%-ZJ

MUN^^5A5]3#/ST\<]/GY&^AS[Z /^GP@9X[M"<.%.W60B]_H5#;;M[FH9E+G M6RA[0.DK>X#(DDSX+|$C;K7+FJK3M\T4%7[$46Y]0CQOM^U\3U1Q-52{GR)N MKVA%4,F1;*
*[F&HY7:A?6>>O7C]M:&VOKYAZW 55SV",./:V^HIN:>;94!:,)(JQ'WI^ M29?AP2B"*AXQ;0 M@HPI*F*/F7/8[# =;#?5!Y"KV:7TZ7)!H%JX2JP2&Y=:,DHM,1R[G;HIM3KX MY.??*
7=#9#8&[07+]0&E=QH'53K,O0DCDL&7BHM0,+# M>7%08;J7($&6-T#QIWSVDSMVT-E1RN"_@=2K$!V!^RT!R_#HFC;TKA8U.0+*
*MVA59*N%%.0_8=E,PPTHDM7MFVY,W0[\6L8EAAC6PL %+:5]4C-X8<= (4#Q-M^^[ZQ/&'45W^DCEMY9PFS!GCO!H{9W%8V\"D=/1)2Y30(SNKPKR&#K4S8+UVS=BQ9549,\I/*
M%>XMZ>6AJ'DBS+ <]?5=\H&&R)Z GL9V&-L&S!Z.P?Q/K>#&TWI4.8@]#CF M8V(R:M2RK1@,2C@-DQKUKC$8]OK-H//P$& D!NO.SVI,/9G|>8[7|=:@M.= MOVR!?*
*5X0)!PDMUU%G+IB4] (6_R[ZVDLAOO*U84F*J^U9-*/L9G%0]7TZ MBHK)O5#E_E*SLG3#{!L\C&?5RGF\-"E*X3G "7Q3GC#*#P\[F-LX]T"%#SJ9T MAI"_4_V3_@'5S]_Y*
,M2X0MOR7:IK=9,JOVIHN]^V+BA%NVM3G;_:(M^A+:,L-W^DN\%6I/+;,,X6)IY^6Z0;+|+>/2Q2F,ET]_W)LI<6.WFVWKTEMX"
M.^E1&6B/D046VB;H[K\YHFS5V-.ROL2]4J;5%EIAY[|>#),>V2=|I1OF78[MSC0}^)^/_?-_/1(++84=_/A|M2]A!S^B_;N4F]OLZMW;V]5_>2RXE<[4\7M; M8'.WJ-D7[+YLHP,A7]X*^-
?L=H! "%/.|S0F=?CY/;>ZJ_&K3]R>9_M?RPQ M9Y?<[^/+6Z;Z_[OGYZ=JZ.=#P?_[],IB\|_W*D__B_;Y(&)O"K9_M#(MV>:.M(R5@1V\>G)T)''?Z."_7%D^+?_1.U=*
*[Q_L(06C]Q/>=2"?/7U6<14*RZNC,_% M'SL\:XP94^P-V$4C3.+8H.21U^K5YDO4P>;31(_-AW^9RZSVGL\TS\?OU!%T M(EW([#>;\;9;#$(U&I.6+V7.B[ZN&;#W2[,EZ,G?H,P/K\Y*
*.9B=P 9LXY\V M>7\UO.^QO>9RHI(&GW);POH=U;W:)? '_=\M\OG)OOZ?V9s&&^8DPf].U/_[M\X\O7]tQ"+8< LI*25$2$@^2MPXW$3;J.#|ZV8OP\<$4S|SZJG-\P4=EVVG
*M\DTNWY)8= __,LY>KY-O6^RIF?#M:SX8.;C$?Z?9#!LN2(U\)2XYX6LD1-TANVKN_Y";7 M8]+E#-[+N^^%K(OWVRDHE W#*XLVV.+L$2\H!UUPMQ_J]#:B'P7Q=Z$9'_*R
*M_.OSS7\P^[_X_4$L#!!0 (-!.&;EF4V06! MBAT %N : 96$P,C(Q,#(U,#%E>=#,M,5]B:6]M>"YH=&WM/6MSVS:V MWS6C_X#-[';L&=JQG:1M;&IF_$R\-[$]MMO;?H1(2$+#AT]0LM5??
*\|# $&* MLIW;HNXW9TEMO0*\^?!1/;?W7QX_K4ZU\HQP,H7H17+|U[E;JK-F2]\FN^/5D6NV))3)83#;|N/7NS?_CF6Z7J1[H2+S:W M]*\? AR7G1{\XWMB;,%G;[-f)1V:VM_S68*$-
P(%'.WO$*J]4^>S-X=G%AY_$ MV?G1VF?>"//Q=/'A\N+Z[.9$')U3^] M_FA8"'+_C+V"XYV_W2T3]OQ3.,<@4WFB$B'S1%P14\D?CE29:7'.H9?1#6$ M9WEG9U?7-,NM!&3#Z-\40P-
K7?]P^0;< MOMUYNBI#8NC(A='"E@@VKJ;PATR2 M4AF#D!T5\|$Y\|$&_38@2RAJSPUR+KS;NSJPY59S40SlQ#2Y5/ *%(#IDO!*BK M<9T*&8.I+_$O/4>RP4[B=JKC:2AT!F!?
*("\4Y43F(,2]J"'"Q&=X[& M(PYP6G'-"N3;H_=_44$\O?CAZN9=FV3$|AB^95*G.I)K=K2U M#4?X.*TS'#PW:LMI[$#@)<:K:.E;P:MXW$3)9B+E-8I9^-,1V/ M<9A*-!'+##<0/4&7[18G_03*6/G
*.UR$%"K(W?\UPAZ'!^? MG;_]I[.M9_3{|>7!D?O]_PG21E7,"'"S_P:BHP)&TG]WJ|)KB>EO_@MCOYLIM M@WXD>IH.=EAEQ6'P ,?N-;O[S9W7NF\05BJQE4GC'U:WOJ]FU^'(V-[)(?RI
*MLTPZMQB|(:O-'((,DZ-[*]H)2+(>#E< MPT&FR@D6H=K>/3A1I/X@! 0/"KRZ&/PXH]D/XT? &89G##P"?CR_K^SGAHX MUUP(D2[8LU$G!),1+,7(1@W
*X'.I\7Z=QA_JB#OC"Z=N\KBDD[]f#8SY[_M!C@'@'9H:-*0_+ BZE*2"+!?898%@EXARQ*/C'K<8-@E*S'!V*H!+#U30-@T MQOA-AK"!%9T>*V".A^RM-&&>E6,+#0\'+?'[$O8]f\'^@HG@
4 -?)\,EQ5C] M$L7D(WS%V66%X3M:,0 ^A6"S$M]O_W@/(9!&@VH<;(%&?!+]B=@O]!B,U.O!K8FXCR' MW4=%)9&Q $KS,;+SJ(",(.D>V1QO@&G]@9MI/F%)4!H(APH&[+D_ST']N-
*C\X^4"--E9E;,K%_ #YTDK+K@S@(M> M5!;(*7Q&,*UNYBU-A,_M4%\9KJ:!$2"I\Q8^]P-X3X&;@?&DT\P>WP95I66 M;+,G)=5*G'Y;HJO+1&@BRIK&8L\HTQ5IU#X-1QQ6F3*
*[T4I'H)2":P)Q"W!X M4S L[L" 7X.K'-L4K=*PI^L3B>4IFVZ%!HEUNBO@Y@*%-NO M7[R,2.!L0[6#{'S0&UDP$GAF.+1-[G1/UFCQ1MD5,\!=Q?(-(1L%Z(//=>G3 MH<42DD%%H-
*ZWBG$ CKH)Z.YM=<@; MMD(3?H0;(.RTHU;@2,*I\[0;*ACZYKYH^B(RJH]1,2_4*.."%"X3U\980%AP M<*QC;%/EC)8G)GA(#ARW4RY8X&+-# 4-DMP9Q&\LY1GZPW 3L.WC,#^^9
*M4>,?Q>2 M"GZ"0Q_Z_4]$^^3HR1PH2B; .;R3OT!G36NA7!Y!= -RO 16!['-2,5U"W1+ M6WO8N2Z#^9.H'#2B&X@ZNF6I",H2?GKLPVA#6+(?$N)L++I(8#5S9<>5BN]"W9
M\8@LY@S]/MM&VW$+5BN^-<)72!?C1,ZD3].?3N$ZYR,SQQFW1)!02 MN3#MUJ|/H!8;@A.Y6F)I#|$A(*@($)TL!STM+T%$K1DXCA^89R/%'|BBUZH MGPQSB8\7VUS>M-
TX%\F0N:V> "<@^QU"NI9D%90+3]=.HF; M,C&)!G(15]3;84 UA;]>6@"/C<.$$"\Y ;)AV@CEY ^%IL4')%B=[\"D M+.J9S[?AZ\S;F#.3N641-T>Q_6(M65]H\>[8)G2-
*UYONWF#)=8(H:IU;&<% M^B08_B4JLXB)<MQ0004IYH0IlQ":M:?8,7>_FZZ[.M;&UB3LA&X1;>4 L> *^4N',* MVAYY*>#F$83JH*HT1>O%++.L%V\7BZ'4O\L,G[Z4*X8I?9#5N^WX?-
*_&U"5@ M3I?ECBVJ16A+),RVRU:,A;.6@<]"XL|!$USW9-U$8^7[2.A&A'0N(/<&-&+ M3-ML 7$PIB|ST.A FHG&# MEF3F2+ $>4YK;>>*E
*MN9V_9FGN2^7$S|W125|8NI1%30K8I*V&5L2N2/!LO 33D8/CT331|OF(.%+8 M54MPO56>FO?#'7'4/ 3]&-JK-[\O90?2@8^P'Y!X\,)2VRU)O(Y4+5\+L/%BO MA&N0$?
*N>T@3!"7;J2;"VX.!QZY.FFHUSH @)S:C5O>\P4>'%T Z=3*J,F MD&7K2E!QA3VM-#V<47.I=6B;H(*\?A.7>N3|_N%@C=W&X"V;1,IFJ;*N?F "M.& -#FJK#<]&:[9=E4++'(6
*W;=Q6GLOTL>X+EX1 MB1NM,=`|fL8H'Y:G[4. ^F[OZ:\-V|[]>/!WK];D>K 15F3\+H#!J%W.?,H MD[DV5$"1N<|CV,X,9\"!,77,20)NC;&&ZOM6FZ72=K4V* G!:G'$FG4KL3D_*N^&5
*F*XB=47P:0AT >S/S;O3K*;2!WQP!6@51.EJ9I.\M#EIB:\ MQ6Y-TKU@5!*>D6N(V'##"(I7AP.6_B9GX\O0"(P Z&73:-.FD!PYL4#I+,TX' M^(<|16:7R..P2[$Y524=3-
LZ"IJ0R6OE+NN>TH(B"&D_&U14D'--4&T M\5("KV#T@;D71]1W.-F$-"-4R",R2L)C2* Y$$0)PS!YG 0I<75D!C M7<9UA@P3>^S)?M3RF'0($5L_Y&PG1+.M'"%B<-
FUR8PU2GRPOO@UJNO=4MH:# M'I,(4QQ(\%QW;.0]XRA6?.O?3'E0W4(GIRKYZ4;_]'I1NP)Z=SPK;+_ ^ XNX8M_+'*9^[*C91-,N@>>'@^K]?H]>>(*
*M?'[(AWW9P*W;_1I[1_K:UDPHN1B _RM M7F0:{\\]M6Z;P\UF)K.M=YOI&Z[($*LU,V#$UX;Z 8JR-076#@I!%V;R(_;P MIA6^3Z6<2/C.UH3\#II$G"F9/D)#@.">:7[^_]JU>(C.@5N*/;S?
*7*Y;=4! MSPU+E(0K-)\U!TY/KL[57];0.FI "LO)#IE:B\ MQ6Y-TKU@5!*>D6N(V'##"([

ME@$F&Q\USA&3K74I!$T1"HJOY,%I[_](RU@*FCS"]DU'*SCU!6M8:LH%OT" MDF$F.BUSEG9;MO[XW1?3@GM/(TG?WQG]7'_4>6T|PF6=F]>N\MW3=D!!>GLC MOZ1%)I@P;%$).A9HMIYV!4<(+-;+OV&QO@7W[\<0 ; 96$P,C(Q,#(U,#%E M>#,Q+3%?8FEO;7@N;'1MY5EM3^-&$/X>*?]A%*D52.8E!U>ID"(%DNNEHD"# MD=]/&WN=;+&]N5T[(?WU?6;7#H&$.]"UAUKX -BI.S,[\\PSL|I,Q_#7]Y-F MH_,QW^WA+_%/)QR$Y_V3S[I_B]&];KAS>MG[@Z]#^/\[//I42G1='U-Z?%A2J M3%[ZS:,ZDSD@<7]\1T+4T*FEA(99+USPN-\>U+$>?5?LB%2-\R.R:CJ9CBH[HS#DZI&(YZI>D8RI^\>T[CN2>2'-,0+$=#LVNLSC MG4BVAS1?* (*V3KY/A_9Z?%K:854FX)TWFQ\T":#]IW?2"=TJG3V.PWR M:/>,&/JO)O2?I>4 ?T;]NUTZ%1;>T3EE"[K-]3R5\5@&$8;SE_%>BC4LR'5! M$1+ZC,"U-*LH4H9 :HL_<$S(%_E4@I$1%>&=(9>+/0?M[:A%Q&TEIA M%CPE$[<2<5]1:9N-3,0R(,A,F9A9"<^(E(G*#/-RK(P3G5X,) MP>=@(BE1,>+ ,;WW>P",8#Z&S?< 0DC71P1%C5*);N;), S2I6=| J>EH%IF&WX.58V2K4ML8XYR.C4 MQW-J="1CO+:TA?#%$H#P,>K?1:AV8]EL=)'>PS+%%-<@O-^2WHSV^]@_;3O] MC\&0LQA@+(@?F*IW$M+ "9P\!MN\)Y;34W6RT#]"9L,+D@?KD:?5*

*<13UI,1LN=:1^CP&7{)M $'#%B41\U]<\B1LP T@B>)4J7TMT:2 R3]3 MUE$*9LG%V:'JIK"'+#>AF 63+;&CT&6YWZ2Z@]F?MKF'L^:SP;>H#K3,7 MO9""HI%GSA06<.3^AV$F3%Q""!48J1252RXQFW2RQG@P.'B[K{8.I*_^2H M^:[;T;0T4P#/,NQ)1)$VL;/ M5)CF;/6IL ?1N24DLF7&VBXINHB7.)(IPL8=,S"WRPL8I"/]_=]X#C5 MG0#EI,FPBX+*[.(0Z,,F6!!. RBBOP6. S> MRK0Z-#Y;$'RUD]XT&M]_35_O/KG$-9:#^WQG_F$X486F^]1G/#PI,EP,_9ES M0WP%V]M"& ILL;^%9&:9*@HIUT]RZ4CC0+*X[&"@4](%NH>R.PR6^(O<0WH:V+)>SD91YY(Z7VV^Z4^_BA,Y=C (@^/C"9Z%(282/FP5_F]O.IW,I M;KG62%O3@F^ W,>B^K3^(E14K:T_5&Z@"!%CH<4#+'$4\10,ZK8):P #-#>! M+W@6GK)E!B^IOZ2#5T7.&[]LO&GZX$ZZBY*5&&1?@++>220/<8?SGMPH%@6=|-ME<]T.I-,^[D85Y\13? 792&;35"\D1N<3I.E%/ 9,/'BHHB,70?0[BM\Z@VI MI^=],NN?GU]?=<\&%S_,U-ION>>K;]17/[_8FKF*BPE/W?_N25LP &Q+PR]3 M,;7RB.K_6N[&K1,..\TS9GN4\AH!A9ZVJENY3MBK9U5:?]C_KG72^7!Y$:X: MOF.1-=[ZUDD/ #BB"X0B&R'&[<. WNV_,^SL\2J^X,NM2Z^L'>FBT-D1C5)L MB]]f[^$-=XA> [OKPR_KW]-[:559;4(,,=)^BG_812D)V"6EP |Z2|%"B2T MD2C0L.C:\ZN-_&QNT|MW:2Y7W_/V)L0(+2@7N%'\'-MB3TSGGGFF?&Z/2\'| M>!8K[4^=-I=_"7^:86]\+]1V-KR7 S&Z50VWCLX]7^@R_'+:;?==(=%[L4W-[M7%"H,FGI3$ZIKS.1! Y%0)?2]*2!A5AZ,5]7R&_%ADC5,-\GHX:CXH R888* MC]N-P|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|\&0LQA@+(@?F*IW$M+ $9P\!MN\!Y;307:\U=]&7L,+DEOKD8?5*

*7_,@/$#P XD85:I\R="E M@0#D^$19QQR8)7,GA[NB!>G4:\O,960J7-2KHG$3MJ!B-1Y4(" 88W6J8E$X M2P=6Q0I=&;\ #,)5R9%ISI)*R^7&Y8YUMN,_@>2)X#"LE_&KY:RUP5VPS3-| ;4'4_P>YAY/#H^& M'N Z43%P;Z1 BRZ8&H4%'+G-89@)$\|\C#A J,5"I*F9IJZ[1G-4=R[C$U?5,[BAE?!X N5P|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~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

*O)2|H/UG*AH/Y\FGX2%?%(O)\-MOC3@;(DE*93)2]PTRWG)1L'10]GGUH5KX3@XHBYR=M/$KN1J8/-D4.3^O99<1 M%N-)8N|S75+7@6V=30>PT_1ZTQM@NI^?N4E!*

!ZG7)&.@U+!>BIO M-W(((N"CTV,.":BQ8/;Y_"MCK-N>IQD,9>G-Z#DE8,>S\)%((PB6\S ;$S#B MNJ4L.`2T8'3 M*Q(++\U?=XQ=MH: W-Q4E-[T9_8-)+,&(5(.+;*

8#DYEZWLWJ[U]fQM D0KO MW6QX4PX >@[8NXZSVDLEWS;X\U+?E$5)QF*=<,A2%,_GG M$>7/GU5DFOQNQPCC_"7]Y&7U-R\//Z^V>V1>D)47QIU9+;_>J2@&L_=TB-0O*

M[LB+++6$[?D4#8"L#%\R+-5G?D=12NJU/M]8(@TN/!0_0\,9%C40WJ]=AS&KG]MKBCMB@/V9YU28UNS(E]S$@+Y%B=+$K_U1Q'+.T.2]>LO(NR/1S\-^+!,7*

M\Q[^O8W.SW>>Z2(I;U-F=QGW5@[%EM6S7WK9'1=!-=Y+9J5>DBC/Z1]PN\7% M.$6R7-76TRD#A774$(=_,8TMPSN\9VF;=.H>-2N5IMBJ>?7U,DW6W2#,$ZVL MDI0Z+3_?T4_X>O@)S]*,A+_)R>5H1+&ML6 KJ+..9J,PE>O0BMNW,\E,O M33=TI^0')&"L5&C6:I4%>D]-,<)E*#XM?%V@NR:4K]"O\H@K9H&A$M-PMZR, M@9$(IP+B-?@Z*[\8FMP!*

*(R$@T&)WO%"(1%/A\$..0^--<2OZN;))MQ*S M+:,2[T#FL3_`IB\LO.6B6WR(I$9V*>>UFE"%<[-6BXWBKD>BDQ44WY&*R9-M3FB4"3?QB@=WU5/56@3UF94P:-*

*BJ*6P[5C!8]:8-I%/TP6D19I0JOEF$;%[-MC3A@[MT#6^L?P3%2DAK#)F^&DEIB^AV_XVHZ8ZE$"2=T&5,>?))EP)231W MS%'C(A90A<=;;# \,;8^9Z/8BW5F^_]Y9ZM>:!"$*?E*BW*

OX>6,"-3#[<>):"-MT/2"6BJIH>T+^_E^J1<0I.A@I++*)9>65LK1R4OE !6VZVKN=T@Q4_4Q)SN MYG9 Z<1F$N,"6%#-5&# M#P9R%- =!,=`14LL!/+1.\4]D4*

/4JII33!2J1$>TN*I,_)^":?/[TR+++DS5)-MM_L@I3>: MO:M+1%JUHN /MMR1%'*,<:,C)N0N!F$/E4)<2/M7_6II%@?\LB)K/'("QDA) M:F+2BTV@Y*

IH(;XA&,X156D7D#08=;&W+/902$U8=/3LFE"!585=*3DK<)M8+E1*.7DA<)36#1=5M62THs>$)W1 MA_L547.UBZP*(^%/G&_&>5*=():-V%-;CQA1KAROWKUJQ15D*#;&? >-# KO9RYZKL>B08 J-*

%'] 58@X_J5&,SG6J.C@D'UF2$>J.%"BE+:/=4-[M-)):-!;DCZ&/JDG,8U\9-5*747NRH UU/0H<$0-'C1]T.L,,0>3OH.4

*M2=7DD2/EA<8G*DA7%Q@E[0DXW9;"K#%57$.B7D$,B*F,^*37]@)25=VI8Y63 MOJA("IPHZ@D_&_8%N"#G9[==@Z3]_#;[2AH=E;O19KXA 2\&A3O;4XH(=$=B M*

*4VOQY._Z>TW8J7V4R^[OXB2+U(+VM. UN-G^';SD%2?*I0D9^/1!?X84D&< M;#YEK*S]MH+OS,_#Q{if'<[$.C P#@=>@?F>BV$M8)2"!-^*Y]===H_6>(2PB MC<*

*.*T%)F>:.ZW"HC*Q'T:DQ<5MGHK/K{@*IH'S>&*]$DC#RGQ0OXB M8JT-UDF:A]!CQ.%4E%Q>OPMO%IOZHI0ZM9)4C^CJ K'P6TE#=[8=*

MEN(52L#BI3;K=\%S&K)X_2KY]^U\0P12\?+Z3AUP5W K!"Y26.3+BB?%%D8 MDRRCYN..JA43<%G@?,5]TI"S+9U.6>1\QL[?*WXJR4[OV3\O8ZJ7!3^DB#^[*

*MVXYO7@/KS%!.Q+XDAOS!J<0++>AV04+]\,$%TE.Y2!D_0T M\D+P0K1VM+^YOS+"/@-EQ-ZQNSX1K!ZQ_V=(/[&^TZZ01A=?M*V QZRGM* MO(R R?B29R_PH%0-*

*/(3]**6"IGXM3-M1BH9E>P0*K{]\5MTNHMHM$D(Q_MU<(*;QT!,S<*\-\UZPO.@AL*-6CHFT#/<&\QO2N&+UPTB[!B;/JJ,AYO2X+P:K]>@Z4;DX>+#'*

*M>F&9"^;%P;9'C>8,WBD#8D=IMD<)/]W!BG:/W'$3.EB+PY*XPRN)+IK0RNBP M%+.;'>'3S?ODD:0QX[/N$\(6V?M6XZ5>SAR/Z0OIS&HZXA1N0Q'*KKI8UZ M>,FZZ,2JT_-*

*Y!U2V%53&(G+DY0C>Y@+M#VQ({U 0J1S*DA3'FA.CY"&._,M M:]KE\(BE8U(/"_JR@:6>W"<1)9RQA*]=P7>H(%,Y*1+:[@W>U5<_E,+')"?X MGHDY77=:+<;O('W)3'I.0D8G7L8N-*

*X*S,"IR>H!.LNS<2V]&K"NCS!C2" MM#\XEN!+R'1=!?F8FFIG(J3\,RRIZXM9L MOMP;N)(2EJ8;$AW%M:9A=IFI"':ZK320'&Q4Y*:$F)]F$_Z4D?GR(,O#*

*MM9>#E\;,&]QA9IH=$/M"0>H%>5)UNSI-UG=AS%'/VIL!E'63$W(7WI*T9@I9 MH36AV>8GSH5)L"A8F=%T><2U \Y0ABC5LO>C1;C]D(|:5);.5FKZ!UD]PUZS M.+B,L5>;9?*

HC+G06A>S\FRDB5+%[":YTN X36+ZS{(%33:$3V]-?DJ^ MHKULC[H6A$!]4BW.8%13,V/#,F<4X1K4H<_?P\(ZN]E1=L*=3(R^B9MGKA/4^O MP]5]/OL:@IBA+*

<[UYB\"%ISVDLDU.FG%]1:8L"%? QH_OO5T#BA(T667A'EN% Q ML8'V+N;+O%W)XD/+;5!N+,/(G4;K#0S#=]\13QLG0GGCWY.@B'AQ&#]9Q>'O

*M)+@,Z*85+D,2E'YRW7R^:-%"!T%-]Q M64>DFOUH3C:_.RI3LNIBFV69]7G<"YX,HCA@#+HX\G96'CA8H.N!'43$*IUN MZ?'XK%$D& >TU50I&E96^=C$]?U?_)[!?*

8]#X+>$O\^#G\K*F<0_Y?QDOU/]5U(-^66U">P>5@+U"0 /GA)%FV0 M[1NMS+);M,;6FYOK@;Q\"-Y<7DW8EGX!1@4I7++ES8"E3W%REY'TD7%V&3\4 M.3O&T$4:A.CV&(7%=80*

H7(I?(T?F?N//?6^4&.04HSI]#U+[2W]T=2V"I MW0Z)3/%]"BWA"1?(LA'O:.IEZ=;2L6R6%;'Z M83"*Y_5(^]@D7MEOT1,_&*_OVZJf.;SG1)WY<+E1&;S#[RY?K&R,!DLLA9.Z*

MG"2@2Y8%BF9?O#3@3eC,X^,W(UA7E]VCESP8RHR#,N4W;LU(/$"S0S]9[>ERQ M=)\U$T462,DZ'T@HCZI.R"7198MTV-B\MUNLD+MDI\BSWXH">1H>'UY./J0!M M+5^3=RO]

(#]?/T3)AI ;DCZ&/MG9\HK.W>5IB;BP_\^,#+O4B_(!.&O+,H__M ,VGP_BEC<: PV-RWSA\D1^,8^]4;_TT3E)Q'@9,;.$C50!Z";-GI_,O9;M'.MU@N)A%1=TX9JD@0 H-.#;A%<2$,;/

=_'WB?$'.M@MRH$W=CHO)U)OJ+&:C MU]K008^*V:1QIUHE3-;)E-[V"1@UV57>Y'[D!M90"Y(K#I(Q\%)3KMK/>[H_ M\#DCN1=&&;"(3=X(

5/6&WH'KXOL5&#_N1&TO"%>+'6[\&42)E=T(SEXA7FR M^>+#[F]0\01A&9.-9<08BM6)IQEUK]M<$#;_=6,+%CX;.W)B@/[&RI.WY4

MU6$%&0(NEK7)=04VXN"/L3IA[O2!UK"P&SWCZN(_+(K4OZ=G^D5*3_BJL[S% MDR[U""Y3M;I9L>U6KQ$-RCH4U$)Y?&ZTVUN4#XY8,V3Z"Q;O>?2B9GE"O+H] MD,PZ5!U3EW

*HV,#O5+B"@W+=S'"Y)O3(&OKTW,FZ M[=V.3Q+'1FBQ^]X_=8 MU4[.L[O,99?*I\\0>PWE=BMM-[SC.3G)LLC*3P???3-7<.(V4.]M--0@9O+_K M4WX.V*

AMAYV&:W0H#6UQN!'L.U&W2/BPQ[_B8@$8-ATD=T8I^$@_)?,.GiS9@32Z_5?>MA52M6F 793TY.A2Z/N3\MX_Z1WI5>.M.3Z@H$V/BI<\F2[LNL)4L8I%V=+0O?O($]F*

*MBUN>!UB]|FH(;I@DNG89NVR_CMT!>G@Y=L:<], ^9%E"W*NZ'<'H#9F[(*N" MVH53BQ$J=;_[PUX9;R>,6SH&0M*>,5F'A#ABEYMDN$G-*

*LF()%200R)0^>B6<#KL/TNR&@Q4BZ]WEHO,84Y=H!=!W< M'|_I.U5S0|5N.W@@*9.\YTZH7). D#4O09+$CR3-6/"BK9";L,2HREEB12_0V>WZ.@2QHN0T1-B(?*

@P;^QA@8>[Y'PKRTK&+ M"E=\LY%Y:5VD^(B4#-;EGW$T9(@UW-0BN<#10'<1290 B((0_]E8$>_0*;D. M-]T2(AIP@>*

O#C8_39X,P$%&)K(E)I:NK*6^(R9LG[!C.TP333^VPQS+:^O1 MML.4V>JR-3U[.8P2,-221U\J#P/A#U(OB7I>J#%=T#0 M87YNWY5W*#S@'HTRTM=A]ODB):2.6U]*

[^3#&4T%XNBM0)4W07HU/[5)LK$Y\ M;RKT>%C6UF]47MX"WC!6)$>0T.U 2/<=K 8^#"8EV;9]IL5B^)PH :A6#; MTC5+EM4;B]H4/]0=&FLINZ6]!3=?ECUE3[VR9+S559BF(Z

-7O7L45!U!@7 M<@;"\9%PBP>71QV1J_L(:X0$4;JR VY;U3^/\S(MWS DJ8=,/#026MH0I+&> M-O"2" >Z/J2.FGG@L ,8@\:@!-%"$_U308$4(U23,PL/ID/#03@0!@OP("#W

*M*V6D01NK8 M84F]9_&]YH.7F@SF$C&G.ZJB9 ;PBUZ7&DC7--=EB)3+>9%NU]BV-+EY=P5W M&9A6G\R\:*)((HQ.$&5'G32"&6Q'9%P-(&A)E5NJ[,/CHRS M_!KEXE9%R>5-*

*;2>{)D12)$)\<]R@^F8PX-X\5>#>V"0L@0'W=C#@WCY5X-X; MIREU!.[JQ\'^I]&3 RD\!"'F-,D"[5!E*FFTM?DAB;5A4YETE!S%OHS4_56'I-.N6IN%?4L MS!@YJI?*

0)M:2NDNS:P^]M6S1%F9I:?#QE--QF]9F#9U"8 8,9!>(FH42Q3>G3W%REY'TD3%1/DL@?D)9I P"R]#ART@6>P=' ^W/ M#&J5&RCV\):U_HX6026%42,P*

*(?,@#Y>SEH6:0!>M#CWLIP;&NAJ;CY(8AEDM(?I*ND60GF$14.1@!' M'>LOCTR$Q_K+Q_K+Q_K+NC5!K+!\K+!\K+!\\K+QRC_N RI9<0?3Q^.,?]C MS\A8\S_&_(\Q?Q$[&CH2*

*T(5Q4XD)Z&OR>;VITIR0A3[%!,G82*E,S;#)A&7CV/1;0&2E; MPY\F69Y})"AKYX#&U);-H9"TWGD/2$]G"M&6M0E,;)V(1%2A\;UNB>#ZQ#/?-M9VG>X>391>S%8(L$-*

#Q;XQ;,6+H>WS!@H=PZUX1;BY^D>1)S$X!RI;*FY?1" "MS<3&--'2" TM&YWO_OQLA>%$E@;/^V+;R@,2B0VK&AGSILUWHKU W_=VSI& MC^6\H&?TJ:H.$]PFO==&H(IE?*

<]=;=9K^'#H$!R/.5]C=#PLIAAFIE"MG[$[/ M^YT-[ZP$+70L%Y'1IVHMD6 UB4$ZMY:B(KICMI5"?EU&KR=@%148:]_6H[ZK M+SGC9?O8N_GZ2;TV G%,@>.&P(V*

Z1OE5A/!\GM&%L762++[_I\ENE6KNLC (MO71SXT5DON3S0 A3R^DX?.0/ND;.!6JD4L6+O.PHL9SI^1+[#90!0:FJ&GM,0-3'

AE'J/E4ZI:VLP$IQ[G>U(X;^4!V;^,\S2DF[G/HQ#C5=$!/H_]=G-(.4/L/3@N>T!K.$ADC@E6IN_3!;R.J;M&I#S;S# #IFI2:A]<'-YD:1+ M$N9%2K.S&)FY%'%X-)>&2%8ZJZ=Q.8H-5F;G\-

J#3Y':R; MNFN/<%:PPB8E)YSSC/]RRV[)#+AQM&?@>[-'6"HX^-(SP+/ZZ7;)Y41MFPWS M3U$9!X;_5N3QW?14C++$D5'>*Q[R=[Q7U")8]YO\DL:QJHW)6)Q?3RN]$"*

*M5MC1/K0WHI>$X8)_7G]_+'P(I9V_V8LKREZS."I;OA#*T*MU>Z*P#38;LZ[M*]!:5S40-I3#282?=@,YX_Q<(+'W3G/OR\?@F?"6Q>\&P<)>)Q1:0&2Q/R[,B MOT_2\'<2?*

'++,6TVNU\S$8630(W XA?HP8#95ZVCU1'O01D9& MO!YR.F OK'X<.]]E@V@0@#11CBY.Y1P$5@=]J-5?%5T^@IBL(]6!?]FN],Z MW#OU/6X' OO8X_;8XU:.T[''|;%UC7$5?8E8@-

*=)LRM";7O+&]K;Y,8/Z9$V M7(,^15*P3=:,^883ID&.[T $YRNQWG3"6K\F;7FN0K^B>&]&1]ULR&(1^7+\ MZ2ZPL,DDAM,%1!4$H-G@P0@QX\$FTBG!4D)H3]HYIP:,*

[4M/=B)PVHOSV/AB MCX<1^C!](^-+^3DCHTO@.;||^?:?O!UE5?'BC&3]&UC6.]L9;VVE'OYSY?;.MFAHD?:0K6)Q2O(>C_YHOKXF?K&++FLI6I=*=)EF>"-]#^TD!A$6_;'.^A>&#*$*

M3]Y/+V-]&T!BDGH11J3P+UE1,69[RAAV8)K1='GFL4;04(Q8 M73]+9D$XAVIX(=81D.B3S'GW53>>KPQ#[FS. ^#,"]8(EZ$L1?[H1?M^B9I MSKH=-,%!\X;X+$ 7DNS|QO\5=-*

*@+B@T35)%7_N.YE[*TZ(QZCUR46&=>,+:Z M9\1MG>R>O. >>D&8<]'D$5KQQ(=>&.SZ5\UVLSI/-N(!$$[,F)PBW25W.&]#*

MFH+6_H2),U(BCI@DJ!.+%AE:]?]O)?.N"Q!B]#NH6OT\K6O] M&J7KFWJ$9?Z216.6Y%.?P14;(2NG#]WHD1.[)@$A:^984;),U#^L\%%3%) MT^]\rR_B^$FA8F-F PJ,,LXS8X&*

LPPBHH65SOQ MLM#WXN",384$5TG&PO>*DQE$&LF!,.XR7DD VE&2D>GIX7TD>1E-9V;/7IA MQ$1SFS1>[53/@:A8D:;5E0NGWJ$.\N;2ZBQFG&NE%CN86#IV&'MJMQ1!I'2(*

*M7=_-X-^GQ(FTMN$>>5E.UV,OC;F=-V]U@+!$VT+,6"<;>^F(V[,"I9O!=CAJQ@-MK'[VDX/0UW70A?4V^L:U@47]E Y#(>3V;J50P!OP,735 $3!8-6-. AU*IJ MI%$8N?*

*Y;EUME'_&W)VP2N(>TI3)\A[&F4N13!.SM)%;.NYQ_#C'?AD75MTX/ M!(Y2^9DXMN@NCV/G5A0/?DH>KC@<+&%>;N>?7H[YL'%6DYEBR$QH.-8U5*3V+ M6DD-*

*U$\54/[TD,2+E%RP$C3;6B?UR_P.H*G'>WK(:>0'[UD>DK\HHFCS#Y+E M8 ^J1IS$*<$60:4(D:J/'"3V(<0 Q#3<17![XZ<1GXM3)A<|=J)Z'5:4NI7D! M7?VITR2B/TG*)V?-!D6S./B8Q+*

[DUI;T?QD5'CN476&5UX=DK8LM,(O>O'^_MZ+OA*]TC +LU<4+)]''^;TNEQ5'&7A4'HI9L;C[V+X#X.1CEZ*1W7=7$5;MIZ*

*MB207%%KR\Z,22B<5+QOJA5.;74_0:34%K;JV(#.0GT/LX*N9FZ'GMCPY+('(&_M\1;Z-2:MW]"7El-L/S*)^0Z 8!V5M+(*6"Q]5(L+Z_W\'C44JRBF@>6GF!E!*

*M$^5LN>1B..%K)T5&3]19-O.I MRY\96BVIE)"N@$7TV#]3@E,]0$_/N3W3**H.KW3IX3P3T1(& MMW1FP#DT?)"P(1?^X_V8%EZ:,YH!QY--\S<(MM&"L+O:JC;&TD:2^I2,OEBB*

MV$L! >'<&TEZ!9;"AGF,/"8$;10DZ#]T@-#881]EON%R_(#8IT ?/A;PP1C M'ZE$K2E==_?L:@P[2!#VO,65Z -)5R3MT)!^^'3M!3Y%KM=,N+9(O9S6T2> MSP_9'22L&6+LLM9)*

,SP>ZW85EG?SSKSYUW.L,E0\DOT^"#XOS\P!V.FX^ MG,N]PD3Q+01C$?0\2MU%6T>'X+@%17H:WPO:'8D$Y00_@\,M\^PF@T-69[Y@IP?=W3]H\ M

*Y:L]%OY254'/=$1,KFU,H6YR:LK3C4OYNG,-8NX$4QZJOKU(4F)?]T@3:5 M\$]YF3(0D/$?2'0UE]^(#) !O?ZJE]I31-I"WT9&9#+CDZE%A10\Z*E)[RB-. M2?XC^<),!9^P8T3T:4-*

*N*GFK:A*)3MWF0E:T3>87VGZ"=[VMV$1V3 MH ZOS7R_6!<\'/"=&!>V#PVU T&%M0&RL3<1=0?T#4)OY[W+GV+9^9"K1K\G]*

MCX!!P/.O#V%:=C6D"MGFRR@4]!S@::)H(+@]7>@209*=S SN6G?G2$NXSP1 M%)0P@GP(/I[@?C />BFXP_TA8.Q6J1(1J4)Y5MR70,=B.3#$:]=\7EEI-P!K=*

*M[#/4&]4=]D9+*0DN/_P6=6FB!HY[*"1#+@>@$V80U)H 7FCZ@6F51'02 55 .@NV M_\RRC.ST$%H#C$@^O9W!3N(UX/((7Q>TWR=)\"7<%V1VZNM>#_LTO?]#Z=7H*

M.)RO?"9Y_W.782. VN(C*&T0HN7.7ADO6 RV<^YY&=Y,H]$.2:8N\M=3$:AV20RNQ("'4M>%^&QEI!SMK< C.O).76*=$#*.@I*Y$9SEO<;W5?LD-& MM\NH_'1@*

*f1M/I8LZ6'"B_W0BRYCRGK!S;%!L M&6PZZR(E:.4D:.EW>ZAA)EGS6I(VXR&:*6F9R8Z8;G=M*WD-6V$R2_-_7S,? MQ/0A.OV@H8CTOW9*V!X+R0,S>UG>04,96GO2@'Y/,?:1-*

*P#M(97/A@7 MZE!+G$AOJ?;&-WOW;2E1\X^\3>5IH6&;5IX3Z#S7O1L0OC.@G?;=%OW3_]IFXC W195-T>G M"7-G^U+<4*2WI#7D7]X\;3[.-<_3J[*

\4;.C:W7BOJ;C09\K MW4W$Y>&BAVQ-P!'UZBY\{6N23KJ(<1=EE=3]_IY8D LK_M>C%_X/?]\8I3"4H#B!6LT!#KF S8DHIY#$+PF8M0@QD V\B":++] P@=E>=8

*MLUBN>W8EBP>HD0N,R;%B<2\TCA6+=6C@52SFBI;>ZPLONB7I&L%]2.9@UB@V:1<2;+Z^\&/IA1F-@ MIV(W/P]*1(*T+R^\#;]!O4C2:[+_$K)_18.]T2?[OHHA:.OS(\O A#-*

RE^]>@VX+ >T20'9/ MR,M@<54)#/H)3W<^IK7>LA,7!BEF1H$QY6\'8Z!%&U!=DF4M0@?R@=((..$N51STHC*_230=*TN5I7>+ M>G"VYWAC>1RSE0%B\);.US%3^9BJ?*

$Q5A@Z%.TM5EMJTD\U'+R]27B"R_C%& MEST+PFB'.33KTD6Z2)>5+0XJZC@7@0I*0]PTJ>X"K95<#N*>"-%:BRFHPM\1 MZJ!S>TV(A9[AS:'M-K5(DZ#M[P\WF5!PWE:PF'G9YIE$L(-

/^W0885#J@(9>;6 MSPP-P=B.;)U:_9D+Q(@LLFI0;BP&E <.;1]<(!W-7C*_4R2ST27<9Q\L@C M6+,BOT_2,-]8W*SKQG#W;L' R]D>S;62P,AF.-UD>>A?A'=!DH59A;V%Z%7?*

MN[CK,#@$6(O8(5N?X\O/X!G/\;S#YTIC3I4'2A1<&L_C3 V4KSJM;?B.[MH/A\+-98&2=531^AWV!U-BN8.UO2-)2SVJ>=%L(6?9O)$2;*]:-QDE MR_Q_7@*O?!665U6\RO|*

/L<:DW6;#F@$F[TH37)RNH#YP8N+)HZ4C^W8*HE=/WJ_4+_RI;=)[D5LT9IY6<(O)^!* M2B:-T%JG7$0D+$TDNO>)PZS@"PDNC]D]XW':29,+R(E28YKHCV;KB\G8*

*M@+V)ZGNY=![G5_UZ@WI/LU:-A"KZ;AIJ*IROOO5*IUQ./OIN$P5V. Z&'IOA MEZFI"4<[)EOKX M(T.=Y.KO&M(Q^WE%O2;X55^[<2>SIAJB,&D"TN$^,.IHKA6QH*<"%&WGXU?BU*

M7#9=TP84S\AC=?EVBJ/OEY<.0[ZO')KI(4$9S7!`Y$I\3<=]J.Q MQD@RYFGD%L.A?%!*GD71+9*;",@9T6LK@EO0+SPTGS3Z,F!D$&JHN0X+\I>*

*ME=M!,H4(T1(.)5115AI9A>T.U9PD=`Y*22",)8G,>]6S,TJKRE]P\E++) MMVX">+]:.D84'}4>(#+7MZ"SR8H;M'D#;(F^.EV:L'-VEO&,#6(F;/G73LQ' M+Y$K)*\-*

<3A&52'AT,97595'NKHV++#F4U[B(>;,)+U;-6$*0 <&Q4M!P$B_KB M!<&>078$0KWMZIZ?%3G!>C9_X]_3F4?L19#W$%#774M8+3SBK8DTM&_9HD5*

*M[.Y%N0^%:%&:6_;QX"_H. ^&T*XXG%4+O:$<7I?L'=<%8DPOXR$9S9*C-9W3 ME 1A?N'YO DQ@FT1$$#4=G@S(Q+0(%C@E/T7D1@DHJ8P/G(=E .:7O)?0 V^ MZ+\$#8=FJ3L6>*

*7_V3+=U29$L%$" I.R42(<#&;EN,TVP2*UQBGM@&R,B#]Y%/K-MHAR.IHR WY!J"((,+'4L3MV?LB@E3OD)3

*M(GLN#NHIZ2B[=:'Z8VPC9)1DA5J5JN5-VGR?CAO4NH0:V)'1G#28 MAF+55X*_@95W9UFD8>R'#UZ$"^<>K2D|/1HIXK1)V3/@N/N>V_QKZ,W.I" %*
M0A(8fX!TGT24=';^6\'B5^4="DLLW|8-.\@'ZW13V.AB>B 9A.[@5\W<+NN@ MA%HPYCE>)N/@;(TX4L)QC8^820$@!=MG6X,BKLL#$(OW=QX;!D>M%V'NA^0*
*MTL&#S>SFTT)%6[<$DXO48$!1$Q;N\F[G)OAIL"L))2.E.UDG+!H5R RWN\(A&8\FFU6IG M*Y=*(*&TK+8#6O Y;6(\7%JU?FC@Y;75=7!F/EV_68A4MD!&Q7F&6T<+)I4:*
MJ"M)/4'VSY3@+Y/IZ3DW!P(4 M:[4WN-OXG$<91.+2%?:Z"ZCH3#9LK!-& (#"G-^+)0TA/^N M>A>NTU8M0LCO+A4TL>+]CE04.%9OF2!3F*^^E%>[QV.[59)94G[KUL+A*
M4"9(("^6:!(2LF7$]3>)'DN8A_>>"2IZD*0GP4#&GZZ[SB!E6%A)$Z&.JH<[> MY]H\';08;KRKR%HP)O=3'2K4T@G=,Q$O+A?G-@5_!=\Y3 P61V%V!6A%LT0R M5HLT?/1R0CGRI8^-=Y,"(DX5; W3FAKOY$02\L\A6'PB2JO?IND!V?ZF#O MA+)-;P(H=-WENM1$3@GKHDB"RC>UV=1DWSHNXJ _2.[[(,MF#YZ'69%K6XY.*
M,E<.X52_[22O%@6L2]>B3I^\K^&Z6((%]OC.1&\) A;Q!?V9@R=8L=)T(F"M'K4UWBB%VIXQCE&V)&\:9M:\A(ODC,3-Q#011^<65#&YV*RE2!J86$4^KD@-*
*RLR. ^-3/-P='Y<&I;&$PNR0 M:8H*14!)@>'+"2^,>AAA99<=B852OI'/9 7EH;8 M-.#22<;TQW'_9L20@LAZLN0=#Y_J7@HKZ#89?U\^8G*<% T#XE/"5*!. UJF70(*
M<"BYR$RN&'>L7L9Y4IU5EHW=W2AR,@0?#]\8+6J#8(-1Z=$[/5;D? 'ZF%5.9 M"C0R(=6H0+_-4SIC_)?S!W]DJEX];^(&V/$\(6C="'' M,3&14?OJ.@'5D"CB&=V28G9W5XU -=^4?D0
\GJBE-Q&K:2"X&K!@AT\0> C M^<) _]"5[A[--:PP,_'5Z"F"&'TKBM=W#(V[IZ@S3<{Q:SXT?)DL_N3ZI:(-P$O;R%V7:$R?C=Q>^_%50Q[MEJE M9$5/J9=Q3G>&+/3YKL :C\/?*
*&#B;Q22LA2N3;Z75A96&[$+UYGD+FV.7JJU@ M@+!00#0ERO%ZHW;KI0L3>=MV',=H3=FS6@LI'B<4E$__(3TC+M>A>)TI%O5@9: T!%SO4YL ML(OL6$D*R&WCX\)6+ C;H6"?*
\,.QW),8E>D33QMG-SB^&1S+R[$N;P8'T(7C MB\&QO!@$JC;%32R=-X[2>8HL.O#7@M&_K+N)S?+X39>Q+,'DE#0S_Y9F7DPMZ7N%9!A@9)*.8*
MUS3R/DEBW]%5\6YE\;4X\CJ!./JYN5Y"Y=&#EVW-3+ M\Y"?*\)'LCONGW_UHX(.RQX^,H$7.9?W?+G/U ^H0 L C*UNT3YS.,PS]VS' M1%N7TB0^:%W8'F6MQ=D[!{#;88KZ-*
FS4O3X&<-KYH6UM'(]-*WH_*WSTU* M4>+;$CY7ME:#]P=8^G7V$B?\A_MO8O2)(AV'F'P&<"?/IS-F /!IM%AK>4[W1RG;6Y362;3BC=#"3MYPW=X);^#09H4OSG&OR'S1.\[&WO!*
*M)..BP6:A53Z3F)"TANKNT?TS> R(7D!?894(P^.'^_^0@ .W.P.X) 6?WI'-M.OI+D]])WO9)W8+NNB?'0SG7{QS(Z1HMNEQ4&=[%4>;#IFD$6]8[_[22_ZW MB*D!(5#K'C%J 0$5*
UP0A%%XS 2"12BTQ=-&P\$0W_74"(/@P)+TN3?C&;! MLV7;4Z+7OO/H!W]JPX$4/86 #6W?9D-(Y0=5,[LP8,N1#@G&*)5W@%I_@VT# M=!JFM0&5""^$-*
*@0X3VT#A;PWL$:MKD_LT1IZ\E-!*C+%KP_(IWKLITGH#:[_.LEI7Y,R M.R>5):YFK&V*

+0,7)5?@@<!J9!LU'"G5@<(;7M.VD<)'U=,5XN@B"E'W.T0A M)OQ6%R3E<13';OELZ+S"9OJ2Q$\6>'SKQ?I,"#3$,44LTVH PET(D9-T'@"$Y MU76,D(3K@$-BP!J3
F]\TM;\$AZ!ZGS8M7T,8#!^BH:>M;5K81;F ZFIM#] MZSP-28^^P0@#IN@;HI=+!]%K%)U4L=42UAZ3?OD+6)2:5MI!\]IK-J/@#9!? M-EZ.0
*<WJD*3N@93P0S07A6!R6)IVUZ3G^6S06:Y?IDL-M/O1;0M_@>X1%N;$[\V%?&^CUORR4%B MF.]2',J!8UYT>R5;_5MSC1URPMB'8KX@:9O/BZ[6 V':?VV1<##:!HL/*
*MQE(DGX%H!$D3XLX>O8|Z)WO'Q+HS<+2 MZ39Q4_^9>&GU'\U%"9OWVXLSQSG+NZ@'L$,-T>D31*7KU2G;VC\U28K^P B5 MF2)%3SZ#RBQ\AHD->-((CP:>%.:ZX+G-N\"A[*[1G*
[1\2"\4(WT!&+\)F22[" MK_P02<;6$$HC//1$4IB30>BJ:#YVA"D+X:0UBPI(A23P/_#Y1.S$\V#+X0ZM M@<AW4^CA/TQ'K_F+VI<+PNR_TQ(NM%K("<>P!^0>1ZJ))?QB57Y.IV
M5Z(=E-=7LP5!JIXA>[$ZIA4^C(>KTY78BV>6KT-FK0$G!>D3!(]P[8LKVOI9=[+Y(XU_ MDYU[$#2<]O&HS>.U$_J_D.":.BRA,HL#WR ^(Z@)-/")"?IRO[VD%3"-
R4ML<]E@.YIQ$#V&2 M7$2;1T0%T[N#;K1&C*&SKH=(^2L?1SED3_8F+EJ*,?00B_4(X239;= OAWAB M.0"#YOTM^@?!#4UO/_*UL&Z&0U9]$0TTLXJ^>)W+8!1 M5LAU)$I-
B?)E3A9=^*,3QTZ8SN,[?_V4#@ [-AVS.&/RT15$FK< 2-N1-F- M5Z?P&HY-[LA5\7,#G607$Z_/+-SNTH&T%I.,2;7Q.D_*X?I5]] MGX/B>ZL8$9$/QD?G8%552G&
(,>&Q.?'BT4<747QOIP%.$MNYH8>YK)#DK@! M4*EQOH ;SKWKJ9.%CW8TU!]0Y]#TXC-.3]0;#K0.6CETZL!/?OTFCZT8[M_$9^O4'+/\PJ5HABP<@@9!";,"Q8(_77HKWP7FU-
*58U"TI@//1H;(3CDVLD;R MIT$=3E>.',_@!#MXZ2=N$.'->"A_<4F9JEYP>&&Y*U 30-I@_5;7;JC9;I,_MXJ%I-1M^"@&Q-AP37?/LQTQI7_=ZHD|QT+D+),9J;M+:,WEK.=)]IDEC5+5*
M0JNY;X='30#G\IFU_WO"AO@V7'-8_'CW[Z]!!& MCPF,G[\7E7A $GS;A2P+M)A)\BOTXRZ.D>%W[B1^4BR4/>EK*-1]Y7&H .?. M4/A!AL/*S%%&NS^V.JO:7 M#H(VZ=+3/L6|?*
JU!4_&##H47+3TF;#@1@_H,8 MM2E65LZ+&&X=WV9+3^,&&8P$GHS=,G&#=]L@QT)!:A,;A-&'E=05-P#Y%\6U M_FB.R I"K^-8=GHT+D&D
M(_^,;S5_<_"V+../&FL,=&E^"]DA5O-H(0 ML/&D]5>1GVHD>(LF$;1((U[F(N^@%Y1[2=P-X=D(S,*9=*PK.C[L.G$S(*QR8"M+0-0U@X1P9\E?24X|#Y46TV?*
*A!IEP[]+*B'FL8XL"5ZEY0(&#(T38<(2[#&S.J ML^R#7, U>AF19.&$@490N?1DR2JJ[=,;_O/A_F/T#..0Y$/&1610;YC@1QS* MSM!>N"%!WLDW[T\(^F2Z,G2*DF") ,6'S^_!U5[4'9*
@)=U8=NKIB!####+9 MR5'= R_A8S]XRF.0T6{\E0;G0=FX:MP?;R%\0;@9&M)-KNFKB#%,QD6GV M(&L@?!QT;M)6:DFG9AK1I9J_MQN-!=%,=/T!)/#LJTFGYS88&^BI4[-OT]Z
*M.G$&$L@WC+=,=LY2-&DT3D^M42GI%Y@@!^[+)PXW2_1%I3@9,)1. .>)2, M[AH<1A@(R5L T@34VE 8P$O C*LHZ=K.(]IR26,_63\|SIRL]WCS*"1-MHQ\ASMT*
OT35"VL[1"4;V/O(? XG])[U>?6P.0O3 MV \3WQWB6=-P? [S1L7DIM(<$,LGMU[')!TM*# _/7@+ ^KC<0.B8'6]<4.0QF MM)C;)MJCHFT,"C];K<$R ^ Z4?*
4KWN\>$]_SG7A_[P1PP+++03#]&RT*S^&!= M9#E9V"}^K0MV:)\>,&&8P$GHS=,G&#=]L@QT)!:A,;A-&'E=05-P#Y%\6U M_FB.R I"K^-8=GHT+D&D
M(_^,;S5_<_"V+../&FL,=&E^"]DA5O-H(0 ML/&D]5>1GVHD>(LF$;1((U[F(N^@%Y1[2=P-X=D(S,*9=*PK.C[L.G$S(*QR8"M+0-0U@X1P9\E?24X|#Y46TV?*
*A!IEP[]+*B'FL8XL"5ZEY0(&#(T38<(2[#&S.J ML^R#7, U>AF19.&$@490N?1DR2JJ[=,;_O/A_F/T#..0Y$/&1610;YC@1QS* MSM!>N"%!WLDW[T\(^F2Z,G2*DF") ,6'S^_!U5[4'9*
@)=U8=NKIB!####+9 MR5'= R_A8S]XRF.0T6{\E0;G0=FX:MP?;R%\0;@9&M)-KNFKB#%,QD6GV M(&L@?!QT;M)6:DFG9AK1I9J_MQN-!=%,=/T!)/#LJTFGYS88&^BI4[-OT]Z
*M.G$&$L@WC+=,=LY2-&DT3D^M42GI%Y@@!^[+)PXW2_1%I3@9,)1. .>)2, M[AH<1A@(R5L T@34VE 8P$O C*LHZ=K.(]IR26,_63\|SIRL]WCS*"1-MHQ\ASMT*
OT35"VL[1"4;V/O(? XG])[U>?6P.0O3 MV \3WQWB6=-P? [S1L7DIM(<$,LGMU[')!TM*# _/7@+ ^KC<0.B8'6]<4.0QF MM)C;)MJCHFT,"C];K<$R ^ Z4?*
4KWN\>$]_SG7A_[P1PP+++03#]&RT*S^&!= M9#E9V"}^K0MV:)\>,&&8P$GHS=,G&#=]L@QT)!:A;-A-&'E=05-P#Y%\6U M_FB.R I"K^-8=GHT+D&D
M(_^,;S5_<_"V+../&FL,=&E^"]DA5O-H(0 ML/&D]5>1GVHD>(LF$;1((U[F(N^@%Y1[2=P-X=D(S,*9=*PK.C[L.G$S(*QR8"M+0-0U@X1P9\E?24X|#Y46TV?*
*A!IEP[]+*B'FL8XL"5ZEY0(&#(T38<(2[#&S.J ML^R#7, U>AF19.&$@490N?1DR2JJ[=,;_O/A_F/T#..0Y$/&1610;YC@1QS* MSM!>N"%!WLDW[T\(^F2Z,G2*DF") ,6'S^_!U5[4'9*
@)=U8=NKIB!####+9 MR5'= R_A8SJXRF.0T6{\E0;G0=FX:MP?;R%\0;@9&M)-KNFKB#%,QD6GV M(&L@?!QT;M)6:DFG9AK1I9J_MQN-!=%,=/T!)/#LJTFGYS88&^BI4[-OT]Z
*M.G$&$L@WC+=,=LY2-&DT3D^M42GI%Y@@!^[+)PXW2_1%I3@9,)1. .>)2, M[AH<1A@(R5L T@34VE 8P$O C*LHZ=K.(]IR26,_63\|SIRL]WCS*"1-MHQ\ASMT*
OT35"VL[1"4;V/O(? XG])[U>?6P.0O3 MV \3WQWB6=-P? [S1L7DIM(<$,LGMU[')!TM*# _/7@+ ^KC<0.B8'6]<4.0QF MM)C;)MJCHFT,"C];K<$R ^ Z4?*
4KWN\>$]_SG7A_[P1PP+++03#]&RT*S^&!= M9#E9V"}^K0MV:)\>,&&8P$GHS=,G&#=]L@QT)!:A,;A-&'E=05-P#Y%\6U M_FB.R I"K^-8=GHT+D&D
M(_^,;S5_<_"V+../&FL,=&E^"]DA5O-H(0 ML/&D]5>1GVHD>(LF$;1((U[F(N^@%Y1[2=P-X=D(S,*9=*PK.C[L.G$S(*QR8"M+0-0U@X1P9\E?24X|#Y46TV?*
*A!IEP[]+*B'FL8XL"5ZEY0(&#(T38<(2[#&S.J ML^R#7, U>AF19.&$@490N?1DR2JJ[=,;_O/A_F/T#..0Y$/&1610;YC@1QS* MSM!>N"%!WLDW[T\(^F2Z,G2*DF") ,6'S^_!U5[4'9*
@)=U8=NKIB!####+9 MR5'= R_A8SJXRF.0T6{\E0;G0=FX:MP?;R%\0;@9&M)-KNFKB#%,QD6GV M(&L@?!QT;M)6:DFG9AK1I9J_MQN-!=%,=/T!)/#LJTFGYS88&^BI4[-OT]Z
*M.G$&$L@WC+=,=LY2-&DT3D^M42GI%Y@@!^[+)PXW2_1%I3@9,)1. .>)2, M[AH<1A@(R5L T@34VE 8P$O C*LHZ=K.(]IR26,_63\|SIRL]WCS*"1-MHQ\ASMT*
OT35"VL[1"4;V/O(? XG]}[U>?6P.0O3 MV \3WQWB6=-P? [S1L7DIM(<$,LGMU[')!TM*# _/7@+ ^KC<0.B8'6]<4.0QF MM)C;)MJCHFT,"C];K<$R ^ Z4?*
4KWN\>$]_SG7A_[P1PP+++03#]&RT*S^&!= M9#E9V"}^K0MV:)\>,&&8P$GHS=,G&#=]L@QT)!:A;-A-&'E=05-P#Y%\6U M_FB.R I"K^-8=GHT+D&D
M(_^,;S5_<_"V+../&FL,=&E^"]DA5O-H(0 ML/&D]5>1GVHD>(LF$;1((U[F(N^@%Y1[2=P-X=D(S,*9=*PK.C[L.G$S(*QR8"M+0-0U@X1P9\E?24X|#Y46TV?*
*A!IEP[]+*B'FL8XL"5ZEY0(&#(T38<(2[#&S.J ML^R#7, U>AF19.&$@490N?1DR2JJ[=,;_O/A_F/T#..0Y$/&1610;YC@1QS* MSM!>N"%!WLDW[T\(^F2Z,G2*DF") ,6'S^_!U5[4'9*
@)=U8=NKIB!####+9 MR5'= R_A8SJXRF.0T6{\E0;G0=FX:MP?;R%\0;@9&M)-KNFKB#%,QD6GV M(&L@?!QT;M)6:DFG9AK1I9J_MQN-!=%,=/T!)/#LJTFGYS88&^BI4[-OT]Z
*M.G$&$L@WC+=,=LY2-&DT3D^M42GI%Y@@!^[+)PXW2_1%I3@9,)1. .>)2, M[AH<1A@(R5L T@34VE 8P$O C*LHZ=K.(]IR26,_63\|SIRL]WCS*"1-MHQ\ASMT*
OT35"VL[1"4;V/O(? XG])[U>?6P.0O3 MV \3WQWB6=-P? [S1L7DIM(<$,LGMU[')!TM*# _/7@+ ^KC<0.B8'6]<4.0QF MM)C;)MJCHFT,"C];K<$R ^ Z4?*
*4KWN\>$]_SG7A_[P1PP+++03#]&RT*S^&!= M9#E9V"}^K0MV:)\>,&&8P$GHS=,G&#=]L@QT)!:A,;

*S]'(5SY M:7(/$X#@#1}\P7_9%ED&?K%=Z5EE$8XN=$&F?RPM)S0*6"R6-KU-M&BN#HF'F*TU;C_B0:Y@D$#;S.0\6(M0!S,+1E,\1*X9U.KFO/>RU$;T]+5&*
M(&OW0/L4'O=3DLT$OP@J(@W=AC-F*$A)$C=]0H1CCQ6C.K^YF2W)\UXPN;T$_M%W/RQ'QZ>_B^W$ZDJHKT#ZMR2\Z18OV'A_O*_"OB_C'-[#:&_5&&[2,:E[&=_M5X8K!M
>/K__"R<_S"]N\5H(T"[FUSDL/MX-[FU%!*G(KW2)29$W6OPW44 MKILK7)^^_%X,;V[9?3\Z5M7<6546.W9 ZQ1]*5 M%/61IQ#/8NUOHQ0.OT.*TS4-)&';6&>#Y?
SBK]_/KR^G=_=@^K>'V?{GVPB3 M%G+#^>):#@VE#>@4B_R#\SA+/SC\/98L'S8#?B5Y%;&G-]M(fMEY\3%W@4;O MA/TLV$**0D H@RRI/OY{G1.KD>]J 46_Z5*9:RAL W,*:%Z]
{]DM+KF.$ROX\;L)5)}W%"]8IF;] M)TS6@F-$E#?6I>;+UL^KJ33 96E;EA6P<#;>PYE0!$TT)RKMND+C%T_@8O8 M=V!QU+QG>IVI2CQ8.-&4XE3)E*S9H"T
PL89\5^[,;CZ0.'AF]%>:9LU'13 MYI;6MJ(4[)8(=HL$FV#!UDO!5;^U?!3.OL ME)M3YI56F^Y W)U" O>4\ND MMD0PA(C/.D7\[IY@SWIX *A$;W;-";Z/+)5;6Z=WF$6D3=&@G1D*2
MY?BOG.PGT%@ZV9Y_I"*VG M%RY0V;!0A@#3,(S: N<@H^GR:.0GH?^R?+8=`G>MQ3+<=(D\6VAFT+OAPCG
MK0C|=`^GWSMM@F/$8:G##XKM$2VT'Y!16WOE(^I6I6(M4T"WNRA$R;\5%L MEW=^\LM5#.$L1%*&23KVS9+*KX60EZ"Q%B3^-/C%?H6^/G'(,9E7ANIY>O?
M+WFH'&RW9(JAOS.OYL:XBX+(@*HHQ$Z;\=4+4K8>-=7$H$BR6=0%(!'(6!U;$ MB5GU8*@!@1/X)317JK!575,Y4UGH^"Q(6VG*'SO=6YY0\F(L_
4T7K#H&K+IIY43'OFV9P+U.R[2_+ =3(5VZ;N1:0S?[K]"4-:0:")FQ M*X:!T*S5>E!<_I96?\;)*UW[,LR/T430.D+UA9_]_J7O@*4-2]\66G9.CCD MG."+C%78Z;7'ZS _H
M(A;G9IRJR:N7-/EGN#8>NZGQ?I-G^#O= V;/F7+R*W?06S#8 2 M]2EVI96$0+3 M[8XH)S8R5G#Y1,,G2W,PT?E(=' MXB8+9X_]T(Q$1^$V*AV^@ &2MF&3Z>|$[+7X8AS^VZQ+O=Q M MKZ6C0OF!
fFYK#,SM,G[1GM3'#\NUO.9%BL Q7^V[_5(F[TMS2K82@L&"S M(&N-_,VW^:H&&9O7T$%V5/[WO=!IP00?!M>@J3$O/1XEU'AWR^ GX.@^-[.&C2- MM.H)@2$)V;M 6%F
M&\;5.O)^B;33=HW-E#''WR^@.>C K%TRJ!VM>.,>)T=;WW%%\+PKRQGN&3M^7 M*5+KX,=%N''7H-F$Z(3@92^3F2$E5O8=:654D2XWB?+&
M&+$5BV20).IPE5/K!K9SZ#/.,/P>S-YX<'EA78T7Z3!)(U"U C!G[?YA]>Y# M2$"EZ=\[>I&>[4 .;NO7'XDN(D&F!Z*3IRNZ9(*PIPQH->MTLA+(.H.+>@R M:?''7=9G<3.F_XQ(HC"G%
{JVI>@&U1;G[UJ.)\I>NAL8KV%W>2,Q\BU<428Y4^A!Z,@SWV+S|CLQL?P.LIU$>R M3XO*MZ[0A69$\7G%8=^-RB9&(&>C."&,1H M5E!6LT#V."&D2L/,JQ9T*7> M2+_1
$Z!^&+"R. H],TK^BH?#$QMX4N=KT\E]H,/Q KR9@'!O;$;%-YV2SB MDBN&=%V+H//"78MT\=6$.D=B,Y* D+E& ^E]-.08^ HT,*=W]RRU4,X2Q$DP>3 M],Y)S>RN',+V-
1Z;.99+!C4X7[$6P,^;@!&@_W$ M+K=M9 M3<[8XH>SBR5G#Y1,,G2W,PT?E(=' MXB8+9X_]T(Q$1^$V*AV^@ &2MF&3Z>|$[+7X8AS^VZQ+O=Q M MKZ6C0OF!
M36UH6KW0F& &6>%/1W3#$S9OY6C058X]*_Y^,?F?7;__^QI)\W0A(6MJ0].R MIC'!>OZ]F(W^&-P]C6H]GY*6^,6=@B>!$J9,P>](O/EIVC9%.T2)_26G[^N MLI^'|
ZN_03[VIQ+/X9N.E^M(,Y5H* %>G1O?*!0YY4!.RP?4/4 LBY T0=' MUUB 7G\@E #M.9%)DC0:YI.5OTHA#%OTKQ!29.QFP.[.^G<%N6(%<.'6X/1+ MHNZ^& 7B)$56V< 2$Z$:HY4LR_
MW++M/B#FT3N,T"F\B#P:#K#0^+>/12%QV6/4F<9OCO-%QU@J09K9M.RF!-E*R M=$Y#CV"DZ68;1'L(AWL$1J-@'$H4)E@^$.(5SYX'+; ML-C:9DFR@]XRNG?]+!.)BTX5V-
$N;_Z+=FFTX*T<;QUG@(}>{}$DWI,ABV1%8 M93U1X05)P*]+)>(&6]M$VZ4ZS_91["D<*AA-#6=UIG/!NJ++//^9[PXR# MA2^$$A2=:6;
%IM!X'_*3DW,AO+CPIBMZ6AIV7F.K#F^X-.A9T M'L9?I6$4413=0[,:<6W!JT"W01A3@3(%*#628#"=.)T=2PZ43G@B'YZN.B M7N4H3">^$$K3B3-4U7-<1]8'64A(=&<&)N*
<*>=U&4$F$$69E@B3G*4!/.Y= MB2'D..Q(Z>+6!+DM!3DFS6!,EB>]%D>1F)9DG$U\DKCOQ4\TVQLL*@,@,.!8 M&@PV6!]G_&M0^QS\C!M8=QMV2(V6]YLV9N4BWQR:.2VRR
M\WW]+P. 28*PIAV*ARQQOIC[$_E.G)ENIS#.?\3-?*S-6K"S!+!3A<(+(V*=Q_5(L "6 M4\T1C$$]Y\O8NCYZ97CDS3A-CUF3UI-L_O9>'A[RP+K.]IX=)+)YV(.-M9X%'(IGJ6V0>3_0G_]E$)O\HQ.ZFM8)
(08(:**%7SYW QQMA/ M%O,PY#<(*\^N/ M1@G*-@*Y)/CC/',"0>2$8)6WM^1$DI=T X^2TZ'\5K1 =^Y=`W" Y%$ROW-R MN&'G=*4M*I.59/K/ ->*'[2B_@1$68=8UPRHONPO]P?
L)9V'N>F1W&J_2^%1 M,@\H#C>=.ZG=Y^G= FL\5>\8IR)LFE5PBS1\$]>--=R3C.(&J9@")T;3S%KV3 M+Y.EGWT%_/PSNQ.9E%3919%Y4Z
';^11^B+V0J?:1.L&P.#N@9=S^J\+#TU6^ MA_. 9M^-(F9>2(<@%&&WL.X/AO4AS6?;+P2/&\!TZ$R:84S1,(Q@WH]SFG6
M3YK'=_@@>;O(;/)XOBKR4<+DP@D"ZW O]PB8Y$/M=+[ID07-/J9X]8!9U)(UP*YW@0NCEMMS(<_M-BH.N"O/HZ-YE8'#'!8\H40'E3 M2A]K#PL)69%9C2)2=3+/%H4+R515D0>(?
Q>E:MP0%V2,6[^8?(_,\KRG5F5L M.PX%&2D?.!>$9T1##"'M^!LA0$H .;$8?G]88J@56[#"15A6LS I!=)9_L!G@ MRY5J1PW @[GH@3%:=8F!BEEQ28VEVDM'-;N\"3HT-
BJ.O)8Z(IS*5IVSH;-_M*LX\,E\5)=FF88JLM%IEQ"$2S:AR8<&#HX!KU#3#68]T(\):ACM6I0+4!8[>)$?MK5]**E)N5+67 MG8P>^-V'F-
%M'@"Q@36L.AKTG&)M(:G(B@2FSWMHILXJA09Z&I/@!XD-4[8Q>/<-MN1GE)D#;P@XMQ6"GNS>$*8)BYKIB[LZ6<2B. 08X!=>)>2O&F'!$MJ[SH'X
MCB1[X(AMVC7$UVCG^^J3/&/GY),3>YF+L+IN2XCC2W"6^/$4*;8,[<9ZMB@VU;>.Q,== M&%Y7NR#8>WZP0[UF1IADRDKQWHRF$A-FBWL1$)(.L'VTPETNG;Z)6UM9F.84^;V-
@;F^L0,%F^:\M?_33IXL= L8&EJ5A=8<[\&D9MRJY1#?4'YA4'O8"7U(22[1!E!-YYAI.&X MG=_!9QCN(#K+1>O0_TW|84B2N.E\:+7>4L"::,/IY;+V|@^_JM)7QB<|#E23U"(-MM+*?
8'_J8O@A^M%%/CN/OO_)7Q)SU'[7W1?*XD1M7&_*<8: Y@/H;/S?&Q: M(!EZ..,4 U=^Z(2NCPX*]RG:K9JE0>W<'TF)O'%=)#XYRF<"[/)"_7E99-*@ M,.22LA(BRVA(&;U/0MP#F.
3:*.#$6C"3DD>Z#W^Z)4Q]9# ^6J.I/X&K4#= M=^0'G1NWWYKT69HH(3;0S+) ML#A0: 6%D&FCC.T* TU% U!K8?/JKUMH':D>Z\-5MZ7*D^A\52ZDVO%V$!B) MT33O!A+BBU4@J-
1"?M7"KAJ2$FT=;.+SH.BYF#IQB"RQI+C""M9DZ]!F6G5U M\,/27\B.=8$3>]:PU@<4 1TF9O8-[:V\KQ9SG62U"Z=<2)3$E/A/91Y'WR@\Y 2 MXK>Z:%)Q"">6VVE8Y$D0-
J_MQ)ECOZS,6XZ&LF>W}I=)B;F1VEYL.1OZS[^V<(-C/-OCT$B/C@1*2F]Q ?!..K^Y)2E0W3>[PJHQ*' M^_!SUN0?MM'<%ON-B]D^\Z98G&JR6"8D4$Z4T-/P*E<\$*
M@5HL__B'K\],/WR7@'HC"IQ,QW[P!5'5%F0/=X#MBE/NIH,;6L6;^NPG_-DW-MNYCU"_!$UB[*4]IQ@M3/+LRG+RY:W\5QX :F3Y%WLYA,;R06I41WAA>J.&>L MU/:X@^.1:Y!U
8H^0-8)>(,!=G;R'>F-_/OTN[?CP)>|H*NT^:)3I^!-3>+T MGS=^Z&]V&W';!36JV2WHI\IF:?=G,'Z]19Q9*X%)8QT>S,G' *_/1E7$SHM> M$3?Z,RWB.G%F(?N7\8B8-
OFEB%N#48T$OB;9V=80). M'?1+ÝY3_&4>(GBSC"2?\E MP.)K;SK[#YL55A@=:.0&*)B!O8UIQ*$BE2@34.6SE6EG+Z87,../ZW/0649%F M;?KH ^L!/F-
2*YN^.0!%ESHCEAM';^.WA^X3G(=P&&^D!&4;CG0).IBWVG&2 M@OQCZWC]{7&!X'_FM*AM.]>1$RJ9H)1V9LNE4SA@F9\XVSS'^K2@;CC37MF? MC &]WS!?U^HC#*)J*
1LE\7@(P-]2((IR:=6S8MN&;$]76C0 541 YEK!5H[MTS]@Q0%3!X1K0{J=D&^M;O)=$U_3 O0A*MXB?0]C=Q?@1+9;/\7Q4]Z$P)F- MS4]=Q09#],7G(/\>G3[=<|(HL
M\#*]D]'6>%{]H:Z3$43XO"P',0C'P)5%I".\!W?>>3$WGQUZ/"?QUAW.>Z?-0M@=6>AO$@ M4AH7K'R7Y;> -?#P*EPM75 V7+'.DZCC)B]"00+7++./XNI-74@=@,8)@'$'("T
M.6!=^^$/L4XAGX*?LX^M8H.M'DHEH<,1*L>Q9_E[I-_"A'0!L$%G89FY<&# M!94!!C*R;T'\%2BPP952X!T8V#*HG&OM$>4Y],R%5O^|)@AOZI.^T"A8#A':/-03<0*> ?
&O_YIEF2&=P2#/D'_^(7B3?:]VM8%8\&^PH[QT;S#& MI^3';O3%V$-$1'RP.YB7<|?!FT)8U'8^P*F_]%M$UUA[6PY4?^BF\QMGN#Q^0
MWSC_BF*B4VZ=#!ODYY"E;G0WD62.G6(%!7),N@&MY -'@'0%LGT(=|;>.P8 M+8K ;&1D49C'GO4)4P=/TCNW2?H[0(8K 73WY$:6W _'HHD)1K.#$V(@H{JJ)-/EPS) M)I-
3!C72M*W;EBX?!HJ'6\$ 4E.,9J8\<1_J-.HE9?A8MYREHDZS F;SN*AXNT0]#.@!%2!K1K/+LL5WLA;M0=8!
M/B$?71P!W,E8+!99X;==LH)3I5P$*E_[\Q4M)P'=7>:V]=,!C_OZST>@>PG9ME]&Q6;#OZE?1!#IK_C9I)H=$##9HSPIR8O(?I MP:>~<)81^PNF2&_7XR%NN)"MJ#](3!9+0-
Y#%7EH:ESE5I"]\OR/PS"2A5F' MW20E@QYNHAOH)+N87$_,PNTN'!2-YH(5*%W41@7/X*"+@!T0A+Z#Z%_|[MJK-&7ZKG(5@UZ\,<<"0LAV>ERUNK(CO+U2'H?+%R\F04I-
6CV4?!0=.@/Q M-905-3B[!O>>H<L9M8L=*,-E(\= M[$8*IW\#NK23"396\F)B62/ CBPTJ^^$158#3$V+_S441!"Y,"D|VK5(O85?!2.[^R27FYKQ3&,C@3!K9\(P/I7@Z-
TGXUTB)1+UC3 M[^):^]K]/R_0Q720BRG,EO$N1L2]?)FDXSPX9L?(@9'UFOP@ZDX/L85(|82\ M4C?(X#Z/EF77:[*QZ1."#V'TF,#X&2]QXG[&M;R10 ,_<[T;>7.@BSU+MJ$F
M]COWRZ/&>BI(@2@>$)3%]V!.KW\C]U)<6O7*)H12EV.,N6D&M:DD9G!MT&= M+!)H,OQAB`}XC5\1F-\7]L4NW?"U[(^Q+9$W*2*QD2+5Q)T&++,TC6F7/E?
%]]LW#V^'#O48;A$6CR1(&& "K(!]NP S_'D]Z=2WX$LC#WG^.>ZRM.QC@6X.% M$Z=[$BKIN)BI018)GY9)M',Y89;7)6T :01JK4."8B%)UN'8/0D[<$5-*##$
ML9E#R&#D#9L+^>P1HSB*=LNO,WW$88H,,3 .ZJC706(2U_7H+ ^WJR12S^&$@LFH"BC.CR(\C(L$ZF#]'KE8PH[|8 ML@<9O!LI=(B=K+&=6*SGAP2M.O3,V'4M=DAD#%3;F.!
_D*8.,ZY (0-V_]S.&UO+P=7]+*[W&[MCG*LD]Q0OMHL&A@R:R_VY57H9*+G>QN.8U@LLJQ1V. ^M&MH#(4#0J..MDQT6S)T.XN/);BPNR@*Q29 M;ZIP/XQST)'/V'% +TF*DY'
M6@TH/A$3B-/"J08;*,\?Y 0:Y]%78M\((4;&A.F>YP$4MXC=\OD1I),V"& I@TF'?"W85-T?$C1[MB7-3.!X+.8C;F1/U=Q4'+U>O\<=#^13XMRZB<=):]0 C+7RX7#8__N8, ^
M=NEI&FW_3$BN=91U3TD?Z[E,2S?=:,(-H#^$!C)^1^<"P[(,@)S]?X2#.=8B- MD06_ 0A]EZ2#Y",:AD>S5^&#C(&U'G"7QZ1/D)^Y0.U(=@2F+]OLT35^T9-7
MT<;]'X))MI17_M;SVP!9'V#Z>(>60"!NPM8CPBM[OPZ04?^\K7-O?)!KR<'`MK;UJ4*6OP-8(-@=YK@5B,S"IXW)MT=->C,84T@VR[OU'<<[UE6#)BXH,8Q)U-MT[-?
C*7)$*MR/263_U%1DX&4D-R_"PNU(%TZ9$&6M77]Y.OA+(SN0:G/0\:R-ML#"SRJK5T.6DTUVRXOUG[CWW5FS3I5]637#=U,4XL(%56QG9N),.*XF);W M/5& ?
A/%)+!*^_A(R>V3L,OY<O,:+/^15M9,/D73R'<'>L?R:GX(%#?NJG1/M[5]*9A*5< ,WCS 6P7!BM1Z;P;3,-?(AD R[7"%<!(HTI,> MCDNE&JE8LCK=R1G-
O]21X$M+VD2KCAE5R4JF,-28C"F+BOK;SL$9PXE2N_03 M-XCP2AP^W: @=3L)!<68ZP':459(D ,$-,>,Q,0I>C&N(0GUR1YGI]Q@">/- M((=+#B AZ,"P;Z2
-0:P%PDW$<,+ME5P=5O]#EC2NB9DFO\GLLI9G)K,1- MGB=^_J9H?%=D3WFY^3'&I[K'Y>GPPS7!U\LR7@VUI740,QM$PV>&#YH1!1I
M";"N+00&KH]FZRA)L!Y"G3M7.).R*.G)}5>8O=M!#=<%AB(R:\G+O&\P1@. M_YU2*EP!_/$]FB8/=]:G$#)Y@F)RH82S\:3*ZI8C>S]K38.BNGJX_Q@]
MPSC$LU48TET9V1;4V2*0:@'CZ__QQ4?92\PQ>63>CTE_R4BU5 MF.1DJ:9\H)*9%&08"DT&=)2^C&V3@=$SU0=L8_(\[@N3CC#%'/>ZM8^CYZ96# M\[/%,-
")6$X!R6%!=:>2#X%0;>V[?741.35N>%DC574-_ 3O*,.@HQFWX8# MFQK$&6#(OQD+'"*BR]$N_/2;ET+9+^)A6|SF#O2IADC'WI3%!#,5Z&-:N^OB M//IZQD@^4+[=F+E#.N%4-
E^LH7).+#-2Y_"4$]]$QTX3% =,I&*Z/R:T30<68 M-/PN0517$[PA]TB*5SZO*%^79I5>$+DT)S?4P5R.MJU7P.*\B<%N-"\,E&1. M?Y,C.CFLAV@950L%D
1*EV"/V)M6Q9@TUUR1^Q'YB%ASP?:HA&U&M'S:.. M190=Q?Q N/(CTQ'L;!*2ZT[#?870F6HS8Q.PWQ1D"B#$F .CT>9 M*RY*5A_*D-5"GI=^BC>U6>CYS[ZWC7T3/%/8!,^4-T'2-
RZ;Z**%>(D?_T(/W\(=/NZ5=@(/[FGNJDR2.]9[M6]P+T5YX/X $%[TINGV=@VM.]?_IX^=0LBs7$89BRPI M%-6=B5^,.'_2^DB3TKG#Z$UN3S1FH>.`]7EV7R%0R:2A+ &F9M U0"K%:=L M
E;0LKIG#]4M /Z@C>_-=7YPI09\.+V*XFL'682KS F3QU)<7L]OQ"3CY?V M512#P,%F\PILZGV!-W_\P|=G9R??X4[)/T^_>VOQ%E)N%KA"%9U$VJNQN8R M2IT &Q5B(DWQY^3Z?
B12*OGG"N-@E#;F/(9XN[!?/9)(O%F(CI-L!9=]#)+|\M;^"3SRWN*C3NVS/.'J.5&8]<"+T$[W&4.#_VW&?-LFW]L:@!ZU8M;2*?/R:* M1 3FP(YLMC!.]Y/0PR^OM_CC!:+RA M2(-
R0QXV5<.(2%9H@:X6$8H;>,G8\ MF/_(D2#IG#PDA47W8%OTCU=35N+=#X&3D\#&,W&[XD8IIE+\QK)%H6.F.+C0 M-\]V;DGOH O]9^CQPVZ*KW)7NSWMV62W)0S:.:*S,.K1W
AS6?.>DI,7E[,$C MKK0"HA#$10L0-V,IC<]PG?7V!+<'9MY50IRK^#H#>I>IV _7R#[QH_SB0N1R M(_M+)GA2]A6E$]=QV^|Q"^"GW7_N$$> 13L@]TI:P8]4[_P4M:!A2BHCPYN^
MH9U1%6]YB7G!N\1T2P)H)TXCQEW+>"%I Y,Z)6=CDV$,CMP54B-!D-'1B!!0 M"!QI7-YA$^-]3,\!B!1_CG1/O<7CH>Q(>VAE\,R(X]HD]4?CUEY!Y'4B,_46D M?E8B@'E501P;Y9.$-?
G8HD5#8;TE*>,P;"OLPHQ0#$/U(C;S)HTIV]$"OJL MCR+&@7!2W!*2QZUXO2YN4:?SNISB59;C"K8_5O&;/>27AH=(&%YA#
M+)'>)&]%DUK(13TV5C+BU\9R$1U*2TIR^4MZL9N2O'N4=9E)3X[1JJ7Y$^W'A*ADS, I;=LA M7X&?B^_L)O=N\DR;:]HJ3*8W=I(GM#KQ?
[*DT=Z.0@;A%&X4XVLG/L@\.I_Y"8D)UF@A7JFL3'G^^K3_*+_@DZ[WAY ME.M5%*^@C^O;)K.P_^Z9&@WW>1JC.'$I>9E(@>]/\Y)>F5[S=.$!2W2.SW]>130+X%Q<=65CR#
M;J(N&,SNZ;+'A_M.Q?TFQ@=QFMV1TB^O25\)2<\#CM^WZ!//:]T6O8%&/YLH[M!K6>\Y2$ '<.2.]C*9TB/R_4Q=A(GHW"HI4%.#O*L$RV1D4G7I]Q:E MC((F'^Z S>;
K>'@%HTQ3VK68?_4&AV!]AG5^K%9)I*;!H%5ZAQ.. MAM 3^/9VM./TR<8UWZ%0S:#*$&6=I[*LM/$.C2KCF@VU1$QM@3EL'U%\4^,1,#2^_\4?
T; TC(8%$5@=_ZFHE6AA?B=N4!"=1:6O2Z#O!> M;-I[^0%B=S+T)L\P=M;PX*%CY60FI298 0Q%)R#O!507)5E'H-,3$2!]V2WA M)35LVFI4F#>C)Z$JP@%[FFNA#QF'Y,Z &Q-
:Q)Z0]D?UP)2C0JA%)[;K-0B. ME29&J6DR8+?G:L)_1D9 <>>>3Q18LHWO7S]*LNE<1B<+@&_-Y+]4+SZP?L(Q MU1/(NP)97Q8#YF6&3%&L\C-
F6,]R+O!NG!37]=GS<+'6+;*.NAJ52+3L'E M;9-<=*A4M2HU3>#;E:BUVCX'0%MQU+#SR;;7N#!.6C7MG&OOM1<0&A04B,$3:VA">&;.7R=Z_
M=DF*F2+^+B=Y(D5*EA%.#QZZ?@!O89HI;<+%R981OAA$AO"S[T'O?/^0X(<3-M94;PB9OZS]EHL-S6*.;>0[Q!2HA?83?%9?4 2(/,0K@#>;@+?XSN6XMN,#N

MD#>8$>"';VLYX"MFQG(;_1D4\^=1@1LJ"I5,:CB|%5+>X0C+_$U1Y:X/KOF M6B)5F" >\S^S"_$5Y|):?T>@UAJ0YK8-9<51TU#1;P)M:AE-/$\PJL3X$0* ML_#"V?JI$}1B>*

{5"I6M|8FU2]0IPM_BZ/N_X(]@ROH^ F4LV@$>[.H2Z7GI MT!.*\VP4%M=1N%[">',)']/<.<:\I$*?'N-O ?ZXN(Q?AX2D*[Y=O)+PA[DGR<:YE,;Q83 $?43&PRJ9CU\.*

*M<_32'*QU_02R+O)8H\+/V1<8=%TU, A.A4F2\"F:H[N@R:X52 MP2CT\G)%|2N6 SN97X55'SD3&D4SSUA,O""K^.IQSYP3 74[(|:IGN#8JXQ0 MXT*P(&7WB9EV4%4OR_0*P^:lE7U?*

*%%|I&A-N HA'(6H&JF:YG95IKW9P:=%KF MP6+H>(X/YB6(6/,M8H>7I:@KCYTHI+9\55!^?I">O;T:30M*8KPMN4G/E=EP M5Y[=*

<@L_D3\EK.M9$1,/=9)],6X#KQRKM'5W,$NF@\%K.&K=$??$AM=7V1'E M0MV6P,0&=WAD$IT.H^NK,#C1)CI#JCI<^^6^NH@"W]UW1C85/9#[N:J/W(0Y M EDWX.?

*|O[2P)8N6>?>X>6:ZZ*R9/|@(DPW;PO;%T.G M8=|FY"N'4P$FPH/=.ZQAYY?G<1Y2H@8CL$\Z?HA-C7E9?16[YC]2[>%&Q2T6 MN53(,P'4FMK>OKGCHFJ1|HDP*)8,$E7D/O,&*

*(%^*U?,?WG?^AWXU3$ 1M16S8$>U=2_;>&(_M2G2RSM)S:.HF=c:G;=Q2H=0=S6)-0AP 30ESE|_E?4 "D#6 M |W-+'COPXQ%LJ0F7?*YR]3,WX|*

<]1&CU)';.,JE%GK7&K?|FX#9UK,34?. M-9_+ZDO#ZVP6>Y-S&L!E>K^1Z;_&(G!"?8(I" GWS|LM=WKHC(.4:?(8+US=OOOGS/3+=4 MGHCQM,=B-4X6I<0EG|'8ZU/9JCV7:((CA!

G0$/I8G"&,XH$|E_&&8<)\)Z M!YDAXP22Q(Y74OX3"<6A#4 IC.%1!.ZH#%<81NK7V4$(^D;AH9DV9EGBD[_H M.@M"/E_OGB%BH_G(G?=ZWX5!'Q"O3"^P,287DCTD88L1Y #%

]O4[?_]M0 MB_T[<7BW;54W%P]"#GO,2G| K.P%,DS7CYF.B4-APS39RQ'+ >+7UVMO[C%% M_O/9=Z>%(#1#P:K*8=+#X<53?EL6[V#=T3+&U%T&5O'+K0/NC#9!WQDNM<2*

M;GZ?7&N:/#G1DPUR9),Z@?(1Q)V3L(LH%T2\]*=*8 ?7,KG"-./L8KSN8"M M[;&\)\6-C<.OQ/RD^ANG&R+1:'"|6;_5 6UDSQ@|M,Z%MK."3TL[>\V=> M_'25EV+I;"O.F&$6,3*E&?*

*VH&G,_TE-=Y6/5PYQM:N42F"6(.HON,!AZ MU<-65;5QG_BC'9,*IC,9Y\=,C^(VK6 Z/XD(RQX:X1ZO),)G7:90/_<(|,,?_M\H(+L;>4#NMA>3O.0=PW|P/W98=D]{L.*

B9/CY=06M26_HGK7L$>Y#BJRH E M.O0|4ZMA?K]PDQ##"4)\Q"[)>,.7%04A#[}Z=PU!E%.51*%|BF1G+'Y3\Z! MATI:M]ZXRL%ZNST\'HJLY;MW?)]O4RK3$PW=69Z9[?

Y_X@0 3A]H|(KE" M,HY7/S7Y;,X4),5 ?YW^LGTH|_\Z8&634'R,_MV:):VJ:*=N:-;/O>14I=?D(K:U")>/ MVABG@I2A|AT$*CL?7MV,|8$YPH'EJB|QP\JA!#J,/3KI9W]_7_%Z\(ZH4*

M]V:OD%U<;.Z;.UVZ6T@Y]D9WE]F49 MT8FM#CB. M9>P"0N$B//RNFW(I/HX 6;$7I.0.)96.|TG)2G2E$5;S)U[&IV$4B- MY[S>[6HH'Z7^\UX VJV[F1V P1'[

*.XE+ZNGH)X(&;0W=&ZCA M/+U.PVTR=]-*ZEV$5 5QQ,19$_]|\AU7DID$N!-Q#,"%YU-B5G>JJX^Y"^&4N]-%.LS<1QBB2V3(P+\%TT8VLYEV.4=AA'7I<&KS@C M<' WXA\(.-*

C#!6R=C^4E|;V+|+P/X>C$AX_]"4\%/W>NE"|.]@PC%"%"E=%"/]"#8RE\%5)O%|.T6M66.B:%V1 X@\C5"R,<#+.QFKZ&ZW;-Y*D M!_$?$Y3B<47>|6 3.ZE"WZA9"*&5(RX?*

GXKJA7,%&/H4/CE!E4T-LI0(="=] MV#H%F$&;KW.L8EJH<+.,]3,("_I@!E,N:K-OC<[JN)A M;3ZP0,HHN<_E#NS'?'US\.BF]RDNGGK>6WVS++26L/;%EL54"B_(,1AM|(*

*MYQ4_!X%@-IJ<{6\X'ZK/1%;,77[^D&U35^_0G+@Y*_.M4>Q 7Y 3&)L$5W6:+P&.Z6"VQ'S8?R3E!1)|&;DL*NGH5_Z$YZC26B MRK>Z^UK=/52'1B5GW5;"1LRS"+7_FY8'WF_N$(A)Z*

M+.N.2?VBS"/=%3XTEWG4-EV4$L/_(#SA.2L@,*% XN /4*IS\ NKI7H8QWZZ M#E#$5'6XS5I^*3:T6SN!<5=/[&&'T@"2PL- M;8,|ON2U*X3 ,%*<56\M")K7N0+99?*

*_:0R(9OIYE!WY1TPU,I3RX7,_^*5 M%'72+,>5#A$_B8&MTB%&,|_+XT@5D044$9F_/7S%1&8R>0E%B/M*R7*V<\. MD)O; NN2@RPO BA-*

*#+XQ\DC8DR47(AK^WP+""W*SP0F@JK(MV)3A=7IOC?K MN5/37RC)*+1Q"OTXBDY4[9W!(=]U.VE\\.VWR,J8OR\" M$I01*DJ;VH.!0/XSNBHE|]XO?*

DH+73F<^.08NXNC=:9.9_$!NQ|NRSO M@VS]VUR]OXIGKU-6A9[_Q1FI[Y^2L_?G>,/:^O"SV_AQF[\]3]AYC:U@+4?-==M7AS: .)EWRI^5%0UPQ&0P MBWU49J)\ 7%&D4U/_YMEG?

*XWX=-/&5]%S^#'>/;^N"SV_AAF[X_)V?N7>/;^ M95GL_4N8O7])SMX_Q[/WS\MB[Y_#/[US_\:9N]?D[/WEWXV M_K(L]OX29N\Q"1R=&*S[3WY8'C>V_4]+R2SP4(69>8),("VU6-*

4\ORJ5#LKV MQ<2%2">& SH&724U##/(C=)675\K=$P;E2,%N\VA'U_(8]E&N[ZD0ZY??GG(% M+=-1M-\N1T=#[2$\MQQLH M_;2@7!"$9FSAYW*.\@[HTQ!49'G9N8O$|?

*>)U_YEC>;^]+(\D=W<(!)\X"4 M:AFC#Z%*G6,-*]6:H20NL1PL=9# ',)1C\Y\SM'&T(HM=U547R'Q5/RSSS@] M=PC(1?^.A7*ZY,F%@16$*_S4YW"!Nf;@(?WX#]"85.&/H(*

*(VQ;G83N5Q>\# MK^]Y/8WWQN1 U=8=')[-*F/(&.W#127K1(Q1$'EJ$307,H#UNC25A!U= MNO!N\$6*R:S8D[P37L.HID*6Q,"FB|&+.YY5|<55E(FS?$F8CEV"Y"N-J7_*

MYV;)/P_%R|M?WOI%LU- $/ ;LMNTD-N8).?NFB<%%+>%OJV,B$[$O;#!">Z M[F?=9]4%,BG8DU67EI TOLQ'$7;"PAR@W/;^Y,QP_JZ2R,.|W795KH8Y=ZJ M03(0|;$\|\7F5?=3

*+S5JJOP"5=Y7]Q$ZTHJ^'^H2O[R(;M_MYRT$ #9KH7W6}8N@KJN?AR+10S>F^LG82/'P9Z"HJ[Z+J& 8(V1I2*X09S^ M=KHE2%Z*L#7_S@&/B^_68AMF]WQP7=(8*

[HK)B9#-.S&;U$2\!S?GVNOXJI M,\:"$RUZG:5O6.PP1>D,#SW8DH3HSTWF?PS;&EP<LV5WZ9IZ[] VUSN63*

M!-7D.DNO)=A9|EX)SO.I"X4|ZE1Y1'KE0[51DVS97.94=N8WA9.$OA31S'$N MER/%G\+(6+'I],6BBT?QOA#G4SU^.D:E?$6=2V" WY;#@7SK0K@$93AD.(998O.XBQHU)

*MV<) .WY|L7XRM5Y4HIG:?IM:WG)S(;8O{1MQ'>>L72J&E] ?)MH@=88J1URL;1BJS6/3VDB7]>[M_SPT+:.B9';)^XWHA,1#EKIM5KR!QD6(O35Y5SLT$0FL'I%?M=*I57\U (4/Q*

MW94@=0QQ0DZW]#/97V9U<0T)22LI9RP#]/G%7X4+"#_^ EFK(^W.P"CVQYUN+9 EP]4D""1UGDUE#%|{'701LA1KRN@C"5=YL ML^++?>59?*

*EKMW6>LN":O:.]6!00\FNC#HD^BP^,BPN1TFE\|$.(4$N3H4Q8LJ M[7@:?(H<2%?I] "HI-#W9U$]1.2A'\.Q$H+K-H6W:K-Q9L*MWE2GW8BG\2CFX MJVRU],C$\K-*

\DK>^GFG'I&1;GVFWIYW%>L*"@W,LEKO%7^W/|ZF$!,O_D_^=%'MG,^2ZL%TEQ53G9CHQ.!, MPI?)3K'F[%Y("I+1@SZ<=6]B@6GD_(L -0;GF167(->F&?+F,<_45"*

*M;|PYYSU3OAA$8.G01 @=$=^EBs:+%|;O++UF3Z(+3BSU) M_E%EN/=|PE>],sLM)!9,K\1V_ B#A@M(" 2;DH8M86/-M) M +<)5/8-H--9@=1+L\(DZ9NJY<3Q>*8X>Y;R2+XB2U'*

F.SE7"#6D M3F9/=6D7;QTEME<:R2E4R7'+F9I8!%/GP1B/;8T>);4EX-(P]K++<$9>(BE+,X M@B[]*K|A)=*\4SV_J*I<$877[2BFE==7YJJ5S+M?:>K: 4FESR$;/W&RV*

*M4:GK[ZNL7-_77$K;@;A1T91U;:=@,M32'S+UB0SH)(_X17L'>5+5D_(,R4/= MN$V+?5N)MJ=:IZX5.)T_[@1ST4E=.4VI:U30&H"R',13IP'<(*B;[ZN:]W9W MV3>(9G5+]M(WYC?*

*262D_IK$\2QDS'>\# MK^]Y/8WWQN1 U=8=')[-*F/(&.W#127K1(Q1$'EJ,

*M7%Q5>99NI62_N3SN@=/AUB%E, N[9YZ7*0:F(AS?NPA/G'L_X>V28>]`)%"P M'5$]SDEIA5OL?%I^?$6Y.,W!>YC+M>WE;# .D0/$UHUE\ITI3N,BA/^%8Y?@,,N>*

*(*AM&'),2^M!+AE_?B&X"]!:)FC:Z(9Y127"R\[-1A>T M\\)9T15'[P"D9RIG($.L G&BNEF)F&#I_{):\L&N T2=L32F\%2RlL[C0[# M52LV5P9EJEZSE&H%+_^,XR8?*

H&7/X+;">C)L%9G;[T%X:S, _<#!R4Y93,!2S MQOJ6,@DR#U,V#?AS6M=W@JI\DZV:#4,G@JO@X6;"N_@7Z/K4!O%,)N"%2U_M&68S;^,'/M\$;!MLAYU=T# ## U^=A(-+@U@Q-,B->;%YM[Q*=\,;^,)%4N@M$%S/4H>'$B+!73CVISK.MV*!<2(4U&D0NH8!/?1QS>/;*<,<3]TZ/:"_M;3^K7>=-/^Z(@R+:8ZR KT; =3"=BFZTRJQ#%'\!3MM81 0JF#0!ZQKDBN26 N ZFM/B%L-HI1)!IV\$7S@TYP.D@T0 >:8 M&,9$%*Z$0"7WL%KK'DQUR0> ^6.9<"65"ITY*]}*#*(4A/Q/^6)-XLP=FMM?D M*MW<$CI?'5RXV#B.>K"GIVX-KTK3D/U(_4 FVA7C:OKG4A3Z9{(4@B<^T7]/5 P@="$Y^A/(CV05M%$=)}L"-]J_M9 -LSF-HT3Q"-LXP;.T M-I:#[<+8+KHA3R*L;L&*B1, &$V21>E@"@A44;YC$<-5N&U')HIF[5COC\-*3 M1I-!!TE.Q5XT!@K_GE_8EK&H4FONSC;=RUCNTU1Y?]@2&5>9Y5R9$^5/# MTY0RO!.9XGF1L ND*G_B!N_*X(=BZKL/HE*1$3-+TC0+)X/#*\YL =Q1>-VF MK{.1$'=-9IM,9O\VO_P/'LDU/5C\&(7??CC2"0:'W0)43&;AK<**ZZ(0M"$P M98??2EC4G@Q0M@IMG$6*&[GO5R2C<$)?]9@+?H[P?+N@->(W.DZH24> %=DZG*

ME0@CD2559+!#!XOBL,P/C[0K3CODU_"_&9C7Q=A$A71U:IR3UN7I_N[-(_;2<=#![KC3B4,P0>P_C5@ C86"0,4L2G*%[" P331 ?6LKDF< M4-]-BNS[]*M#O8\4_A&/&0Y8JFG LZGJ=K4P"KFE MZU(0[!FS-5M>O+DF'j^])&&C/UF8DNUDU4#GL2088F M.0'?:UN]2QJ0^S+@$S__+/TXU2TOA&36Z:0S=K!(1I6_%;953Q?:'ZT^B/-7QI5U) ML?*

*R"1BXA7M;\93<)DQHVBN;*6P%@-.(6NKV"5&A)%994IO#6Z)8N[Z9A5I9_M\?:H[Y!*=O(*9F_@/^=1E.QL5O& LP7T+UQNA@C:.) MP33T2ZS7X9I.;2G]W+&C .Q;TWT:@E0*\WS7;8!;&+B.>5@Y=/R UC)<1K@:P MCBYF-@A&PNQS%+M'TBEA4%T_9TWHS3813?P_;-PGM$'"OZMQ6):N5[]A6*

*M:)C+)>G]T3.3@ZXK)Q01J$KC;I9GN+92TM8&'MM-P1"(=MK##9LSGEE64L+B M_!TY'.00!$,@6HC>>Y!=/S5QG,9^2.*8::Y,)]><#_EXF#5O 1.%,=LU+=A# M'?;3C'*

*G=_R/%R$3]#2+2?7/K.K1_XR78=L' -A?5S5%/2#2034B_&7H(3 MDS"UZ718M_7[2+9LP9==L"U$Q9S0/8C M%?-I08L*KJLG(TZP"Z-L9?=@<#)-9_;"OA?")6/.*

*<0#_3@41$&Z@ U@:: M@/,1+C*S,.I.7X?^RG=Y+X@\PN0S8-FFW4KE[:',)K;=+"^K=&!F'19J0DF%D\)Y,F*R =9W0!^1K&%M4,E0[^-U<'K,GGN2>\?W*

MBEECS#3G#7(SO"54.R=$!W*/ W-(/VN>80LDW'2= 9,/1M/)2 B;+K=R>B2- MM(&FU#=6+^D4>CQLMG]"="#W.$'-"Q/?I2EC<=$WF;LIA4!5?K17LP56M@X=

*M,'(C\0%UA*D5!2S5<#%$]"G.VO@#>XEY]M:.K.-Q4V3))>|'RVI=S*W9M@Z M@=$3,3LJHZ*+F*-.D3BC0\AO(31";W=S,SVL(JMU]P!RWYIBQ;L'F\L*

*M5.#8.DF:P%$O=4QDH5:]HTGHD=N:SS_J40B"S M$HCXY$FNEQ27,O +VU>6'!TC+)&3#7K&+6C%"SID:_<>?)CIV87R5YIWZ0\J9$41R? M.31D'AOO&Y*57*

*&GS9K+VSHIL C#&;4D:"]HZ(G(XR/%V%^-JW4'DO!\UT%W. M4#08U"/5AQ,2S)/%2,*827RYHWRRT0<*!0>GBG6CH!:2CW+.'K/HFI>S4)GW8_,@%]2:IC4DO F#\&KR]HS8.7PD%_,-S.N/JK;RFQ1NV>'!9\'6^S M^\DCV'YWOU,I->0A33Q?-18NZ&3K6"@"'GC&7%*G1>*G< MRTGPF4%"N!8*$PQRP;.C-J9)\BFNT@9_G"SBCGF0&_3,6 1.',]718N+.,WV MUW?)I-$"'R&@A8.4]Y6?D5I]0DX>$);!\>PTVCA^. 37"DC(W9^2I+;3BR7! M*AE#[5-4[P_SB6QN"572=.(/D6\W&9#>E@#HPED9LP\X]53*

M8]^X=\1+@ZQ'E1NMF6DBWH7'!N:O?.+E\4'6TX;7"(2UAU=QG&Z(EVW%VIT< M,'8H.=%V%Z9V>P?-#,ABU1ZB5:8(]T,DC[>5O^65AF6GX[QEW1QF'98&D2XP

M!$>@LB.54IHW^[J*0EK^-;L+Y-]G MG%H2]R[T?T\+W6V]$556G#%2D>JR.!#?D"Z38II43AL+]3S>]<#+&X+O0C\]-M(6/K5@2,_6TO7$8@QQ P"<7$C(!@W3+

*[7!Q6M.B"1N<1W43Z7X8K_)Q>52Y4; MFM#';JNT]0D\9"@UE =.UG&Z',+V6D#*79&0\4P?=<,-M:M:D_V+T"ZI_#Z#8F](`OX"%3Q,>K$#"?A6-,P5%*?9]0R4251S$OT.O7H MI;=;*&^$ MBVMC>V_^C/-M7X*?3S,*8P]7[2"_J]*9KXQ\9@#X$FRV5>'>MF$YO?9C=7. M9%XN0/.?#;2809##+A[5$B00:F#&VHU#46!'07!>43Y9H82'27H$UQW=3$*

*MFH!WB##OY!B%.=II$B=.Z+$H?'A!T,5C.B*A36&X,7=]A>-LVQ//-K,21YDRV65NOMBG;SG!)\(-H#+ HTG:B)81[; &03Y>@VACYF=-M<'^]/:8STWF,_NXP*1EP?U0?= L((AL%S3ZM!]G@SG"EB;2V>&=[0[0O%Q7%'A83:KYG3&C0K@_@::%B5U'E&KTH\BV+?YW= M6TUF'8I\RV82#$K_BV(U>S,1.AH=4 #!&?XL V4)(X?Q,!4'F:(#RY?\>+ M2]G5I?*

BMG8TJM;_'I].P?>"KDP0E(!0>H MO7Y3D,BB'DT5%Z;C.14HXP 'L"H+)>B>JB4QUX1Y-[[+(BN7;55)BP^%"_8- MFJK<#<8;L%@771U6=YF5.8U9'1XB^WS5H8!Q4'=_V$*YH-$]HI]9.?BKAW2 ZH9YA@BS?Q7!FRR"@1Q[S4Q+53)H1ZM./$ M"2RTPNK%E;_H5[@/6)YL,]N7OJ.6PU;"'Z(1?BD*R=I/A=\R97=K<[D=#'T M .,?B6VRL)#3'X.64WON9?GO6V2_?X_)*1N$(84TO8!0MKP]6+E)R/6A54L MGZ]S6>-5F2_6N:FHR^&RIFD.*(?1?IQ9?CNP)+$3RVP,5*@7K9CGP/MX^UZFY:-P29TPSC%/HMEBF94G%L_O*A2V7;(W7RWEB"VC*

MV7TB0:QO\5Y_P/C]1BT$H\#(-1A]*<2X":?) &]@K!53&\;6-M'G.[*1I19X'-MT(]=\7;)UK!0+Z@,%GNRJQ6-51OQI.P K*K2CHVQ%:S,(E &B_T\0O,$J3._M2MKZU

*S6:6[]YZB4L_^LR,.UA_#6U@SO@AH!3_R0(]U\0C9).U:XE"MF3" M"UL7)2+VV*H.%[-4H0^S-2B+]3[^2%5ZQ@2H.&E3]*]Z!5+ ![4M&[4Q*

MXUF)"L(RYQU8T#5]9)C&YX6)40=6J#OH(8*0S3UQSM21VC&$x='DBN1K+D M"-O90K\JLXF]I2=F"2M:.1SKZ\(84+/3-U0_8.QA@07JO%0V:ZEM*8$C!3:.*

M9N46=5M5B.3AA $ G0)X?SAXU6 L1.<+AI@!ST,:.0\IA-S)I8GCV2*CK MQP.R5P01V2'NPV(A 4&;D?3F<8:,3U' 2,K+4@;ALACF=$^RA(;8_0X/I?&> M\>"2T(W YWF X"H!KS?*

43XD'NJPL2:"UW\]Y9P24L;IUTXRC;YN 3S=(U& M3> Y8R}3UL?NB'?/;1\JB?FD4O7]X0#=5=X\B)L/ZUD;@S[%1#LTC&AE[>R MK_0;;FIU8 6I!?HIBY:4_]ZC!GWE)U]_G\WB);?

*9$2:I[_$*Z-TXVCA:%?7^ M9>M[X.N #O#S"GC#*VP$3*)I6C(_V;1WHJW)..P8AMZ_?!^'=4O-5OO:)D[>^ MU\JQJZ*O W)C(,(93GIN4,8L3/)R=44ONYN[XJ4Q7!+ETUCA*

*ME80PPUL,S#Q^'!(XLY9D^4=$[-IDB.^&U]>GFBXQPK+H-AO%3GD;%$A WQV M>>1"JZN0?U'FCBO5R3D)0]8&]I_K:HV"ZI6C*8GUB. MJ}^,>,>M_/K =S#%NJ=DH$*G*

MC7#0!-ZSBU>UAJT$8_,8[<,=63-MWO97D^:M.[..!&*IFU;(,'!95B/_'$<5ENY9XAK.OA0CUN/LD#W>[OIX-Y\% M -2]VUZ2!Q+8.,BO!A3+YQQ;0D3[!U\&*

*(.H5+*O\2&R5M[;Z<$>R_VBTID2 M2H$:B>OO[OJR-[/8G";"^9G.^D_M2/W2#B0@YM3#6AXQI8??9K4Q?*

M039^R!W;9[H<#G;]l#9_6TC6PR&&:#3>F0[OS<;VB;%/T4@+:0H8TAHV"@IY M,UQ&FUHX#P6V%_YO/-]WF__L'NA0KRV>](><-0&WHP)5QA[X"%O.@C2Q19 MW4XN3$-

=V8#]0}T:,!K'MHMB<,9ZF"OX/$.S*O,3@?KH^!Z7[SG@76($\-)= M866(]YIVER#S 3Z'T6U;Z .G9/YVC;@10XI1^,#8"#I"(4>0":U/RK6+^,A M41Q+ USU$R9,.H+)-UY/E)<;>

(48!UB/8=V\O]SUC/&N!^C1V#,X{]\&$]UJ M7E1E\,.?W!V@'M=QCZ\R9-B%H^->P$I.#X=66W-7%EBL+FZN"?4C_CS!=I\ M0: MO

L:N81X\3EN-9#/]6@_H.3D$7@N,3",&E%H$_{76.5]+U4>8+?E MWJ>(O=_2,.E?SI2)'FLEPR)8%XB4#Z5VQ.0VMW>'TC >N_?KVZE8ON@U9'>H!LL5Bf\BRG[05-

)JO9=AYFE5T[(17[H$>7)' M:/[R+G]P!]B6;_O3>X=W^/N:QB3$IB=]U;ML$S/Y,>(,27A QG:%"):TK 3]#2JC%RP M8^4-SN-I*

*?,DBI/XBE@YB@>'Z29K6O2F4IDD]Q$}G]f)'M'"XDT.%#891O4H:T$Y-\,H 2&\1?3D-[M2G:-FJ&^2>_O@RS7Z02?0Y*I;OZW8Q*2E9_$-X3)#<\$E#\ UH/Z\%%SU?KZ MT(#*

<%$"@'M732K;}UJD.B5Y6H-HWP8T/#4MZ.)-$BI>X=TU65ZD3'VHUX M293]V2X*V-8L/9T08+248[2L863X?@(S)/1@;AM/(%M G6;&A"Z-,+91/JR M//.1(46W;N//@^P?*

WC[?!WY,WR0WY^Q_?O__R M^,Z]3-[^]_GYTW5MS?OOGR>_W[TP]-_S+_=AI\6M]^^?4_=]XM/'SY$_]S\:WEU=D1^N_GE MS]'YW=]6=!&?[fSSTP_SSZZF^_^^/(WYS]^_N_O?

*[LYOOC7R57P[55X^WOT M);G[E_/]/IYI;IQ_OGEW_!BIB:]^_^/1^^,7K>?=O/I'>GGZ^1^G]HQ_OJ"G M;__C^^\NWOQ ORP?+C[*_[I]_7*^?W/]J/[M[^\^=OET>JIV_^X3H_/IAZ<*

MX+N3?_[]_,#\[[^_N<K_^8O9>IV<_NM]Y+];ORVVG_YY.YNF M=1$ZD_[@<O3H6M"#7@I_'*^D]%8XR+6=E#5!VKT:[$%/C1106HE(H.9V:\ M:7_]]P__AAU/@@GC'/;(2_3O\?

*W6H9^E)RPHYC?T!)+3H4 MM9RU%:[TB8@N%O-3XF8*Y=W]H[?O?M!0I[)OL4^LE W2S:++! .G$/"&']0F*_%A)N+5:TY[],ICB7^-W M0]RM=>*,8_TA<*0UF >/9A\V)M)U@ENA*

ZC/L]%0H@.O!#];>M)TT_QVP?.M[?'@>-_^89^P+ ^-/D4<"N*?=$JRRSG_@?"G M!S3E#.3]M"QD1UI!8?DX@RBCJIEL)SB6&-3P)S2)PFP75I(ML;!04Y[HZ"* MS ZRP?;2>;JG*

L+PP;1M,I?;65QCP_[F"R-G!N!!!HZCVL1T:>K@2TQ%JZX8 0:6-3>LSZ5X@O:N9Z NI7 MS&6PE^5V7R+G6\CZG_&7QN6[R8Y7QH;/C&O_I#"1T3\0=RVG76.D$"@K$;OO*

*MNKH=B" _B9=T-/338T6!5LPX=]@6S'M5L\XEM[^O^0[==WCA]W]E>+,24Y7"P M7ID#*81ZEQ(1,1%?))==Q*0CQ. .L36GB>&Y%EU2+>JT9FEJV-.0;-2I;_\7 M3,,X%9Y2JE$=""^L-*

*1EE9EL3:^R*NM%+&O1$^9!+9TC665=|,"^A MLJU9R,=K^#1;892*V>I>GNYU.IYX%.?CSY.[<9_O"@B;&QZ9S(LP2%'@RKPL M!/3[$2OP+F[JY#H,&OT7CQI"!@JY_P"K=ZWS#*Y-*

*>?_+';-LAW'VC[MMY4B# M*UU[!)ZF=V# B$)R/O0?HHRE+O.M3%19ZB#_-&5V8 $H;S!0AAR#WSC^^G9D M_9PUWOCY":T)'TO)-*

+Y<.PL!VTE@F'O$,4MMIP9^653EI<';GP15Q=P=!&O MWS..6:@%U\CC?*>K-#_%[S11X6,KE-._3 M*AL:4I0&A/5+VK87STO4[CV@H(^C<-N]T5MMQ^B:\,[K[..WBZKL70HE#*?^_+MJ<&DU9I4S0R+MO"""">6VGDWJ(2/<,AC_]FD MQA"MO#X$XDSO!XI\0!MZWEPSI_?Y-_^YT+UA6)O^4-\Q"@T(_DIRBQ-IB+[M_T&\STQ5T,!:(H@$15SMS&X">#Z8;EN=N-

*RW9]1B]_Y;OG4%4(QE89N3!?,3_; ?%(+D?WA'F, M'J8%.L]@OI+6'/D&6 NWBV375"49*UDQYL)3B\3G5XF.HU+*%XF.KU,=)KH1*?,-ZE>]?$&LF%,XHZK)\.[*

M)RDXPYNE[O7ZU,'MP.S:E1'ZP$ZSY HUR)9C?Y]OKHD;K4,>#.<QU=1G,2" M.Z/^&4,K."(TGK%UZP2 $<Y3.4C4\N&VA%=O.NFBY 1+W+#;)#}O(]-O{T+B MI@T2&AP\"L\[EF M-

*9BX&EF3SXIDA!LT\O1-%82_;4YOD/>]Q>:))]Y+(1S ITL1*8NQDZQJBK% M01M2YXOA9V'B>WZ0*-#Y XPH<18;S0OB?^QU\OQ A92 S8Q1:W6LJ(.:Q;7)H_1"DIK M4RSR6B?*

[LSYJ<)#CW &,KG1J2)W>V/-QGT^'T, \%Y<8 =RJZW"9/SUCFV"4 MR6I=->HX)9_BAN<#\5!&-J1)JM?$(V3#311#C(7NB<_^N"CA;W-68[EGP6T= M\@(6M;UX30KQ%TSI+

()W/I#%:9B,RXO<$*H%.S0'%KF09I$MF+W]VI,2^_MZX1>%HHS%.87{>'U3],:9)-V&ZK'_P(-CFJ^-(DE^!\$)-7MP_{-3*

*M9QE5BIV+*NJ,L):V98H%LM'H8GKU'!H3&GJ08@_YL,EU1%"HYTF0\MJ(@_(F-MW29,W$_F!GY+XX2G(_%.F8!.=Q!48/ %K@MN_I>"T.)IM%+^$]% M- PH#UTCH";VS5]ZA<;*

*[*4I.5MQ.60@9M\-C^_M14ZPH$];SO"56QMZ HJV,CQHNF1,1&-NH8PBCWZSX 5(ENX/8>]WKG20\B(-M A9/55I4& !V-;26_7VZCL:F'-MU/;UGAAG.XB'XBL?8GB>:L'V)Q(G8*

*QN6W$BP9$&AUOIAU3E9K1=\,E.VDF6 MZ8]%_<'Y:?;2+6)83P);DO(:^BBVRE[*MX@%ZT-Y25-)B(UIVLG(_(4#]) MPC@*%"]G;N@M*NC.5IO?3KNWTY+7@KU%$ 8G75-;I[+ZL*

*C1=\8=OJ*_23* MGYA7I\6RG5]%H2OYYR7[4\SVS!--E[9&04"BAJE.0"6>]Q>AX"!.>4AO8]_S M';J]<7;-B&S,.I#"07(:6PYI[16FG#XP3#/CVAZ7*V?#_E=Y.';F%G0#Q)T+*

*MVR7&-9XJ4*_1.$>33T7[^D7@N)DF,&@/W[$$]M.(%7!W40'S?GJGI/.Z&U[O M'H69SK;@^UIAH9P,5>W73B6\1R<-?*SH/#$,U&?<*D);BV'$9*HK-*

S/7'@ZL+5FQ]3ACL{5#EF&J1$[I9XG,9^2.)XYC*#'?N6FD#+H&#I3D6 OP R6.^,5$SO9(HSX'RFQ.T&S&OZV^>10X"YV-H@'T,'YAE"?EZ)1{/%,JZ^']PBB2?XCI M"JR2;1DRNC-

*S=++Y<@N^)MOJ'=CQMOHO%LR@!F 9\69V>?= Z5^G*X;H7A2=.@ M%OP V/$9:-A.I8)B?QYX1%',R^IRX4"Q7'!DV5(Y?KK-*7,[N>N0(F%?F;_1/AS:T2T*^IRX8"Q<$?*

*>)@ICR)#F5>M7!.NIO*Q M"#?W@0_]AD(%(G+"8Q"MT45T\!0AS!'"$:QYEA<0K@!F9ZZ;,-(M"3\G*=\$% M0P$@:MVW;.E0(;AY, KQRD\XIKY\HJ@/M=O91*I^-*

*<8W"$UPN&fVQI#SA3B M]/WP]N?L\=ZG&0=.F8#7T5?*Z;4N\%39W4ZU@IL_#&TQ6IW@6*4,;!]C781) M)&AGH2020^#O)"W0(PLI//#T/?>53>\O+9GB-*

*WZ8<8ZQ:N?]C4P]WYL"44G MW*BU@DZ@6Z(Q)-4(WT94PH4 M0&JUQT15Q)R_P 896ME?,@KD6&[M5}@GX7T]#&AE)G!KZA+=,_]T$\(P#;K*

*M,9%FN^76<1,'9" _9T++*B!/(IFB0|FI>BT?^NVT0N/D:1!]4/ F#>[Y9]]B'. M(?U*/@)D2?LPT4O'_3)???+H%Y(X MMWI@=]O3R_DGM1!2;\FG:+YUJ5H*@$%Z4A1@@L]\]-*

*>AO^+#'1.9FVV9TZB MP'=]$G>V1#,<@'H R%*GLQ9 IIW>\S1E+Z=ZGE@Y%M!83M.W2P43"R74 VW M6NWYFD0!G89.(CX!%Y[08.1OMF OJ%%+O7.CSGH|C?*

6U,/Q5@U'.=0@PO#I,'<{J#]] M5N%@#[;'8\-P0RE:-WHTW+N6*]TF^^2'_B;=@%&OOAY2I5DK^1HI@BE!SO!Q*

*M'F%)7UMOE*2O[QBZU'O\ZM+860#HV&@4{L=QFL^R/8_I'NGPAK@[]9.BOS*O MG^'M$XI+R).(>_,I\9:1,?D;";SC;7G/%-$;0A^8DQ^\)RN&:,WT\SP%C_.+*

M/,8U6P\Z!,?;R$A<+3VWM"]LF$ &Y3O-LMVP]-MM&@9?NW"7Q@MB+\.3U*& M4>AN^7ZY^YKMR)9SKXL&9N(30/#,R8\RQ6>'=@MJ@L@'6E@TH4]>/6F3&[PE M*'2^Z)*

*(G)*VDA?*5+26"&HOK'I.;KM73.X+/>F1QYO=994RXSL\U='KKHLPO.2EN>[0S77WU']/M/^[$M6M M]GXW-]BE2Y,ZP9+0C07E)@6#4B:EIMGDI $9;P'%+2OZK0409L57):U=[.O?*

*M*RY;=:.F)#OT&FVMA:^.P0/K(*=XPW:)[=$>_RY/"69Y@\'2E!)GKUT0NCW M,96%D253+4RD]1$K1(%+ZIEU[W"V69+^/*+7I/E"MG^OCL;JD^/4 7D E4G_*

*MD+5$SFHHO@."Z[S]\TY&*ZB;MI[*I9R -]TYJKC!EXY.3!['KI F[3LEMLG^! MO.O.M,_%/&'I)YG[P *KO.1B34*E-S.FV>,"WJP),W?!*

M:NEV40^VOO_334OU.?5M4PK#+0FJ:UZ(.U0)Q=."/=1G8$<\@.N5&2$&^%/ MJYY<\SA9JR5_*29_*29_*29:2:W[4(W#>7O[LI)F!7BC=O'|L8!*8!&"?;G_$%?G;N?%L@X:.\]<?2*

*SN4&!0^*7K28=!%3AP0781@]Y/1(MD[N(^LE6XV*X;PW4^W8CPG=2!>G"AROU!8V\U$WFQ1,!*%]8N.QD]*&<, "7 MW(8$#,$%<1RCGC#V$+AS?FX6?[]G.PJ2XPE22R9;/1V5)*

*MA?GAMKWCO%0KP/, ^PK/%RY%H-/@KRXEX89CZ?'[MEY3LG82 M,MMP/3]?Y,*H= AEWTZ#/[*=PU6!F'=H74.)$W -H>9#"K\+-34+-5](B=+1U MYCY+#'C(S.M2 ^FH5X.NS0?*

*M%=1/]63'[G0S/F;UTHD%WTW ?D6;A=NJHJ1L6;&Q=X+@*f/;"X_?K4OIPS<-MN!PCGS<[LMNSQWL2@C=B;PP^@;,D(POZ?\KQ.)U\-TEML(Z--F"QT*>0R3.F M+-Q*

*&L.2Z35S&N&?, ^W7G=_YK1"CQWR9?D>4OY9Q@H"GA37\Z,.OIG!H!'N% M'ND"7:G^^>8C1+V45*5C='W21^^B5@;+Y VD\J2=W?D#B)_]SJ>$98EFI4S4AE'R+E>;4 M]#*

(RL91M'[#%C'[64Y\5@L\FQ_71IN$[4.G?9?%401QGE4)$C0_RKY'4M $W M6B@ 5BGSDHX&8U=G3MH@PP73>_:\,K;K-](F)5?%5.A!>D5 !^S#=8(@\'V*

*MQ'4[Y0!++,&QT'R]J17A;&BM=!++%;;<+D #1/@P":FCT)I=[;*I#;]PJ)EH! M?]_CW/O,ZA;#-SB@I D2PZ1%7=6;," "MZ<,)*-J6^-G9)B4#F!,R >8VY4R2\]J4Q:\5S*

M$FWXU6Z^X:\,]7@&@JF9>;C1@4%'A6E'CEGM(B(TY9@UZV% ?,3<\?-QI%, M4&\" &BJBS4TG8@N:*W+Z\C8&]^F7DA$:S%P3?C9B(PFWBN%C5.QIK4?SPNU%37++!-G(9/?

*R/430,2 M%SF0B]#*5(+OTXQ'37KYAZ!><([5MFCDW@'8,IMY)EFJN;@W8XAVNCULM:90- MK8U+,"08U,6Q62^Q/=X,$W]]EQ!O]D"HLR;E7&4+!#[%5K:+JJ-ZL5J8M;JZD M&O24*

=^;]PY(;+GZJ!Q8A=D["ROS3HD!GUUKP4SN(1C$7MW@9IXGJ^E8A0 M;HP)=Q>4W!>]; B)Y^',>W!"EP|\ -]+U0)IXMQM)2+FA)2Z8\T!9YH-ZW-=*

*MFO+Q+KE,6LU*R&:L.G..*A(5J; ' ^VRPRX+ZH>O?.X%=GC=@3=MOZZ C[N"4 MAEVQ:Y'QKTJ@K3!DNPT;=5+91*;[*& XQF>_I_SB)\4\%KYQ5LU$TG* M 5BJA6HLKNN*MA-*

*"O1I*91WSB[3J@:\#,,0P5OZR6NJ$=BC%_Y#MW>,%RI'QEAZKYD,)\TJ<.QZF6AI33"ZE*JH('OT&;KVP_1%_MB.OL=(ETC9!*U(.IMV+NTH.3D$7@N:*:.8#X4@@$.=#088B,3%*

)0:,CQLB5 M(5.U/#:4I!3.Q)2DG%X E55]W1([556' -#3LUU26ZNM$A (I+**YW.C,%O7 MBL8[7!]9V6E1_9 XYGH.[+D1(1M^LHL1R#[XZ)$Q!X?U>%B.OI:W-4@L;E:

*M/_"Z7+_5 nT4:RTW@.H0!_*18+ ^F:#.7V>G8M]181 8%R]89.BA2 M8H%42X+QC_^1$CMUD]WPL/V7#HGNXF>#>+#VZBBPN%F<.6K#RZ\BY8@4*5O>& M/+?*

CAE"?,&5\$7K^@^^E3A!I+S8;]JFI[P2"O0A-4_\@S!0-3+]$XZR8DQEW MMN?.9N=ZGK^WBD+"^X%9#,2%L%"R6WU#<3'5$,LD&PA9,7)B&,((-JDN,I M"9GJY@PD,/_U[3^A^1C\?*

E7J'XD$&,*;UBO9#L=ED?>DN&<]UC;E7^"$_+;! M@N6]+8T39!M:JCI1S(N&>CY;]&P8H\;BZ->DXF$4,0/B+;,#*L{3@S-2$KT*

*MW24D)MP@+6#BE0VH^VO7:"==0(YOW:V%X39JH+%}YZHTH[NF'71U@ZQ"?&37 M22A0-6(YWH1S2I?I)/SZ&_2#1CUZNLA^2ZMY&OL&.?-2X.(!*2OK;>*$E? MWS%N;J.XA?*

C9H;RIW9Q>\X=1-CJT2.%,JZ@A5[FQ:P0]05UC&P6&@@AX5ZJ M=4IQ)PLANA^PF(I/$21>L;3,_;?L6^RTA1)EI!M^2NLW"IF,^-&Z!:;3(C6N MM%,!RO!,3'4WZ\/-

YU#V;_98R>_E%_KS-(D3}_3|<&TO&WH(;B0:1ERV+TF(.M"@@&U^|=A)GY.R7;?"R@3)>%)9F0^Q,VT9JER5U$_3_L<[_"10NE $/]\1"M?2E?P8Q9@CG-DO9>-

*HY@@6BK&W+UV2B&.PU70XJN<>G =?R"NGRP?U@&4V%L M%\T F]$#^\2@DZL(=#*6596(4"_B30MI&'*YS3]-*?/;&&)^5!2T5NM^P(M@_?;6^FYFNGTIKB@LH'B>E9S/E_*

:=,W3T38V)SW?.T!"0G&CESE#)L?<<<,]0$=Z<(=YK M8^DGW CN&XX"]282KSO*5M1'PEY%$L*`L*DWDW]VD[MK$F2DB^_|^V64J_W4 MNUKHL]\#(HJ!{91?*2^[Z&?*

*7&)_T"\3#'5?V5'QI38J6$M [#TY7LO=\VW<,9#PC762Q_O-W__M2G%;.?XJN<)XF]SZ_EG1,6]QZS]9J2M9/P(@_,?,6^FYFNGTIKB@LH'B>E9S/E_*

:=,W3T38V)SW?.T!"0G&CESE#)L?<<<,]0$=Z<(=YK M8^DGW CN&XX"]282KSO*5M1'PEY%$L*`L*DWDW]VD[MK$F2DB^_|^V64J_W4 MNUKHL]\#(HJ!{91?*2^[Z&?*

*7&)_T"\3#'5?V5'QI38J6$M [#TY7LO=\VW<,9#PC762Q_O-W__M2G%;.?XJN<)XF]SZ_EG1,6]QZS]9J2M9/P(@_,?,6^FYFNGTIKB@LH'B>E9S/E_*

:=,W3T38V)SW?.T!"0G&CESE#)L?<<<,]0$=Z<(=YK M8^DGW CN&XX"]282KSO*5M1'PEY%$L*`L*DWDW]VD[MK$F2DB^_|^V64J_W4 MNUKHL]\#(HJ!{91?*2^[Z&?*

*>P9.#.XZ839ZO3GU*7/8;\9&%WE0>K.U%G,^^W8_ARI2@5ZXXX1>VOV@M_N9K7DL8M!;1OCA.+(*.M[205[QAS/%I_GG.'I$KLRDO'H9/?(R>N1E] C0_>3X]4!{(ZQ>_QE>WOYA MZX_!W_YA==QZ>?DW\I=__6HN=61B&25.4(KN>1H%6\\/TJ1\OKY@&';.K]6R MQ^JKC;IAA 91D%L0OS1"U*VZ4FB$"/#8#_RMWS6)$Z8VDN+917:Y]V%&\:!] M7^1{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|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end XML 81 ea0221025-10q_biomxinc_htm.xml IDEA: XBRL DOCUMENT 0001739174 2024-01-012024-09-30 0001739174 2024-11-12 0001739174 2024-09-30 0001739174 2023-12-31 0001739174 2024-07-012024-09-30 0001739174 2023-07-012023-09-30 0001739174 2023-01-012023-09-30 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0001739174 us-gaap:CommonStockMember 2023-12-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001739174 us-gaap:RetainedEarningsMember 2023-12-31 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-01-012024-03-31 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-01-012024-03-31 0001739174 us-gaap:CommonStockMember 2024-01-012024-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001739174 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001739174 2024-01-012024-03-31 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-03-31 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-03-31 0001739174 us-gaap:CommonStockMember 2024-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001739174 us-gaap:RetainedEarningsMember 2024-03-31 0001739174 2024-03-31 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-04-012024-06-30 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-04-012024-06-30 0001739174 us-gaap:CommonStockMember 2024-04-012024-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001739174 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001739174 2024-04-012024-06-30 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-06-30 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-06-30 0001739174 us-gaap:CommonStockMember 2024-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001739174 us-gaap:RetainedEarningsMember 2024-06-30 0001739174 2024-06-30 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-07-012024-09-30 0001739174 us-gaap:CommonStockMember 2024-07-012024-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-07-012024-09-30 0001739174 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001739174 us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0001739174 us-gaap:RedeemablePreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001739174 us-gaap:RetainedEarningsMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2022-12-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001739174 us-gaap:RetainedEarningsMember 2022-12-31 0001739174 2022-12-31 0001739174 us-gaap:CommonStockMember 2023-01-012023-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001739174 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001739174 2023-01-012023-03-31 0001739174 us-gaap:CommonStockMember 2023-03-31 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001739174 us-gaap:RetainedEarningsMember 2023-03-31 0001739174 2023-03-31 0001739174 us-gaap:CommonStockMember 2023-04-012023-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001739174 2023-04-012023-06-30 0001739174 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001739174 us-gaap:CommonStockMember 2023-06-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001739174 us-gaap:RetainedEarningsMember 2023-06-30 0001739174 2023-06-30 0001739174 us-gaap:CommonStockMember 2023-07-012023-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001739174 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001739174 us-gaap:CommonStockMember 2023-09-30 0001739174 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001739174 us-gaap:RetainedEarningsMember 2023-09-30 0001739174 2024-03-15 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-03-152024-03-15 0001739174 phge:PrivatePlacementWarrantsMember 2024-03-152024-03-15 0001739174 us-gaap:CommonStockMember 2024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:RedeemableConvertiblePreferredStockMember 2024-03-152024-03-15 0001739174 phge:MergerWarrantsMember 2024-03-152024-03-15 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-gaap:CommonStockMember 2024-03-152024-03-15 0001739174 phge:MergerWarrantsMemberus-gaap:CommonStockMember 2024-03-15 0001739174 2024-03-152024-03-15 0001739174 us-gaap:RedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-03-152024-03-15 0001739174 us-gaap:CommonStockMember 2024-03-152024-03-15 0001739174 phge:APTsStockholdersMemberphge:PrivatePlacementWarrantsMember 2024-09-30 0001739174 phge:APTsStockholdersMember 2024-09-30 0001739174 phge:APTsStockholdersMember 2024-01-012024-09-30 0001739174 phge:MultiPeriodExcessEarningsMethodMPEEMMember 2024-07-092024-07-09 0001739174 phge:MultiPeriodExcessEarningsMethodMPEEMMember 2024-07-09 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember 2024-07-092024-07-09 0001739174 phge:PurchasePriceAllocationMember 2024-03-15 0001739174 us-gaap:CommonStockMember 2024-01-012024-09-30 0001739174 us-gaap:RedeemableConvertiblePreferredStockMember 2024-01-012024-09-30 0001739174 phge:MergerWarrantsMember 2024-01-012024-09-30 0001739174 phge:MergerWarrantsMember 2024-01-012024-09-30 0001739174 phge:MergerWarrantsMemberus-gaap:MeasurementInputSharePriceMember 2024-09-30 0001739174 phge:MergerWarrantsMemberus-gaap:MeasurementInputExercisePriceMember 2024-09-30 0001739174 phge:MergerWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001739174 phge:MergerWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001739174 phge:MergerWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001739174 phge:AdaptivePhageTherapeuticsLLCMember 2024-01-012024-09-30 0001739174 srt:MinimumMember 2024-01-012024-09-30 0001739174 srt:MaximumMember 2024-01-012024-09-30 0001739174 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001739174 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001739174 us-gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2023-01-012023-09-30 0001739174 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberphge:MeasurementInputUnderlyingValueOfCommonStockMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberphge:MeasurementInputUnderlyingValueOfCommonStockMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001739174 us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001739174 2019-08-09 0001739174 2019-08-092019-08-09 0001739174 phge:LeaseAgreementMember 2019-08-09 0001739174 phge:LeaseAgreementMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0001739174 2021-08-312021-08-31 0001739174 phge:IsraelInnovationAuthorityMember 2024-09-30 0001739174 2022-03-312022-03-31 0001739174 2023-03-312023-03-31 0001739174 phge:CysticFibrosisProductMember 2024-01-012024-09-30 0001739174 phge:CysticFibrosisProductMember 2024-09-30 0001739174 2022-06-232022-06-23 0001739174 2024-01-182024-01-18 0001739174 phge:MTECMember 2024-09-30 0001739174 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-08-16 0001739174 phge:LoanAgreementMember 2024-09-30 0001739174 us-gaap:LineOfCreditMember 2024-01-012024-09-30 0001739174 2024-03-192024-03-19 0001739174 phge:LongTermDebtsMember 2024-03-192024-03-19 0001739174 phge:HerculesCapitalIncMember 2024-09-30 0001739174 srt:MaximumMember 2024-09-30 0001739174 srt:MinimumMember 2024-09-30 0001739174 us-gaap:CommonStockMember 2024-07-09 0001739174 2024-07-09 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-03-152024-03-15 0001739174 phge:PIPEMemberus-gaap:PreferredStockMember 2024-03-15 0001739174 us-gaap:RedeemableConvertiblePreferredStockMemberus-gaap:PreferredStockMember 2024-07-152024-07-15 0001739174 us-gaap:CommonStockMember 2024-07-152024-07-15 0001739174 us-gaap:PrivatePlacementMember 2023-02-22 0001739174 phge:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember 2023-02-22 0001739174 srt:MaximumMemberphge:PreFundedWarrantsMember 2023-02-22 0001739174 srt:MinimumMemberphge:PreFundedWarrantsMember 2023-02-22 0001739174 phge:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember 2023-02-222023-02-22 0001739174 us-gaap:PrivatePlacementMember 2023-02-222023-02-22 0001739174 phge:PreFundedWarrantsMember 2024-09-30 0001739174 phge:PrivatePlacementWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0001739174 us-gaap:CommonStockMember 2024-01-012024-09-30 0001739174 phge:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-09-30 0001739174 phge:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0001739174 phge:PrivatePlacementWarrantsMember 2024-01-012024-09-30 0001739174 phge:PIPEMemberphge:PrivatePlacementWarrantsMember 2024-09-30 0001739174 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-09-30 0001739174 us-gaap:PrivatePlacementMember 2024-01-012024-09-30 0001739174 phge:March2024PIPEMemberus-gaap:PrivatePlacementMember 2024-01-012024-09-30 0001739174 phge:March2024PIPEMember 2024-01-012024-09-30 0001739174 2023-12-312023-12-31 0001739174 phge:PIPEMember 2024-03-15 0001739174 phge:PIPEMemberphge:AgentsWarrantsMember 2024-03-15 0001739174 2024-07-092024-07-09 0001739174 2024-09-162024-09-16 0001739174 srt:BoardOfDirectorsChairmanMember 2024-07-112024-07-11 0001739174 2024-07-112024-07-11 0001739174 phge:IPODecember132018Memberphge:PublicWarrantsMemberus-gaap:WarrantMember 2024-01-012024-09-30 0001739174 phge:IPODecember132018Memberphge:PublicWarrantsMember 2024-09-30 0001739174 phge:SPAJuly282021PMemberphge:TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMemberus-gaap:WarrantMember 2024-01-012024-09-30 0001739174 phge:SPAJuly282021PMemberphge:TwoThousandTwentyOneRegisteredDirectOfferingWarrantsMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:MergerWarrantsMemberus-gaap:WarrantMember 2024-01-012024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:MergerWarrantsMemberus-gaap:WarrantMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:PrivatePlacementWarrantsMemberus-gaap:WarrantMember 2024-01-012024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:PrivatePlacementWarrantsMember 2024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:AgentsWarrantsMemberus-gaap:WarrantMember 2024-01-012024-09-30 0001739174 phge:MarchFifteenTwoThousandTwentyFourMemberphge:AgentsWarrantsMemberus-gaap:WarrantMember 2024-09-30 0001739174 us-gaap:BlackScholesMertonModelMember 2024-09-30 0001739174 us-gaap:BlackScholesMertonModelMember 2024-01-012024-09-30 0001739174 us-gaap:EmployeeStockMember 2023-12-31 0001739174 us-gaap:EmployeeStockMember 2024-01-012024-09-30 0001739174 us-gaap:EmployeeStockMember 2024-09-30 0001739174 us-gaap:WarrantMemberphge:PrivateWarrantsIssuedToScientificFounderMember 2024-01-012024-09-30 0001739174 us-gaap:WarrantMemberphge:PrivateWarrantsIssuedToScientificFounderMember 2024-09-30 0001739174 us-gaap:WarrantMemberphge:LandlordWarrantsMember 2024-01-012024-09-30 0001739174 us-gaap:WarrantMemberphge:LandlordWarrantsMember 2024-09-30 0001739174 us-gaap:WarrantMember 2024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001739174 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-*

30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001739174 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001739174 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001739174 us-gaap:WarrantMember 2024-07-012024-09-30 0001739174 us-gaap:WarrantMember 2023-07-012023-09-30 0001739174 us-gaap:WarrantMember 2024-01-012024-09-30 0001739174 us-gaap:WarrantMember 2023-01-012023-09-30 0001739174 phge:ContingentSharesMember 2024-07-012024-09-30 0001739174 phge:ContingentSharesMember 2023-07-012023-09-30 0001739174 phge:ContingentSharesMember 2024-01-012024-09-30 0001739174 phge:ContingentSharesMember 2023-01-012023-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-07-012024-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2023-07-012023-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2024-01-012024-09-30 0001739174 phge:RedeemableConvertiblePreferredSharesMember 2023-01-012023-09-30 0001739174 us-gaap:SubsequentEventMember 2024-10-172024-10-17 shares iso4217:USD iso4217:USD shares pure utr:sqm iso4217:HLS10-Qtrue2024-09-302024false001-38762BiomX Inc.DE82-336402022 Einstein St.,Floor 4Ness ZionaIL7414003+972723942377Common stock, $0.0001 par valuePHGENYSEYesYesNon-accelerated
Filertruefalsefalse1817660223537000149070001114000957000366500017680002831600017632000960009700000349500065810003902000152870003166400073970005998616618400016297000037896000308100059980000250290007279000564100018281000140230003248000215400087560006053000801000801000-11328000-7795000-27838000-2007600084000890002189000270000500057400086800018840002055900024417000332000382000-1104000103400096420000-7898000-3204000-2065600080001000022000964200-7906000-3214000-20678000-0.311.30.324.29-0.311.32.454.291636612260587749944267481965816387633605877411294880481965847233203000166048000-16297000030810004047012561000916497100032270003228000477827500050001000751819000190009000900900021641719859000541000541000-17327000-17327000256887324200006125162400017074900-180297000-954400098081110001000770007700-256887-32420000256887324200003242000044710004471000256887324200007105973500017082600-17582600027425000-109152-13775000109152001000137740001554298290008290009642000964200014773518645000181766026000185429000-16618400037896000312298720001578380000-13680100021039000176000319950129300012930001750001750000-6361000-6361000344293720001593060000-14316200016146000157000127979610005858000585900027100027100-6411000-6411000472273330001654350000-14957300015865000195000195000-7906000-7906000472273330001653000-15747900081540003214000-20678000882000659000108300064100045300047800029300060004000-24417000732000197600014500080100021300-6790000-2691000241000-11690000335400018100060000-30690000-15044000-663000200000072000190004300071600019570002874500021269000507000333000748500060001900013000107470002929000387720004223000879800088640001100037000158640000322940002465100023393000235700002245000011140009430002465100023393000143700014550001000050000110005000168500030410001261000020000000style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 1 – GENERAL   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">A.</td> <td style="text-align: justify">General information</td></tr> </table>   BiomX Inc. (individually, and together with its subsidiaries, BiomX Ltd. (“BiomX Israel”), RondinX Ltd. and Adaptive Phage Therapeutics LLC, (“APT”), the “Company” or “BiomX”) was incorporated in 2017. The Company’s shares of Common Stock are traded on the NYSE American under the symbol PHGE. The Company’s units, consisting of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (“Units”), were traded on the NYSE American under the symbol PHGE.U until a mandatory unit separation of the units became effective on October 25, 2024. Certain warrants were quoted on OTC Pink under the symbol “PHGEW” and expired on October 28, 2024.   BiomX is developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, focusing its efforts, at this point, on cystic fibrosis and on diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The Company’s headquarters are located in Ness Ziona, Israel.   On March 6, 2024, the Company entered into an agreement and plan of merger (the “Merger Agreement”) with APT and certain other parties, as a result of which APT became a wholly-owned subsidiary of the Company (the “Acquisition”), as further described below. Additionally, on March 15, 2024, concurrently with the consummation of the Acquisition, the Company consummated a private placement (the “March 2024 PIPE”) with certain investors pursuant to which such investors purchased an aggregate of 216,417 shares of the Company’s Series X non-voting convertible preferred share, par value $0.0001 per share (the “Redeemable Convertible Preferred Shares”), with each share of Redeemable Convertible Preferred Shares being convertible into 100 shares of the Company’s Common Stock, after giving effect to the Reverse Split (as defined below), and warrants (the “Private Placement Warrants”) to purchase up to an aggregate of 10,820,850 shares of the Company’s Common Stock, for aggregate gross proceeds of approximately $50,000. See Note 1D for further information regarding the Acquisition and the conversion of the Redeemable Convertible Preferred Shares.   On August 8, 2024, the Board of Directors approved a 1-for-10 reverse stock split of the Company’s shares of Common Stock (the “Reverse Split”), effective on August 26, 2024. See Note 10A for further information.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">B.</td> <td style="text-align: justify">The war with Hamas and Hezbollah </td></tr> </table>   On October 7, 2023, an unprecedented attack was launched against Israel by terrorists from the Hamas terrorist organization that infiltrated Israel’s southern border from the Gaza Strip and in other areas within the state of Israel attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. In response, the Security Cabinet of the State of Israel declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In addition, Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, has attacked military and civilian targets in Northern Israel, to which Israel has responded. Moreover, Iran recently launched a direct attack on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. Such clashes may escalate in the future into a greater regional conflict.   To date, the State of Israel continues to be at war with Hamas and Hezbollah and in an armed conflict with Iran and its rebel militia groups.   BiomX headquarters are located in Ness Ziona, Israel; as well as most of its operations. In addition, most of the key employees and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect its business.   While a few employees of the Company were called to reserve duty in the Israel Defense Forces, the ongoing war with Hamas and Hezbollah has not, since its inception, materially impacted BiomX’s business or operations. Furthermore, BiomX does not expect any delays to its programs as a result of the situation. However, at this time, it is not possible to predict the intensity or duration of Israel’s war against Hamas and Hezbollah, nor predict how this war will ultimately affect BiomX business and operations or Israel’s economy in general. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">C.</td> <td style="text-align: justify">Going concern</td></tr> </table>   As of September 30, 2024, the Company has an accumulated deficit of $166,184 and has incurred significant losses and negative cash flows from operations. These are expected to continue in the foreseeable future. The Company plans to continue to fund its ongoing operations, as well as other development activities relating to additional product candidates, through issuance of debt and/or equity securities, loans, and government grants. Management believes that its current funds are not sufficient to fund its operations for at least one year from the issuance date of these financial statements. Increased research and development, clinical, or operating expenses may require additional funding or expense postponement. The Company’s ability to raise capital is subject to market conditions and other aspects, which may affect the terms and availability of such funding. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of such circumstances.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">D.</td> <td style="text-align: justify">Merger Agreement</td></tr> </table>   On March 6, 2024, the Company, entered into the Merger Agreement with BTX Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“First Merger Sub”), BTX Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Second Merger Sub”), and APT. Pursuant to the Merger Agreement, First Merger Sub merged with and into APT, with APT being the surviving corporation and becoming a wholly owned subsidiary of the Company (the “First Merger”). Immediately following the First Merger, APT merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity. APT was a U.S.-based privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infection. As a result of the Acquisition, the Company is expected to have a pipeline that includes two Phase 2 assets each aimed at treating serious infections with unmet medical needs.   On March 15, 2024, the effective date of the Acquisition (the “Closing Date”), APT’s former stockholders were issued an aggregate of 916,497 shares of the Company’s Common Stock, 40,470 Redeemable Convertible Preferred Shares and Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock (“Merger Warrants”). Each share of Redeemable Convertible Preferred Shares is convertible into an aggregate of 100 shares, after giving effect to the Reverse Split of Common Stock. The Merger Warrants will be exercisable at any time after the date of the receipt of BiomX stockholder approval at an exercise price of $50.00 per share and will expire on January 28, 2027. In the event the Redeemable Convertible Preferred Shares are not converted by the earlier to occur of (i) the time that meeting of BiomX stockholders is ultimately concluded or (ii) five months after the initial issuance of the Redeemable Convertible Preferred Shares, the Company may be required to pay to each holder of the Redeemable Convertible Preferred Shares an amount in cash equal to the fair value of the Redeemable Convertible Preferred Shares. On July 9, 2024, the Company’s stockholders approved the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock and the issuance of shares of Common Stock upon the exercise of the Merger Warrants.   The Redeemable Convertible Preferred Shares are entitled to receive dividends on shares of the Redeemable Convertible Preferred Shares equal to, on an as-if-converted-to-Common-Stock basis, and in the same form as, dividends actually paid on shares of the Common Stock. Except as otherwise required by law or with respect to the Redeemable Convertible Preferred Shares protective provisions set forth in the Company’s Certificate of Designations, the Redeemable Convertible Preferred Shares does not have voting rights.   At the Closing Date, the Redeemable Convertible Preferred Shares were classified as temporary equity in accordance with the provisions of ASC 480-10-S99, as they included clauses that could constitute redemption clauses that were subject to the Company’s stockholder approval and outside of the Company’s control. On June 17, 2024, the Company filed a definitive Proxy Statement on Schedule 14A with respect to a meeting of stockholders to approve, among other things, the conversion of the Redeemable Convertible Preferred Shares into shares of Common Stock. In addition, the majority of the Company’s stockholders signed a binding support agreement that contained their commitment to vote in favor or deliver a written consent regarding any stockholders’ matter in the stockholders’ meeting which took place on July 9, 2024. These circumstances led the Company to determine that the Redeemable Convertible

*Preferred Shares meet the definition of permanent equity as the Company is able to control the redemption. Therefore, the Redeemable Convertible Preferred Shares were reclassified as equity. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Company's Common Stock according to beneficial ownership limitations set by certain investors. The Merger Warrants are classified as equity, as they are indexed to the Company's own shares and meet the classification requirements for stockholders' equity classification under ASC 815-40.   Concurrently with the consummation of the Acquisition, the Company entered into a securities purchase agreement with certain investors, for aggregate gross proceeds of $50,000. See Note 10A for further information.   Immediately following the Acquisition, and without taking into account the PIPE Preferred Shares and the Private Placement Warrants as defined and described in Note 10A, the Company's stockholders prior to the Acquisition owned approximately 55% of the Company and APT's stockholders prior to the Acquisition owned approximately 45% of the Company on a diluted basis.   The Acquisition was accounted for in accordance with Accounting Standards Codification ("ASC") Topic 805, "Business Combinations," using the acquisition method of accounting. The Company was identified as the accounting acquirer, based on the evaluation of the following facts and circumstances: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Pursuant to the Merger Agreement, the post-Acquisition board of directors of the Company consisted of seven directors, out of which the Company designated four board seats, with the Company's chair of the board prior to the Acquisition continuing in his position, i.e. the majority of the post-closing board was designated by the Company.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">The Chief Executive Officer and the majority of management roles are held by individuals who were affiliated with the Company prior to the Acquisition.</td></tr> </table>   The Acquisition-related transaction costs are accounted for as expenses in the period in which the costs are incurred. The Company incurred transaction costs of $874 during the nine months ended September 30, 2024, which were included in general and administrative expenses in the condensed consolidated statements of operations.   Purchase Price Allocation   The following sets forth the fair value of acquired identifiable assets and assumed liabilities of APT, after considering measurement period adjustment as described below, which includes adjustments to reflect the fair value of intangible assets acquired as of March 15, 2024:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">509</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Restricted cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">1,780</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Property, plant and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,748</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease right-of-use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,953</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">IPR&D assets and Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,088</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,232</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,667</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,895</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,851</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The fair value estimate for all identifiable assets and liabilities assumed is based on assumptions that market participants would use in pricing an asset, based on the most advantageous market for the asset (i.e., its highest and best use).   The Company recognized intangible assets related to the Acquisition, which consist of IPR&D valued at $15,287 using the Multi-Period Excess Earnings Method valuation method and of goodwill valued at $501. The goodwill is primarily attributed to the expected synergies from combining the operations of APT with the Company's operations and to the assembled workforce of APT. The IPR&D is considered indefinite lived until the completion or abandonment of the associated research and development efforts. Upon successful completion of the project, IPR&D assets are reclassified to developed technology and amortized over their estimated useful lives During the three months ended September 30, 2024, the Company made measurement period adjustment to the purchase price allocation, which resulted in an increase to goodwill of $300. The increase resulted from a provision for a contingency not provided in the initial Purchase Price Allocation, following a term sheet for a settlement agreement between APT and Oyster Point Pharma, Inc. ("Oyster") in connection with the Collaboration and Option Agreement signed in May 2021 as discussed in Note 7A. The fair value of assets acquired and liabilities assumed have been finalized. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">These intangible assets are classified as Level 3 measurements within the fair value hierarchy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes the fair value of the consideration transferred to APT shareholders for the Acquisition:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common Stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,041</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,610</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Merger Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of shares of Common Stock issued by the Company was determined using the Company's closing trading price on the Closing Date adjusted by a discount for lack of marketability ("DLOM") of 9.4% as a registration statement was filed within 45 days. The fair value of Redeemable Convertible Preferred Shares was determined using the Company's closing trading price on the Closing Date adjusted by a DLOM of 14.9% as the conversion of the Redeemable Convertible Preferred Shares to shares of Common Stock was subject to the stockholder approval, which was obtained on July 9, 2024. The Company determined the fair value of the Merger Warrants using the Black-Scholes model as of the Closing Date. The main assumptions used are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.5</td><td style="text-align: left"> </td></tr> </table>   The actual APT net loss included in the Company's condensed consolidated statements of operations for the nine months ended September 30, 2024, is as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Net loss attributable to APT</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,884</td><td style="width: 1%; text-align: left"> </td></tr> </table>   The unaudited pro forma financial information below summarizes the combined results of operations for BiomX Inc. (including its wholly owned subsidiaries, BiomX Ltd. and RondinX Ltd.) and APT. The unaudited pro forma financial information includes adjustments to reflect certain business combination effects, including: acquisition-related costs incurred by both parties and reversal of certain costs incurred by BiomX Inc. which would not have been incurred had the acquisition occurred on January 1, 2023. The unaudited pro forma financial information as presented below is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved if the Acquisition had taken place at the beginning of fiscal 2023.   The following unaudited table provides certain pro forma financial information for the Company as if the Acquisition occurred on January 1, 2023: <p style="font: 10pt Times New*

Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024*</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,698</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 0.25in">*</td> <td style="text-align: justify">The pro forma amounts above are derived from historical numbers of the Company and APT.</td></tr> </table>2164170.000110010820850500000001-for-109164974047021665010050202 7-01-28109152109152005000000000.550.45874000The following sets forth the fair value of acquired identifiable assets and assumed liabilities of APT, after considering measurement period adjustment as described below, which includes adjustments to reflect the fair value of intangible assets acquired as of March 15, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">509</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Restricted cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,780</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Property, plant and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,748</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease right-of-use asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,953</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">IPR&D assets and Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,088</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,232</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,667</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Other accounts payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,895</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">15,851</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr>
</table>5090001540001780000374800079530001608800030232000366700028950007819000143810001585100015287000501000300801000The following table summarizes the fair value of the consideration transferred to APT shareholders for the Acquisition:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Common Stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,041</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,610</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Merger Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,851</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>3041000126100002000000158510000.0940.149The Company determined the fair value of the Merger Warrants using the Black-Scholes model as of the Closing Date. The main assumptions used are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.7</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.5</td><td style="text-align: left"> </td></tr>
</table>0.375117.72.874.5The actual APT net loss included in the Company's condensed consolidated statements of operations for the nine months ended September 30, 2024, is as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Net loss attributable to APT</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5,884</td><td style="width: 1%; text-align: left"> </td></tr> </table>5884000The following unaudited table provides certain pro forma financial information for the Company as if the Acquisition occurred on January 1, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024*</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,698</td><td style="width: 1%; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0%"></td> <td style="width: 0.25in">*</td> <td style="text-align: justify">The pro forma amounts above are derived from historical numbers of the Company and APT.</td></tr> </table>2698000 NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">A.</td> <td style="text-align: justify">Unaudited Condensed Financial Statements</td></tr> </table>   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for condensed financial information. They do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments except as otherwise discussed).   The financial information contained in this report should be read in conjunction with the annual financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that the Company filed with the U.S. Securities and Exchange Commission (the "SEC") on April 4, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">B.</td> <td style="text-align: justify">Principles of Consolidation</td></tr> </table>   The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">C.</td> <td style="text-align: justify">Use of Estimates in the Preparation of Financial Statements</td></tr> </table>   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. The most significant estimates in the Company's financial statements relate to accruals for research and development expenses, valuation of stock-based compensation awards, purchase price allocation related to the Acquisition and the Private Placement Warrants fair value revaluation; estimates used in the IPR&D impairment assessment for calculating the fair value of the Company's assets by using discounted cash flow incorporate the Company's estimated post-tax weighted average cost of capital, amounts and timing of projected future cash flows that are influenced by the expected outcome of research and development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company's specific market share. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.   The full extent to which Israel's war with Hamas and Hezbollah may directly or indirectly impact the Company's business, results of operations and financial condition will depend on future developments that are uncertain, as well as the economic impact on local, regional, national and international markets.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">D.</td> <td style="text-align: justify">Business Combination</td></tr> </table>   The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. The excess of the fair value of the consideration transferred over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The fair value of the consideration

transferred included equity securities. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective dates of Acquisition. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">E.</td> <td style="text-align: justify">Financial instruments</td></tr> </table>   When the Company issues freestanding instruments, it first analyzes the provisions of ASC 480, "Distinguishing Liabilities From Equity" ("ASC 480") in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the consolidated statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-10 in order to determine whether the instrument is considered indexed to the entity's own stock and qualifies for classification within equity.   When the Company issues preferred shares, it first considers the provisions of ASC 480, in order to determine whether the preferred shares should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrument's characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. See Note 1D regarding the reclassification of the Redeemable Convertible Preferred Shares.   When the Company issues warrants, it first considers the provisions of ASC 815-40, "Contracts in Entity's Own Equity" ("ASC 815-40") in order to determine whether the warrants should be classified as equity. Equity classification is permitted when warrants are indexed to the Company's own shares and meet the classification requirements for stockholders' equity classification under ASC 815-40. If the warrants are not within the scope of ASC 815-40, the Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 ("ASC 815"), "Derivatives and Hedging", under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the Private Placement Warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the condensed consolidated statements of operations. See Note 10A for further information regarding the Private Placement Warrants.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">F.</td> <td style="text-align: justify">Basic and diluted loss (earnings) per share</td></tr> </table>   Basic loss (earnings) per share is computed by dividing net loss (income) by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Company's Common Stock and fully vested Pre-Funded Warrants for the Company's Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. The calculation excludes shares of Common Stock purchased by the Company and held as treasury shares. Diluted loss (income) per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period, plus the number of shares of Common Stock that would have been outstanding if all potentially dilutive shares of Common Stock had been issued, using the treasury stock and if-converted method, in accordance with ASC 260-10, "Earnings per Share."   The Company computes net loss (income) per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its Redeemable Convertible Preferred Shares to be participating securities as the holders of the Redeemable Convertible Preferred Shares would be entitled to dividends that would be distributed to the holders of Common Stock, on a pro-rata basis assuming conversion of all Redeemable Convertible Preferred Shares into shares of Common Stock. These participating securities do not contractually require the holders of such shares to participate in the Company's losses. As such, net loss for the periods presented was not allocated to the Company's participating securities.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">G.</td> <td style="text-align: justify">Intangible Assets</td></tr> </table>   Goodwill   Goodwill reflects the excess of the consideration transferred at the business combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, "Intangibles—Goodwill and Other" allows an entity to first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The Company's goodwill is tested for impairment at least on an annual basis, on the last day of the third quarter of the fiscal year and whenever events or changes in circumstances indicate the carrying value of a reporting unit may not be recoverable. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount of the respective reporting unit exceeds its fair value. However, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information.   Intangible assets   IPR&D assets acquired in a business combination are recognized at fair value as of the acquisition date and subsequently accounted for as indefinite-lived intangible assets until completion or abandonment of the associated R&D efforts. Indefinite-lived intangible assets are reviewed for impairment at least annually, on the last day of the third quarter of the fiscal year or whenever there is an indication that the asset may be impaired.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">H.</td> <td style="text-align: justify">Recent Accounting Standards</td></tr> </table>   Recently issued accounting pronouncements, not yet adopted   In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09"). This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.   In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures" ("ASU 2023-07"). This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, "Segment Reporting". The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity's financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">A.</td> <td style="text-align: justify">Unaudited Condensed Financial Statements</td></tr> </table> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for condensed financial information. They do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair statement have been included (consisting only of normal recurring adjustments except as otherwise discussed). The financial information contained in this report should be read in conjunction with the annual financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, that the Company filed with the U.S. Securities and Exchange Commission (the "SEC") on April 4, 2024. The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2023. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">B.</td> <td style="text-align: justify">Principles of Consolidation</td></tr> </table> The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">C.</td> <td style="text-align: justify">Use of Estimates in the Preparation of Financial Statements</td></tr> </table> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the financial statements and the amounts of expenses during the reported years. The most significant estimates in the Company's financial statements relate to accruals for research and development expenses, valuation of stock-based compensation awards, purchase price allocation related to the Acquisition and the Private Placement Warrants fair value revaluation; estimates used in the IPR&D impairment assessment for calculating the fair value of the Company's assets by using discounted cash flow incorporate the Company's estimated post-tax weighted average cost of capital, amounts and timing of projected future cash flows that are influenced by the expected outcome of research and development activities, the probability of success and timing in gaining regulatory approval, size of the potential market and the Company's specific market share. These estimates and assumptions are based on current facts, future expectations, and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. The full extent to which Israel's war with Hamas and Hezbollah may directly or indirectly impact the Company's business, results of operations and financial condition will depend

on future developments that are uncertain, as well as the economic impact on local, regional, national and international markets. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">D.</td> <td style="text-align: justify">Business Combination</td></tr> </table> The Company allocates the fair value of consideration transferred in a business combination to the assets acquired, liabilities assumed based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred. The excess of the fair value of the consideration transferred over the fair value of the assets acquired, liabilities assumed in the acquired business is recorded as goodwill. The fair value of the consideration transferred included equity securities. The allocation of the consideration transferred in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective dates of Acquisition. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">E.</td> <td style="text-align: justify">Financial instruments</td></tr> </table> When the Company issues freestanding instruments, it first analyzes the provisions of ASC 480, "Distinguishing Liabilities From Equity" ("ASC 480") in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the consolidated statements of operations in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of ASC 815-10 in order to determine whether the instrument is considered indexed to the entity's own stock and qualifies for classification within equity. When the Company issues preferred shares, it first considers the provisions of ASC 480, in order to determine whether the preferred shares should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyzes the instrument's characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. The Company reassesses the classification of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. See Note 1D regarding the reclassification of the Redeemable Convertible Preferred Shares. When the Company issues warrants, it first considers the provisions of ASC 815-40, "Contracts in Entity's Own Equity" ("ASC 815-40") in order to determine whether the warrants should be classified as equity. Equity classification is permitted when warrants are indexed to the Company's own shares and meet the classification requirements for stockholders' equity classification under ASC 815-40. If the warrants are not within the scope of ASC 815-40, the Company accounts for the warrants in accordance with the guidance contained in Accounting Standards Codification 815 ("ASC 815"), "Derivatives and Hedging", under which the warrants do not meet the criteria for equity treatment and must be recorded as derivative liabilities. Accordingly, the Company classifies the Private Placement Warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until the warrants are exercised or expire, and any change in fair value is recognized in the condensed consolidated statements of operations. See Note 10A for further information regarding the Private Placement Warrants. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">F.</td> <td style="text-align: justify">Basic and diluted loss (earnings) per share</td></tr> </table> Basic loss (earnings) per share is computed by dividing net loss (income) by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Company's Common Stock and fully vested Pre-Funded Warrants for the Company's Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration. The calculation excludes shares of Common Stock purchased by the Company and held as treasury shares. Diluted loss (income) per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the period, plus the number of shares of Common Stock that would have been outstanding if all potentially dilutive shares of Common Stock had been issued, using the treasury stock and if-converted method, in accordance with ASC 260-10, "Earnings per Share." The Company computes net loss (income) per share using the two-class method required for participating securities. The two-class method requires income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considers its Redeemable Convertible Preferred Shares to be participating securities as the holders of the Redeemable Convertible Preferred Shares would be entitled to dividends that would be distributed to the holders of Common Stock, on a pro-rata basis assuming conversion of all Redeemable Convertible Preferred Shares into shares of Common Stock. These participating securities do not contractually require the holders of such shares to participate in the Company's losses. As such, net loss for the periods presented was not allocated to the Company's participating securities. 0.001<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">G.</td> <td style="text-align: justify">Intangible Assets</td></tr> </table> Goodwill Goodwill reflects the excess of the consideration transferred at the business combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The primary items that generate goodwill include the value of the synergies between the acquired company and the Company and the acquired assembled workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, "Intangibles—Goodwill and Other" allows an entity to first assess qualitative factors to determine whether a quantitative goodwill impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The Company's goodwill is tested for impairment at least on an annual basis, on the last day of the third quarter of the fiscal year and whenever events or changes in circumstances indicate the carrying value of a reporting unit may not be recoverable. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount of the respective reporting unit exceeds its fair value. However, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. During the three months ended September 30, 2024, the Company recorded goodwill impairment in the amount of $801. See note 12 for further information. Intangible assets IPR&D assets acquired in a business combination are recognized at fair value as of the acquisition date and subsequently accounted for as indefinite-lived intangible assets until completion or abandonment of the associated R&D efforts. Indefinite-lived intangible assets are reviewed for impairment at least annually, on the last day of the third quarter of the fiscal year or whenever there is an indication that the asset may be impaired. 801000<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px">H.</td> <td style="text-align: justify">Recent Accounting Standards</td></tr> </table> Recently issued accounting pronouncements, not yet adopted In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09"). This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures" ("ASU 2023-07"). This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280, "Segment Reporting". The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity's financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures. NOTE 3 – FAIR VALUE OF FINANCIAL INSTRUMENTS   The Company accounts for financial instruments in accordance with ASC 820, "Fair Value Measurements and Disclosures" ("ASC 820"). ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.   Level 2 – Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.   Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.   There were no changes in the fair value hierarchy levelling during the nine months ended September 30, 2024 and year ended December 31, 2023. The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Cash equivalents:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 9pt">Money market funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width:

1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign exchange contracts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,325</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,340</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Private Placement Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,489</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,489</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"> Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Cash equivalents:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 9pt">Money market funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign exchange contracts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,377</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,633</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Contingent consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>   The changes in the fair value of the Company's Level 3 financial liabilities, which are measured on a recurring basis are as follows: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td colspan="2" style="text-align: right"> - </td><td> </td> <td colspan="2" style="text-align: right"> - </td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; text-align: left">Private Placement Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,417</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Ending balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   Financial instruments with carrying values approximating fair value include cash and cash equivalents, restricted cash, short-term deposits, other current assets, trade accounts payable and other accounts payable, due to their short-term nature. The Company determined the fair value of the liabilities for the contingent consideration based on a probability of discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy.

*The fair value of the contingent consideration is based on several factors, such as: the attainment of future clinical, developmental, regulatory, commercial and strategic milestones relating to product candidates for treatment of primary sclerosing cholangitis. The discount rate applied ranged from 3.84% to 4.52%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of operations. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liability. Changes in contingent consideration for the nine and three months ended September 30, 2024 and September 30, 2023, resulted from the passage of time and discount rate revaluation.   The Company uses foreign exchange contracts (mainly option and forward contracts) to hedge cash flows from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, the Company recognizes gains or losses that offset the revaluation of the cash flows also recorded under financial expenses (income), net in the condensed consolidated statements of operations. As of September 30, 2024, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $3,410 with a fair value asset of $15. As of December 31, 2023, the Company had outstanding foreign exchange contracts for the exchange of USD to NIS in the amount of approximately $4,136 with a fair value asset of $256.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company determined the fair value of the liabilities for the Private Placement Warrants using the Black-Scholes model, a Level 3 measurement, within the fair value hierarchy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main assumptions used are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> </table>The following table summarizes the fair value of our financial assets and liabilities that were accounted for at fair value on a recurring basis, by level within the fair value hierarchy:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Cash equivalents:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 9pt">Money market funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,325</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,325</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign exchange contracts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,325</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,340</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">161</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Private Placement Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,489</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,489</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Cash equivalents:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-left: 9pt">Money market funds</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,377</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">11,377</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Foreign exchange contracts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,377</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">256</td><td*

style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,633</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Contingent consideration</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">155</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
</table>20325000203250001500015000203250001500020340000161000161000432800043280004489000448900011377000113770002560002560001137700025600011633000

changes in the fair value of the Company's Level 3 financial liabilities, which are measured on a recurring basis are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td colspan="2" style="text-align: right"> - </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> - </td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 76%; text-align: left">Private Placement Warrants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">28,745</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,417)</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td><td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Ending balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"> - </td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table>28745000-244170004328000.03840.045234100001500041360002560000The main assumptions used are as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">117.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> </table>1.022.31117.61.753.6 NOTE 4 – OTHER CURRENT ASSETS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Government institutions</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">66</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">574</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Grants receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">574</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">892</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">495</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Other current assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,665</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,768</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Government institutions</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">66</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">505</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">574</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Grants receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">574</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">892</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">495</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Other current assets</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,665</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,768</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>84000660001165000505000574000128000950000574000892000495000366500017680000 NOTE 5 – OTHER ACCOUNTS PAYABLE   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employees and related institutions</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,421</td><td style="text-align: left"> </td><td> </td> <td>

style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Government institutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid sublease income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Severance related to former employees of APT</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,069</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,344</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"> September 30,
  2024 </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Employees and related institutions</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,852</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Government institutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">622</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Prepaid sublease income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Severance related to former employees of APT</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,069</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,344</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr>
</table>956000185200034210001289000622000175000280007000050690003344000 NOTE 6 – LEASES   On August 9, 2019, APT entered into a lease agreement (the "Lease Agreement") with ARE-708 Quince Orchard, LLC (the "Landlord"), for office and lab spaces in Gaithersburg, Maryland starting on September 1, 2019. Over the course of years, APT and the Landlord amended the Lease Agreement in order to expand the square footage and to extend the lease period until November 28, 2034. The agreement included 49,625 square feet of area. The monthly lease payments under the lease agreement were approximately $255. On March 5, 2024, in connection with the Acquisition, APT and the Landlord, signed an amendment to the lease agreement. Pursuant to the amendment, the leased area will be decreased to 25,894 square feet (the "Remaining Area"), effective as of December 31, 2024. Following the amendment, the revised monthly lease payments are approximately $134. In exchange, APT was required to pay a relinquished premises fee in an amount equal to $1,500 within 10 business days following March 15, 2024 (the "Amendment Effective Date"). In addition, the Company issued the Landlord warrants (the "Landlord Warrants") to purchase up to an aggregate of 25,000 shares of the Company's Common Stock at an exercise price of $50.00 per share. The Landlord Warrants became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on January 28, 2027. The amendment also included a one-time option to early terminate the lease agreement on February 28, 2029 with respect to the Remaining Area under certain terms. The execution of the early termination will require APT to pay a termination fee of $3,000.   APT accounted for the decreased leased area and the termination option as a modification as it continues to use the area for a period of time after the termination. The modification occurred before the Acquisition as APT signed the amendment before the Closing Date but was contingent upon the Acquisition. The operating lease right-of-use assets and operating lease liabilities contemplate the termination option.   Lease expenses recorded in the condensed statements of operations were $2,543 and $995 for the nine and three months ended September 30, 2024, respectively, and $488 and $161 for the nine and three months ended September 30, 2023, respectively.
4962525500025894134000150000025000503000000254300099500048800016100 NOTE 7 – COMMITMENTS AND CONTINGENCIES   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt"> </td> <td style="width: 24px; font-size: 10pt">A.</td> <td style="text-align: justify; font-size: 10pt">In May 2021, APT entered into a Collaboration and Option Agreement (the "Oyster Agreement") with Oyster, a wholly owned subsidiary of Viatris Inc., to collaborate on the use of APT's proprietary phage technology for the treatment of certain ophthalmic diseases. Upon execution of the Agreement, Oyster paid an upfront payment of $500 to APT, a portion of which APT claims it has spent in the course of performing its obligations under the Oyster Agreement. In April 2022 and September 2023, APT received letters from Oyster and Viatris Inc. raising concerns about APT's actions, including allegations that APT had breached the Oyster Agreement. APT and Oyster have agreed to settle their dispute related to the Oyster Agreement, including the allegations described in the letters, and to terminate the Oyster Agreement under a term sheet (the "Term Sheet"). Under the terms of the Term Sheet, APT and Oyster will sign a final settlement agreement, which will include a payment of $300 from APT to Oyster. As of September 30, 2024, the final settlement agreement had not yet been signed. The Company has recorded a provision of $300 as other accounts payable in the condensed consolidated balance sheets.</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="text-align: justify; font-size: 10pt"> </td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt">B.</td> <td> In August 2021, the Israeli Innovation Authority ("IIA") approved an application that supports upgrading the Company's manufacturing capabilities for an aggregate budget of NIS 5,737 (approximately $1,778). The IIA committed to fund 50% of the approved budget. The program was for the period beginning July 2021 through June 2022. The program does not bear royalties. Through September 30, 2024, the Company received NIS 1,912 (approximately $577) from the IIA with respect to this program.   In March 2022, the IIA approved an application for a total budget of NIS 13,004 (approximately $4,094) in relation to the Company's cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2022 through December 2022. Through September 30, 2024, the Company received NIS 1,365 (approximately $395) from the IIA with respect to this program.   In March 2023, the IIA approved an application for a total budget of NIS 11,283 (approximately $3,164) in relation to the Company's cystic fibrosis product candidate. The IIA committed to fund 30% of the approved budget. The program was for the period beginning January 2023 through December 2023. Through September 30, 2024, the Company received NIS 2,783 (approximately $768) from the IIA with respect to this program. </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td> According to the agreement with the IIA, excluding the August 2021 program, BiomX Israel will pay royalties of 3% to 3.5% of future sales up to an amount equal to the accumulated grant received including annual interest of LIBOR linked to the USD. Starting January 2024, the IIA has notified that the interest has changed to the 12-month Secured Overnight Financing Rate ("SOFR") as published on the first trading day of each calendar year. BiomX Israel may be required to pay additional royalties upon the occurrence of certain events as determined by the IIA, that are within the control of BiomX Israel. No such events have occurred or were probable of occurrence as of the balance sheet date with respect to these royalties. Repayment of the grant is contingent upon the successful completion of the BiomX Israel's R&D programs and generating sales. BiomX Israel has no obligation to repay these grants if the R&D program fails, is unsuccessful or aborted or if no sales are generated. The Company had not yet generated sales as of September 30, 2024; therefore, no liability was recorded in these condensed consolidated financial statements. IIA grants are recorded as a reduction of R&D expenses, net.   Through September 30, 2024, total grants approved from the IIA aggregated to approximately $9,353 (NIS 32,068). Through September 30, 2024, the Company had received an aggregate amount of $8,003 (NIS 27,423) in the form of grants from the IIA. Total grants subject to royalties' payments aggregated to approximately $7,413. As of September 30, 2024, BiomX Israel had a contingent obligation to the IIA in the amount of approximately $8,250 including annual interest of SOFR applicable to dollar deposits. </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt"> </td> <td style="width: 24px; font-size: 10pt">C.</td> <td style="text-align: justify; font-size: 10pt">On June 23, 2022, BiomX Israel entered into a research collaboration agreement with Boehringer Ingelheim International GmbH ("BI") for a collaboration to identify biomarkers for Inflammatory Bowel Disease. Under the agreement, BiomX Israel is eligible to receive fees totaling $1,411 to cover costs to be incurred by BiomX Israel in conducting the research plan under the collaboration. The fees were paid in four installments according to certain activities under the agreement. In December 2023, the Company completed its obligations with respect to this agreement and the last installment of $211 was received on January 18, 2024. The consideration was recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. </td></tr>
</table>5000003000003000005737000177800000.501912000577000130040004094000030136500039500011283000316400000.3027830007680000.030.035935300032068000 NOTE 8 – U.S. GOVERNMENT CONTRACTS AND GRANTS   In 2019, APT entered into a Base Agreement and Research Project Award (collectively, the "Agreement") with the U.S. Army Medical Research Acquisition Activity ("USAMRAA") and the U.S. Army Medical Research & Development Command ("USAMRDC") to advance personalized phage therapy from niche to broad use. Awards under the Agreement are intended to lay the groundwork for rapid advancement of personalized phage therapy to commercialization for the variety of clinical indications and bacterial pathogens representing unmet needs with a focus on infections with significant military relevance. The competitive award was granted by USAMRAA and USAMRDC in collaboration with the Medical Technology Enterprise Consortium ("MTEC"), a 501(c)(3) biomedical technology consortium working in partnership with the U.S. Department of Defense. Since Agreement inception, APT entered into certain modifications to the Agreement to include additional activities and perform pre-clinical activities to advance the Diabetic Foot Osteomyelitis ("DFO") clinical program. Under the Agreement, MTEC reimburses APT for approved costs as incurred that are based upon the achievement of certain milestones up to a contract value of $36,214. In September 2024, the Agreement was amended to extend the period of performance to continue and complete the pre-clinical activities for the DFO clinical program, which increased the total contract value to $39,081. In conjunction with this Agreement, APT is subject to an assessment fee of an amount equal up to 3% of the total funded value of the research project award which should be paid by the Company upon signing the agreement or the modifications. For the period between the Acquisition and September 30, 2024, the Company received grants of $2,895 from MTEC with respect to the cost reimbursement contract. During the nine

and three months ended September 30, 2024, the Company recorded $1,802 and $849 as a reduction of R&D expenses, net, respectively. The remainder of the consideration the Company is entitled to receive is recorded as other current assets in the condensed consolidated financial statements. See Note 14B for information regarding grants received subsequent to the financial statement date. 36214000390810000.0328950001802000849000 NOTE 9 – LONG-TERM DEBT   On August 16, 2021 (the "Closing Date"), the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Hercules Capital, Inc. ("Hercules"), with respect to a venture debt facility. Under the Loan Agreement, $15,000 was advanced to the Company on the date the Loan Agreement was executed. The Company was required to make interest only payments through March 1, 2023, and started to then repay the principal balance and interest in equal monthly installments through September 1, 2025.   The Loan Agreement provided that the Company could prepay advances under the Loan Agreement, in whole or in part, at any time subject to a prepayment charge equal to 1.0% after 24 months but prior to 36 months following the Closing Date. Upon prepayment or repayment of all or any of the term loans under the Term Loan Facility, the Company was required to pay an end of term charge ("End of Term Charge") equal to 6.55% of the total aggregate amount of the term loans being prepaid or repaid. On March 19, 2024, the Company prepaid the entire balance under the Term Loan Facility in a total of $10,428. The prepayment included the End of Term Charge of $983 and accrued interest of $69. The Company received from Hercules a waiver regarding the prepayment charge that should have been 1% out of the prepaid principal amount that equals to $94.   Interest expense relating to the term loan, which is included in interest expense in the condensed statements of operations was $850 for the nine months ended September 30, 2024. No interest expense was recognized in connection with the term loan for the three months ended September 30, 2024. Interest expense for the nine and three months ended September 30, 2023, was $1,884 and $574, respectively. 150000000.010.065510428000983000690000.019400085000018840005740000 NOTE 10 – STOCKHOLDERS EQUITY   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">A.</td> <td> Share Capital.   Reverse Stock Split: On July 9, 2024, the Company's stockholders approved a reverse stock split at a ratio within a range of 1-for-5 and 1-for-10 at such time as the Board of Directors shall determine, in its sole discretion, at any time before July 9, 2025. On August 8, 2024, the Board of Directors approved a 1-for-10 Reverse Stock Split of the Company's shares of Common Stock (the "Reverse Stock Split").   On August 20, 2024, the Company filed the Certificate of Amendment with the Delaware Secretary of State to effect the Reverse Stock Split, which became effective on August 26, 2024 (the "Effective Date"). The Company's Common Stock began trading on a Reverse Stock Split adjusted basis on the NYSE American at the opening of the markets on the Effective Date.   As a result of the Reverse Stock Split, the number of shares of Common Stock outstanding was reduced from 178,958,447 shares to 18,021,173 shares. No fractional shares of Common Stock or Units were issued in connection with the Reverse Stock Split. Stockholders of the Company who otherwise were entitled to receive fractional shares or Units, because they held a number of shares or Units, as applicable, not evenly divisible by the Reverse Stock Split ratio were automatically entitled to receive an additional fraction of a share of the Common Stock or Unit, as applicable, to round up to the next whole share. As a result, 125,328 shares of Common Stock were issued. The Reverse Stock Split did not change the par value of the Common Stock nor the authorized number of shares of Common Stock, preferred stock or any series of preferred stock.   Unless otherwise indicated, all amounts of issued and outstanding stock contained in the accompanying condensed consolidated financial statements have been adjusted to reflect the 1-for-10 Reverse Stock Split for all prior periods presented. Proportional adjustments were also made to shares underlying outstanding equity awards, warrants and Redeemable Convertible Preferred Shares, and to the number of shares issued and issuable under the Company's stock incentive plans and certain existing agreements.   Authorized shares of common stock: On July 9, 2024, the Company's stockholders approved increasing the number of authorized shares of Common Stock from 120,000,000 shares, par value $0.0001 per share, to 750,000,000 shares, par value $0.0001 per share.   Preferred Stock: The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors (the "Board").   On March 15, 2024, the Company issued 40,470 and 216,417 Redeemable Convertible Preferred Shares, par value $0.0001 per share, as part of the Acquisition and the March 2024 PIPE, respectively. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares were converted into 10,915,200 shares of the Company's Common Stock. </td></tr> </table> Private Investment in Public Equity: On February 22, 2023, the Company entered into a Securities Purchase Agreement to issue and sell an aggregate of 1,599,746 shares of its Common Stock and 1,461,072 pre-funded warrants (the "Pre-Funded Warrants") at a price of $2.45 per share and $2.44 per Pre-Funded Warrant in a private placement (the "February 2023 PIPE"). The net proceeds from the PIPE were approximately $7,152, after deducting issuance costs of $333. During the nine months ended September 30, 2024, 533,031 Pre-Funded Warrants were exercised into 533,031 shares of Common Stock for total consideration of $6 at an exercise price of $0.01 per share of Common Stock, and 928,041 Pre-Funded Warrants were exercised into 925,607 shares of Common Stock through cashless mechanism with no consideration. As of September 30, 2024, there are no outstanding Pre-Funded Warrants.   On March 15, 2024, in connection with the Acquisition, the Company issued to APT's former stockholders 916,497 shares of the Company's Common Stock, 40,470 Redeemable Convertible Preferred Shares and Merger Warrants to purchase up to an aggregate of 216,650 shares of the Company Common Stock. See Note 1D for further information.   Concurrently with the consummation of the Acquisition as described in Note 1D, the Company entered into the March 2024 PIPE, pursuant to which such investors purchased an aggregate of 216,417 Redeemable Convertible Preferred Shares ("PIPE Preferred Shares") and Private Placement Warrants to purchase up to an aggregate of 10,820,850 shares of the Company's Common Stock, at a combined price of $231.10 per share. The PIPE Preferred Shares and the Private Placement Warrants were issued in a private placement pursuant to an exemption from registration requirements under the Securities Act for aggregate gross proceeds of $50,000. Each Private Placement Warrant's exercise price equals to $2.31, subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, became exercisable from the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on July 9, 2026. Under certain circumstances, the Company may be required to pay to each holder of the Private Placement Warrants (i) an amount in cash equal to the holder's total purchase price for the shares of Common Stock purchased (the "Buy-In Price") or credit such holder's balance account with the Depository Trust Company ("DTC") for such shares of Common Stock shall terminate, or (ii) promptly honor its obligation to deliver to such holder a certificate or certificates representing such shares of Common Stock or credit such holder's balance account with DTC, as applicable, and pay cash to such holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) Weighted Average Price (as defined in the Private Placement Warrant) on the trading day immediately preceding the exercise date.   The Company accounted for the Private Placement Warrants as liabilities as the Private Placement Warrants are not considered indexed to the entity's own stock based on the provision of ASC 815. The Private Placement Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized in the condensed consolidated statements.   The terms of the PIPE Preferred Shares are substantially the same as those of the Redeemable Convertible Preferred Shares issued under the Acquisition and were accounted for as temporary equity at the issuance date and were reclassified as equity. See Note 1D for further information. On July 15, 2024, 109,152 Redeemable Convertible Preferred Shares that were issued under the Acquisition and the March 2024 PIPE were converted into 10,915,200 shares of the Company's Common Stock according to beneficial ownership limitations set by certain investors.   In connection therewith, the Company issued warrants to purchase shares of the Company's Common Stock to the Placement Agents (the "Agents Warrants"). See Note 10B for further information.   The Company allocated the total consideration from the issuance of the 2024 March PIPE first to the fair value of the Private Placement Warrants and then to the PIPE Preferred Shares. The Company had transaction costs of approximately $3,317 out of which $1,273 is Stock-Based Compensation due to issuance of the Agents Warrants. The transaction costs were allocated in the same manner as the consideration. Issuance costs which were allocated to the PIPE Preferred Shares were $1,410 and deducted from Redeemable Convertible Preferred Shares, and issuance costs that were allocated to the Private Placement Warrants were $1,907 and were expensed immediately.   At-the-Market Sales Agreement: In December 2023, pursuant to a registration statement on Form S-3 declared effective by the SEC on January 2, 2024, the Company entered an At the Market Offering Agreement with H.C. Wainwright & Co., LLC ("Wainwright"), pursuant to which the Company may issue and sell shares of Common Stock having an aggregate offering price of up to $7,500 from time to time through Wainwright. During the nine months ended September 30, 2024, the Company sold 7,518 shares of Common Stock under this agreement, at an average price of $2.71 per share, raising aggregate net proceeds of approximately $19, after deducting an aggregate commission of $1. Warrants: As of September 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration
 Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
 Price
 Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Shares of
 Common Stock
 Underlying
 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 39%; text-align: left">Public Warrants</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">IPO (December 13, 2018)</td><td style="width: 1%"> </td> <td style="width: 15%; text-align: center">October 28, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">115.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td> </tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2021 Registered Direct Offering Warrants</td><td> </td> <td style="text-align: center">SPA (July 28, 2021)</td><td> </td> <td style="text-align: center">January 28, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">281,251</td><td style="text-align: left"> </td></tr> <tr

style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Merger Warrants</td><td> </td> <td style="text-align: center">March 15, 2024</td><td> </td> <td style="text-align: center">January 28, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216,650</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Private Placement Warrants</td><td> </td> <td style="text-align: center">March 15, 2024</td><td> </td> <td style="text-align: center">July 9, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,820,850</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Agents Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">March 15, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">July 9, 2026</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">2.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">952,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12,621,132</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px"> </td> <td style="width: 24px">B.</td> <td style="text-align: justify">Stock-based Compensation:</td></tr> </table>   On March 15, 2024, the Company issued Agents Warrants to purchase up to an aggregate of 952,381 shares of the Company's Common Stock to the Placement Agents in connection with the March 2024 PIPE. The exercise price of the Agents Warrants is $2.31 per share and they became exercisable at any time after the date of the receipt of BiomX stockholder approval, which was obtained on July 9, 2024, and will expire on July 9, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounted for the Agents Warrants under the scope of ASC 718-10 "Stock-Based Payment", ("ASC 718-10"), and treated them as issuance costs of the March 2024 PIPE as the Company considers these Warrants as consideration for receipt of Private Placement Services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left"> </td></tr> </table>   On July 9, 2024, the Company's stockholders approved increasing the number of shares of Common Stock under the Company's 2019 Omnibus Long-Term Incentive Plan (the "2019 Plan") to be equal to 15% of the total number of fully-diluted shares of Common Stock outstanding as of the approval date, or 7,800,000 shares.   On September 16, 2024, the Company granted 155,429 RSUs to four senior officers and one service provider. The RSUs were fully vested and issued on the grant date and are not subject to continued service to the Company. The RSUs' fair value is the Company's stock closing price as of the grant date, which was $0.99. As of September 30, 2024, the Company has no unvested RSUs.   On July 11, 2024, the Board of Directors approved the grant of 1,567,795 options to 51 employees, six senior officers and seven directors under the 2019 Plan, without consideration. Options were granted at an exercise price of $3.63 per share with a vesting period of four years. Directors and senior officers are entitled to full acceleration of their unvested options upon the occurrence of both a change in control of the Company and the end of their engagement with the Company. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="text-align: justify">A summary of options granted to purchase the Company's Common Stock under the Company's share option plans is as follows:</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended
  September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
  Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
  Average
  Exercise
  Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
  Intrinsic
  Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">528,112</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,567,795</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,808</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,449</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Outstanding at the end of period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,062,650</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercisable at the end of period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">351,109</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right">5.79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average remaining contractual life of outstanding options - years as of September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Warrants: As of September 30, 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance
  Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration
  Date</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
  Price
  Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
  Shares of
  Common Stock
  Underlying
  Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Private Warrants issued to scientific founders</td><td style="width: 1%"> </td> <td style="width: 15%; text-align: center">November 27, 2017</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">298</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Landlord Warrants*</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">March 15, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center">January 28, 2027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: right">50.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align:

left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">25,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">(*)</td> <td style="text-align: justify">See Note 6.</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="text-align: justify">The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:</td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Research and development expenses, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">273</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">336</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">202</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">829</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">195</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,083</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">641</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr>
</table>1789584471802117312532812000000000.00017500000000.000110000000.000140470216417000110915210915200159974614610722.452.447152000333000533031500 of September 30, 2024, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration
 Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
 Price
 Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Shares of
 Common Stock
 Underlying
 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 39%; text-align: left">Public Warrants</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">IPO (December 13, 2018)</td><td style="width: 1%"> </td> <td style="width: 15%; text-align: center">October 28, 2024</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">115.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">350,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">2021 Registered Direct Offering Warrants</td><td> </td> <td style="text-align: center">SPA (July 28, 2021)</td><td> </td> <td style="text-align: center">January 28, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">281,251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Merger Warrants</td><td> </td> <td style="text-align: center">March 15, 2024</td><td> </td> <td style="text-align: center">January 28, 2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">216,650</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Private Placement Warrants</td><td> </td> <td style="text-align: center">March 15, 2024</td><td> </td> <td style="text-align: center">July 9, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,820,850</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Agents Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">March 15, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">July 9, 2026</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">2.31</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">952,381</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">12,621,132</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>IPO (December 13, 2018)2024-10-281153500000SPA (July 28, 2021)2027-01-2850281251March 15, 20242027-01-2850216650March 15, 20242026-07-092.3110820850March 15, 20242026-07-092.319523811262113295238195238312.31The Company determined the fair value of the Agents Warrants using the Black-Scholes model as of March 5, 2024. The main assumptions used are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Underlying value of Common Stock ($)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2.31</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price ($)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected terms (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left"> </td></tr> </table>2.312.311.006P2Y3M25D0.0440.1578000001554290.9915677953.63A summary of options granted to purchase the Company's Common Stock under the Company's share option plans is as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended
 September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate
 Intrinsic
 Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding at the beginning of period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">528,112</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">5.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,567,795</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(26,808</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.96</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,449</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> - </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Outstanding at the end of period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">2,062,650</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-

align: right">4.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercisable at the end of period</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">351,109</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td> <td style="padding-bottom: 4pt; text-align: right">5.79</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average remaining contractual life of outstanding options - years as of September 30, 2024</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">8.85</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>5281125.417200015677953.63268083.9664494.5820626504.08220003511095.79P8Y10M6DAs of September 30, 2024, the Company had the following outstanding compensation related warrants to purchase Common Stock:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuance
 Date</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expiration
 Date</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise
 Price
 Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of
 Shares of
 Common Stock
 Underlying
 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Private Warrants issued to scientific founders</td><td style="width: 1%"> </td> <td style="width: 15%; text-align: center">November 27, 2017</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right"> - </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 8%; text-align: right">298</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Landlord Warrants*</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt">March 15, 2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center">January 28, 2027</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">50.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">25,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">(*)</td> <td style="text-align: justify">See Note 6.</td></tr> </table>2017-11-272982024-03-152027-01-28502500025298The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Research and development expenses, net</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">273</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">336</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">202</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">164</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">747</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">439</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">829</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">195</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,083</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">641</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>27300031000336000202000556000164000747000439000829000195000108300064 1000 NOTE 11 - BASIC AND DILUTED LOSS (EARNINGS) PER SHARE   Basic loss (earnings) per share is computed on the basis of the net loss (income) for the period divided by the weighted average number of shares of Common Stock outstanding during the period, fully vested warrants with no exercise price for the Company's Common Stock and fully vested Pre-Funded Warrants for the Company's Common Stock at an exercise price of $0.001 per share, as the Company considers these shares to be exercised for little to no additional consideration.   Diluted loss per share is based upon the weighted average number of shares of Common Stock and of potential shares of Common Stock outstanding when dilutive. Potential shares of Common Stock equivalents include outstanding stock options and warrants, which are included under the treasury stock method when dilutive.   The calculation of diluted loss per share for the nine and three months ended September 30, 2024 and September 30, 2023, does not include the shares underlying the following financial instruments because their effect would be anti-dilutive: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,041,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">591,034</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,062,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">591,034</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,646,132</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">921,251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,825,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">921,251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Contingent shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,773,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,773,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> </table>   The following table presents the computation of basic and diluted loss (earnings) per share: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black

1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Basic loss (earnings) per share of common stock</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income) </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,642</td><td style="width: 1%; text-align: left">) </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,906</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,678</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Amount allocated to Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,575</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income) attributable to shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,067</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Number of shares of common stock outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,365,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,597,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,943,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,951,624</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Number of shares upon Pre-Funded Warrants exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,461,073</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">867,736</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Number of shares upon Fully vested Warrants exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,366,122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,944,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Basic loss (earnings) per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.31</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,642</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Change in fair value of Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">- </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,642</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average number of shares of common stock outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,366,122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,944,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,350,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,387,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,294,880</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.31</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left"> </td></tr> </table>0.001The calculation of diluted loss per share for the nine and three months ended September 30, 2024 and September 30, 2023, does not include the shares underlying the following financial instruments because their effect would be anti-dilutive:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,041,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">591,034</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">2,062,650</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">591,034</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,646,132</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">921,251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,825,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">921,251</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Contingent shares</td><td> </td>

<td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,773,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,773,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr>
</table>204113959103420626505910341264613292125118252819212512000004000002000004000001477350014773500The following table presents the computation of basic and diluted loss (earnings) per share:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended
 September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Basic loss (earnings) per share of common stock</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(9,642</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,906</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">20,678</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Amount allocated to Redeemable Convertible Preferred Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,575</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income) attributable to shares of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,067</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Number of shares of common stock outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,365,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,597,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,943,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,951,624</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Number of shares upon Pre-Funded Warrants exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,461,073</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">867,736</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Number of shares upon Fully vested Warrants exercise</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">298</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total weighted-average number of shares of common stock, shares upon Pre-Funded Warrants and Fully vested Warrants exercise used in computing basic loss (earnings) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,366,122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,944,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Basic loss (earnings) per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.31</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss (income)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,642</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Change in fair value of Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,642</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average number of shares of common stock outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,366,122</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,944,267</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,350,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> - </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total weighted-average number of shares of common stock outstanding, after giving effect to dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,387,633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,058,774</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,294,880</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,819,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Diluted net loss per share of common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.31</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left"> </td></tr> </table>9642000-7906000-3214000-20678000-4575000-5067000790600032140002067800016365824459740399439683951624146107386773629829829829816366122605877499442674819658-0.311.30.324.299642000-7906000-3214000-20678000-24417000-964200079060002763100020678000163661226058774994426748196581350613251111638763360587741129488048196580.311.32.454.29 NOTE 12 – GOODWILL   Following the APT Acquisition, the Company recognized goodwill valued at $801 after adjustment made during the measurement period as described in Note 1D above. In the third quarter of 2024, the Company experienced a

decline in its stock price resulting in its market capitalization being less than the Company's stockholders' equity. Thus, the Company performed quantitative assessments of the Company's goodwill. The assessments utilizes the Company's market capitalization plus an appropriate control premium. Market capitalization is determined by multiplying the outstanding number of shares of Common Stock by the Company's stock price. The control premium is determined by utilizing publicly available data from studies for similar transactions of public companies. As a result of this assessment, the Company recorded a goodwill impairment of $801 during the three and nine months ended September 30, 2024. 801000801000801000 NOTE 13 – EVENTS DURING THE PERIOD   In October 2021, the Company entered into a Stock Purchase Agreement with a subsidiary of Maruho Co. Ltd., ("Maruho"), pursuant to which the Company issued to Maruho shares of Common Stock of the Company and granted Maruho a right of first offer to license its atopic dermatitis product candidate, BX005, in Japan. The right of first offer was supposed to commence following the availability of results from the Phase 1/2 study which were expected in 2022. Part of the consideration paid under the agreements, equal to the grant date fair value of the shares issued to Maruho was attributed to the issuance of shares. The remainder of $1,976 was attributed to a contract liability, to be recognized as other income, at a point in time, once the clinical trials related to the product candidate are completed. In April 2024, following the Acquisition, the Company decided to pause the development of BX005. As a result, the parties agreed that the right of first offer to license BX005 is no longer applicable. As a result, the Company reversed the full amount of the contract liability and recognized $1,976 as Other Income in the condensed consolidated statements of operations. 19760001976000 NOTE 14 – SUBSEQUENT EVENTS   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt">a.</td><td style="text-align: justify">On October 15, 2024, the Company announced that effective October 25, 2024, the Company's Units will be mandatorily separated and the Units will no longer trade on the NYSE American. In the separation, Unit-holders received shares of Common Stock and warrants underlying their units, which warrants expired on October 28, 2024. The Common Stock continues to trade on the NYSE American under the symbol "PHGE" with the other existing shares of the Company's Common Stock.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt">b.</td><td style="text-align: justify">On October 17, 2024, the Company received a payment of $600 from MTEC in connection with the Agreement for reimbursement of approved costs. See Note 8 for further information.</td></tr></table>600 -166184000 false--12-31Q30001739174 All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A. All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A. Less than $1. See Note 10A. See Note 1D. All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A. The pro forma amounts above are derived from historical numbers of the Company and APT. See Note 6.

\.D02#.G8:0GWO-(3-61MO M!<+[#/[>+9Z,34+4